
<html lang="en"     class="pb-page"  data-request-id="b60e7160-6753-4de3-9ced-1b68162b3f78"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";article:article:10.1021/acs.jmedchem.5b01434;requestedJournal:journal:jmcmar;issue:issue:10.1021/jmcmar.2016.59.issue-1;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="Discovery of N-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2S,5R)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide. A Highly Selective and Orally Bioavailable Matrix Metalloproteinase-13 Inhibitor for the Potential Treatment of Osteoarthritis" /></meta><meta name="dc.Creator" content="Peter G.  Ruminski" /></meta><meta name="dc.Creator" content="Mark  Massa" /></meta><meta name="dc.Creator" content="Joseph  Strohbach" /></meta><meta name="dc.Creator" content="Cathleen E.  Hanau" /></meta><meta name="dc.Creator" content="Michelle  Schmidt" /></meta><meta name="dc.Creator" content="Jeffrey A.  Scholten" /></meta><meta name="dc.Creator" content="Theresa R.  Fletcher" /></meta><meta name="dc.Creator" content="Bruce C.  Hamper" /></meta><meta name="dc.Creator" content="Jeffery N.  Carroll" /></meta><meta name="dc.Creator" content="Huey S.  Shieh" /></meta><meta name="dc.Creator" content="Nicole  Caspers" /></meta><meta name="dc.Creator" content="Brandon  Collins" /></meta><meta name="dc.Creator" content="Margaret  Grapperhaus" /></meta><meta name="dc.Creator" content="Katherine E.  Palmquist" /></meta><meta name="dc.Creator" content="Joe  Collins" /></meta><meta name="dc.Creator" content="John E.  Baldus" /></meta><meta name="dc.Creator" content="Jeffrey  Hitchcock" /></meta><meta name="dc.Creator" content="H. Peter  Kleine" /></meta><meta name="dc.Creator" content="Michael D.  Rogers" /></meta><meta name="dc.Creator" content="Joseph  McDonald" /></meta><meta name="dc.Creator" content="Grace E.  Munie" /></meta><meta name="dc.Creator" content="Dean M.  Messing" /></meta><meta name="dc.Creator" content="Silvia  Portolan" /></meta><meta name="dc.Creator" content="Laurence O.  Whiteley" /></meta><meta name="dc.Creator" content="Teresa  Sunyer" /></meta><meta name="dc.Creator" content="Mark E.  Schnute" /></meta><meta name="dc.Description" content="Matrix metalloproteinase-13 (MMP-13) is a zinc-dependent protease responsible for the cleavage of type II collagen, the major structural protein of articular cartilage. Degradation of this cartilag..." /></meta><meta name="Description" content="Matrix metalloproteinase-13 (MMP-13) is a zinc-dependent protease responsible for the cleavage of type II collagen, the major structural protein of articular cartilage. Degradation of this cartilag..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="December 24, 2015" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.5b01434" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2015 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.5b01434" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.5b01434" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.5b01434" /></link>
        
    
    

<title>Discovery of N-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2S,5R)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide. A Highly Selective and Orally Bioavailable Matrix Metalloproteinase-13 Inhibitor for the Potential Treatment of Osteoarthritis | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.5b01434" /></meta><meta property="og:title" content="Discovery of N-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2S,5R)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide. A Highly Selective and Orally Bioavailable Matrix Metalloproteinase-13 Inhibitor for the Potential Treatment of Osteoarthritis" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01434/20160113/images/large/jm-2015-01434x_0018.jpeg" /></meta><meta property="og:description" content="Matrix metalloproteinase-13 (MMP-13) is a zinc-dependent protease responsible for the cleavage of type II collagen, the major structural protein of articular cartilage. Degradation of this cartilage matrix leads to the development of osteoarthritis. We previously have described highly potent and selective carboxylic acid containing MMP-13 inhibitors; however, nephrotoxicity in preclinical toxicology species precluded development. The accumulation of compound in the kidneys mediated by human organic anion transporter 3 (hOAT3) was hypothesized as a contributing factor for the finding. Herein we report our efforts to optimize the MMP-13 potency and pharmacokinetic properties of non-carboxylic acid leads resulting in the identification of compound 43a lacking the previously observed preclinical toxicology at comparable exposures." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.5b01434"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.5b01434">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.5b01434&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.5b01434&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.5b01434&amp;href=/doi/10.1021/acs.jmedchem.5b01434" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2016</span><span class="cit-fg-volume">, 59</span><span class="cit-fg-issue">, 1</span><span class="cit-fg-pageRange">, 313-327</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/59/1" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.5b01399" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.5b01465" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Discovery of <i>N</i>-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2<i>S</i>,5<i>R</i>)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2<i>H</i>-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide. A Highly Selective and Orally Bioavailable Matrix Metalloproteinase-13 Inhibitor for the Potential Treatment of Osteoarthritis</span></h1><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Peter+G.++Ruminski">Peter G. Ruminski</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mark++Massa">Mark Massa</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Joseph++Strohbach">Joseph Strohbach</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Cathleen+E.++Hanau">Cathleen E. Hanau</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Michelle++Schmidt">Michelle Schmidt</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jeffrey+A.++Scholten">Jeffrey A. Scholten</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Theresa+R.++Fletcher">Theresa R. Fletcher</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Bruce+C.++Hamper">Bruce C. Hamper</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jeffery+N.++Carroll">Jeffery N. Carroll</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Huey+S.++Shieh">Huey S. Shieh</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Nicole++Caspers">Nicole Caspers</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Brandon++Collins">Brandon Collins</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Margaret++Grapperhaus">Margaret Grapperhaus</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Katherine+E.++Palmquist">Katherine E. Palmquist</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Joe++Collins">Joe Collins</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=John+E.++Baldus">John E. Baldus</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Jeffrey++Hitchcock">Jeffrey Hitchcock</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=H.+Peter++Kleine">H. Peter Kleine</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Michael+D.++Rogers">Michael D. Rogers</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Joseph++McDonald">Joseph McDonald</a></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Grace+E.++Munie">Grace E. Munie</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Dean+M.++Messing">Dean M. Messing</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Silvia++Portolan">Silvia Portolan</a></span><span class="author-xref-symbol author-aff-symbol"><sup>§</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Laurence+O.++Whiteley">Laurence O. Whiteley</a></span><span class="author-xref-symbol author-aff-symbol"><sup>∥</sup></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Teresa++Sunyer">Teresa Sunyer</a></span><span class="author-xref-symbol author-aff-symbol"><sup>‡</sup></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Mark+E.++Schnute">Mark E. Schnute</a></span><span class="author-xref-symbol "><sup>*</sup></span><span class="author-xref-symbol author-aff-symbol"><sup>†</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-text"><sup>†</sup>Worldwide Medicinal Chemistry and <sup>‡</sup>Inflammation and Immunology Research, Pfizer, 610 Main Street, Cambridge, Massachusetts 02139, United States</span></div><div class="aff-info" id="aff2"><span class="aff-symbol">§</span> <span class="aff-text">Pharmacokinetics, Dynamics, and Metabolism, Pfizer, 700 North Main Street, Cambridge, Massachusetts 02139, United States</span></div><div class="aff-info" id="aff3"><span class="aff-symbol">∥</span> <span class="aff-text">Drug Safety, Pfizer, 1 Burtt Road, Andover, Massachusetts 01810, United States</span></div><div class="corresp-info"><strong>*</strong>Phone: 617-674-7362. E-mail: <a href="/cdn-cgi/l/email-protection#4d202c3f266328633e2e25233839280d3d2b2437283f632e2220"><span class="__cf_email__" data-cfemail="c0ada1b2abeea5eeb3a3a8aeb5b4a580b0a6a9baa5b2eea3afad">[email protected]</span></a></div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.5b01434&amp;href=/doi/10.1021%2Facs.jmedchem.5b01434" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2016</span></span><span class="cit-volume">, 59</span><span class="cit-issue">, 1</span><span class="cit-pageRange">, 313–327</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">December 12, 2015</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>15 September 2015</li><li><span class="item_label"><b>Published</b> online</span>24 December 2015</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 14 January 2016</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.5b01434" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b01434</a></div><div class="article_header-article-copyright"><strong>Copyright © 2015 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D313%26pageCount%3D15%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DPeter%2BG.%2BRuminski%252C%2BMark%2BMassa%252C%2BJoseph%2BStrohbach%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D59%26issueNum%3D1%26contentID%3Dacs.jmedchem.5b01434%26title%3DDiscovery%2Bof%2BN-%25284-Fluoro-3-methoxybenzyl%2529-6-%25282-%2528%2528%25282S%252C5R%2529-5-%2528hydroxymethyl%2529-1%252C4-dioxan-2-yl%2529methyl%2529-2H-tetrazol-5-yl%2529-2-methylpyrimidine-4-carboxamide.%2BA%2BHighly%2BSelective%2Band%2BOrally%2BBioavailable%2BMatrix%2BMetalloproteinase-13%2BInhibitor%2Bfor%2Bthe%2BPotential%2BTreatment%2Bof%2BOsteoarthritis%26numPages%3D15%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D327%26publicationDate%3DJanuary%2B2016">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.5b01434"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">2234</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">20</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.5b01434" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Discovery of N-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2S,5R)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2H-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide. A Highly Selective and Orally Bioavailable Matrix Metalloproteinase-13 Inhibitor for the Potential Treatment of Osteoarthritis&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Peter&quot;,&quot;last_name&quot;:&quot;G. Ruminski&quot;},{&quot;first_name&quot;:&quot;Mark&quot;,&quot;last_name&quot;:&quot;Massa&quot;},{&quot;first_name&quot;:&quot;Joseph&quot;,&quot;last_name&quot;:&quot;Strohbach&quot;},{&quot;first_name&quot;:&quot;Cathleen&quot;,&quot;last_name&quot;:&quot;E. Hanau&quot;},{&quot;first_name&quot;:&quot;Michelle&quot;,&quot;last_name&quot;:&quot;Schmidt&quot;},{&quot;first_name&quot;:&quot;Jeffrey&quot;,&quot;last_name&quot;:&quot;A. Scholten&quot;},{&quot;first_name&quot;:&quot;Theresa&quot;,&quot;last_name&quot;:&quot;R. Fletcher&quot;},{&quot;first_name&quot;:&quot;Bruce&quot;,&quot;last_name&quot;:&quot;C. Hamper&quot;},{&quot;first_name&quot;:&quot;Jeffery&quot;,&quot;last_name&quot;:&quot;N. Carroll&quot;},{&quot;first_name&quot;:&quot;Huey&quot;,&quot;last_name&quot;:&quot;S. Shieh&quot;},{&quot;first_name&quot;:&quot;Nicole&quot;,&quot;last_name&quot;:&quot;Caspers&quot;},{&quot;first_name&quot;:&quot;Brandon&quot;,&quot;last_name&quot;:&quot;Collins&quot;},{&quot;first_name&quot;:&quot;Margaret&quot;,&quot;last_name&quot;:&quot;Grapperhaus&quot;},{&quot;first_name&quot;:&quot;Katherine&quot;,&quot;last_name&quot;:&quot;E. Palmquist&quot;},{&quot;first_name&quot;:&quot;Joe&quot;,&quot;last_name&quot;:&quot;Collins&quot;},{&quot;first_name&quot;:&quot;John&quot;,&quot;last_name&quot;:&quot;E. Baldus&quot;},{&quot;first_name&quot;:&quot;Jeffrey&quot;,&quot;last_name&quot;:&quot;Hitchcock&quot;},{&quot;first_name&quot;:&quot;H.&quot;,&quot;last_name&quot;:&quot;Peter Kleine&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;D. Rogers&quot;},{&quot;first_name&quot;:&quot;Joseph&quot;,&quot;last_name&quot;:&quot;McDonald&quot;},{&quot;first_name&quot;:&quot;Grace&quot;,&quot;last_name&quot;:&quot;E. Munie&quot;},{&quot;first_name&quot;:&quot;Dean&quot;,&quot;last_name&quot;:&quot;M. Messing&quot;},{&quot;first_name&quot;:&quot;Silvia&quot;,&quot;last_name&quot;:&quot;Portolan&quot;},{&quot;first_name&quot;:&quot;Laurence&quot;,&quot;last_name&quot;:&quot;O. Whiteley&quot;},{&quot;first_name&quot;:&quot;Teresa&quot;,&quot;last_name&quot;:&quot;Sunyer&quot;},{&quot;first_name&quot;:&quot;Mark&quot;,&quot;last_name&quot;:&quot;E. Schnute&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2015&quot;,&quot;month&quot;:&quot;12&quot;,&quot;day&quot;:&quot;24&quot;,&quot;issue&quot;:&quot;1&quot;,&quot;volume&quot;:&quot;59&quot;,&quot;pages&quot;:&quot;313-327&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.5b01434&quot;},&quot;abstract&quot;:&quot;Matrix metalloproteinase-13 (MMP-13) is a zinc-dependent protease responsible for the cleavage of type II collagen, the major structural protein of articular cartilage. Degradation of this cartilage matrix leads to the development of osteoarthritis. We previously have described highly potent and selective carboxylic acid containing MMP-13 inhibitors; however, nephrotoxicity in preclinical toxicology species precluded development. The accumulation of compound in the kidneys mediated by human organic anion transporter 3 (hOAT3) was hypothesized as a contributing factor for the finding. Herein we report our efforts to optimize the MMP-13 potency and pharmacokinetic properties of non-carboxylic acid leads resulting in the identification of compound 43a lacking the previously observed preclinical toxicology at comparable exposures.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.5b01434&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b01434" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.5b01434&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b01434" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.5b01434&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b01434" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.5b01434&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b01434&amp;href=/doi/10.1021/acs.jmedchem.5b01434" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.5b01434" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.5b01434" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (998 KB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b01434&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.5b01434%26sid%3Dliteratum%253Aachs%26pmid%3D26653735%26genre%3Darticle%26aulast%3DRuminski%26date%3D2016%26atitle%3DDiscovery%2Bof%2BN-%25284-Fluoro-3-methoxybenzyl%2529-6-%25282-%2528%2528%25282S%252C5R%2529-5-%2528hydroxymethyl%2529-1%252C4-dioxan-2-yl%2529methyl%2529-2H-tetrazol-5-yl%2529-2-methylpyrimidine-4-carboxamide.%2BA%2BHighly%2BSelective%2Band%2BOrally%2BBioavailable%2BMatrix%2BMetalloproteinase-13%2BInhibitor%2Bfor%2Bthe%2BPotential%2BTreatment%2Bof%2BOsteoarthritis%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D59%26issue%3D1%26spage%3D313%26epage%3D327%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291012" title="Organic acids">Organic acids</a>,</li><li><a href="/action/doSearch?ConceptID=290703" title="Pyridines">Pyridines</a>,</li><li><a href="/action/doSearch?ConceptID=292143" title="Metabolism">Metabolism</a>,</li><li><a href="/action/doSearch?ConceptID=292464" title="Rodent models">Rodent models</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/59/1" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/jmcmar.2016.59.issue-1/20160114/jmcmar.2016.59.issue-1.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01434/20160113/images/medium/jm-2015-01434x_0018.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01434/20160113/images/large/jm-2015-01434x_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01434&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Matrix metalloproteinase-13 (MMP-13) is a zinc-dependent protease responsible for the cleavage of type II collagen, the major structural protein of articular cartilage. Degradation of this cartilage matrix leads to the development of osteoarthritis. We previously have described highly potent and selective carboxylic acid containing MMP-13 inhibitors; however, nephrotoxicity in preclinical toxicology species precluded development. The accumulation of compound in the kidneys mediated by human organic anion transporter 3 (hOAT3) was hypothesized as a contributing factor for the finding. Herein we report our efforts to optimize the MMP-13 potency and pharmacokinetic properties of non-carboxylic acid leads resulting in the identification of compound <b>43a</b> lacking the previously observed preclinical toxicology at comparable exposures.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_12526" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_12526" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Osteoarthritis (OA) is a highly debilitating disease characterized by the degeneration of synovial joints especially of the hand, knee, hip, and spine leading to pain and reduced mobility. Based on 2005 data, an estimated 27 million people in the US suffer from OA.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> As the proportion of elderly in the population and obesity rates are increasing, both risk factors for disease,<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> the incidence of OA disease is expected to continue to rise. At this time, available treatment strategies have been limited to symptomatic pain relief; however, many of these agents have undesired side effects, and they do not address the cause of the disease.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> The goal of developing a disease modifying osteoarthritis drug (DMOAD) able to halt disease progression has been elusive. However, continued understanding of the underlying biology and advances in clinical trial design are offering new opportunities for potential treatment options.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a></div><div class="NLM_p">A hallmark of OA disease onset is the degradation of articular cartilage, and therefore the prevention of this process is a promising strategy to limit the progression of disease. The major structural protein of articular cartilage is type II collagen. Matrix metalloproteinase-13 (MMP-13), a member of a family of zinc-dependent proteases, shows a high specificity for the cleavage of type II collagen. In preclinical models of OA disease, transgenic mice lacking MMP-13 as well as MMP-13 inhibitors have shown reduced cartilage damage compared with control animals.<a onclick="showRef(event, 'ref5 ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref5 ref6 ref7">(5-7)</a></div><div class="NLM_p">Several broad spectrum metalloproteinase inhibitors have been investigated in human clinical trials; however, a tendinitis-like stiffening of the joints referred to as muscular skeletal syndrome (MSS) has limited development.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> The lack of this finding in the phenotype of the MMP-13 null mouse as well as individuals possessing a missense mutation of the MMP-13 gene has suggested the poor selectivity profile of the agents studied was a factor leading to MSS development.<a onclick="showRef(event, 'ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref9 ref10">(9, 10)</a></div><div class="NLM_p">Significant progress in the design of MMP-13 selective inhibitors has occurred over the last 15 years such that several highly selective compounds have been reported in the literature, <a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>. The first reports of MMP-13 specific inhibitors included compound <b>1</b> from workers at Aventis<a onclick="showRef(event, 'ref11'); return false;" href="javascript:void(0);" class="ref ref11">(11)</a> and compound <b>2</b> from workers at Pfizer.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> Both compounds were very potent inhibitors of MMP-13 (IC<sub>50</sub> = 8 and 0.67 nM, respectively) while showing greater than 10 000-fold selectivity against a panel of related MMP enzymes. Compound <b>2</b> was reported to significantly reduce cartilage lesion areas when dosed orally in a rabbit anterior cruciate ligament transection/partial meniscectomy model while not showing MMS-like fibroplasia in rats.<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> The high selectivity was hypothesized to arise by the compound adopting a non-zinc binding mode with the inhibitor occupying a deep region of the S<sub>1</sub>′ binding pocket unique to MMP-13. Additional reports of selective MMP-13 inhibitors have appeared from Pfizer (<b>3</b> and <b>6</b>), Takeda (<b>4</b>), Alantos Pharmaceuticals (<b>5</b>), and Boehringer Ingelheim (<b>7</b>), <a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>.<a onclick="showRef(event, 'ref12 ref13 ref14 ref15 ref16 ref17'); return false;" href="javascript:void(0);" class="ref ref12 ref13 ref14 ref15 ref16 ref17">(12-17)</a> The evolution of highly selective MMP-13 inhibitors has led to several core structures; however, with the exception of compound <b>1</b>, a terminal carboxylic acid has been maintained as a design element. The preference for the acidic substituent is understandable due to its proximity to Lys-119 in the binding pocket and the potential to form an energetically favorable hydrogen-bond or salt bridge, <a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>.<a onclick="showRef(event, 'ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref13 ref14">(13, 14)</a> Additional important protein–ligand contacts observed for compound <b>6</b> include hydrogen bond contacts between the amide and two residues, Ala-217 and Thr-224, as well as a π–π interaction between His-201 and the benzyl ring.</div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01434/20160113/images/medium/jm-2015-01434x_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01434/20160113/images/large/jm-2015-01434x_0002.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Representative non-zinc binding, highly selective MMP-13 inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01434/20160113/images/large/jm-2015-01434x_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01434&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01434/20160113/images/medium/jm-2015-01434x_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01434/20160113/images/large/jm-2015-01434x_0003.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Key protein–ligand interactions between MMP-13 and compound <b>6</b>.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> Blue shading indicates ligand exposed regions; purple indicates polar residues; green indicates hydrophobic residues.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01434/20160113/images/large/jm-2015-01434x_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01434&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">As described in our previous reports, compounds <b>2</b>, <b>3</b>, and <b>6</b> were highly potent and selective MMP-13 inhibitors that demonstrated promising in vivo cartilage protection and safety in preclinical rodent studies.<a onclick="showRef(event, 'ref6 ref12 ref13'); return false;" href="javascript:void(0);" class="ref ref6 ref12 ref13">(6, 12, 13)</a> Further studies of all three inhibitors in cynomolgus monkeys however revealed the consistent observation of nephrotoxicity characterized by diffuse tubular epithelial cell degeneration–regeneration.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> Since these compounds are organic anions, their ability to be transported by human organic anion transporter 1 and 3 (hOAT1/3) was evaluated.<a onclick="showRef(event, 'ref18'); return false;" href="javascript:void(0);" class="ref ref18">(18)</a> Indeed compounds <b>2</b>, <b>3</b>, and <b>6</b> inhibited the uptake of hOAT3 radiolabeled substrate in transfected cell lines (IC<sub>50</sub> = 18, 59, and 6 μM, respectively) and were found to be accumulated in cultured proximal tubular cells. These results suggested that all three compounds are substrates for the hOAT3 transporter. Carboxylic acids also present the risk of generating reactive metabolites through protein conjugation of the resulting acyl glucuronide.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> It was hypothesized that the nephrotoxicity finding observed was the consequence of compound accumulation in the kidney epithelial cells followed by a cytotoxic event mediated through the acyl glucuronide metabolite. Compound <b>6</b> was specifically selected for its reduced propensity to undergo glucuronide acyl migration to form the reactive species (rearrangement <i>T</i><sub>1/2</sub> = 67 h compared with <i>T</i><sub>1/2</sub> = 0.5 h for diclofenac). Unfortunately, nephrotoxicity was still observed. As a result, a chemistry strategy was undertaken to identify a potent and highly selective MMP-13 inhibitor based on <b>6</b> lacking an organic anion functionality to mitigate the transporter mediated accumulation risk.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Chemistry</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_15316" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_15316" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Pyridine tetrazole <b>12</b> was utilized as a versatile intermediate allowing for diversity exploration to either the left- or right-hand side of the molecules, <a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>. Compound <b>12</b> was prepared from pyridine carboxylic acid <b>8</b> by first transformation of the carboxylic acid to the nitrile via dehydration of the <i>tert</i>-butylamide <b>9</b>. Sodium azide addition to cyanopyridine <b>10</b> afforded tetrazole <b>11</b>, which was subjected to palladium-mediated carbonylation to provide ester <b>12</b>. In order to facilitate a systematic survey of substituents to the tetrazole, ester <b>12</b> was condensed with 3-methoxybenzylamine to provide amide <b>13</b>, <a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>. Alkylation of the tetrazole occurred with high regioselectivity at the 2-position to provide analogs such as <b>14a</b>–<b>k</b> (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>) employing the reaction with alcohols under Mitsunobu conditions or with arylsulfonate esters in the case of <b>14e</b> and <b>14i</b>. Additional examples of 4-substituted methylenecyclohexane analogs were prepared as described in <a class="ref internalNav" href="#sch3" aria-label="Schemes 3">Schemes 3</a>–<a class="ref internalNav" href="#sch5" aria-label="5">5</a>. Compound <b>13</b> was alkylated by methyl <i>trans</i>-4-(hydroxymethyl)cyclohexane carboxylate using Mitsunobu conditions to provide ester <b>17</b>. The resulting ester was then converted to the primary amide <b>18</b> and subsequently through dehydration to the nitrile <b>19</b>. Similarly, 4-amino-substituted analogs were prepared by alkylation of <b>13</b> with <i>trans</i>-or <i>cis</i>-alcohols <b>20</b> and <b>24</b> using Mitsunobu conditions, <a class="ref internalNav" href="#sch4" aria-label="Schemes 4">Schemes 4</a> and <a class="ref internalNav" href="#sch5" aria-label="5">5</a>. Subsequent deprotection afforded the corresponding amines (<b>22</b> and <b>26</b>), which through either acylation or sulfonylation provided <i>trans</i>-isomers <b>23a</b>,<b>b</b> and <i>cis</i>-isomers <b>27a</b>,<b>b</b>. Piperidine analogs were also prepared through Mitsunobu alkylation of <b>13</b> with alcohol <b>28</b>, <a class="ref internalNav" href="#sch6" aria-label="Scheme 6">Scheme 6</a>. Deprotection of the resulting product (<b>29</b>) followed by acylation or sulfonylation provided piperidine amide <b>31a</b> or sulfonamide <b>31b</b>.</div><figure id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01434/20160113/images/medium/jm-2015-01434x_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01434/20160113/images/large/jm-2015-01434x_0006.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Pyridine Tetrazole <b>12</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01434/20160113/images/large/jm-2015-01434x_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01434&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) oxalyl chloride, DMF, CH<sub>2</sub>Cl<sub>2</sub>; <i>t</i>-butylamine; (b) POCl<sub>3</sub>, toluene, 110 °C; (c) Et<sub>3</sub>N·HCl, NaN<sub>3</sub>, toluene, 110 °C; (d) Et<sub>3</sub>N, dppf, Pd(OAc)<sub>2</sub>, MeOH, CO, 100 °C.</p></p></figure><figure id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01434/20160113/images/medium/jm-2015-01434x_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01434/20160113/images/large/jm-2015-01434x_0007.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. General Synthesis of <b>14a</b>–<b>k</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01434/20160113/images/large/jm-2015-01434x_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01434&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) 3-methoxybenzylamine, 100 °C; (b) PS–PPh<sub>3</sub>, DBAD, ROH, THF; or in the case of <b>14e</b> and <b>14i</b>, ROSO<sub>2</sub>Y (Y = 4-toluenyl, 4-nitrophenyl), Et<sub>3</sub>N, DMA, 85 °C.</p></p></figure><figure id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01434/20160113/images/medium/jm-2015-01434x_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01434/20160113/images/large/jm-2015-01434x_0008.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of <b>18</b> and <b>19</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01434/20160113/images/large/jm-2015-01434x_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01434&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) PS–PPh<sub>3</sub>, DBAD, methyl <i>trans</i>-4-(hydroxymethyl)cyclohexanecarboxylate, THF; (b) HCONH<sub>2</sub>, THF, 80 °C, NaOMe; (c) PS–PPh<sub>3</sub>, CCl<sub>4</sub>, DCE, 80 °C.</p></p></figure><figure id="sch4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01434/20160113/images/medium/jm-2015-01434x_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01434/20160113/images/large/jm-2015-01434x_0009.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of <b>23</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01434/20160113/images/large/jm-2015-01434x_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01434&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) PS–PPh<sub>3</sub>, DBAD, <b>13</b>, THF; (b) TFA, CH<sub>2</sub>Cl<sub>2</sub>; (c) Et<sub>3</sub>N, CH<sub>3</sub>SO<sub>2</sub>Cl or Ac<sub>2</sub>O, silica-bound DMAP, CH<sub>2</sub>Cl<sub>2</sub>.</p></p></figure><figure id="sch5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01434/20160113/images/medium/jm-2015-01434x_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01434/20160113/images/large/jm-2015-01434x_0010.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of <b>27</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01434/20160113/images/large/jm-2015-01434x_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01434&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) PS–PPh<sub>3</sub>, DBAD, <b>13</b>, THF; (b) TFA, CH<sub>2</sub>Cl<sub>2</sub>; (c) Et<sub>3</sub>N, CH<sub>3</sub>SO<sub>2</sub>Cl or Ac<sub>2</sub>O, silica-bound DMAP, CH<sub>2</sub>Cl<sub>2</sub>.</p></p></figure><figure id="sch6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01434/20160113/images/medium/jm-2015-01434x_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01434/20160113/images/large/jm-2015-01434x_0011.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthesis of <b>31</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01434/20160113/images/large/jm-2015-01434x_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01434&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) PS–PPh<sub>3</sub>, DBAD, <b>13</b>, THF; (b) TFA, CH<sub>2</sub>Cl<sub>2</sub>; (c) Et<sub>3</sub>N, silica-bound DMAP, CH<sub>2</sub>Cl<sub>2</sub>; CH<sub>3</sub>SO<sub>2</sub>Cl or Ac<sub>2</sub>O.</p></p></figure><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. SAR of Non-carboxylic Acid Substituents<a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01434/20160113/images/medium/jm-2015-01434x_0015.gif" alt="" id="fx1" /></img><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01434/20160113/images/medium/jm-2015-01434x_0016.gif" alt="" id="GRAPHIC-d7e1027-autogenerated" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup>Table a</sup><p class="last">All values are the mean of two or more independent assays. ND, not determined.</p></div></div><div></div></div><div class="NLM_p">In order to survey substitution to the benzylamide, carboxylic acid <b>33</b> was employed as the common intermediate, <a class="ref internalNav" href="#sch7" aria-label="Scheme 7">Scheme 7</a>. Compound <b>13</b> was alkylated with <i>trans</i>-cyclohexane-1,4-dimethanol using Mitsunobu conditions to provide ester <b>32</b>, which was subsequently saponified to provide acid <b>33</b>. Amide analogs <b>34a</b>–<b>k</b> (<a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>) were then prepared by coupling of the corresponding substituted benzylamine with compound <b>33</b>.</div><figure id="sch7" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01434/20160113/images/medium/jm-2015-01434x_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01434/20160113/images/large/jm-2015-01434x_0012.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. General Synthesis of <b>34a</b>–<b>k</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01434/20160113/images/large/jm-2015-01434x_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01434&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) PS–PPh<sub>3</sub>, DBAD, <i>trans</i>-cyclohexane-1,4-dimethanol, THF; (b) LiOH, THF, water; (c) 1-hydroxybenzotriazole, DMF, <i>N</i>-methylmorpholine, EDCI, corresponding benzylamine.</p></p></figure><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. SAR of Benzylamide Substituent<a class="ref internalNav" href="#t2fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01434/20160113/images/medium/jm-2015-01434x_0017.gif" alt="" id="GRAPHIC-d7e1105-autogenerated" /></img><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center">X</th><th class="colsep0 rowsep0" align="center">Y</th><th class="colsep0 rowsep0" align="center" char=".">MMP-13/FL <i>K</i><sub>i</sub> (nM)</th><th class="colsep0 rowsep0" align="center" char=".">CYP2C9 inh (%)<a class="ref internalNav" href="#t2fn2" aria-label="b">b</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>34a</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char=".">119</td><td class="colsep0 rowsep0" align="char" char=".">78</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>34b</b></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="char" char=".">32.9</td><td class="colsep0 rowsep0" align="char" char=".">56</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>34c</b></td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char=".">110</td><td class="colsep0 rowsep0" align="char" char="."><a class="ref internalNav" href="#t2fn3" aria-label="c">c</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>34d</b></td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char=".">38.5</td><td class="colsep0 rowsep0" align="char" char="."><a class="ref internalNav" href="#t2fn3" aria-label="c">c</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>34e</b></td><td class="colsep0 rowsep0" align="left">CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char=".">47.2</td><td class="colsep0 rowsep0" align="char" char=".">93</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>34f</b></td><td class="colsep0 rowsep0" align="left">CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char=".">23.8</td><td class="colsep0 rowsep0" align="char" char=".">94</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14g</b></td><td class="colsep0 rowsep0" align="left">OCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">H</td><td class="colsep0 rowsep0" align="char" char=".">2.1</td><td class="colsep0 rowsep0" align="char" char=".">66</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>34g</b></td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="char" char=".">29.3</td><td class="colsep0 rowsep0" align="char" char=".">83</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>34h</b></td><td class="colsep0 rowsep0" align="left">Cl</td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="char" char=".">4.0</td><td class="colsep0 rowsep0" align="char" char=".">90</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>34i</b></td><td class="colsep0 rowsep0" align="left">CH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="char" char=".">3.8</td><td class="colsep0 rowsep0" align="char" char=".">96</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>34j</b></td><td class="colsep0 rowsep0" align="left">CF<sub>3</sub></td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="char" char=".">6.3</td><td class="colsep0 rowsep0" align="char" char=".">90</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>34k</b></td><td class="colsep0 rowsep0" align="left">OCH<sub>3</sub></td><td class="colsep0 rowsep0" align="left">F</td><td class="colsep0 rowsep0" align="char" char=".">1.2</td><td class="colsep0 rowsep0" align="char" char=".">39</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t2fn1"><div class="footnote" id="t2fn1"><sup>a</sup><p class="last">All values are the mean of two or more independent assays.</p></div><div class="footnote" id="t2fn2"><sup>b</sup><p class="last">Inhibition of the metabolism of probe substrate diclofenac (5 μM) at an inhibitor test concentration of 3 μM after 8 min incubation with pooled HLM.</p></div><div class="footnote" id="t2fn3"><sup>c</sup><p class="last">Not determined.</p></div></div></div><div class="NLM_p">The synthesis of pyrimidine tetrazole analogs followed a similar synthetic sequence to that of the pyridine series employing cyanopyrimidine <b>35</b> as a key intermediate, <a class="ref internalNav" href="#sch8" aria-label="Scheme 8">Scheme 8</a>. Dichloropyrimidine <b>35</b> was hydrolyzed under acidic conditions to afford compound <b>36</b>. The resulting desymmetrization allowed for the effective monocarbonylation of compound <b>35</b> through the sequence of palladium mediated carbonylation resulting in compound <b>37</b> followed by chlorination yielding ester <b>38</b>. Tetraethylammonium cyanide was found to efficiently effect displacement of the chloride to provide cyanopyrimidine <b>39</b>. Condensation of compound <b>39</b> with either 3-methoxybenzylamine or 4-fluoro-3-methoxybenzylamine afforded amides <b>40a</b> and <b>40b</b>, respectively, <a class="ref internalNav" href="#sch9" aria-label="Scheme 9">Scheme 9</a>. Tetrazoles <b>41a</b> and <b>41b</b> were provided by heating a water suspension of the nitriles with sodium azide and zinc bromide. In contrast to the pyridine tetrazole series where alkylation was regioselective at the 2-position, alkylation of <b>41a</b>,<b>b</b> by tosylate <b>16</b> derived from <i>trans</i>-2,5-bis(hydroxymethyl)-1,4-dioxane<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> resulted in a mixture of regioisomers (1/1, N2-desired/N1). The pure 2-substituted tetrazoles <b>42</b> or <b>43a</b>,<b>b</b> could be obtained after chromatographic separation. It was subsequently found that the use of metal additives could alter the alkylation regioisomeric ratio to favor the 2-position presumably through chelate formation with the pyrimidine nitrogen. The best selectivity obtained was 5/1 (N2-desired/N1) employing Co(acac)<sub>2</sub> in DMA. The absolute stereochemistry of compounds <b>43a</b>,<b>b</b> (and by inference tosylate <b>16</b>) was established by single crystal X-ray analysis of the bromomethyldioxane <b>44</b> (<a href="/doi/suppl/10.1021/acs.jmedchem.5b01434/suppl_file/jm5b01434_si_001.pdf" class="ext-link">Supporting Information</a>) obtained by halogenation of <b>43a</b> with polymer-supported triphenylphosphine and carbon tetrabromide. Oxidation of <b>43a</b> by pyridinium dichromate afforded the corresponding carboxylic acid <b>45</b>.</div><figure id="sch8" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01434/20160113/images/medium/jm-2015-01434x_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01434/20160113/images/large/jm-2015-01434x_0013.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 8. Synthesis of Cyanopyrimidine <b>39</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01434/20160113/images/large/jm-2015-01434x_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01434&amp;id=sch8"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) 13 M H<sub>2</sub>SO<sub>4</sub>, rt; (b) Pd(dppf)Cl<sub>2</sub>, iPr<sub>2</sub>EtN, MeOH, CO, 85 °C; (c) oxalyl chloride, DMA, CH<sub>2</sub>Cl<sub>2</sub>, reflux; (d) Et<sub>4</sub>N(CN), DABCO, CH<sub>2</sub>Cl<sub>2</sub>.</p></p></figure><figure id="sch9" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01434/20160113/images/medium/jm-2015-01434x_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01434/20160113/images/large/jm-2015-01434x_0014.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 9. Synthesis of <b>42</b>, <b>43</b>, and <b>45</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01434/20160113/images/large/jm-2015-01434x_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01434&amp;id=sch9"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) corresponding benzylamine, iPr<sub>2</sub>EtN, MeOH, 35 °C; (b) NaN<sub>3</sub>, ZnBr<sub>2</sub>, water, reflux; (c) <b>16</b>, Et<sub>3</sub>N, DMA, 85 °C; (d) <b>43a</b>, pyridinium dichromate, DMF, rt.</p></p></figure></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i14">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_87530" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_87530" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The carboxylic acid functionality in compound <b>6</b> had been found to impart favorable properties in previous MMP-13 inhibitor SAR studies including good potency, high metabolic stability, and excellent oral bioavailability. We anticipated several challenges by departing from the carboxylic acid in order to test the transporter-driven toxicology hypothesis. The carboxylic acid provided excellent potency through interactions with Lys-119; therefore an appropriate surrogate would need to be identified or potency enhancement elsewhere in the molecule utilized. Also, carboxylic acid based analog <b>6</b> demonstrated high metabolic stability with low clearance and excellent oral bioavailability in rat (<i>F</i> = 100%, CL = 14 mL min<sup>–1</sup> kg<sup>–1</sup>). Due to the relatively high lipophilicity of the scaffold in the absence of the acid (cLogP = 5.2), metabolic stability concerns were anticipated. Lastly, the potential for low aqueous solubility of a non-carboxylic acid series was another design concern since salt formation by the core scaffold would be more limited.</div><div class="NLM_p">Initial efforts focused on the identification of an appropriate replacement for the cyclohexane carboxylic acid motif found in <b>6</b>, which maintained MMP-13 potency and selectivity, <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>. For the tetrazole substituent, the structural motif of a methylene linker to a six-membered ring was desired to be maintained due to the importance of this substituent to be accommodated in the tunnel region beneath the MMP-13 S<sub>1</sub>′ loop region, <a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>. For this initial survey, we also chose the 3-methoxybenzylamide for the left-hand substituent as this was one of the most potent substitution patterns in the previous carboxylic acid series (<b>14a</b>, MMP-13 <i>K</i><sub>i</sub> = 0.16 nM).<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> As anticipated, truncation of the carboxylic acid to afford the unsubstituted cyclohexyl analog <b>14b</b> resulted in a significant but potentially optimizable loss of potency (<i>K</i><sub>i</sub> = 33.6 nM). We were further pleased to see that oxygen heterocycles including tetrahydropyrans (<b>14c</b>–<b>e</b>) and the dioxane (<b>14f</b>) offered comparable potency to the cyclohexane ring and allowed for a potential strategy to reduce the lipophilicity of this group (vide infra). Substitution of the cyclohexane ring at the 4-position by either hydroxymethyl (<b>14g</b>,<b>h</b>) or hydroxyl (<b>14j</b>) provided a significant improvement in potency consistent with the potential for hydrogen bond interactions with Lys-119 or Asn-194. Transformation of the carboxylic acid to the primary carboxamide <b>18</b> again resulted in significant loss of potency, while the nitrile <b>19</b> allowed for a partial recovery of potency similar to that observed with hydroxymethyl substitution (<b>14g</b>). <i>N</i>-Acyl and sulfonyl derivatives of 4-amino substituted cyclohexane (<b>23a</b>,<b>b</b>, <b>27a</b>,<b>b</b>) also showed good potency with the sulfonamide <i>trans</i>-isomer <b>23a</b> achieving MMP-13 potencies comparable to that achieved with a carboxylic acid (<i>K</i><sub>i</sub> = 0.25 nM). Moving the nitrogen atom into the ring as in acetyl- (<b>31a</b>) and methylsulfonylpiperidines (<b>31b</b>) was not as favorable.</div><div class="NLM_p">The preferred substitution pattern of the benzylamide group was next re-examined using the <i>trans</i>-hydroxymethylcyclohexane analog <b>14g</b> as a base example, <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>. A methoxy group at the 3-position of the phenyl ring was clearly favored in the case of monosubstituted analogs (<b>14g</b>, <b>34a</b>–<b>f</b>). The replacement of hydrogen by fluorine at the 4-position of the phenyl ring (<b>34g</b>–<b>k</b>) consistently improved the potency compared with the monosubstituted analogs with 3-methoxy derivative <b>34k</b> being the most potent. Several benzyl substitution patterns however were found to present elevated risk of CYP2C9 inhibition, <a class="ref internalNav" href="#tbl2" aria-label="Table 2">Table 2</a>. Consequently, from this survey 3-methoxybenzyl and 4-fluoro-3-methoxybenzyl were identified as having the best combination of potency and reduced drug–drug interaction liability.</div><div class="NLM_p">As earlier feared, profiling of select cyclohexyl-based leads for metabolic stability and rat in vivo clearance confirmed that achieving acceptable pharmacokinetics in the non-carboxylic acid series would be a hurdle, <a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>. Compounds <b>14g</b>, <b>23a</b>, and <b>23b</b> each showed moderate to low in vitro intrinsic clearance in human liver microsomes (HLM); however, in vivo clearance after intravenous administration to rats was unacceptably high. In the case of <b>14g</b>, a higher clearance in rat liver microsomes (RLM) than in human was consistent with the in vivo observation, and as a result a closer inspection of compounds in assays for both species was warranted. Although amide and sulfonamide derivatives <b>23a</b>,<b>b</b> avoid the potential direct glucuronide elimination pathway possible with <b>14g</b>, the modest cLogP reduction (ΔcLogP = 0.7–0.9) predicted by modifying the terminal substituent was not sufficient to impact clearance. In order to further reduce the lipophilicity we needed to turn our attention to the cyclohexyl ring.</div><div class="NLM_table-wrap" id="tbl3"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 3. In Vitro and Rat In Vivo Pharmacokinetic Data for Select Pyridine Tetrazoles<a class="ref internalNav" href="#t3fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center" char=".">cLogP<a class="ref internalNav" href="#t3fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" char=".">LogD<a class="ref internalNav" href="#t3fn3" aria-label="c">c</a></th><th class="colsep0 rowsep0" align="center" char=".">HLM<a class="ref internalNav" href="#t3fn4" aria-label="d">d</a> (μL min<sup>–1</sup> mg<sup>–1</sup>)</th><th class="colsep0 rowsep0" align="center" char=".">RLM<a class="ref internalNav" href="#t3fn4" aria-label="d">d</a> (μL min<sup>–1</sup> mg<sup>–1</sup>)</th><th class="colsep0 rowsep0" align="center" char=".">rat CL (mL min<sup>–1</sup> kg<sup>–1</sup>)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14b</b></td><td class="colsep0 rowsep0" align="char" char=".">5.03</td><td class="colsep0 rowsep0" align="char" char=".">4.37</td><td class="colsep0 rowsep0" align="char" char=".">41.7</td><td class="colsep0 rowsep0" align="char" char=".">98.5</td><td class="colsep0 rowsep0" align="char" char=".">63.5<a class="ref internalNav" href="#t3fn5" aria-label="e">e</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14c</b></td><td class="colsep0 rowsep0" align="char" char=".">3.14</td><td class="colsep0 rowsep0" align="char" char=".">3.22</td><td class="colsep0 rowsep0" align="char" char=".">53.1</td><td class="colsep0 rowsep0" align="char" char=".">192</td><td class="colsep0 rowsep0" align="char" char=".">54.5<a class="ref internalNav" href="#t3fn5" aria-label="e">e</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14f</b></td><td class="colsep0 rowsep0" align="char" char=".">1.80</td><td class="colsep0 rowsep0" align="char" char=".">2.49</td><td class="colsep0 rowsep0" align="char" char="."><8.0</td><td class="colsep0 rowsep0" align="char" char=".">74.0</td><td class="colsep0 rowsep0" align="char" char=".">25.8<a class="ref internalNav" href="#t3fn5" aria-label="e">e</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14g</b></td><td class="colsep0 rowsep0" align="char" char=".">3.56</td><td class="colsep0 rowsep0" align="char" char=".">3.57</td><td class="colsep0 rowsep0" align="char" char=".">32.7</td><td class="colsep0 rowsep0" align="char" char=".">94.9</td><td class="colsep0 rowsep0" align="char" char=".">76.6<a class="ref internalNav" href="#t3fn5" aria-label="e">e</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14i</b></td><td class="colsep0 rowsep0" align="char" char=".">1.11</td><td class="colsep0 rowsep0" align="char" char=".">2.04</td><td class="colsep0 rowsep0" align="char" char="."><8.0</td><td class="colsep0 rowsep0" align="char" char=".">15.7</td><td class="colsep0 rowsep0" align="char" char=".">7.7<a class="ref internalNav" href="#t3fn5" aria-label="e">e</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23a</b></td><td class="colsep0 rowsep0" align="char" char=".">2.63</td><td class="colsep0 rowsep0" align="char" char="."><a class="ref internalNav" href="#tbl3-fn1" aria-label="f">f</a></td><td class="colsep0 rowsep0" align="char" char="."><8.0</td><td class="colsep0 rowsep0" align="char" char="."><a class="ref internalNav" href="#tbl3-fn1" aria-label="f">f</a></td><td class="colsep0 rowsep0" align="char" char=".">42.6<a class="ref internalNav" href="#t3fn6" aria-label="g">g</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>23b</b></td><td class="colsep0 rowsep0" align="char" char=".">2.84</td><td class="colsep0 rowsep0" align="char" char="."><a class="ref internalNav" href="#tbl3-fn1" aria-label="f">f</a></td><td class="colsep0 rowsep0" align="char" char=".">24.7</td><td class="colsep0 rowsep0" align="char" char="."><a class="ref internalNav" href="#tbl3-fn1" aria-label="f">f</a></td><td class="colsep0 rowsep0" align="char" char=".">77.6<a class="ref internalNav" href="#t3fn6" aria-label="g">g</a></td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t3fn1"><div class="footnote" id="t3fn1"><sup>a</sup><p class="last">All in vitro values are the mean of two or more independent assays.</p></div><div class="footnote" id="t3fn2"><sup>b</sup><p class="last">Calculated LogP using ACD version 12.</p></div><div class="footnote" id="t3fn3"><sup>c</sup><p class="last">Measured pH 7.4 LogD by shake-flask method.</p></div><div class="footnote" id="t3fn4"><sup>d</sup><p class="last">HLM or RLM in vitro intrinsic CL calculated from metabolic stability data as described in ref <a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">21</a>.</p></div><div class="footnote" id="t3fn5"><sup>e</sup><p class="last">Intravenous bolus administration of 1.0 mg/kg (<i>N</i> = 2).</p></div><div class="footnote" id="tbl3-fn1"><sup>f</sup><p class="last">Not determined.</p></div><div class="footnote" id="t3fn6"><sup>g</sup><p class="last">Intravenous bolus administration of 0.2 mg/kg in cassette PK format (5 compounds, <i>N</i> = 2).</p></div></div></div><div class="NLM_p">Metabolic liability of cyclohexane-containing compounds is commonly encountered due to the high relative lipophilicity/atom count of the cyclohexane ring and the susceptibility of all six carbon atoms to oxidative metabolism; therefore, a common strategy has been to replace the cyclohexyl ring with oxygen containing isosters.<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> Guided by the predicted cLogP, the replacement of either one or two cyclohexane carbon atoms with oxygen afforded compounds with lower measured lipophilicity as in the case of tetrahydropyran <b>14c</b> (ΔLogD = −1.15) and dioxane <b>14f</b> (ΔLogD = −1.88). Although compound <b>14c</b> still showed high clearance, results for dioxane <b>14f</b> were promising, <a class="ref internalNav" href="#tbl3" aria-label="Table 3">Table 3</a>. Compound <b>14f</b> had low clearance in human liver microsomes and even though rat liver microsomal clearance remained high, it showed the lowest rat in vivo clearance to date in the series. Saturated heterocycles are common elements in medicinal chemistry with nitrogen heterocycles being ubiquitous and oxygen heterocycles such as oxetanes and tetrahydropyrans finding growing utility.<a onclick="showRef(event, 'ref23 ref24'); return false;" href="javascript:void(0);" class="ref ref23 ref24">(23, 24)</a> The dioxane ring however has not been widely utilized in drug design.<a onclick="showRef(event, 'ref25 ref26 ref27'); return false;" href="javascript:void(0);" class="ref ref25 ref26 ref27">(25-27)</a> Nonetheless, encouraged by the trend, we next combined the dioxane ring with a hydroxymethyl substituent (<b>14i</b>) to further reduce the lipophilicity (LogD = 2.04) and block the potentially metabolically labile carbon on the dioxane ring. Compound <b>14i</b> maintained good MMP-13 potency (<i>K</i><sub>i</sub> = 11.7 nM) and now achieved low clearance in human and rat liver microsomes. Likewise, <b>14i</b> demonstrated low rat in vivo clearance (7.7 mL min<sup>–1</sup> kg<sup>–1</sup>) after intravenous injection and good oral bioavailability (<i>F</i> = 48%). Even though the primary metabolic pathway in rat hepatocytes was found to be similar for <b>14g</b> and <b>14i</b>, <i>O</i>-glucuronidation and hydroxymethyl oxidation, the proximity of the dioxane ring to the hydroxymethyl moiety has a remarkable suppressive effect on the overall metabolism.</div><div class="NLM_p">To further reduce the lipophilicity, we also considered the transformation of the pyridine core to a pyrimidine (predicted ΔcLogP = −0.58). Compound <b>42</b> was prepared to enable direct comparison with pyridine analog <b>14i</b>, <a class="ref internalNav" href="#tbl4" aria-label="Table 4">Table 4</a>. Indeed as predicted, pyrimidine <b>42</b> demonstrated a lower measured lipophilicity compared with the pyridine (ΔLogD = −0.74). The pyrimidine analog also maintained good MMP-13 potency (<i>K</i><sub>i</sub> = 5.8 nM) and high selectivity against MMP-3. While clearance in human liver microsomes remained low for <b>42</b>, other pharmaceutical properties were improved compared with the pyridine analog. Compared with pyridine <b>14i</b>, aqueous solubility of pyrimidine <b>42</b> was improved by more than 8-fold (237 vs 28 μM) and human plasma protein binding was also reduced (69% vs 86%). Rat pharmacokinetics for <b>42</b> was comparable to the pyridine analog with low clearance (10.6 mL min<sup>–1</sup> kg<sup>–1</sup>) and good oral bioavailability (65%), <a class="ref internalNav" href="#tbl5" aria-label="Table 5">Table 5</a>. To further explore potential differentiation, both compounds were dosed orally to dogs in a cassette experiment such that each animal received a dose equivalent to 1.0 mg/kg of <b>14i</b> and <b>42</b> in a single experiment. Pyrimidine <b>42</b> demonstrated a significantly better oral absorption profile compared with the pyridine analog showing a more than 8-fold increase in free <i>C</i><sub>max</sub> exposure and a 2.6-fold increase in free AUC possibly driven by the improved aqueous solubility. Therefore, for the minimal increase in molecular weight by one mass unit, the transformation of pyridine to pyrimidine resulted in a significant improvement in lipophilic ligand efficiency (ΔLIPE = 1.05, LIPE = 6.94) and pharmaceutical properties such as solubility and oral absorption while maintaining MMP-13 potency, selectivity, and metabolic stability.</div><div class="NLM_table-wrap" id="tbl4"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 4. In Vitro ADME Property Comparison of Pyridine <b>14i</b> and Pyrimidine <b>42</b><a class="ref internalNav" href="#t4fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center" char=".">LogD<a class="ref internalNav" href="#t4fn2" aria-label="b">b</a></th><th class="colsep0 rowsep0" align="center" char=".">MMP-13/FL <i>K</i><sub>i</sub> (nM)</th><th class="colsep0 rowsep0" align="center" char=".">MMP-3/CD <i>K</i><sub>i</sub> (nM)</th><th class="colsep0 rowsep0" align="center" char=".">HLM<a class="ref internalNav" href="#t4fn3" aria-label="c">c</a> (μL min<sup>–1</sup> mg<sup>–1</sup>)</th><th class="colsep0 rowsep0" align="center" char=".">sol<a class="ref internalNav" href="#t4fn4" aria-label="d">d</a> (μM)</th><th class="colsep0 rowsep0" align="center" char=".">hPPB (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14i</b></td><td class="colsep0 rowsep0" align="char" char=".">2.04</td><td class="colsep0 rowsep0" align="char" char=".">11.7</td><td class="colsep0 rowsep0" align="char" char=".">>10000</td><td class="colsep0 rowsep0" align="char" char="."><8.0</td><td class="colsep0 rowsep0" align="char" char=".">28</td><td class="colsep0 rowsep0" align="char" char=".">86</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>42</b></td><td class="colsep0 rowsep0" align="char" char=".">1.30</td><td class="colsep0 rowsep0" align="char" char=".">5.8</td><td class="colsep0 rowsep0" align="char" char=".">>10000</td><td class="colsep0 rowsep0" align="char" char="."><8.0</td><td class="colsep0 rowsep0" align="char" char=".">237</td><td class="colsep0 rowsep0" align="char" char=".">69</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t4fn1"><div class="footnote" id="t4fn1"><sup>a</sup><p class="last">All values are the mean of two or more independent assays.</p></div><div class="footnote" id="t4fn2"><sup>b</sup><p class="last">Measured pH 7.4 LogD by shake-flask method.</p></div><div class="footnote" id="t4fn3"><sup>c</sup><p class="last">HLM in vitro intrinsic CL calculated from metabolic stability data as described in ref <a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">21</a>.</p></div><div class="footnote" id="t4fn4"><sup>d</sup><p class="last">Thermodynamic solubility of crystalline solid in pH 7.4 phosphate buffer.</p></div></div></div><div class="NLM_table-wrap" id="tbl5"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 5. Pharmacokinetics of Pyridine <b>14i</b> and Pyrimidine <b>42</b></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center"> </th><th class="rowsep1 colsep0" colspan="2" align="center" char=".">rat<a class="ref internalNav" href="#t5fn1" aria-label="a">a</a></th><th class="rowsep1 colsep0" colspan="3" align="center" char=".">dog<a class="ref internalNav" href="#t5fn2" aria-label="b">b</a></th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center" char=".">CL (mL min<sup>–1</sup> kg<sup>–1</sup>)</th><th class="colsep0 rowsep0" align="center" char="."><i>F</i> (%)</th><th class="colsep0 rowsep0" align="center" char=".">PPB (%)</th><th class="colsep0 rowsep0" align="center" char=".">Cmax<sub>free</sub> (nM)</th><th class="colsep0 rowsep0" align="center" char=".">AUC<sub>free</sub> (nM·h)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14i</b></td><td class="colsep0 rowsep0" align="char" char=".">7.7</td><td class="colsep0 rowsep0" align="char" char=".">48</td><td class="colsep0 rowsep0" align="char" char=".">76</td><td class="colsep0 rowsep0" align="char" char=".">66</td><td class="colsep0 rowsep0" align="char" char=".">1230</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>42</b></td><td class="colsep0 rowsep0" align="char" char=".">10.6</td><td class="colsep0 rowsep0" align="char" char=".">65</td><td class="colsep0 rowsep0" align="char" char=".">63</td><td class="colsep0 rowsep0" align="char" char=".">580</td><td class="colsep0 rowsep0" align="char" char=".">3240</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t5fn1"><div class="footnote" id="t5fn1"><sup>a</sup><p class="last">Rat: Crossover design, intravenous bolus administration (1.0 mg/kg, <i>N</i> = 2), oral suspension administration (1.0 mg/kg, <i>N</i> = 2). Complete rat pharmacokinetic parameters are available in Table S2 (<a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>).</p></div><div class="footnote" id="t5fn2"><sup>b</sup><p class="last">Dog: Oral suspension administration to male beagle dogs in cassette dosing format (5 compounds, 1.0 mg/kg each, <i>N</i> = 3).</p></div></div></div><div class="NLM_p">Utilizing learnings from the benzylamide substituent survey, the corresponding 4-fluoro-3-methoxybenzyl analog in the pyrimidine series was next targeted with the intent to further improve MMP-13 potency while maintaining the favorable pharmacokinetic properties. Both enantiomers <b>(2</b><i><b>S</b></i><b>,5</b><i><b>R</b></i><b>)-43a</b> and <b>(2</b><i><b>R</b></i><b>,5</b><i><b>S</b></i><b>)-43b</b> demonstrated excellent MMP-13 potency with <b>43a</b> being the more potent of the two (MMP-13 <i>K</i><sub>i</sub> = 1.5 nM), <a class="ref internalNav" href="#tbl6" aria-label="Table 6">Table 6</a>. High selectivity was maintained against MMP-3, and <b>43a</b> was further found to be highly selective against a panel of 14 matrix metalloproteinases, TACE, ADAMTS-4, and ADAMTS-5, <a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>. Both enantiomers also showed favorable in vitro and rat in vivo pharmacokinetic profiles demonstrating low clearance and very high oral bioavailability, <a class="ref internalNav" href="#tbl6" aria-label="Table 6">Table 6</a>. The pharmacokinetics of enantiomer <b>43a</b> in dog and cynomolgus monkey was also favorable with low clearance (8.2 and 2.1 mL min<sup>–1</sup> kg<sup>–1</sup>, respectively) and high oral bioavailability (64% and 88%, respectively). In in vitro metabolic drug–drug interaction assays, the IC<sub>50</sub> of compound <b>43a</b> was >30 μM for the inhibition of CYPs 1A2, 2C9, 2D6, and 3A4.</div><figure id="fig3" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01434/20160113/images/medium/jm-2015-01434x_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01434/20160113/images/large/jm-2015-01434x_0004.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Metalloproteinase selectivity (pIC<sub>50</sub>) of <b>43a</b> compared with broad-spectrum agent marimastat (highest concentration tested 10 μM, pIC<sub>50</sub> = 5).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01434/20160113/images/large/jm-2015-01434x_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01434&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl6"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 6. Comparison of In Vitro and Pharmacokinetic Properties of <b>43a</b> and <b>43b</b><a class="ref internalNav" href="#t6fn1" aria-label="a">a</a></div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col><col align="char" char="." /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compound</th><th class="colsep0 rowsep0" align="center" char=".">MMP-13/FL <i>K</i><sub>i</sub> (nM)</th><th class="colsep0 rowsep0" align="center" char=".">MMP-3/CD <i>K</i><sub>i</sub> (nM)</th><th class="colsep0 rowsep0" align="center" char=".">HLM<a class="ref internalNav" href="#t6fn2" aria-label="b">b</a> (μL min<sup>–1</sup> mg<sup>–1</sup>)</th><th class="colsep0 rowsep0" align="center" char=".">rat CL<a class="ref internalNav" href="#t6fn3" aria-label="c">c</a> (mL min<sup>–1</sup> kg<sup>–1</sup>)</th><th class="colsep0 rowsep0" align="center" char=".">rat<a class="ref internalNav" href="#t6fn3" aria-label="c">c</a><i>F</i> (%)</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>43a</b></td><td class="colsep0 rowsep0" align="char" char=".">1.5</td><td class="colsep0 rowsep0" align="char" char=".">>10000</td><td class="colsep0 rowsep0" align="char" char="."><8.0</td><td class="colsep0 rowsep0" align="char" char=".">18.2</td><td class="colsep0 rowsep0" align="char" char=".">95</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>43b</b></td><td class="colsep0 rowsep0" align="char" char=".">4.2</td><td class="colsep0 rowsep0" align="char" char=".">>10000</td><td class="colsep0 rowsep0" align="char" char="."><8.0</td><td class="colsep0 rowsep0" align="char" char=".">9.8</td><td class="colsep0 rowsep0" align="char" char=".">113</td></tr></tbody></table></div><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t6fn1"><div class="footnote" id="t6fn1"><sup>a</sup><p class="last">All in vitro values are the mean of two or more independent assays.</p></div><div class="footnote" id="t6fn2"><sup>b</sup><p class="last">HLM in vitro intrinsic CL calculated from metabolic stability data as described in ref <a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">21</a>.</p></div><div class="footnote" id="t6fn3"><sup>c</sup><p class="last">Rat: Crossover design, intravenous bolus administration (1.0 mg/kg, <i>N</i> = 2), oral suspension administration (1.0 mg/kg, <i>N</i> = 2). Complete rat pharmacokinetic parameters are available in Table S2 (<a class="ref internalNav" href="#notes-1" aria-label="Supporting Information">Supporting Information</a>).</p></div></div></div><div class="NLM_p">Treatment of human articular cartilage ex-vivo cultures with cytokines results in the degradation of type II collagen and the production of a 45-amino acid fragment known as type II collagen neoepitope (TIINE). Compound <b>43a</b> (PF152) inhibited cytokine-induced TIINE production in a dose dependent manner.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> The in vivo effect of compound <b>43a</b> on joint lesion progression was evaluated in the canine partial medial meniscectomy model of OA.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> As a result of joint destabilization induced by the model, TIINE levels are increased and joint deterioration occurs. Administration of <b>43a</b> returned elevated TIINE levels to prestudy baseline suggesting suppression of MMP-13 mediated cartilage degradation in vivo. A corresponding reduction in the severity of the resulting OA-like joint lesions based on histological evaluation was also observed.</div><div class="NLM_p">The hydroxymethyl substituent plays a necessary role in pharmacologic potency and in suppressing overall metabolism. However, in the latter it also poses a risk if oxidative metabolism results in the carboxylic acid metabolite, a species we were intending to avoid. In both rat and cynomolgus monkey PK studies, the carboxylic acid metabolite of <b>43a</b> (<b>45</b>) was present at very low levels, and the metabolite concentrations and half-life appeared to be dependent on the parent, <a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>. As anticipated, carboxylic acid <b>45</b> has a lower in vitro <i>K</i><sub>i</sub> against human MMP-13 (0.2 nM) than <b>43a</b> (1.5 nM) and is thus presumed to be pharmacologically active. In cynomolgus monkey PK studies, the AUC ratio of parent/metabolite after oral dosing was 1460 at 1 mg/kg and 107 at 100 mg/kg. In in vitro incubations of <b>43a</b> in pooled human hepatocytes, at least six primary metabolites were identified. In addition to <b>45</b>, the metabolites resulted from demethylation, methyl oxidation, and both a glucuronide and a sulfate conjugate were observed. These metabolites were also identified in cynomolgus monkey hepatocyte incubations and in in vivo cynomolgus monkey urine samples. Since hydroxymethyl oxidation was not the only observed metabolic pathway in human and cynomolgus monkey and exposures of <b>45</b> were predicted to be very low, we had sufficient confidence to proceed to an exploratory toxicology study to assess nephrotoxicity risk.</div><figure id="fig4" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01434/20160113/images/medium/jm-2015-01434x_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01434/20160113/images/large/jm-2015-01434x_0005.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Mean plasma concentration–time profiles of <b>43a</b> and carboxylic acid metabolite <b>45</b> after oral administration of <b>43a</b> (1.0 mg/kg) to female cynomolgus monkeys (<i>N</i> = 3).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01434/20160113/images/large/jm-2015-01434x_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01434&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Compound <b>43a</b> was dosed orally (50, 100, and 1000 mg kg<sup>–1</sup> day<sup>–1</sup>) to cynomolgus monkeys for 14 days targeting free exposures that significantly exceeded efficacious levels observed in the canine OA model and the level where nephrotoxicity was observed with the previous carboxylic acid based MMP-13 inhibitor <b>6</b>. The compound was well tolerated and histological evaluation of the kidneys did not reveal abnormal pathology. Free exposures of <b>43a</b> achieved in the study were 22 times the projected efficacious AUC and 8.5 times an AUC exposure where nephrotoxicity was observed with compound <b>6</b>.</div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i19">Conclusion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_02408" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_02408" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p last">We have shown that the carboxylic acid functional group found in previously disclosed highly selective MMP-13 inhibitors is not required to achieve excellent target potency, selectivity, and in vivo efficacy. The strategy to optimize nonacidic analogs of compound <b>6</b> has successfully identified inhibitor <b>43a</b> lacking the preclinical renal toxicity observed with previous lead molecules. Critical to achieving this milestone was the discovery that replacing the cyclohexane ring in initial leads with a dioxane ring could have a profound impact on metabolic susceptibility and overall pharmacokinetic properties. The use of a substituted dioxane ring to reduce lipophilicity and thus improve metabolic stability is an important tool medicinal chemists should consider when challenged by poor pharmacokinetics.</div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i20">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_51066" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_51066" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i21" class="anchor-spacer"></div><h3 class="article-section__title" id="_i21"> General Methods</h3><div class="NLM_p last">All reagents and solvents were used as purchased without further purification. The purity of the final compounds was characterized by high-performance liquid chromatography (HPLC) using a gradient elution (C18 column, acetonitrile/water, 5/95–75/5, 5 min, 0.1% trifluoroacetic acid) and UV-detection (254 nM). The purity of all final compounds was 95% or greater. Proton (<sup>1</sup>H) NMR chemical shifts are referenced to a residual solvent peak.</div></div><div id="sec5_1_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i22" class="anchor-spacer"></div><h3 class="article-section__title" id="_i22"> <i>N</i>-<i>tert</i>-Butyl-2-chloro-6-methylisonicotinamide (<b>9</b>)</h3><div class="NLM_p last">Oxalyl chloride (95 mL, 1.10 mol) was added to a solution of <b>8</b> (95 g, 0.55 mol) in dichloromethane (950 mL, anhydrous). The mixture was cooled in an ice/water bath, and DMF (2.0 mL) was slowly added. When gas evolution subsided, the ice/water bath was removed, and the mixture was allowed to reach rt and stir for 15 h. The solution was then concentrated in vacuo and azeotropically distilled twice from toluene (200 mL) at reduced pressure. The residue was taken into dichloromethane (800 mL, anhydrous) and cooled in an ice/water bath, and a solution of <i>tert</i>-butylamine (175 mL, 1.7 mol) in dichloromethane (300 mL, anhydrous) was added dropwise. The mixture was allowed to reach rt and stir for 15 h. The reaction mixture was diluted with water (250 mL). The organic layer was washed with water (200 mL) followed by brine (200 mL), dried (MgSO<sub>4</sub>), filtered, and concentrated to afford 120 g (96%) of <b>9</b> as a beige solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.39 (s, 1 H), 7.38 (s, 1 H), 6.05 (s, 1 H), 2.59 (s, 3 H), 1.5 (s, 9 H).</div></div><div id="sec5_1_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> 2-Chloro-6-methylisonicotinonitrile (<b>10</b>)</h3><div class="NLM_p last">POCl<sub>3</sub> (572 mL, 6.26 mol) was added to <b>9</b> (120 g, 0.53 mol) in toluene (2.5 L, anhydrous). The resulting mixture was refluxed 15 h, cooled to ambient temperature, and concentrated in vacuo. The residue was dissolved in dichloromethane (1.0 L) and aqueous saturated sodium bicarbonate (500 mL) was carefully added. Solid sodium bicarbonate was then added portionwise until the aqueous layer was basic. The organic layer was washed with brine (300 mL), dried (MgSO<sub>4</sub>), filtered, and concentrated to afford 76 g (94%) of <b>10</b> as a pale tan solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.41 (s, 1 H), 7.37 (s, 1 H), 2.61 (s, 3 H).</div></div><div id="sec5_1_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i24" class="anchor-spacer"></div><h3 class="article-section__title" id="_i24"> 2-Chloro-6-methyl-4-(2<i>H</i>-tetrazol-5-yl)pyridine hydrochloride (<b>11</b>)</h3><div class="NLM_p last">Triethylamine hydrochloride (72 g, 0.52 mol) and sodium azide (34 g, 0.52 mol) were added to a solution of <b>10</b> (76 g, 0.50 mol) in toluene (1.2 L, anhydrous). The mixture was refluxed for 4 h behind a blast shield. <i><b>CAUTION!</b> Tetrazoles represent an explosion hazard at elevated temperatures. Adequate blast shielding is recommended.</i> After cooling to rt, water (1.5 L) was added, and the layers were separated. The toluene layer was washed with water (500 mL), and the combined aqueous layers were acidified with 6 N HCl (100 mL). The resulting precipitate was filtered and dried in vacuo (60 °C) to afford 105 g (91%) of <b>11</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.92 (s, 1 H), 7.89 (s, 1 H), 2.79 (s, 3 H).</div></div><div id="sec5_1_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i25" class="anchor-spacer"></div><h3 class="article-section__title" id="_i25"> Methyl 6-Methyl-4-(2<i>H</i>-tetrazol-5-yl)picolinate (<b>12</b>)</h3><div class="NLM_p last">Triethylamine (120 mL, 1.63 mol), 1,1′-bis(diphenylphosphino)ferrocene (8.0 g, 14 mmol), and Pd(OAc)<sub>2</sub> (9.2 g, 40 mmol) were added to a solution of <b>11</b> (88 g, 380 mmol) in methanol (1.5 L, anhydrous) in a pressure reactor. The reactor was evacuated, purged with carbon monoxide gas twice, and finally pressurized to 120 PSI and heated to 100 °C for 24 h (190 PSI final pressure). <i><b>CAUTION!</b> Tetrazoles represent an explosion hazard at elevated temperatures. Adequate blast shielding is recommended.</i> After cooling to rt, the mixture was filtered through Celite and concentrated in vacuo. Water (700 mL) and aqueous saturated sodium bicarbonate (200 mL) were added to dissolve all solids. HCl (3 N) was added until a pH of 2 was reached. The resulting solid was filtered and dried in vacuo (50 °C) to afford 78 g (94%) of <b>12</b> as a solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.48 (s, 1 H), 8.15 (s, 1 H), 3.95 (s, 3 H), 2.67 (s, 3 H).</div></div><div id="sec5_1_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i26" class="anchor-spacer"></div><h3 class="article-section__title" id="_i26"> <i>N</i>-(3-Methoxybenzyl)-6-methyl-4-(2<i>H</i>-tetrazol-5-yl)picolinamide (<b>13</b>)</h3><div class="NLM_p last">A mixture of <b>12</b> (3.29 g, 15.0 mmol) and 3-methoxybenzylamine (6.17 g, 45.0 mmol) was heated at 100 °C with removal of methanol in a stream of nitrogen for 1 h. A solution of 1 N HCl (50 mL) was added. The resulting precipitate was filtered and washed with ethyl ether. The solid was suspended in a solution of 2.5 N sodium hydroxide (30 mL)/water (50 mL) and extracted with EtOAc (2 × 50 mL). The aqueous layer was cooled in an ice bath and acidified to pH 1 with concentrated HCl. The resulting precipitate was filtered and dried to afford 4.69 g (96%) of <b>13</b> as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.28 (t, <i>J</i> = 6.3 Hz, 1 H), 8.49 (d, <i>J</i> = 0.8 Hz, 1 H), 8.13 (d, <i>J</i> = 1.2 Hz, 1 H), 7.24 (t, <i>J</i> = 8.1 Hz, 1 H), 6.94–6.90 (m, 2 H), 6.82 (dd, <i>J</i> = 8.0, 2.1 Hz, 1 H), 4.51 (d, <i>J</i> = 6.3 Hz, 2 H), 3.73 (s, 3 H), 2.68 (s, 3 H). MS (ES+) <i>m</i>/<i>z</i> 325 (M + H).</div></div><div id="sec5_1_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i27" class="anchor-spacer"></div><h3 class="article-section__title" id="_i27"> 4-(2-(Cyclohexylmethyl)-2<i>H</i>-tetrazol-5-yl)-<i>N</i>-(3-methoxybenzyl)-6-methylpicolinamide (<b>14b</b>)</h3><div class="NLM_p last">Polymer supported triphenylphosphine (698 mg, 1.5 mmol, 1.5 equiv), <b>13</b> (324 mg, 1.0 mmol), and cyclohexylmethanol (137 mg, 1.2 mmol, 1.2 equiv) were suspended in THF (16 mL). DBAD (345 mg, 1.5 mmol, 1.5 equiv) was added. The mixture was allowed to stir for 18 h. The reaction mixture was filtered, and the resin was washed with THF (20 mL). The filtrate was concentrated. The crude product was purified by column chromatography (heptane/EtOAc, 6/1; 4/1) to afford 248 mg (49%) of <b>14b</b> an oil. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.29 (t, <i>J</i> = 6.4 Hz, 1 H), 8.43 (s, 1 H), 8.09 (s, 1 H), 7.25 (t, <i>J</i> = 8.0 Hz, 1 H), 6.96–6.89 (m, 2 H), 6.82 (dd, <i>J</i> = 8.2, 2.4 Hz, 1 H), 4.67 (d, <i>J</i> = 7.0 Hz, 2 H), 4.51 (d, <i>J</i> = 6.3 Hz, 2 H), 3.74 (s, 3 H), 2.68 (s, 3 H), 2.08–1.99 (m, 1 H), 1.74–1.54 (m, 5 H), 1.29–1.00 (m, 4 H). MS (ES+) <i>m</i>/<i>z</i> 421 (M + H).</div></div><div id="sec5_1_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i28" class="anchor-spacer"></div><h3 class="article-section__title" id="_i28"> (−)-<i>N</i>-(3-Methoxybenzyl)-6-methyl-4-(2-((tetrahydro-2<i>H</i>-pyran-2-yl)methyl)-2<i>H</i>-tetrazol-5-yl)picolinamide (<b>14c</b>)</h3><div class="NLM_p last">Following conditions analogous to those described for <b>14b</b>, reaction of tetrahydropyran-2-methanol (0.348 mL, 3.08 mmol) afforded the racemic product, which was resolved by SFC (Chiralcel OD-H, 30 mm × 250 mm, 25/75 ethanol/CO<sub>2</sub>, 70 mL/min). Isolation of the first eluting isomer afforded 250 mg (39%) of <b>14c</b> as an oil. Chiralcel OD-H analytical column (4.6 mm × 250 mm; 20/80, ethanol/CO<sub>2</sub>), 8.06 min, > 99% ee; [α]<sub class="stack">D</sub><sup class="stack">21<sup>°</sup>C</sup> = −22.7° (<i>c</i> = 8.3, DMF). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.23 (m, 1 H), 8.40 (s, 1 H), 8.05 (s, 1 H), 7.23–7.19 (m, 1 H), 6.89–6.87 (m, 2 H), 6.80–6.77 (m, 1 H), 4.79–4.74 (m, 2 H), 4.48 (d, <i>J</i> = 6.0 Hz, 2 H), 3.93–3.75 (m, 3 H), 3.70 (s, 3 H), 2.65 (s, 3 H), 1.80–1.25 (m, 6 H). MS (ES+) <i>m</i>/<i>z</i> 423 (M + H).</div></div><div id="sec5_1_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i29" class="anchor-spacer"></div><h3 class="article-section__title" id="_i29"> (+)-<i>N</i>-(3-Methoxybenzyl)-6-methyl-4-(2-((tetrahydro-2<i>H</i>-pyran-2-yl)methyl)-2<i>H</i>-tetrazol-5-yl)picolinamide (<b>14d</b>)</h3><div class="NLM_p last">Isolation of the second eluting isomer from above afforded 260 mg (41%) of <b>14d</b> as an oil. Chiralcel OD-H analytical column (4.6 mm × 250 mm; 20/80, ethanol/CO<sub>2</sub>), 9.99 min, > 99% ee; [α]<sub class="stack">D</sub><sup class="stack">21<sup>°</sup>C</sup> = 19.0° (<i>c</i> = 9.8, DMF). <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.23 (m, 1 H), 8.40 (s, 1 H), 8.05 (s, 1 H), 7.23–7.19 (m, 1 H), 6.89–6.87 (m, 2 H), 6.80–6.77 (m, 1 H), 4.79–4.74 (m, 2 H), 4.48 (d, <i>J</i> = 6.0 Hz, 2 H), 3.93–3.75 (m, 3 H), 3.70 (s, 3 H), 2.65 (s, 3 H), 1.80–1.25 (m, 6 H). MS (ES+) <i>m</i>/<i>z</i> 423 (M + H).</div></div><div id="sec5_1_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i30" class="anchor-spacer"></div><h3 class="article-section__title" id="_i30"> <i>rac</i>-<i>N</i>-(3-Methoxybenzyl)-6-methyl-4-(2-((tetrahydro-2<i>H</i>-pyran-3-yl)methyl)-2<i>H</i>-tetrazol-5-yl)picolinamide (<b>14e</b>)</h3><div class="NLM_p last">A mixture of <b>13</b> (79 mg, 0.23 mmol), <b>15</b> (77 mg, 0.25 mmol), and triethylamine (0.40 mL) in DMA (0.1 mL) was stirred at 85 °C for 15 h. The reaction mixture was purified by reverse phase preparative HPLC to afford 62 mg (61%) of <b>14e</b> as a solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.20 (br. s., 1 H), 8.08 (s, 1 H), 7.24 (t, <i>J</i> = 8.1 Hz, 1 H), 6.93 (br. s., 2 H), 6.82 (d, <i>J</i> = 7.7 Hz, 1 H), 4.75 (dq, <i>J</i> = 13.0, 6.8 Hz, 2 H), 4.51 (d, <i>J</i> = 6.2 Hz, 2 H), 3.73 (s, 5 H), 3.68 (br. s., 1 H), 3.41 (br. s., 1 H), 3.37 (d, <i>J</i> = 2.2 Hz, 1 H), 2.68 (s, 3 H), 2.28 (br. s., 1 H), 1.74 (br. s., 1 H), 1.62 (br. s., 1 H), 1.50 (d, <i>J</i> = 8.8 Hz, 1 H), 1.35 (d, <i>J</i> = 9.5 Hz, 1 H). MS (ES+) <i>m</i>/<i>z</i> 423 (M + H).</div></div><div id="sec5_1_10" class="NLM_sec NLM_sec_level_2"><div id="ac_i31" class="anchor-spacer"></div><h3 class="article-section__title" id="_i31"> <i>rac</i>-4-(2-((1,4-Dioxan-2-yl)methyl)-2<i>H</i>-tetrazol-5-yl)-<i>N</i>-(3-methoxybenzyl)-6-methylpicolinamide (<b>14f</b>)</h3><div class="NLM_p last">Following conditions analogous to those described for <b>14b</b>, reaction of <i>rac</i>-(1,4-dioxan-2-yl)methanol (142 mg, 1.2 mmol) afforded 250 mg (59%) of <b>14f</b> as an oil. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.29 (t, <i>J</i> = 6.5 Hz, 1 H), 8.44 (s, 1 H), 8.10 (s, 1 H), 7.25 (t, <i>J</i> = 8.1 Hz, 1 H), 6.95–6.90 (m, 2 H), 6.82 (dd, <i>J</i> = 8.2, 2.6 Hz, 1 H), 4.96–4.85 (m, 2 H), 4.51 (d, <i>J</i> = 6.3 Hz, 2 H), 4.19–4.11 (m, 1 H), 3.92 (dd, <i>J</i> = 11.4, 2.4 Hz, 1 H), 3.74 (s, 5 H), 3.58–3.40 (m, 3 H), 2.69 (s, 3 H). MS (ES+) <i>m</i>/<i>z</i> 425 (M + H).</div></div><div id="sec5_1_11" class="NLM_sec NLM_sec_level_2"><div id="ac_i32" class="anchor-spacer"></div><h3 class="article-section__title" id="_i32"> <i>N</i>-(3-Methoxybenzyl)-4-(2-(((<i>trans</i>)-4-(hydroxymethyl)cyclohexyl)methyl)-2<i>H</i>-tetrazol-5-yl)-6-methylpicolinamide (<b>14g</b>)</h3><div class="NLM_p last">Following conditions analogous to those described for <b>14b</b>, reaction of <i>trans</i>-cyclohexane-1,4-dimethanol (178 mg, 1.23 mmol) afforded 102 mg (37%) of <b>14g</b> as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.23 (m, 1 H), 8.39 (s, 1 H), 8.05 (s, 1 H), 7.12–7.28 (m, 1 H), 6.94–6.84 (m, 2 H), 6.82–6.72 (m, 1 H), 4.63 (d, <i>J</i> = 7.0 Hz, 2 H), 4.47 (d, <i>J</i> = 6.4 Hz, 2 H), 3.70 (s, 3 H), 3.21–3.08 (m, 2 H), 2.64 (s, 3 H), 2.04–1.81 (m, 1 H), 1.78–1.50 (m, 4 H), 1.43–1.16 (m, 2 H), 1.15–0.71 (m, 4 H). MS (ES+) <i>m</i>/<i>z</i> 451 (M + H).</div></div><div id="sec5_1_12" class="NLM_sec NLM_sec_level_2"><div id="ac_i33" class="anchor-spacer"></div><h3 class="article-section__title" id="_i33"> <i>N</i>-(3-Methoxybenzyl)-4-(2-(((<i>cis</i>)-4-(hydroxymethyl)cyclohexyl)methyl)-2<i>H</i>-tetrazol-5-yl)-6-methylpicolinamide (<b>14h</b>)</h3><div class="NLM_p last">Following conditions analogous to those described for <b>14b</b>, reaction of <i>cis</i>-cyclohexane-1,4-dimethanol (89 mg, 0.62 mmol) afforded 62 mg (45%) of <b>14h</b> as an oil. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.26 (t, <i>J</i> = 6.4 Hz, 1 H), 8.42 (d, <i>J</i> = 0.9 Hz, 1 H), 8.08 (d, <i>J</i> = 1.1 Hz, 1 H), 7.24 (t, <i>J</i> = 8.1 Hz, 1 H), 6.93–6.90 (m, 2 H), 6.82 (ddd, <i>J</i> = 8.2, 2.5, 0.9 Hz, 1 H), 4.76 (d, <i>J</i> = 7.7 Hz, 2 H), 4.51 (d, <i>J</i> = 6.4 Hz, 2 H), 4.37 (t, <i>J</i> = 5.4 Hz, 1 H), 3.73 (s, 3 H), 3.33 (dd, <i>J</i> = 6.4, 5.5 Hz, 2 H), 2.68 (s, 3 H), 2.31–2.21 (m, 1 H), 1.65–1.27 (m, 9 H). MS (ES+) <i>m</i>/<i>z</i> 351 (M + H).</div></div><div id="sec5_1_13" class="NLM_sec NLM_sec_level_2"><div id="ac_i34" class="anchor-spacer"></div><h3 class="article-section__title" id="_i34"> <i>rac-N</i>-(3-Methoxybenzyl)-4-(2-(((2<i>S</i>*,5<i>R</i>*)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2<i>H</i>-tetrazol-5-yl)-6-methylpicolinamide (<b>14i</b>)</h3><div class="NLM_p last">Tosylate <b>16</b> (1.4 g, 4.3 mmol) was added to a mixture of <b>13</b> (1.0 g, 3.1 mmol) and triethylamine (0.4 g, 4.0 mmol) in anhydrous DMA (1 mL). The mixture was stirred at 85 °C overnight and then was purified by reverse phase preparative HPLC to afford 1.04 g (70%) of <b>14i</b> as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.20 (t, <i>J</i> = 6.2 Hz, 1 H), 8.43 (s, 1 H), 8.08 (s, 1 H), 7.24 (t, <i>J</i> = 8.1 Hz, 1 H), 6.93 (br. s., 2 H), 6.83 (d, <i>J</i> = 1.5 Hz, 1 H), 4.80–4.95 (m, 2 H), 4.65 (t, <i>J</i> = 5.7 Hz, 1 H), 4.52 (d, <i>J</i> = 6.2 Hz, 2 H), 4.05–4.15 (m, 1 H), 3.99 (dd, <i>J</i> = 11.3, 1.8 Hz, 1 H), 3.77 (d, <i>J</i> = 11.3 Hz, 1 H), 3.73 (s, 3 H), 3.30–3.50 (m, 4 H), 2.68 (s, 3 H). MS (ES+) <i>m</i>/<i>z</i> 455 (M + H).</div></div><div id="sec5_1_14" class="NLM_sec NLM_sec_level_2"><div id="ac_i35" class="anchor-spacer"></div><h3 class="article-section__title" id="_i35"> <i>N</i>-(3-Methoxybenzyl)-4-(2-(((<i>trans</i>)-4-hydroxycyclohexyl)methyl)-2<i>H</i>-tetrazol-5-yl)-6-methylpicolinamide (<b>14j</b>)</h3><div class="NLM_p last">Following conditions analogous to those described for <b>14b</b>, reaction of 4-(hydroxymethyl)cyclohexanol (614 mg, 4.7 mmol) afforded a mixture of isomers, which was purified by reverse phase preparative HPLC (acetonitrile/water, 35/65–55/45). Isolation of the first eluting isomer afforded 298 mg (22%) of <b>14j</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.19 (t, <i>J</i> = 6.4 Hz, 1 H), 8.40 (s, 1 H), 8.05 (s, 1 H), 7.22 (t, <i>J</i> = 8.1 Hz, 1 H), 6.87–6.92 (m, 2 H), 6.77–6.82 (m, 1 H), 4.63 (d, <i>J</i> = 7.0 Hz, 2 H), 4.49 (d, <i>J</i> = 6.2 Hz, 2 H), 3.71 (s, 3 H), 2.65 (s, 3 H), 2.52 (s, 1 H), 1.89–1.98 (m, 1 H), 1.77–1.85 (m, 2 H), 1.53–1.61 (m, 2 H), 1.37 (d, <i>J</i> = 7.3 Hz, 2 H), 1.03–1.17 (m, 2 H). MS (ES+) <i>m</i>/<i>z</i> 437 (M + H).</div></div><div id="sec5_1_15" class="NLM_sec NLM_sec_level_2"><div id="ac_i36" class="anchor-spacer"></div><h3 class="article-section__title" id="_i36"> <i>N</i>-(3-Methoxybenzyl)-4-(2-(((<i>cis</i>)-4-hydroxycyclohexyl)methyl)-2<i>H</i>-tetrazol-5-yl)-6-methylpicolinamide (<b>14k</b>)</h3><div class="NLM_p last">Isolation of the second eluting isomer from the reaction above afforded 520 mg (39%) of <b>14k</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.19 (t, <i>J</i> = 6.4 Hz, 1 H), 8.40 (s, 1 H), 8.05 (s, 1 H), 7.21 (t, <i>J</i> = 8.1 Hz, 1 H), 6.87–6.92 (m, 2 H), 6.79 (dd, <i>J</i> = 8.4, 1.5 Hz, 1 H), 4.65 (d, <i>J</i> = 7.0 Hz, 2 H), 4.48 (d, <i>J</i> = 6.6 Hz, 2 H), 4.30 (br. s., 1 H), 3.73 (br. s., 1 H), 3.71 (s, 3 H), 2.65 (s, 3 H), 2.52 (s, 1 H), 2.04 (br. s., 1 H), 1.54–1.63 (m, 2 H), 1.27–1.48 (m, 5 H). MS (ES+) <i>m</i>/<i>z</i> 437 (M + H).</div></div><div id="sec5_1_16" class="NLM_sec NLM_sec_level_2"><div id="ac_i37" class="anchor-spacer"></div><h3 class="article-section__title" id="_i37"> <i>rac</i>-(Tetrahydro-2<i>H</i>-pyran-3-yl)methyl 4-Nitrobenzenesulfonate (<b>15</b>)</h3><div class="NLM_p last">4-Nitrobenzene-1-sulfonyl chloride (0.62 g, 2.8 mmol) and pyridine (253 mg, 3.20 mmol) were added to a solution of <i>rac</i>-(tetrahydro-2<i>H</i>-pyran-3-yl)methanol (0.31 g, 2.67 mmol) in dichloromethane (5 mL), and the mixture was stirred at rt for 15 h. The reaction mixture was diluted with dichloromethane (10 mL) and washed with water (2 × 10 mL) and brine (10 mL), dried over sodium sulfate, filtered, and concentrated. The residue was purified on silica gel column chromatography (heptane/EtOAc, 100/0–50/50) to afford 0.65 g (81%) of <b>15</b> as an oil. MS (ES+) <i>m</i>/<i>z</i> 302 (M + H).</div></div><div id="sec5_1_17" class="NLM_sec NLM_sec_level_2"><div id="ac_i38" class="anchor-spacer"></div><h3 class="article-section__title" id="_i38"> <i>rac</i>-((2<i>R</i>*,5<i>R</i>*)-5-(Hydroxymethyl)-1,4-dioxan-2-yl)methyl 4-Methylbenzenesulfonate (<i>rac-</i>16)</h3><div class="NLM_p last"><i>trans</i>-2,5-Bis(hydroxymethyl)-1,4-dioxane (342.9 g, 2.31 mol),<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a><i>p</i>-toluene sulfonyl chloride (441.0 g, 2.31 mol), triethylamine (471.5 g, 4.66 mol), and dichloromethane (3 L) were combined in a 5 L round-bottomed flask equipped with a mechanical stirrer under nitrogen. The mixture was maintained at 35 °C for 30 min with water bath cooling (<i><b>CAUTION!</b> Exothermic reaction</i>) and then allowed to stir at rt overnight. The mixture was diluted with 3 N HCl (1 L), and the resulting solids were filtered. The organic phase of the filtrate was separated, washed with 3 N HCl (1 L) followed by saturated ammonium chloride solution (500 mL), dried (MgSO<sub>4</sub>), and concentrated to afford 338.3 g (48%) of <i><b>rac-</b></i><b>16</b> as a white solid. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 7.77 (d, <i>J</i> = 8.1 Hz, 2 H), 7.33 (d, <i>J</i> = 8.1 Hz, 2 H), 3.90–4.02 (m, 2 H), 3.37–3.86 (m, 9 H), 2.43 (s, 3 H). MS (ES+) <i>m</i>/<i>z</i> 303 (M + H).</div></div><div id="sec5_1_18" class="NLM_sec NLM_sec_level_2"><div id="ac_i39" class="anchor-spacer"></div><h3 class="article-section__title" id="_i39"> Chiral Resolution of <b><i>rac</i>-16</b></h3><div class="NLM_p last">Chromatographic separation of <i><b>rac</b></i><b>-16</b> by chiral SFC (AD-H; 30% methanol/dichloromethane, 10/1; 200 mL/min) was performed. Isolation of the first eluting isomer afforded <b>(2</b><i><b>R</b></i><b>,5</b><i><b>R</b></i><b>)-16</b> (>99% ee) as a white solid. Isolation of the second eluting isomer afforded <b>(2</b><i><b>S</b></i><b>,5</b><i><b>S</b></i><b>)-16</b> (>99% ee) as a white solid.</div></div><div id="sec5_1_19" class="NLM_sec NLM_sec_level_2"><div id="ac_i40" class="anchor-spacer"></div><h3 class="article-section__title" id="_i40"> (<i>trans</i>)-Methyl 4-((5-(2-((3-Methoxybenzyl)carbamoyl)-6-methylpyridin-4-yl)-2<i>H</i>-tetrazol-2-yl)methyl)cyclohexanecarboxylate (<b>17</b>)</h3><div class="NLM_p last">Following conditions analogous to those described for <b>14b</b>, reaction of methyl <i>trans</i>-4-(hydroxymethyl)cyclohexanecarboxylate (2.12 g, 12.33 mmol) afforded 1.58 g (54%) of <b>17</b> as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.26 (t, <i>J</i> = 6.44 Hz, 1 H), 8.42 (s, 1 H), 8.07 (s, 1 H), 7.24 (t, <i>J</i> = 8.19 Hz, 1 H), 6.97–6.88 (m, 2 H), 6.86–6.77 (m, 1 H), 4.67 (d, <i>J</i> = 6.98 Hz, 2 H), 4.51 (d, <i>J</i> = 6.18 Hz, 2 H), 3.73 (s, 3 H), 3.57 (s, 3 H), 2.67 (s, 3 H), 2.31–2.19 (m, 1 H), 2.08–1.95 (m, 1 H), 1.95–1.84 (m, 2 H), 1.70–1.58 (m, 2 H), 1.39–1.25 (m, 2 H), 1.21–1.06 (m, 2 H). MS (ES+) <i>m</i>/<i>z</i> 479 (M + H).</div></div><div id="sec5_1_20" class="NLM_sec NLM_sec_level_2"><div id="ac_i41" class="anchor-spacer"></div><h3 class="article-section__title" id="_i41"> <i>N</i>-(3-Methoxybenzyl)-4-(2-(((<i>trans</i>)-4-carbamoylcyclohexyl)methyl)-2<i>H</i>-tetrazol-5-yl)-6-methylpicolinamide (<b>18</b>)</h3><div class="NLM_p last">Formamide (120 mg) was added to a solution of <b>17</b> (100 mg, 0.2 mmol) in anhydrous tetrahydrofuran (1 mL) and the mixture was heated to reflux. A 25% sodium methoxide solution in methanol (120 mg) was added, and the reaction was stirred at reflux for 2 h. The reaction mixture was allowed to cool to rt and then diluted with methanol (2 mL). The resulting precipitate was filtered and washed with a small amount of methanol, and the solid was dried in a vacuum desiccator to afford 78 mg (85%) of <b>18</b> as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.22 (t, <i>J</i> = 6.6 Hz, 1 H), 8.4 (s, 1 H), 8.05 (s, 1 H), 7.21 (t, <i>J</i> = 8.2 Hz, 1 H), 7.15 (s, 1 H), 6.88 (m, 2 H), 6.79 (d, <i>J</i> = 8.1 Hz, 1 H), 6.61 (s, 1 H), 4.62 (d, <i>J</i> = 7.4, 2 H), 4.46 (d, <i>J</i> = 7.4, 2 H), 3.70 (s, 3 H), 2.62 (s, 3 H), 2.02–1.90 (m, 2 H), 1.68, (d, <i>J</i> = 13.6, 2 H), 1.60 (d, <i>J</i> = 13.1, 2 H), 1.35–1.20 (m, 2 H), 1.15–1.00 (m, 2 H). MS (ES+) <i>m</i>/<i>z</i> 464 (M + H).</div></div><div id="sec5_1_21" class="NLM_sec NLM_sec_level_2"><div id="ac_i42" class="anchor-spacer"></div><h3 class="article-section__title" id="_i42"> <i>N</i>-(3-Methoxybenzyl)-4-(2-(((<i>trans</i>)-4-cyanocyclohexyl)methyl)-2<i>H</i>-tetrazol-5-yl)-6-methylpicolinamide (<b>19</b>)</h3><div class="NLM_p last">Polymer supported triphenylphosphine (500 mg, 1.07 mmol) was added to <b>18</b> (77 mg, 0.16 mmol) in a mixture of carbon tetrachloride (0.5 mL) and DCE (4.5 mL), and the mixture was heated at 80 °C for 2 h. The reaction mixture was filtered, and the resin was washed with DCE. The filtrate was concentrated, and the residue was recrystallized from methanol to afford 34 mg (48%) of <b>19</b> as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.29 (t, <i>J</i> = 6.6 Hz, 1 H), 8.43 (s, 1 H), 8.09 (s, 1 H), 7.25 (t, <i>J</i> = 8.0 Hz, 1 H), 6.90–6.94 (m, 2 H), 6.83 (dd, <i>J</i> = 8.1, 2.3 Hz, 1 H), 4.69 (d, <i>J</i> = 6.8 Hz, 2 H), 4.51 (d, <i>J</i> = 6.5 Hz, 2 H), 3.74 (s, 3 H), 2.68 (s, 3 H), 2.59–2.67 (m, 1 H), 1.98–2.13 (m, 3 H), 1.65 (d, <i>J</i> = 13.1 Hz, 2 H), 1.45–1.56 (m, 2 H), 1.07–1.19 (m, 2 H). MS (ES+) <i>m</i>/<i>z</i> 446 (M + H).</div></div><div id="sec5_1_22" class="NLM_sec NLM_sec_level_2"><div id="ac_i43" class="anchor-spacer"></div><h3 class="article-section__title" id="_i43"> <i>tert</i>-Butyl (<i>trans</i>)-4-((5-(2-((3-Methoxybenzyl)carbamoyl)-6-methylpyridin-4-yl)-2<i>H</i>-tetrazol-2-yl)methyl)cyclohexylcarbamate (<b>21</b>)</h3><div class="NLM_p last">Following conditions analogous to those described for <b>14b</b>, reaction of <i>tert</i>-butyl <i>trans</i>-(4-hydroxymethyl)cyclohexylcarbamate <b>20</b> (1.38 g, 6.0 mmol) provided a crude product, which was purified by silica column chromatography (CH<sub>2</sub>Cl<sub>2</sub>/methanol, 100/1; 100/2) to afford 1.824 g (68%) of <b>21</b> as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.23 (t, <i>J</i> = 6.3 Hz, 1 H), 8.40 (d, <i>J</i> = 0.8 Hz, 1 H), 8.05 (d, <i>J</i> = 1.1 Hz, 1 H), 7.21 (t, <i>J</i> = 8.1 Hz, 1 H), 6.90–6.86 (m, 2 H), 6.79 (dd, <i>J</i> = 8.2, 1.9 Hz, 1 H), 6.68 (d, <i>J</i> = 7.8 Hz, 1 H), 4.63 (d, <i>J</i> = 7.0 Hz, 2 H), 4.48 (d, <i>J</i> = 6.3 Hz, 2 H), 3.70 (s, 3 H), 3.13 (br. s., 1 H), 2.64 (s, 3 H), 1.90 (br. s., 1 H), 1.77–1.71 (m, 2 H), 1.59–1.53 (m, 2 H), 1.33 (s, 9 H), 1.14–1.06 (m, 4 H). MS (ES+) <i>m</i>/<i>z</i> 536 (M + H).</div></div><div id="sec5_1_23" class="NLM_sec NLM_sec_level_2"><div id="ac_i44" class="anchor-spacer"></div><h3 class="article-section__title" id="_i44"> <i>N</i>-(3-Methoxybenzyl)-4-(2-(((<i>trans</i>)-4-aminocyclohexyl)methyl)-2<i>H</i>-tetrazol-5-yl)-6-methylpicolinamide (<b>22</b>)</h3><div class="NLM_p last">Trifluoroacetic acid (5.05 mL, 68.0 mmol) was added to a solution of <b>21</b> (1.82 g, 3.40 mmol) in dichloromethane (20 mL). The mixture was allowed to stir for 2 h and was then concentrated. The residue was dissolved in dichloromethane (150 mL) and washed with 1 N NaOH solution (2 × 40 mL). The organic layer was dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated. The residue was triturated with heptane and filtered to afford 1.41 g (95%) of <b>22</b> as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.23 (t, <i>J</i> = 6.3 Hz, 1 H), 8.39 (d, <i>J</i> = 0.8 Hz, 1 H), 8.05 (d, <i>J</i> = 1.2 Hz, 1 H), 7.21 (t, <i>J</i> = 8.1 Hz, 1 H), 6.90–6.86 (m, 2 H), 6.79 (dd, <i>J</i> = 8.2, 1.9 Hz, 1 H), 4.62 (d, <i>J</i> = 7.1 Hz, 2 H), 4.48 (d, <i>J</i> = 6.3 Hz, 2 H), 3.70 (s, 3 H), 2.64 (s, 3 H), 2.45–2.37 (m, 1 H), 1.96–1.84 (m, 1 H), 1.71 (d, <i>J</i> = 12.0 Hz, 2 H), 1.53 (d, <i>J</i> = 12.2 Hz, 2 H), 1.37 (br. s., 2 H), 1.07 (q, <i>J</i> = 12.8 Hz, 2 H), 1.01–0.88 (m, 2 H). MS (ES+) <i>m</i>/<i>z</i> 436 (M + H).</div></div><div id="sec5_1_24" class="NLM_sec NLM_sec_level_2"><div id="ac_i45" class="anchor-spacer"></div><h3 class="article-section__title" id="_i45"> <i>N</i>-(3-Methoxybenzyl)-6-methyl-4-(2-(((<i>trans</i>)-4-(methylsulfonamido)cyclohexyl)methyl)-2<i>H</i>-tetrazol-5-yl)picolinamide (<b>23a</b>)</h3><div class="NLM_p last">Triethylamine (0.096 mL, 0.690 mmol) and methane sulfonyl chloride (0.021 mL, 0.276 mmol) were added to a solution of <b>22</b> (100.0 mg, 0.230 mmol) in dichloromethane (2 mL). The mixture was stirred for 2 h at rt and then concentrated. The residue was purified by reverse phase preparative HPLC to afford 28 mg (24%) of <b>23a</b> as a solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.31–9.04 (m, 1 H), 8.41 (s, 1 H), 8.05 (s, 1 H), 7.29–7.12 (m, 1 H), 6.93 (s, 1 H), 6.90 (m, 2 H), 6.82–6.77 (m, 1 H), 4.64 (d, <i>J</i> = 7.3 Hz, 2 H), 4.49 (d, <i>J</i> = 5.9 Hz, 2 H), 3.71 (s, 3 H), 2.86 (s, 3 H), 2.65 (s, 3 H), 2.04–1.78 (m, 3 H), 1.69–1.49 (m, 2 H), 1.32–0.95 (m, 4 H). MS (ES+) <i>m</i>/<i>z</i> 514 (M + H).</div></div><div id="sec5_1_25" class="NLM_sec NLM_sec_level_2"><div id="ac_i46" class="anchor-spacer"></div><h3 class="article-section__title" id="_i46"> <i>N</i>-(3-Methoxybenzyl)-4-(2-(((<i>trans</i>)-4-acetamidocyclohexyl)methyl)-2<i>H</i>-tetrazol-5-yl)-6-methylpicolinamide (<b>23b</b>)</h3><div class="NLM_p last">Acetic anhydride (0.033 mL, 0.344 mmol) and silica-bound DMAP (833.0 mg, 0.575 mmol, 0.69 mmol/g loading) were added to a solution of <b>22</b> (50.1 mg, 0.115 mmol) in dichloromethane (2 mL). The reaction mixture was stirred overnight at rt, filtered, and washed with DMF. The filtrate was concentrated, and the residue was purified by reverse phase preparative HPLC to afford 22.4 mg (41%) of <b>23b</b>. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.26–9.09 (m, 1 H), 8.41 (s, 1 H), 8.05 (s, 1 H), 7.63 (s, 1 H), 7.30–7.13 (m, 1 H), 6.98–6.86 (m, 2 H), 6.83–6.75 (m, 1 H), 4.64 (d, <i>J</i> = 7.3 Hz, 2 H), 4.49 (d, <i>J</i> = 5.9 Hz, 2 H), 3.71 (s, 3 H), 2.65 (s, 3 H), 2.06–1.89 (m, 1 H), 1.81–1.74 (m, 3 H), 1.73 (s, 3 H), 1.60 (m, 2 H), 1.28–0.99 (m, 4 H). MS (ES+) <i>m</i>/<i>z</i> 478 (M + H).</div></div><div id="sec5_1_26" class="NLM_sec NLM_sec_level_2"><div id="ac_i47" class="anchor-spacer"></div><h3 class="article-section__title" id="_i47"> <i>tert</i>-Butyl (<i>cis</i>)-4-((5-(2-((3-Methoxybenzyl)carbamoyl)-6-methylpyridin-4-yl)-2<i>H</i>-tetrazol-2-yl)methyl)cyclohexylcarbamate (<b>25</b>)</h3><div class="NLM_p last">Following conditions analogous to those described for <b>14b</b>, reaction of <i>tert</i>-butyl <i>cis</i>-(4-hydroxymethyl)cyclohexylcarbamate <b>24</b> (1.41 g, 6.17 mmol) provided a crude product, which was purified by reverse phase preparative HPLC to afford 1.65 g (50%) of <b>25</b> as a solid. MS (ES+) <i>m</i>/<i>z</i> 480 (M – C<sub>4</sub>H<sub>8</sub>).</div></div><div id="sec5_1_27" class="NLM_sec NLM_sec_level_2"><div id="ac_i48" class="anchor-spacer"></div><h3 class="article-section__title" id="_i48"> <i>N</i>-(3-Methoxybenzyl)-4-(2-(((<i>cis</i>)-4-aminocyclohexyl)methyl)-2<i>H</i>-tetrazol-5-yl)-6-methylpicolinamide (<b>26</b>)</h3><div class="NLM_p last">Trifluoroacetic acid was added to a solution of <b>25</b> (1.65 g, 3.1 mmol) in dichloromethane, and the mixture was allowed to stir for 30 min at rt. The reaction mixture was concentrated. The residue was dissolved in dichloromethane, and MP-carbonate resin was added. The mixture was agitated for 1 h, filtered, and washed with dichloromethane and methanol. The filtrate was concentrated to afford 1.09 g (81%) of <b>26</b> as a solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.28–9.19 (m, 1 H), 8.41 (s, 1 H), 8.09–8.03 (m, 1 H), 7.93 (br. s., 2 H), 7.27–7.17 (m, 1 H), 6.93–6.85 (m, 2 H), 6.84–6.76 (m, 1 H), 4.72 (d, <i>J</i> = 7.3 Hz, 2 H), 4.48 (d, <i>J</i> = 6.4 Hz, 2 H), 3.70 (s, 3 H), 3.28–3.18 (m, 1 H), 2.65 (s, 3 H), 2.31–2.17 (m, 1 H), 1.86–1.33 (m, 8 H). MS (ES+) <i>m</i>/<i>z</i> 436 (M + H).</div></div><div id="sec5_1_28" class="NLM_sec NLM_sec_level_2"><div id="ac_i49" class="anchor-spacer"></div><h3 class="article-section__title" id="_i49"> <i>N</i>-(3-Methoxybenzyl)-6-methyl-4-(2-(((<i>cis</i>)-4-(methylsulfonamido)cyclohexyl)methyl)-2<i>H</i>-tetrazol-5-yl)picolinamide (<b>27a</b>)</h3><div class="NLM_p last">Compound <b>27a</b> was prepared analogous to <b>23a</b> from compound <b>26</b>. Yield 57%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.25–9.12 (m, 1 H), 8.41 (s, 1 H), 8.05 (s, 1 H), 7.28–7.13 (m, 1 H), 6.97–6.84 (m, 3 H), 6.84–6.73 (m, 1 H), 4.67 (d, <i>J</i> = 6.6 Hz, 2 H), 4.49 (d, <i>J</i> = 6.6 Hz, 2 H), 3.71 (s, 3 H), 3.48–3.36 (m, 1 H), 2.87 (s, 3 H), 2.65 (s, 3 H), 2.22–1.99 (m, 1 H), 1.79–1.29 (m, 4 H). MS (ES+) <i>m</i>/<i>z</i> 514 (M + H).</div></div><div id="sec5_1_29" class="NLM_sec NLM_sec_level_2"><div id="ac_i50" class="anchor-spacer"></div><h3 class="article-section__title" id="_i50"> <i>N</i>-(3-Methoxybenzyl)-4-(2-(((<i>cis</i>)-4-acetamidocyclohexyl)methyl)-2<i>H</i>-tetrazol-5-yl)-6-methylpicolinamide (<b>27b</b>)</h3><div class="NLM_p last">Compound <b>27b</b> was prepared analogous to <b>23b</b> from compound <b>26</b>. Yield 49%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.23–9.14 (m, 1 H), 8.41 (s, 1 H), 8.05 (s, 1 H), 7.68–7.60 (m, 1 H), 7.25–7.17 (m, 1 H), 6.94–6.86 (m, 2 H), 6.82–6.76 (m, 1 H), 4.68 (d, <i>J</i> = 7.3 Hz, 2 H), 4.49 (d, <i>J</i> = 6.6 Hz, 2 H), 3.82–3.74 (m, 1 H), 3.71 (s, 3 H), 3.31–3.23 (m, 1 H), 2.69–2.62 (m, 3 H), 2.21–2.07 (m, 1 H), 1.80 (s, 3 H), 1.66–1.31 (m, 3 H). MS (ES+) <i>m</i>/<i>z</i> 478 (M + H).</div></div><div id="sec5_1_30" class="NLM_sec NLM_sec_level_2"><div id="ac_i51" class="anchor-spacer"></div><h3 class="article-section__title" id="_i51"> <i>tert</i>-Butyl 4-((5-(2-((3-methoxybenzyl)carbamoyl)-6-methylpyridin-4-yl)-2<i>H</i>-tetrazol-2-yl)methyl)piperidine-1-carboxylate (<b>29</b>)</h3><div class="NLM_p last">A mixture of <b>28</b> (1.00 g, 3.10 mmol), <i>tert</i>-butyl 4-(hydroxymethyl) piperidine-1-carboxylate (0.81 g, 3.8 mmol), and polymer supported-triphenylphosphine (2.90 g, 6.21 mmol) were suspended in anhydrous THF (32 mL). The mixture was cooled to 0 °C in an ice bath for 15 min, and then DBAD (1.11 g, 4.82 mmol) was added. The mixture was allowed to warm to rt while stirring over 15 h. The reaction mixture was filtered, and the filtrate was concentrated. The residue was purified by silica gel chromatography (20 g, 0–50% gradient EtOAc/heptane) to afford 1.52 g (94%) of <b>29</b> as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.22 (t, <i>J</i> = 8.0 Hz, 1 H), 8.40 (s, 1 H), 8.08 (s, 1 H), 7.22 (t, <i>J</i> = 8.2 Hz, 1 H), 6.90 (m, 2 H), 6.80 (m, 1 H), 4.78 (d, <i>J</i> = 7.0 Hz, 2 H), 4.50 (d, <i>J</i> = 7.0 Hz, 2 H), 4.00–3.90 (m, 2 H), 3.75 (s, 3 H), 2.68 (s, 3 H), 2.25–2.15 (m, 1 H), 1.60–1.50 (m, 2 H), 1.38 (s, 9 H), 1.20–1.10 (m, 2 H). MS (ES+) <i>m</i>/<i>z</i> 544 (M + Na).</div></div><div id="sec5_1_31" class="NLM_sec NLM_sec_level_2"><div id="ac_i52" class="anchor-spacer"></div><h3 class="article-section__title" id="_i52"> <i>N</i>-(3-Methoxybenzyl)-6-methyl-4-(2-(piperidin-4-ylmethyl)-2<i>H</i>-tetrazol-5-yl)picolinamide (<b>30</b>)</h3><div class="NLM_p last">Trifluoroacetic acid (6 mL) was added to a solution of <b>29</b> (1.51 g, 2.89 mmol) in dichloromethane (20 mL). The reaction mixture was stirred for 1 h at rt and was then concentrated. The residue was purified by reverse phase preparative HPLC to afford 0.83 g (56%) of <b>30</b> as the trifluoroacetate salt. MS (ES+) <i>m</i>/<i>z</i> 422 (M + H).</div></div><div id="sec5_1_32" class="NLM_sec NLM_sec_level_2"><div id="ac_i53" class="anchor-spacer"></div><h3 class="article-section__title" id="_i53"> <i>N</i>-(3-Methoxybenzyl)-4-(2-((1-acetylpiperidin-4-yl)methyl)-2<i>H</i>-tetrazol-5-yl)-6-methylpicolinamide (<b>31a</b>)</h3><div class="NLM_p last">Acetic anhydride (0.034 mL, 0.356 mmol) and silica-bound DMAP (862.0 mg, 0.595 mmol, 0.69 mmol/g loading) were added to a solution of <b>30</b> (50.2 mg, 0.119 mmol) in dichloromethane (2 mL), and the mixture was agitated overnight at rt. The reaction mixture was filtered, and the resin was washed with DMF. The filtrate was concentrated, and the residue was purified by reverse phase preparative HPLC to afford 24.5 mg (44%) of <b>31a</b> as a solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.27–9.11 (m, 1 H), 8.41 (s, 1 H), 8.05 (s, 1 H), 7.28–7.14 (m, 1 H), 6.95–6.86 (m, 2 H), 6.80 (m, 1 H), 4.71 (d, <i>J</i> = 7.3 Hz, 2 H), 4.49 (d, <i>J</i> = 6.6 Hz, 2 H), 3.71 (s, 3 H), 2.65 (s, 3 H), 2.57–2.44 (m, 2 H), 2.37–2.16 (m, 1 H), 1.94 (s, 3 H), 1.57 (m, 2 H), 1.35–0.98 (m, 4 H). MS (ES+) <i>m</i>/<i>z</i> 464 (M + H).</div></div><div id="sec5_1_33" class="NLM_sec NLM_sec_level_2"><div id="ac_i54" class="anchor-spacer"></div><h3 class="article-section__title" id="_i54"> <i>N</i>-(3-Methoxybenzyl)-6-methyl-4-(2-((1-(methylsulfonyl)piperidin-4-yl)methyl)-2<i>H</i>-tetrazol-5-yl)picolinamide (<b>31b</b>)</h3><div class="NLM_p last">Compound <b>31b</b> was prepared analogous to <b>31a</b> employing methane sulfonyl chloride. Yield 55%. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.19 (s, 1 H), 8.41 (s, 1 H), 8.05 (s, 1 H), 7.27–7.15 (m, 1 H), 6.95–6.86 (m, 2 H), 6.83–6.73 (m, 1 H), 4.76 (d, <i>J</i> = 7.3 Hz, 2 H), 4.49 (d, <i>J</i> = 6.6 Hz, 2 H), 3.71 (s, 3 H), 3.60–3.47 (m, 2 H), 2.81 (s, 3 H), 2.65 (s, 3 H), 2.27–2.07 (m, 1 H), 1.72–1.61 (m, 2 H), 1.48–1.24 (m, 4 H). MS (ES+) <i>m</i>/<i>z</i> 500 (M + H).</div></div><div id="sec5_1_34" class="NLM_sec NLM_sec_level_2"><div id="ac_i55" class="anchor-spacer"></div><h3 class="article-section__title" id="_i55"> Methyl 4-(2-(((<i>trans</i>)-4-(hydroxymethyl)cyclohexyl)methyl)-2<i>H</i>-tetrazol-5-yl)-6-methylpicolinate (<b>32</b>)</h3><div class="NLM_p last">DBAD (4.6 g, 20.0 mmol) was added to a mixture of <b>13</b> (2.19 g, 10.0 mmol), polymer supported triphenylphosphine (9.3 g, 20.0 mmol), and <i>trans</i>-cyclohexane-1,4-dimethanol (2.88 g, 20.0 mmol) in THF (200 mL) cooled to 0 °C. The mixture was allowed to warm to rt. After 18 h, the reaction mixture was filtered, and the resin was washed with THF (100 mL). The filtrate was concentrated. The residue was dissolved in EtOAc (200 mL) and washed with water (50 mL). The organic layer was dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated. The crude product was purified by silica column chromatography (CH<sub>2</sub>Cl<sub>2</sub>/methanol, 100/1–100/4) to afford 2.3 g (67%) of <b>32</b> as an oil. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.40 (d, <i>J</i> = 0.8 Hz, 1 H), 8.12 (d, <i>J</i> = 1.1 Hz, 1 H), 4.67 (d, <i>J</i> = 7.0 Hz, 2 H), 4.35 (t, <i>J</i> = 5.3 Hz, 1 H), 3.93 (s, 3 H), 3.19 (t, <i>J</i> = 5.8 Hz, 2 H), 2.66 (s, 3 H), 2.04–1.90 (m, 1 H), 1.74 (d, <i>J</i> = 10.6 Hz, 2 H), 1.61 (d, <i>J</i> = 10.6 Hz, 2 H), 1.37–1.23 (m, 1 H), 1.08 (dq, <i>J</i> = 12.6, 2.7 Hz, 2 H), 0.87 (dq, <i>J</i> = 12.8, 3.1 Hz, 2 H). MS (ES+) <i>m</i>/<i>z</i> 346 (M + H).</div></div><div id="sec5_1_35" class="NLM_sec NLM_sec_level_2"><div id="ac_i56" class="anchor-spacer"></div><h3 class="article-section__title" id="_i56"> 4-(2-(((<i>trans</i>)-4-(Hydroxymethyl)cyclohexyl)methyl)-2<i>H</i>-tetrazol-5-yl)-6-methylpicolinic Acid (<b>33</b>)</h3><div class="NLM_p last">Lithium hydroxide (479 mg, 20.0 mmol) was added to a solution of <b>32</b> (2.3 g, 6.68 mmol) dissolved in a mixture of THF/water (40 mL, 1/1), and the mixture was stirred at rt for 3 h. The solvent was removed in vacuo, and the residue was diluted with water (20 mL). The solution was made acidic with 1 N HCl solution (20 mL), and the resulting precipitate was filtered to afford 1.03 g (47%) of <b>33</b> as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 13.36 (br, 1 H), 8.40 (d, <i>J</i> = 0.8 Hz, 1 H), 8.09 (d, <i>J</i> = 1.1 Hz, 1 H), 4.66 (d, <i>J</i> = 7.1 Hz, 2 H), 4.35 (br. s., 1 H), 3.19 (d, <i>J</i> = 6.2 Hz, 2 H), 2.65 (s, 3 H), 2.03–1.90 (m, 1 H), 1.74 (d, <i>J</i> = 10.5 Hz, 2 H), 1.61 (d, <i>J</i> = 10.9, 2 H), 1.35–1.25 (m, 1 H), 1.08 (dq, <i>J</i> = 12.6, 2.8 Hz, 2 H), 0.87 (dq, <i>J</i> = 12.8, 3.2 Hz, 2 H). MS (ES+) <i>m</i>/<i>z</i> 332 (M + H).</div></div><div id="sec5_1_36" class="NLM_sec NLM_sec_level_2"><div id="ac_i57" class="anchor-spacer"></div><h3 class="article-section__title" id="_i57"> General Procedure for Synthesis of Amides <b>34a</b>–<b>l</b></h3><div class="NLM_p">A mixture of <b>33</b> (33 mg, 0.10 mmol) and 1-hydroxybenzotriazole (18.9 mg, 0.14 mmol) in DMF (0.5 mL) was shaken for 15 min. <i>N</i>-Methylmorpholine (44 μL, 0.40 mmol) was added followed by the corresponding benzylamine (0.12 mmol) in DMF (0.5 mL). 1-Ethyl-3-(3′-dimethylaminopropyl)carbodiimide hydrochloride (26.8 mg, 0.14 mmol) was then added, and the mixture was shaken for 18 h. The reaction mixture was purified by reverse phase preparative HPLC to afford the title compound.</div><div id="sec5_1_37" class="NLM_sec NLM_sec_level_3"><div id="ac_i58" class="anchor-spacer"></div><h4 class="article-section__title" id="_i58"> <i>N</i>-Benzyl-4-(2-(((<i>trans</i>)-4-(hydroxymethyl)cyclohexyl)methyl)-2<i>H</i>-tetrazol-5-yl)-6-methylpicolinamide (<b>34a</b>)</h4><div class="NLM_p last">76% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.26 (t, <i>J</i> = 6.4 Hz, 1 H), 8.39 (s, 1 H), 8.04 (s, 1 H), 7.18–7.35 (m, 5 H), 4.62 (d, <i>J</i> = 7.0, 2 H), 4.50 (d, <i>J</i> = 6.2 Hz, 2 H), 4.32 (t, <i>J</i> = 5.3 Hz, 1 H), 3.14 (t, <i>J</i> = 5.9 Hz, 2 H), 2.63 (s, 3 H), 1.99–1.86 (m, 1 H), 1.70 (d, <i>J</i> = 11.7 Hz, 2 H), 1.57 (d, <i>J</i> = 12.1 Hz, 2 H), 1.32–1.20 (m, l H). 1.03 (q, <i>J</i> = 12.0 Hz, 2 H), 0.83 (q, <i>J</i> = 12.0 Hz, 2 H). MS (ES+) <i>m</i>/<i>z</i> 421 (M + H).</div></div><div id="sec5_1_38" class="NLM_sec NLM_sec_level_3"><div id="ac_i59" class="anchor-spacer"></div><h4 class="article-section__title" id="_i59"> N-(4-Fluorobenzyl)-4-(2-(((<i>trans</i>)-4-(hydroxymethyl)cyclohexyl)methyl)-2<i>H</i>-tetrazol-5-yl)-6-methylpicolinamide (<b>34b</b>)</h4><div class="NLM_p last">52% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.35 (t, <i>J</i> = 6.4 Hz, 1 H), 8.43 (s, 1 H), 8.09 (s, 1 H), 7.39 (dd, <i>J</i> = 8.4, 5.7 Hz, 2 H), 7.16 (t, <i>J</i> = 8.9 Hz, 2 H), 4.67 (d, <i>J</i> = 7.0 Hz, 2 H), 4.52 (d, <i>J</i> = 6.3 Hz, 2 H), 4.37 (t, <i>J</i> = 5.3 Hz, 1 H), 3.19 (t, <i>J</i> = 5.7 Hz, 2 H), 2.68 (s, 3 H), 1.91–2.02 (m, 1 H), 1.71–1.78 (m, 2 H), 1.58–1.64 (m, 2 H), 1.24–1.37 (m, 1 H), 1.02–1.14 (m, 2 H), 0.81–0.94 (m, 2 H). MS (ES+) <i>m</i>/<i>z</i> 439 (M + H).</div></div><div id="sec5_1_39" class="NLM_sec NLM_sec_level_3"><div id="ac_i60" class="anchor-spacer"></div><h4 class="article-section__title" id="_i60"> <i>N</i>-(3-Fluorobenzyl)-4-(2-(((<i>trans</i>)-4-(hydroxymethyl)cyclohexyl)methyl)-2<i>H</i>-tetrazol-5-yl)-6-methylpicolinamide (<b>34c</b>)</h4><div class="NLM_p last">20% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.37 (t, <i>J</i> = 6.4 Hz, 1 H), 8.43 (d, <i>J</i> = 0.9 Hz, 1 H), 8.09 (d, <i>J</i> = 1.1 Hz, 1 H), 7.40–7.34 (m, 1 H), 7.21–7.13 (m, 2 H), 7.07 (dt, <i>J</i> = 8.5, 2.4 Hz, 1 H), 4.66 (d, <i>J</i> = 6.9 Hz, 2 H), 4.55 (d, <i>J</i> = 6.4 Hz, 2 H), 4.35 (t, <i>J</i> = 5.3 Hz, 1 H), 3.19 (t, <i>J</i> = 5.8 Hz, 2 H), 2.66 (s, 3 H), 2.04–1.91 (m, 1 H), 1.74 (d, <i>J</i> = 11.0 Hz, 2 H), 1.62 (d, <i>J</i> = 12.0 Hz, 2 H), 1.35–1.25 (m, 1 H), 1.08 (q, <i>J</i> = 13.2 Hz, 2 H), 0.87 (q, <i>J</i> = 11.2 Hz, 2 H). MS (ES+) <i>m</i>/<i>z</i> 439 (M + H).</div></div><div id="sec5_1_40" class="NLM_sec NLM_sec_level_3"><div id="ac_i61" class="anchor-spacer"></div><h4 class="article-section__title" id="_i61"> <i>N</i>-(3-Chlorobenzyl)-4-(2-(((<i>trans</i>)-4-(hydroxymethyl)cyclohexyl)methyl)-2<i>H</i>-tetrazol-5-yl)-6-methylpicolinamide (<b>34d</b>)</h4><div class="NLM_p last">35% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.37 (t, <i>J</i> = 6.4 Hz, 1 H), 8.38 (s, 1 H), 8.05 (s, 1 H), 7.26–7.37 (m, 4 H), 4.62 (d, <i>J</i> = 7.0 Hz, 2 H), 4.49 (d, <i>J</i> = 6.6 Hz, 2 H), 4.33 (t, <i>J</i> = 5.3 Hz, 1 H), 3.14 (t, <i>J</i> = 5.7 Hz, 2 H), 2.64 (s, 3 H), 1.97–1.87 (m, 1 H), 1.70 (d, <i>J</i> = 10.6 Hz, 2 H), 1.57 (d, <i>J</i> = 11.3 Hz, 2 H), 1.31–1.21 (m, 1 H), 1.03 (q, <i>J</i> = 12.4 Hz, 2 H), 0.83 (q, <i>J</i> = 12.4 Hz, 2 H). MS (ES+) <i>m</i>/<i>z</i> 455 (M + H).</div></div><div id="sec5_1_41" class="NLM_sec NLM_sec_level_3"><div id="ac_i62" class="anchor-spacer"></div><h4 class="article-section__title" id="_i62"> <i>N</i>-(3-Methylbenzyl)-4-(2-(((<i>trans</i>)-4-(hydroxymethyl)cyclohexyl)methyl)-2<i>H</i>-tetrazol-5-yl)-6-methylpicolinamide (<b>34e</b>)</h4><div class="NLM_p last">77% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.21 (t, <i>J</i> = 6.4 Hz, 1 H), 8.39 (s, 1 H), 8.04 (s, 1 H), 7.17 (t, <i>J</i> = 7.5 Hz, 1 H), 7.07–7.13 (m, 2 H), 7.02 (d, <i>J</i> = 7.3 Hz, 1 H), 4.62 (d, <i>J</i> = 7.0 Hz, 2 H), 4.46 (d, <i>J</i> = 6.2 Hz, 2 H), 4.32 (t, <i>J</i> = 5.1 Hz, 1 H), 3.14 (t, <i>J</i> = 5.9 Hz, 2 H), 2.63 (s, 3 H), 2.24 (s, 3 H), 1.97–1.87 (m, 1 H), 1.70 (d, <i>J</i> = 11.0 Hz, 2 H), 1.57 (d, <i>J</i> = 11.3 Hz, 2 H), 1.30–1.20 (m, 1 H), 1.04 (q, <i>J</i> = 13.2 Hz, 2 H), 0.83 (q, <i>J</i> = 12.2 Hz, 2 H). MS (ES+) <i>m</i>/<i>z</i> 435 (M + H).</div></div><div id="sec5_1_42" class="NLM_sec NLM_sec_level_3"><div id="ac_i63" class="anchor-spacer"></div><h4 class="article-section__title" id="_i63"> <i>N</i>-(3-(Trifluoromethyl)benzyl)-4-(2-(((<i>trans</i>)-4-(hydroxymethyl)cyclohexyl)methyl)-2<i>H</i>-tetrazol-5-yl)-6-methylpicolinamide (<b>34f</b>)</h4><div class="NLM_p last">77% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.43 (t, <i>J</i> = 6.2 Hz, 1 H), 8.37 (s, 1 H), 8.04 (s, 1 H), 7.69–7.48 (m, 4 H), 4.61 (d, <i>J</i> = 7.0 Hz, 2 H), 4.56 (d, <i>J</i> = 6.2 Hz, 2 H), 4.31 (t, <i>J</i> = 5.1 Hz, 1 H), 3.13 (t, <i>J</i> = 5.7 Hz, 2 H), 2.63 (s, 3 H), 1.98–1.85 (m, 1 H), 1.68 (d, <i>J</i> = 11.7 Hz, 2 H), 1.56 (d, <i>J</i> = 11.3 Hz, 2 H), 1.31–1.19 (m, 1 H), 1.02 (q, <i>J</i> = 12.8 Hz, 2 H), 0.82 (q, <i>J</i> = 12.4 Hz, 2 H). MS (ES+) <i>m</i>/<i>z</i> 489 (M + H).</div></div><div id="sec5_1_43" class="NLM_sec NLM_sec_level_3"><div id="ac_i64" class="anchor-spacer"></div><h4 class="article-section__title" id="_i64"> <i>N</i>-(3,4-Difluorobenzyl)-4-(2-(((<i>trans</i>)-4-(hydroxymethyl)cyclohexyl)methyl)-2<i>H</i>-tetrazol-5-yl)-6-methylpicolinamide (<b>34g</b>)</h4><div class="NLM_p last">74% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.36 (t, <i>J</i> = 6.4 Hz, 1 H), 8.38 (s, 1 H), 8.05 (s, 1 H), 7.39–7.30 (m, 2 H), 7.13–7.18 (m, 1 H), 4.62 (d, <i>J</i> = 7.0 Hz, 2 H), 4.47 (d, <i>J</i> = 6.6 Hz, 2 H), 4.32 (t, <i>J</i> = 5.3 Hz, 1 H), 3.14 (t, <i>J</i> = 5.9 Hz, 2 H), 2.64 (s, 3 H), 1.97–1.87 (m, 1 H), 1.70 (d, <i>J</i> = 11.0 Hz, 2 H), 1.57 (d, <i>J</i> = 12.1 Hz, 2 H), 1.30–1.18 (m, 1 H), 1.03 (q, <i>J</i> = 12.8 Hz, 2 H), 0.83 (q, <i>J</i> = 11.3 Hz, 2 H). MS (ES+) <i>m</i>/<i>z</i> 457 (M + H).</div></div><div id="sec5_1_44" class="NLM_sec NLM_sec_level_3"><div id="ac_i65" class="anchor-spacer"></div><h4 class="article-section__title" id="_i65"> <i>N</i>-(3-Chloro-4-fluorobenzyl)-4-(2-(((<i>trans</i>)-4-(hydroxymethyl)cyclohexyl)methyl)-2<i>H</i>-tetrazol-5-yl)-6-methylpicolinamide (<b>34h</b>)</h4><div class="NLM_p last">53% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.40 (t, <i>J</i> = 8.4 Hz, 1 H), 8.42 (d, <i>J</i> = 0.9 Hz, 1 H), 8.09 (d, <i>J</i> = 1.2 Hz, 1 H), 7.56 (d, <i>J</i> = 7.7 Hz, 1 H), 7.39–7.35 (m, 2 H), 4.66 (d, <i>J</i> = 7.1 Hz, 2 H), 4.51 (d, <i>J</i> = 6.4 Hz, 2 H), 4.35 (t, <i>J</i> = 5.3 Hz, 1 H), 3.19 (t, <i>J</i> = 5.8 Hz, 2 H), 2.68 (s, 3 H), 2.03–1.90 (m, 1 H), 1.74 (d, <i>J</i> = 10.6 Hz, 2 H), 1.61 (d, <i>J</i> = 10.7 Hz, 2 H), 1.35–1.24 (m,·1 H), 1.08 (dq <i>J</i> = 12.4, 2.4 Hz, 2 H), 0.87 (dq, <i>J</i> = 12.6, 3.0 Hz, 2 H). MS (ES+) <i>m</i>/<i>z</i> 473 (M + H).</div></div><div id="sec5_1_45" class="NLM_sec NLM_sec_level_3"><div id="ac_i66" class="anchor-spacer"></div><h4 class="article-section__title" id="_i66"> <i>N</i>-(4-Fluoro-3-methylbenzyl)-4-(2-(((<i>trans</i>)-4-(hydroxymethyl)cyclohexyl)methyl)-2<i>H</i>-tetrazol-5-yl)-6-methylpicolinamide (<b>34i</b>)</h4><div class="NLM_p last">79% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.25 (t, <i>J</i> = 6.2 Hz, 1 H), 8.38 (s, 1 H), 8.04 (s, 1 H), 7.21 (d, <i>J</i> = 7.3 Hz, 1 H), 7.17–7.13 (m, 1 H), 7.03 (t, <i>J</i> = 9.2 Hz, 1 H), 4.62 (d, <i>J</i> = 7.0 Hz, 2 H), 4.43 (d, <i>J</i> = 6.2 Hz, 2 H), 4.32 (t, <i>J</i> = 5.1 Hz, 1 H), 3.14 (t, <i>J</i> = 5.7 Hz, 2 H), 2.63 (s, 3 H), 2.17 (s, 3 H), 1.97–1.87 (m, 1 H), 1.70 (d, <i>J</i> = 11.0 Hz, 2 H), 1.57 (d, <i>J</i> = 13.2 Hz, 2 H), 1.30–1.20 (m, 1 H), 1.03 (q, <i>J</i> = 10.6 Hz, 2 H), 0.83 (q, <i>J</i> = 12.4 Hz, 2 H). MS (ES+) <i>m</i>/<i>z</i> 453 (M + H).</div></div><div id="sec5_1_46" class="NLM_sec NLM_sec_level_3"><div id="ac_i67" class="anchor-spacer"></div><h4 class="article-section__title" id="_i67"> <i>N</i>-(4-Fluoro-3-(trifluoromethyl)benzyl)-4-(2-(((<i>trans</i>)-4-(hydroxymethyl)cyclohexyl)methyl)-2<i>H</i>-tetrazol-5-yl)-6-methylpicolinamide (<b>34j</b>)</h4><div class="NLM_p last">59% yield. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.43 (t, <i>J</i> = 6.2 Hz, 1 H), 8.37 (s, 1 H), 8.05 (s, 1 H), 7.73 (d, <i>J</i> = 6.2 Hz, 1 H), 7.71–7.66 (m, 1 H), 7.47–7.40 (m, 1 H), 4.62 (d, <i>J</i> = 7.0 Hz, 2 H), 4.53 (d, <i>J</i> = 6.2 Hz, 2 H), 4.32 (t, <i>J</i> = 5.3 Hz, 1 H), 3.14 (t, <i>J</i> = 5.5 Hz, 2 H), 2.64 (s, 3 H), 1.97–1.87 (m, 1 H), 1.69 (d, <i>J</i> = 10.6 Hz, 2 H), 1.57 (d, <i>J</i> = 11.3 Hz, 2 H), 1.30–1.20 (m, 1 H), 1.03 (q, <i>J</i> = 12.8 Hz, 2 H), 0.83 (q, <i>J</i> = 12.4 Hz, 2 H). MS (ES+) <i>m</i>/<i>z</i> 507 (M + H).</div></div><div id="sec5_1_47" class="NLM_sec NLM_sec_level_3"><div id="ac_i68" class="anchor-spacer"></div><h4 class="article-section__title" id="_i68"> <i>N</i>-(4-Fluoro-3-methoxybenzyl)-4-(2-(((<i>trans</i>)-4-(hydroxymethyl)cyclohexyl)methyl)-2<i>H</i>-tetrazol-5-yl)-6-methylpicolinamide (<b>34k</b>)</h4><div class="NLM_p last">28% yield.<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>) δ 8.70 (s, 1 H), 8.42 (t, <i>J</i> = 6.2 Hz, 1 H), 8.03 (d, <i>J</i> = 1.3 Hz, 1 H), 7.06–6.94 (m, 2 H), 6.92–6.85 (m, 1 H), 4.62 (d, <i>J</i> = 6.4 Hz, 2 H), 4.52 (d, <i>J</i> = 7.0 Hz, 2 H), 3.86 (s, 3 H), 3.48–3.38 (m, 3 H), 2.61 (s, 3 H), 2.14–2.00 (m, 1 H), 1.90–1.66 (m, 4 H), 1.54–1.39 (m, 1 H), 1.19–1.05 (m, 2 H), 1.04–0.91 (m, 2 H). 99%. MS (ES+) <i>m</i>/<i>z</i> 469 (M + H).</div></div></div><div id="sec5_1_48" class="NLM_sec NLM_sec_level_2"><div id="ac_i69" class="anchor-spacer"></div><h3 class="article-section__title" id="_i69"> 6-Chloro-2-methylpyrimidin-4-ol (<b>36</b>)</h3><div class="NLM_p last">4,6-Dichloro-2-methylpyrimidine <b>35</b> (475 g, 2.91 mol) was added portionwise to a solution of 13 M sulfuric acid (1.2 L, 15.6 mol) at 0 °C. The resulting mixture was allowed to warm to rt over 1.5 h. The solution was poured into a well stirred mixture of ice and 6 N NaOH (3.6 L, 21.6 mol). The resulting solids were then collected by vacuum filtration, washed with warm water (3 × 1 L), and dried at 35 °C under high vacuum to provide 393.4 g (93%) of <b>36</b> as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.81 (br. s, 1 H), 6.30 (s, 1 H), 2.26 (s, 3 H). MS (ES+) <i>m</i>/<i>z</i> 145 (M + H).</div></div><div id="sec5_1_49" class="NLM_sec NLM_sec_level_2"><div id="ac_i70" class="anchor-spacer"></div><h3 class="article-section__title" id="_i70"> Methyl 6-Hydroxy-2-methylpyrimidine-4-carboxylate (<b>37</b>)</h3><div class="NLM_p last">A solution of <b>36</b> (36.7 g, 254 mmol), [1,1′-bis(diphenylphosphino)ferrocene]palladium(II) dichloride (10.4 g, 12.7 mmol), and diisopropylethylamine (49.2 g, 381 mmol) in methanol (254 mL) was heated at 85 °C in the presence of carbon monoxide (50 psi) for 24 h. The reaction mixture was allowed to cool to rt. The resulting solids were collected by vacuum filtration, rinsed with methanol (100 mL) followed by diethyl ether (2 × 100 mL), and dried under vacuum to provide 38.7 g (91%) of <b>37</b> as a brown solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 12.79 (br. s, 1 H), 6.68 (s, 1 H), 3.79 (s, 3 H), 2.29 (s, 3 H). MS (ES+) <i>m</i>/<i>z</i> 169 (M + H).</div></div><div id="sec5_1_50" class="NLM_sec NLM_sec_level_2"><div id="ac_i71" class="anchor-spacer"></div><h3 class="article-section__title" id="_i71"> Methyl 6-Chloro-2-methylpyrimidine-4-carboxylate (<b>38</b>)</h3><div class="NLM_p last">Oxalyl chloride (18.6 mL, 213 mmol) and DMA (3.5 mL, 44 mmol) were added to a solution of <b>37</b> (30.0 g, 178 mmol) in dichloromethane (446 mL). The mixture was heated at reflux for 2 h. After cooling to rt, the mixture was filtered. The filtrate was partially concentrated and purified by silica gel chromatography (35/65, EtOAc/heptane) to provide 26.6 g (80%) of <b>38</b> as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 7.90 (s, 1 H), 3.88 (s, 3 H), 2.65 (s, 3 H). MS (ES+) <i>m</i>/<i>z</i> 187 (M + H).</div></div><div id="sec5_1_51" class="NLM_sec NLM_sec_level_2"><div id="ac_i72" class="anchor-spacer"></div><h3 class="article-section__title" id="_i72"> Methyl 6-Cyano-2-methylpyrimidine-4-carboxylate (<b>39</b>)</h3><div class="NLM_p last">Tetraethylammonium cyanide (27.6 g, 177 mmol) and DABCO (3.60 g, 32.0 mmol) was added to a solution of <b>38</b> (30.0 g, 161 mmol) in dichloromethane (460 mL), and the mixture was stirred for 30 min at rt. The reaction mixture was washed with 1 N NaOH (3 × 100 mL), water (2 × 100 mL), and brine (200 mL). The organic layer was dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated. The crude product was purified by silica gel chromatography (2/1, EtOAc/heptane) to provide 24.4 g (86%) of <b>39</b> as a white crystalline solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 8.38 (s, 1 H), 3.88 (s, 3 H), 2.75 (s, 3 H). MS (ES+) <i>m</i>/<i>z</i> 178 (M + H).</div></div><div id="sec5_1_52" class="NLM_sec NLM_sec_level_2"><div id="ac_i73" class="anchor-spacer"></div><h3 class="article-section__title" id="_i73"> 6-Cyano-<i>N</i>-(3-methoxybenzyl)-2-methylpyrimidine-4-carboxamide (<b>40a</b>)</h3><div class="NLM_p last">Diisopropylethylamine (25.5 g, 198 mmol) was added to a solution of 3-methoxybenzylamine (9.68 g, 70.6 mmol) and <b>39</b> (10.0 g, 56.4 mmol) in DMA (113 mL), and the mixture was heated at 100 °C for 2 h. After cooling to rt, the mixture was diluted with water (250 mL) and extracted with EtOAc (3 × 250 mL). The combined organic layers were washed with brine (250 mL), dried (NaSO<sub>4</sub>), filtered, and concentrated. The crude product was purified by silica gel chromatography (20/80, EtOAc/heptane) to provide 14.6 g (92%) of <b>40a</b> as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.55 (t, <i>J</i> = 6.2 Hz, 1 H), 8.31 (s, 1 H), 7.19 (t, <i>J</i> = 8.1 Hz, 1 H), 6.74–6.89 (m, 3 H), 4.44 (d, <i>J</i> = 6.3 Hz, 2 H), 3.69 (s, 3 H), 2.75 (s, 3 H). MS (ES+) <i>m</i>/<i>z</i> 283 (M + H).</div></div><div id="sec5_1_53" class="NLM_sec NLM_sec_level_2"><div id="ac_i74" class="anchor-spacer"></div><h3 class="article-section__title" id="_i74"> 6-Cyano-<i>N</i>-(4-fluoro-3-methoxybenzyl)-2-methylpyrimidine-4-carboxamide (<b>40b</b>)</h3><div class="NLM_p last">A mixture of 4-fluoro-3-methoxybenzylamine hydrochloride (13.5 g, 70.6 mmol) and diisopropylethylamine (29.2 g, 226 mmol) in methanol (56 mL) was stirred for 15 min at rt. Compound <b>39</b> (10.0 g, 56.4 mmol) was added, and the reaction mixture was heated at 35 °C for 1 h. The methanol was removed in vacuo, and the residue was partitioned between EtOAc (500 mL) and 1 N HCl (500 mL). The aqueous layer was extracted with EtOAc (2 × 250 mL). The combined organic layers were washed with saturated aqueous sodium bicarbonate (2 × 250 mL) followed by brine (250 mL), dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and concentrated. The crude product was purified by silica gel chromatography (1/2, EtOAc/heptane) to provide 11.7 g (69%) of <b>40b</b> as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.58 (t, <i>J</i> = 6.2 Hz, 1 H), 8.32 (s, 1 H), 7.04–7.19 (m, 2 H), 6.79–6.90 (m, 1 H), 4.44 (d, <i>J</i> = 6.2 Hz, 2 H), 3.78 (s, 3 H), 2.76 (s, 3 H). MS (ES+) <i>m</i>/<i>z</i> 301 (M + H).</div></div><div id="sec5_1_54" class="NLM_sec NLM_sec_level_2"><div id="ac_i75" class="anchor-spacer"></div><h3 class="article-section__title" id="_i75"> <i>N</i>-(3-Methoxybenzyl)-2-methyl-6-(2<i>H</i>-tetrazol-5-yl)pyrimidine-4-carboxamide (<b>41a</b>)</h3><div class="NLM_p last">A suspension of <b>40a</b> (14.2 g, 50.3 mmol), sodium azide (3.60 g, 55.3 mmol), and zinc bromide (11.3 g, 50.3 mmol) in water (112 mL) was heated at reflux for 16 h. <i><b>CAUTION!</b> Tetrazoles represent an explosion hazard at elevated temperatures. Adequate blast shielding is recommended.</i> After the mixture cooled to rt, 6 N HCl (180 mL) was added, and the mixture was stirred vigorously for 1 h. The resulting solids were collected by vacuum filtration, rinsed with 6 N HCl (3 × 100 mL) followed by water (2 × 100 mL), and dried at 55 °C under vacuum to provide 15.0 g (92%) of <b>40a</b> as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.53 (t, <i>J</i> = 6.4 Hz, 1 H), 8.42 (s, 1 H), 7.21 (t, <i>J</i> = 8.2 Hz, 1 H), 6.86–6.91 (m, 2 H), 6.76–6.82 (m, 1 H), 4.48 (d, <i>J</i> = 6.6 Hz, 2 H), 3.70 (s, 3 H), 2.82 (s, 3 H). MS (ES+) <i>m</i>/<i>z</i> 326 (M + H).</div></div><div id="sec5_1_55" class="NLM_sec NLM_sec_level_2"><div id="ac_i76" class="anchor-spacer"></div><h3 class="article-section__title" id="_i76"> <i>N</i>-(4-Fluoro-3-methoxybenzyl)-2-methyl-6-(2<i>H</i>-tetrazol-5-yl)pyrimidine-4-carboxamide (<b>41b</b>)</h3><div class="NLM_p last">Following conditions analogous to those described for <b>41a</b>, reaction of <b>40b</b> (4.80 g, 16.0 mmol) provided 5.45 g (99%) of <b>41b</b> as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.55 (t, <i>J</i> = 6.4 Hz, 1 H), 8.42 (s, 1 H), 7.06–7.20 (m, 2 H), 6.81–6.94 (m, 1 H), 4.47 (d, <i>J</i> = 6.4 Hz, 2 H), 3.79 (s, 3 H), 2.82 (s, 3 H). MS (ES+) <i>m</i>/<i>z</i> 344 (M + H).</div></div><div id="sec5_1_56" class="NLM_sec NLM_sec_level_2"><div id="ac_i77" class="anchor-spacer"></div><h3 class="article-section__title" id="_i77"> <i>rac</i>-<i>N</i>-(3-Methoxybenzyl)-6-(2-(((2<i>S</i>*,5<i>R</i>*)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2<i>H</i>-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide (<b>42</b>)</h3><div class="NLM_p last">A mixture of <i><b>rac</b></i><b>-16</b> (4.3 g, 14.0 mmol), <b>41a</b> (3.2 g, 9.8 mmol), and triethylamine (2.0 g, 19.7 mmol) in anhydrous DMA (4 mL) was heated at 85 °C for 18 h. The reaction mixture was purified by reverse phase preparative HPLC to afford 1.38 g (31%) of <b>42</b> as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.52–9.44 (m, 1 H), 8.42 (s, 1 H), 7.24 (t, <i>J</i> = 8.1 Hz, 1 H), 6.95–6.89 (m, 2 H), 6.83 (d, <i>J</i> = 8.1 Hz, 1 H), 4.93 (d, <i>J</i> = 3.3 Hz, 1 H), 4.88 (d, <i>J</i> = 7.7 Hz, 1 H), 4.51 (d, <i>J</i> = 5.9 Hz, 3 H), 4.08 (d, <i>J</i> = 3.3 Hz, 1 H), 3.99 (d, <i>J</i> = 11.3 Hz, 1 H), 3.78 (d, <i>J</i> = 11.3 Hz, 1 H), 3.74 (s, 3 H), 3.48–3.36 (m, 4 H), 3.31 (d, <i>J</i> = 2.2 Hz, 1H), 2.83 (s, 3 H). MS (ES+) <i>m</i>/<i>z</i> 456 (M + H).</div></div><div id="sec5_1_57" class="NLM_sec NLM_sec_level_2"><div id="ac_i78" class="anchor-spacer"></div><h3 class="article-section__title" id="_i78"> <i>N</i>-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2<i>S</i>,5<i>R</i>)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2<i>H</i>-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide (<b>43a</b>)</h3><div class="NLM_p last">A mixture of <b>(2</b><i><b>R</b></i><b>,5</b><i><b>R</b></i><b>)-16</b> (12.4 g, 41.0 mmol), <b>41b</b> (10.0 g, 29.1 mmol), and triethylamine (7.04 g, 69.7 mmol) in anhydrous DMA (31 mL) was heated at 85 °C for 18 h. After cooling to rt, the mixture was diluted with water (300 mL) and extracted with dichloromethane (3 × 200 mL). The combined organic layers were washed with 1 N NaOH (2 × 100 mL), 1 M HCl (2 × 100 mL), water (100 mL), and brine (250 mL). The organic layer was dried (Na<sub>2</sub>SO<sub>4</sub>), filtered, and evaporated. The residue was purified by silica gel chromatography (heptane/EtOAc/methanol, 50/45/5). The resulting mixture of regioisomers was separated by SFC (OJ-H, 30 mm × 250 mm, 40% methanol, 70 mL/min), and the desired isomer was recrystallized from EtOAc/ethanol (80/1, 80 mL) to provide 3.5 g (25%) of <b>43a</b> as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.53 (t, <i>J</i> = 6.3 Hz, 1 H), 8.39 (s, 1 H), 7.19–7.06 (m, 2 H), 6.91–6.83 (m, 1 H), 4.98–4.78 (m, 2 H), 4.68 (t, <i>J</i> = 5.7 Hz, 1 H), 4.47 (d, <i>J</i> = 6.4 Hz, 2 H), 4.10–3.99 (m, 1 H), 3.96 (dd, <i>J</i> = 11.4, 2.4 Hz, 1 H), 3.79 (s, 3 H), 3.74 (dd, <i>J</i> = 11.4, 2.2 Hz, 1 H), 3.47–3.19 (m, 5 H), 2.80 (s, 3 H). MS (ES+) <i>m</i>/<i>z</i> 474 (M + H).</div></div><div id="sec5_1_58" class="NLM_sec NLM_sec_level_2"><div id="ac_i79" class="anchor-spacer"></div><h3 class="article-section__title" id="_i79"> <i>N</i>-(4-Fluoro-3-methoxybenzyl)-6-(2-(((2<i>R</i>,5<i>S</i>)-5-(hydroxymethyl)-1,4-dioxan-2-yl)methyl)-2<i>H</i>-tetrazol-5-yl)-2-methylpyrimidine-4-carboxamide (<b>43b</b>)</h3><div class="NLM_p last">Analogous to the procedures for <b>43a</b>, <b>(2</b><i><b>S</b></i><b>,5</b><i><b>S</b></i><b>)-16</b> (5.2 g, 17.2 mmol) was reacted with <b>41b</b> (4.22 g, 12.3 mmol). The minor regioisomer was removed by SFC (OJ-H, 30 mm × 250 mm, 45% acetonitrile, 70 mL/min), and the desired isomer was recrystallized from EtOAc to afford 1.5 g (26%) of <b>43b</b> as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) δ 9.50 (t, <i>J</i> = 6.2 Hz, 1 H), 8.42 (s, 1 H), 7.17–7.08 (m, 2 H), 6.90–6.85 (m, 1 H), 4.95–4.80 (m, 2 H), 4.69 (t, <i>J</i> = 5.5 Hz, 1 H), 4.47 (d, <i>J</i> = 6.2 Hz, 2 H), 4.09–3.93 (m, 2 H), 3.79 (s, 3 H), 3.77–3.71 (m, 1 H), 3.45–3.20 (m, 5 H), 2.79 (s, 3 H). MS (ES+) <i>m</i>/<i>z</i> 474 (M + H).</div></div><div id="sec5_1_59" class="NLM_sec NLM_sec_level_2"><div id="ac_i80" class="anchor-spacer"></div><h3 class="article-section__title" id="_i80"> (2<i>S</i>,5<i>S</i>)-5-((5-(6-((4-Fluoro-3-methoxybenzyl)carbamoyl)-2-methylpyrimidin-4-yl)-2<i>H</i>-tetrazol-2-yl)methyl)-1,4-dioxane-2-carboxylic acid (<b>45</b>)</h3><div class="NLM_p last">A mixture of <b>43a</b> (952 mg, 2.0 mmol) and pyridinium dichromate (4.61 g, 12.0 mmol) in DMF (20.0 mL) was shaken for 36 h at rt. The reaction mixture was poured into EtOAc (250 mL) and washed with 1 N HCl solution (2 × 50 mL). The organic layer was dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated. The residue was suspended in 1 N sodium hydroxide solution and extracted with EtOAc. The aqueous layer was acidified to pH 2 with concentrated HCl and extracted with dichloromethane. The combined organic layers were dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated. The resulting oil was purified by reverse phase HPLC. The acetonitrile was removed in vacuo, and the aqueous residue was extracted with dichloromethane (2 × 50 mL). The combined organic layers were concentrated. The crude product was triturated with ethyl ether (3×) to afford 361 mg (37%) of <b>45</b> as a white solid. <sup>1</sup>H NMR (400 MHz, DMSO-<i>d</i><sub>6</sub>) 13.03 (s, 1 H), 9.58 (t, <i>J</i> = 6.4 Hz, 1 H), 8.42 (s, 1 H), 7.21–7.17 (m, <i>J</i> = 8.5, 1.5 Hz, 1 H), 7.18–7.11 (dd, <i>J</i> = 11.6, 8.4 Hz, 1 H), 6.93–6.88 (m, 1 H), 4.98 (dd, <i>J</i> = 14.3, 3.8 Hz, 1 H), 4.91 (dd, <i>J</i> = 14.2, 7.9 Hz, 1 H), 4.50 (d, <i>J</i> = 6.3 Hz, 2 H), 4.17–4.05 (m, 3 H), 3.95 (dd, <i>J</i> = 11.8, 2.9 Hz, 1 H), 3.82 (s, 3 H), 3.49 (dt, <i>J</i> = 18.1, 10.8 Hz, 2 H), 2.83 (s, 3 H). MS (ES+) <i>m</i>/<i>z</i> 488 (M + H).</div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i81" class="anchor-spacer"></div><h3 class="article-section__title" id="_i81"> Collagenase Activity</h3><div class="NLM_p last">Apparent inhibition constants (<i>K</i><sub>i,app</sub>) were determined using the synthetic quenched fluorescent peptide substrate MCA-Arg-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-Glu-Arg-NH<sub>2</sub> as previously described.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> Full-length recombinant human proteins were used for MMPs 1, 2, 9, and 13. The catalytic domain of the protein was used for MMPs 3, 7, 8, 10, 12, 14, 15, 16, 20, 24, 25, and 26. Selectivity against ADAM-17 (TACE), ADAMTS-4 (aggrecanase 1), and ADAMTS-5 (aggrecanase 2) was determined as previously described.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a></div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i82" class="anchor-spacer"></div><h3 class="article-section__title" id="_i82"> In Vivo Animal Studies</h3><div class="NLM_p">All procedures performed on animals were in accordance with regulations and established guidelines and were reviewed and approved by Pfizer Institutional Animal Care and Use Committee.</div><div class="NLM_p">For determination of rat in vivo clearance, each test compound was dissolved in 70% PEG400/10% ethanol/20% normal saline vehicle at 0.5 mg/mL and dosed at 2 mL/kg via IV bolus to <i>N</i> = 2 male Sprague–Dawley IGS rats weighing 250–300 g. Blood was collected over a 24 h time course, and following centrifugation the resulting plasma samples were precipitated with acetonitrile and analyzed for test compound concentration using an LC-MS/MS procedure. PK parameters were calculated from plasma concentration–time curves using noncompartmental analysis in Watson LIMS. For cassette dose PK, the procedure was identical except five compounds were dissolved in vehicle at 0.1 mg/mL each and dosed simultaneously, resulting in a combined total dose by mass that was the same as for singleton PK.</div><div class="NLM_p">For dog PK, test compounds were dosed orally as a suspension in 0.5% Methocel/0.1% TWEEN80 to fasted male beagle dogs. Compounds were dosed at 5 mL/kg by gavage in a cassette experiment (<i>N</i> = 5/cassette) such that each animal received a dose equivalent to 1.0 mg/kg of each compound in a single experiment. Blood collection, sample processing, concentration determination, and PK calculations were identical to the procedure used for rat PK.</div><div class="NLM_p last">In cynomolgus monkeys, compound <b>43a</b> was administered once daily by oral gavage using a 50% drug load spray-dried dispersion formulation in a 50% by weight aqueous sucrose solution. Doses of 50, 100, and 1000 mg kg<sup>–1</sup> day<sup>–1</sup> were administered for 14 days (one male and one female per dose group). Gross necropsy observations, clinical pathology, and histopathology of the kidneys were evaluated.</div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i83"><a href="/doi/suppl/10.1021/acs.jmedchem.5b01434">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_13144" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_13144" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.5b01434" class="ext-link">10.1021/acs.jmedchem.5b01434</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">Synthesis and X-ray data collection for the crystal structure of compound <b>44</b> and pharmacokinetic parameters of compounds <b>14i</b>, <b>42</b>, and <b>43b</b> in rat and compound <b>43a</b> in rat, dog, and cynomolgus monkey.(<a href="/doi/suppl/10.1021/acs.jmedchem.5b01434/suppl_file/jm5b01434_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">SMILES representations of compounds with MMP13/FL <i>K</i><sub>i</sub> (<a href="/doi/suppl/10.1021/acs.jmedchem.5b01434/suppl_file/jm5b01434_si_002.xlsx" class="ext-link">XLSX</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.5b01434/suppl_file/jm5b01434_si_001.pdf">jm5b01434_si_001.pdf (179.65 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.5b01434/suppl_file/jm5b01434_si_002.xlsx">jm5b01434_si_002.xlsx (12.93 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.5b01434" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_38605" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_38605" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mark E. Schnute</span> - <span class="hlFld-Affiliation affiliation">†Worldwide Medicinal Chemistry and ‡Inflammation
and Immunology Research, Pfizer, 610 Main Street, Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Pharmacokinetics,
Dynamics, and Metabolism, Pfizer, 700 North Main Street, Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Drug
Safety, Pfizer, 1 Burtt Road, Andover, Massachusetts 01810, United States</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#84e9e5f6efaae1aaf7e7eceaf1f0e1c4f4e2edfee1f6aae7ebe9"><span class="__cf_email__" data-cfemail="9ff2feedf4b1fab1ecfcf7f1eaebfadfeff9f6e5faedb1fcf0f2">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Peter G. Ruminski</span> - <span class="hlFld-Affiliation affiliation">†Worldwide Medicinal Chemistry and ‡Inflammation
and Immunology Research, Pfizer, 610 Main Street, Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Pharmacokinetics,
Dynamics, and Metabolism, Pfizer, 700 North Main Street, Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Drug
Safety, Pfizer, 1 Burtt Road, Andover, Massachusetts 01810, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Mark Massa</span> - <span class="hlFld-Affiliation affiliation">†Worldwide Medicinal Chemistry and ‡Inflammation
and Immunology Research, Pfizer, 610 Main Street, Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Pharmacokinetics,
Dynamics, and Metabolism, Pfizer, 700 North Main Street, Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Drug
Safety, Pfizer, 1 Burtt Road, Andover, Massachusetts 01810, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Joseph Strohbach</span> - <span class="hlFld-Affiliation affiliation">†Worldwide Medicinal Chemistry and ‡Inflammation
and Immunology Research, Pfizer, 610 Main Street, Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Pharmacokinetics,
Dynamics, and Metabolism, Pfizer, 700 North Main Street, Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Drug
Safety, Pfizer, 1 Burtt Road, Andover, Massachusetts 01810, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Cathleen E. Hanau</span> - <span class="hlFld-Affiliation affiliation">†Worldwide Medicinal Chemistry and ‡Inflammation
and Immunology Research, Pfizer, 610 Main Street, Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Pharmacokinetics,
Dynamics, and Metabolism, Pfizer, 700 North Main Street, Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Drug
Safety, Pfizer, 1 Burtt Road, Andover, Massachusetts 01810, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michelle Schmidt</span> - <span class="hlFld-Affiliation affiliation">†Worldwide Medicinal Chemistry and ‡Inflammation
and Immunology Research, Pfizer, 610 Main Street, Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Pharmacokinetics,
Dynamics, and Metabolism, Pfizer, 700 North Main Street, Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Drug
Safety, Pfizer, 1 Burtt Road, Andover, Massachusetts 01810, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jeffrey A. Scholten</span> - <span class="hlFld-Affiliation affiliation">†Worldwide Medicinal Chemistry and ‡Inflammation
and Immunology Research, Pfizer, 610 Main Street, Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Pharmacokinetics,
Dynamics, and Metabolism, Pfizer, 700 North Main Street, Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Drug
Safety, Pfizer, 1 Burtt Road, Andover, Massachusetts 01810, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Theresa R. Fletcher</span> - <span class="hlFld-Affiliation affiliation">†Worldwide Medicinal Chemistry and ‡Inflammation
and Immunology Research, Pfizer, 610 Main Street, Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Pharmacokinetics,
Dynamics, and Metabolism, Pfizer, 700 North Main Street, Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Drug
Safety, Pfizer, 1 Burtt Road, Andover, Massachusetts 01810, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Bruce C. Hamper</span> - <span class="hlFld-Affiliation affiliation">†Worldwide Medicinal Chemistry and ‡Inflammation
and Immunology Research, Pfizer, 610 Main Street, Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Pharmacokinetics,
Dynamics, and Metabolism, Pfizer, 700 North Main Street, Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Drug
Safety, Pfizer, 1 Burtt Road, Andover, Massachusetts 01810, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jeffery N. Carroll</span> - <span class="hlFld-Affiliation affiliation">†Worldwide Medicinal Chemistry and ‡Inflammation
and Immunology Research, Pfizer, 610 Main Street, Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Pharmacokinetics,
Dynamics, and Metabolism, Pfizer, 700 North Main Street, Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Drug
Safety, Pfizer, 1 Burtt Road, Andover, Massachusetts 01810, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Huey S. Shieh</span> - <span class="hlFld-Affiliation affiliation">†Worldwide Medicinal Chemistry and ‡Inflammation
and Immunology Research, Pfizer, 610 Main Street, Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Pharmacokinetics,
Dynamics, and Metabolism, Pfizer, 700 North Main Street, Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Drug
Safety, Pfizer, 1 Burtt Road, Andover, Massachusetts 01810, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Nicole Caspers</span> - <span class="hlFld-Affiliation affiliation">†Worldwide Medicinal Chemistry and ‡Inflammation
and Immunology Research, Pfizer, 610 Main Street, Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Pharmacokinetics,
Dynamics, and Metabolism, Pfizer, 700 North Main Street, Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Drug
Safety, Pfizer, 1 Burtt Road, Andover, Massachusetts 01810, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Brandon Collins</span> - <span class="hlFld-Affiliation affiliation">†Worldwide Medicinal Chemistry and ‡Inflammation
and Immunology Research, Pfizer, 610 Main Street, Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Pharmacokinetics,
Dynamics, and Metabolism, Pfizer, 700 North Main Street, Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Drug
Safety, Pfizer, 1 Burtt Road, Andover, Massachusetts 01810, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Margaret Grapperhaus</span> - <span class="hlFld-Affiliation affiliation">†Worldwide Medicinal Chemistry and ‡Inflammation
and Immunology Research, Pfizer, 610 Main Street, Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Pharmacokinetics,
Dynamics, and Metabolism, Pfizer, 700 North Main Street, Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Drug
Safety, Pfizer, 1 Burtt Road, Andover, Massachusetts 01810, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Katherine E. Palmquist</span> - <span class="hlFld-Affiliation affiliation">†Worldwide Medicinal Chemistry and ‡Inflammation
and Immunology Research, Pfizer, 610 Main Street, Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Pharmacokinetics,
Dynamics, and Metabolism, Pfizer, 700 North Main Street, Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Drug
Safety, Pfizer, 1 Burtt Road, Andover, Massachusetts 01810, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Joe Collins</span> - <span class="hlFld-Affiliation affiliation">†Worldwide Medicinal Chemistry and ‡Inflammation
and Immunology Research, Pfizer, 610 Main Street, Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Pharmacokinetics,
Dynamics, and Metabolism, Pfizer, 700 North Main Street, Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Drug
Safety, Pfizer, 1 Burtt Road, Andover, Massachusetts 01810, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">John E. Baldus</span> - <span class="hlFld-Affiliation affiliation">†Worldwide Medicinal Chemistry and ‡Inflammation
and Immunology Research, Pfizer, 610 Main Street, Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Pharmacokinetics,
Dynamics, and Metabolism, Pfizer, 700 North Main Street, Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Drug
Safety, Pfizer, 1 Burtt Road, Andover, Massachusetts 01810, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Jeffrey Hitchcock</span> - <span class="hlFld-Affiliation affiliation">†Worldwide Medicinal Chemistry and ‡Inflammation
and Immunology Research, Pfizer, 610 Main Street, Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Pharmacokinetics,
Dynamics, and Metabolism, Pfizer, 700 North Main Street, Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Drug
Safety, Pfizer, 1 Burtt Road, Andover, Massachusetts 01810, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">H. Peter Kleine</span> - <span class="hlFld-Affiliation affiliation">†Worldwide Medicinal Chemistry and ‡Inflammation
and Immunology Research, Pfizer, 610 Main Street, Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Pharmacokinetics,
Dynamics, and Metabolism, Pfizer, 700 North Main Street, Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Drug
Safety, Pfizer, 1 Burtt Road, Andover, Massachusetts 01810, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael D. Rogers</span> - <span class="hlFld-Affiliation affiliation">†Worldwide Medicinal Chemistry and ‡Inflammation
and Immunology Research, Pfizer, 610 Main Street, Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Pharmacokinetics,
Dynamics, and Metabolism, Pfizer, 700 North Main Street, Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Drug
Safety, Pfizer, 1 Burtt Road, Andover, Massachusetts 01810, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Joseph McDonald</span> - <span class="hlFld-Affiliation affiliation">†Worldwide Medicinal Chemistry and ‡Inflammation
and Immunology Research, Pfizer, 610 Main Street, Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Pharmacokinetics,
Dynamics, and Metabolism, Pfizer, 700 North Main Street, Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Drug
Safety, Pfizer, 1 Burtt Road, Andover, Massachusetts 01810, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Grace E. Munie</span> - <span class="hlFld-Affiliation affiliation">†Worldwide Medicinal Chemistry and ‡Inflammation
and Immunology Research, Pfizer, 610 Main Street, Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Pharmacokinetics,
Dynamics, and Metabolism, Pfizer, 700 North Main Street, Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Drug
Safety, Pfizer, 1 Burtt Road, Andover, Massachusetts 01810, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dean M. Messing</span> - <span class="hlFld-Affiliation affiliation">Pharmacokinetics,
Dynamics, and Metabolism, Pfizer, 700 North Main Street, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Silvia Portolan</span> - <span class="hlFld-Affiliation affiliation">Pharmacokinetics,
Dynamics, and Metabolism, Pfizer, 700 North Main Street, Cambridge, Massachusetts 02139, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Laurence O. Whiteley</span> - <span class="hlFld-Affiliation affiliation">Drug
Safety, Pfizer, 1 Burtt Road, Andover, Massachusetts 01810, United States</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Teresa Sunyer</span> - <span class="hlFld-Affiliation affiliation">†Worldwide Medicinal Chemistry and ‡Inflammation
and Immunology Research, Pfizer, 610 Main Street, Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Pharmacokinetics,
Dynamics, and Metabolism, Pfizer, 700 North Main Street, Cambridge, Massachusetts 02139, United States</span>; 
    <span class="hlFld-Affiliation affiliation">Drug
Safety, Pfizer, 1 Burtt Road, Andover, Massachusetts 01810, United States</span></div></li></ul></li><li></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ACK-d7e5834-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i84">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_27880" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_27880" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank Jon Bordner for single crystal X-ray data collection, members of Pfizer pharmacokinetics and drug metabolism group for in vivo exposure and metabolite characterization, and members of Pfizer drug safety group for in vivo toxicology support.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i85" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i85"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i86" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i86"> Abbreviations</h2><tr><td class="NLM_term">AUC</td><td class="NLM_def"><p class="first last">area under the curve</p></td></tr><tr><td class="NLM_term">CD</td><td class="NLM_def"><p class="first last">catalytic domain</p></td></tr><tr><td class="NLM_term">CL</td><td class="NLM_def"><p class="first last">clearance</p></td></tr><tr><td class="NLM_term">%<i>F</i></td><td class="NLM_def"><p class="first last">bioavailability (fraction bioavailable)</p></td></tr><tr><td class="NLM_term">DABCO</td><td class="NLM_def"><p class="first last">1,4-diazabicyclo[2.2.2]octane</p></td></tr><tr><td class="NLM_term">DBAD</td><td class="NLM_def"><p class="first last">di-<i>tert</i>-butyl azodicarboxylate</p></td></tr><tr><td class="NLM_term">DCE</td><td class="NLM_def"><p class="first last">dichloroethane</p></td></tr><tr><td class="NLM_term">DMA</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-dimethylacetamide</p></td></tr><tr><td class="NLM_term">DMAP</td><td class="NLM_def"><p class="first last">4-(dimethylamino)pyridine</p></td></tr><tr><td class="NLM_term">DMF</td><td class="NLM_def"><p class="first last"><i>N</i>,<i>N</i>-dimethylformamide</p></td></tr><tr><td class="NLM_term">DMSO</td><td class="NLM_def"><p class="first last">dimethyl sulfoxide</p></td></tr><tr><td class="NLM_term">dppf</td><td class="NLM_def"><p class="first last">1,1′-bis(diphenylphosphino)ferrocene</p></td></tr><tr><td class="NLM_term">EDCI</td><td class="NLM_def"><p class="first last">1-ethyl-3-(3′-dimethylaminopropyl)carbodiimide hydrochloride</p></td></tr><tr><td class="NLM_term">EtOAc</td><td class="NLM_def"><p class="first last">ethyl acetate</p></td></tr><tr><td class="NLM_term">FL</td><td class="NLM_def"><p class="first last">full length</p></td></tr><tr><td class="NLM_term">HLM</td><td class="NLM_def"><p class="first last">human liver microsomes</p></td></tr><tr><td class="NLM_term">HPLC</td><td class="NLM_def"><p class="first last">high-pressure liquid chromatography</p></td></tr><tr><td class="NLM_term">LC-MS/MS</td><td class="NLM_def"><p class="first last">liquid chromatography-tandem mass spectrometry</p></td></tr><tr><td class="NLM_term">LIPE</td><td class="NLM_def"><p class="first last">lipophilic ligand efficiency</p></td></tr><tr><td class="NLM_term">MMP</td><td class="NLM_def"><p class="first last">matrix metalloproteinase</p></td></tr><tr><td class="NLM_term">PPB</td><td class="NLM_def"><p class="first last">plasma protein binding</p></td></tr><tr><td class="NLM_term">rt</td><td class="NLM_def"><p class="first last">room temperature</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationships</p></td></tr><tr><td class="NLM_term">SFC</td><td class="NLM_def"><p class="first last">supercritical fluid chromatography</p></td></tr><tr><td class="NLM_term"><i>T</i><sub>1/2</sub></td><td class="NLM_def"><p class="first last">half-life</p></td></tr><tr><td class="NLM_term">TFA</td><td class="NLM_def"><p class="first last">trifluoroacetic acid</p></td></tr><tr><td class="NLM_term">THF</td><td class="NLM_def"><p class="first last">tetrahydrofuran</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i87">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_42234" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_42234" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 29 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Lawrence, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Felson, D. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Helmick, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arnold, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deyo, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gabriel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirsch, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hochberg, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunder, G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jordan, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katz, J. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kremers, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolfe, F.</span><span> </span><span class="NLM_article-title">Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II</span> <span class="citation_source-journal">Arthritis Rheum.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">26</span><span class="NLM_x">–</span> <span class="NLM_lpage">35</span><span class="refDoi"> DOI: 10.1002/art.23176</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01434&amp;key=10.1002%2Fart.23176" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01434&amp;key=18163497" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01434&amp;key=1%3ACAS%3A280%3ADC%252BD1c%252Flt1Ghsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2008&pages=26-35&author=R.+C.+Lawrenceauthor=D.+T.+Felsonauthor=C.+G.+Helmickauthor=L.+M.+Arnoldauthor=H.+Choiauthor=R.+A.+Deyoauthor=S.+Gabrielauthor=R.+Hirschauthor=M.+C.+Hochbergauthor=G.+C.+Hunderauthor=J.+M.+Jordanauthor=J.+N.+Katzauthor=H.+M.+Kremersauthor=F.+Wolfe&title=Estimates+of+the+prevalence+of+arthritis+and+other+rheumatic+conditions+in+the+United+States.+Part+II&doi=10.1002%2Fart.23176"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II</span></div><div class="casAuthors">Lawrence Reva C; Felson David T; Helmick Charles G; Arnold Lesley M; Choi Hyon; Deyo Richard A; Gabriel Sherine; Hirsch Rosemarie; Hochberg Marc C; Hunder Gene G; Jordan Joanne M; Katz Jeffrey N; Kremers Hilal Maradit; Wolfe Frederick</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis and rheumatism</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">26-35</span>
        ISSN:<span class="NLM_cas:issn">0004-3591</span>.
    </div><div class="casAbstract">OBJECTIVE:  To provide a single source for the best available estimates of the US prevalence of and number of individuals affected by osteoarthritis, polymyalgia rheumatica and giant cell arteritis, gout, fibromyalgia, and carpal tunnel syndrome, as well as the symptoms of neck and back pain.  A companion article (part I) addresses additional conditions.  METHODS:  The National Arthritis Data Workgroup reviewed published analyses from available national surveys, such as the National Health and Nutrition Examination Survey and the National Health Interview Survey.  Because data based on national population samples are unavailable for most specific rheumatic conditions, we derived estimates from published studies of smaller, defined populations.  For specific conditions, the best available prevalence estimates were applied to the corresponding 2005 US population estimates from the Census Bureau, to estimate the number affected with each condition.  RESULTS:  We estimated that among US adults, nearly 27 million have clinical osteoarthritis (up from the estimate of 21 million for 1995), 711,000 have polymyalgia rheumatica, 228,000 have giant cell arteritis, up to 3.0 million have had self-reported gout in the past year (up from the estimate of 2.1 million for 1995), 5.0 million have fibromyalgia, 4-10 million have carpal tunnel syndrome, 59 million have had low back pain in the past 3 months, and 30.1 million have had neck pain in the past 3 months.  CONCLUSION:  Estimates for many specific rheumatic conditions rely on a few, small studies of uncertain generalizability to the US population.  This report provides the best available prevalence estimates for the US, but for most specific conditions more studies generalizable to the US or addressing understudied populations are needed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTRoGBggfl_DDdblLE_E9PWfW6udTcc2ea224UUANEyZrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1c%252Flt1Ghsw%253D%253D&md5=8fb852bfb01285c89db9c7d87369e167</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1002%2Fart.23176&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.23176%26sid%3Dliteratum%253Aachs%26aulast%3DLawrence%26aufirst%3DR.%2BC.%26aulast%3DFelson%26aufirst%3DD.%2BT.%26aulast%3DHelmick%26aufirst%3DC.%2BG.%26aulast%3DArnold%26aufirst%3DL.%2BM.%26aulast%3DChoi%26aufirst%3DH.%26aulast%3DDeyo%26aufirst%3DR.%2BA.%26aulast%3DGabriel%26aufirst%3DS.%26aulast%3DHirsch%26aufirst%3DR.%26aulast%3DHochberg%26aufirst%3DM.%2BC.%26aulast%3DHunder%26aufirst%3DG.%2BC.%26aulast%3DJordan%26aufirst%3DJ.%2BM.%26aulast%3DKatz%26aufirst%3DJ.%2BN.%26aulast%3DKremers%26aufirst%3DH.%2BM.%26aulast%3DWolfe%26aufirst%3DF.%26atitle%3DEstimates%2520of%2520the%2520prevalence%2520of%2520arthritis%2520and%2520other%2520rheumatic%2520conditions%2520in%2520the%2520United%2520States.%2520Part%2520II%26jtitle%3DArthritis%2520Rheum.%26date%3D2008%26volume%3D58%26spage%3D26%26epage%3D35%26doi%3D10.1002%2Fart.23176" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Johnson, V. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunter, D. J.</span><span> </span><span class="NLM_article-title">The epidemiology of osteoarthritis</span> <span class="citation_source-journal">Best Pract. Res., Clin. Rheumatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">5</span><span class="NLM_x">–</span> <span class="NLM_lpage">15</span><span class="refDoi"> DOI: 10.1016/j.berh.2014.01.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01434&amp;key=10.1016%2Fj.berh.2014.01.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01434&amp;key=24792942" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01434&amp;key=1%3ACAS%3A280%3ADC%252BC2cfgsVOqug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2014&pages=5-15&author=V.+L.+Johnsonauthor=D.+J.+Hunter&title=The+epidemiology+of+osteoarthritis&doi=10.1016%2Fj.berh.2014.01.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">The epidemiology of osteoarthritis</span></div><div class="casAuthors">Johnson Victoria L; Hunter David J</div><div class="citationInfo"><span class="NLM_cas:title">Best practice & research. Clinical rheumatology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">5-15</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Osteoarthritis (OA) is a leading cause of disability and its incidence is rising due to increasing obesity and an ageing population.  Risk factors can be divided into person-level factors, such as age, sex, obesity, genetics, race/ethnicity and diet, and joint-level factors including injury, malalignment and abnormal loading of the joints.  The interaction of these risk factors is complex and provides a challenge to the managing physician.  The purpose of this review is to illustrate how each of these factors interact together to instigate incident OA as well as to outline the need for ongoing epidemiologic studies for the future prevention of both incident and progressive OA.  It is only by understanding the impact of this disease and the modifiable risk factors that we will be able to truly target public health prevention interventions appropriately.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSoYx3AVD8nQDjk2McQZ6XmfW6udTcc2ea224UUANEyZrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cfgsVOqug%253D%253D&md5=d8b2c00e1eb2f40c89932f54b6904785</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.berh.2014.01.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.berh.2014.01.004%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DV.%2BL.%26aulast%3DHunter%26aufirst%3DD.%2BJ.%26atitle%3DThe%2520epidemiology%2520of%2520osteoarthritis%26jtitle%3DBest%2520Pract.%2520Res.%252C%2520Clin.%2520Rheumatol.%26date%3D2014%26volume%3D28%26spage%3D5%26epage%3D15%26doi%3D10.1016%2Fj.berh.2014.01.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">Felson, D. T.</span><span> </span><span class="NLM_article-title">Osteoarthritis of the Knee</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">354</span><span class="NLM_x">, </span> <span class="NLM_fpage">841</span><span class="NLM_x">–</span> <span class="NLM_lpage">848</span><span class="refDoi"> DOI: 10.1056/NEJMcp051726</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01434&amp;key=10.1056%2FNEJMcp051726" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01434&amp;key=16495396" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01434&amp;key=1%3ACAS%3A528%3ADC%252BD28Xhsl2gsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=354&publication_year=2006&pages=841-848&author=D.+T.+Felson&title=Osteoarthritis+of+the+Knee&doi=10.1056%2FNEJMcp051726"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Osteoarthritis of the knee</span></div><div class="casAuthors">Felson, David T.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">354</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">841-848</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">A 66-yr old woman who is overweight reports bilateral knee pain of gradual onset during the past several months that increasingly has limited her activities.  Last week, when walking down the stairs, she nearly fell when her knee gave way.  She does not recall having injured her knee, and has no morning stiffness and no pain in other joints.  She has tried taking up to eight extra-strength (500 mg each) acetaminophen tablets daily without successes and has never had ulcers or stomach bleeding.  How should the patient be evaluated and treated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTCATV64Md1bVg90H21EOLACvtfcHk0lhmRIEYKHPsiw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xhsl2gsL8%253D&md5=cf1550c58f79fcd220d8e540c31b47c1</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1056%2FNEJMcp051726&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMcp051726%26sid%3Dliteratum%253Aachs%26aulast%3DFelson%26aufirst%3DD.%2BT.%26atitle%3DOsteoarthritis%2520of%2520the%2520Knee%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2006%26volume%3D354%26spage%3D841%26epage%3D848%26doi%3D10.1056%2FNEJMcp051726" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Hellio le Graverand, M.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clemmer, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Redifer, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brunell, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayes, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brandt, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abramson, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manning, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vignon, E.</span><span> </span><span class="NLM_article-title">A 2-year randomised, double-blind, placebo-controlled, multicentre study of oral selective iNOS inhibitor, cindunistat (SD-6010), in patients with symptomatic osteoarthritis of the knee</span> <span class="citation_source-journal">Ann. Rheum. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x">, </span> <span class="NLM_fpage">187</span><span class="NLM_x">–</span> <span class="NLM_lpage">195</span><span class="refDoi"> DOI: 10.1136/annrheumdis-2012-202239</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01434&amp;key=10.1136%2Fannrheumdis-2012-202239" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01434&amp;key=23144445" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01434&amp;key=1%3ACAS%3A280%3ADC%252BC3s7is1Wjsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2013&pages=187-195&author=M.-P.+Hellio+le+Graverandauthor=R.+S.+Clemmerauthor=P.+Rediferauthor=R.+M.+Brunellauthor=C.+W.+Hayesauthor=K.+D.+Brandtauthor=S.+B.+Abramsonauthor=P.+M.+Manningauthor=C.+G.+Millerauthor=E.+Vignon&title=A+2-year+randomised%2C+double-blind%2C+placebo-controlled%2C+multicentre+study+of+oral+selective+iNOS+inhibitor%2C+cindunistat+%28SD-6010%29%2C+in+patients+with+symptomatic+osteoarthritis+of+the+knee&doi=10.1136%2Fannrheumdis-2012-202239"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">A 2-year randomised, double-blind, placebo-controlled, multicentre study of oral selective iNOS inhibitor, cindunistat (SD-6010), in patients with symptomatic osteoarthritis of the knee</span></div><div class="casAuthors">Hellio le Graverand Marie-Pierre; Clemmer Ray S; Redifer Patricia; Brunell Robert M; Hayes Curtis W; Brandt Kenneth D; Abramson Steven B; Manning Pamela T; Miller Colin G; Vignon Eric</div><div class="citationInfo"><span class="NLM_cas:title">Annals of the rheumatic diseases</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">187-95</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVE:  To determine if inhibition of inducible nitric oxide synthase (iNOS) with cindunistat hydrochloride maleate slows progression of osteoarthritis (OA)   METHODS:  This 2-year, multinational, double-blind, placebo-controlled trial enrolled patients with symptomatic knee OA (Kellgren and Lawrence Grade (KLG) 2 or 3).  Standard OA therapies were permitted throughout.  Patients were randomly assigned to cindunistat (50 or 200 mg/day) or placebo.  Randomisation was stratified by KLG.  Radiographs to assess joint space narrowing (JSN) were acquired using the modified Lyon-schuss protocol at baseline, week 48 and 96.  RESULTS:  Of 1457 patients (50 mg/day, n=485; 200 mg/day, n=486; placebo, n=486), 1048 (71.9%) completed the study.  Patients were predominantly women; 56% had KLG3.  The primary analysis did not demonstrate superiority of cindunistat versus placebo for rate of change in JSN.  In KLG2 patients, JSN after 48 weeks was lower with cindunistat 50 mg/day versus placebo (p=0.032).  Least-squares mean±SE JSN with cindunistat 50 mg/day ( -0.048±0.028 mm) and 200 mg/day (-0.062±0.028 mm) were 59.9% (95% CI 6.8% to 106.9%) and 48.7% (95% CI -8.4% to 93.9%) of placebo, improvement was not maintained at 96 weeks.  No improvement was observed for KLG3 patients at either time-point.  Cindunistat did not improve joint pain or function, but was generally well tolerated.  CONCLUSIONS:  Cindunistat (50 or 200 mg/day) did not slow the rate of JSN versus placebo.  After 48-weeks, KLG2 patients showed less JSN; however, the improvement was not sustained at 96-weeks. iNOS inhibition did not slow OA progression in KLG3 patients.  CLINICAL TRIAL LISTING:  NCT00565812.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSMKkgHsOL37TAyhZbj3lKdfW6udTcc2eYWfJXXDpPTG7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3s7is1Wjsg%253D%253D&md5=8336d2789698ffc1f9fd2861c3530419</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1136%2Fannrheumdis-2012-202239&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fannrheumdis-2012-202239%26sid%3Dliteratum%253Aachs%26aulast%3DHellio%2Ble%2BGraverand%26aufirst%3DM.-P.%26aulast%3DClemmer%26aufirst%3DR.%2BS.%26aulast%3DRedifer%26aufirst%3DP.%26aulast%3DBrunell%26aufirst%3DR.%2BM.%26aulast%3DHayes%26aufirst%3DC.%2BW.%26aulast%3DBrandt%26aufirst%3DK.%2BD.%26aulast%3DAbramson%26aufirst%3DS.%2BB.%26aulast%3DManning%26aufirst%3DP.%2BM.%26aulast%3DMiller%26aufirst%3DC.%2BG.%26aulast%3DVignon%26aufirst%3DE.%26atitle%3DA%25202-year%2520randomised%252C%2520double-blind%252C%2520placebo-controlled%252C%2520multicentre%2520study%2520of%2520oral%2520selective%2520iNOS%2520inhibitor%252C%2520cindunistat%2520%2528SD-6010%2529%252C%2520in%2520patients%2520with%2520symptomatic%2520osteoarthritis%2520of%2520the%2520knee%26jtitle%3DAnn.%2520Rheum.%2520Dis.%26date%3D2013%26volume%3D72%26spage%3D187%26epage%3D195%26doi%3D10.1136%2Fannrheumdis-2012-202239" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Little, C. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barai, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burkhardt, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fosang, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Werb, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, E. W.</span><span> </span><span class="NLM_article-title">Matrix metalloproteinase 13-deficient mice are resistant to osteoarthritic cartilage erosion but not chondrocyte hypertrophy or osteophyte development</span> <span class="citation_source-journal">Arthritis Rheum.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">3723</span><span class="NLM_x">–</span> <span class="NLM_lpage">3733</span><span class="refDoi"> DOI: 10.1002/art.25002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01434&amp;key=10.1002%2Fart.25002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01434&amp;key=19950295" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01434&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFKhtb%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2009&pages=3723-3733&author=C.+B.+Littleauthor=A.+Baraiauthor=D.+Burkhardtauthor=S.+M.+Smithauthor=A.+J.+Fosangauthor=Z.+Werbauthor=M.+Shahauthor=E.+W.+Thompson&title=Matrix+metalloproteinase+13-deficient+mice+are+resistant+to+osteoarthritic+cartilage+erosion+but+not+chondrocyte+hypertrophy+or+osteophyte+development&doi=10.1002%2Fart.25002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Matrix metalloproteinase 13-deficient mice are resistant to osteoarthritic cartilage erosion but not chondrocyte hypertrophy or osteophyte development</span></div><div class="casAuthors">Little, C. B.; Barai, A.; Burkhardt, D.; Smith, S. M.; Fosang, A. J.; Werb, Z.; Shah, M.; Thompson, E. W.</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis & Rheumatism</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3723-3733</span>CODEN:
                <span class="NLM_cas:coden">ARHEAW</span>;
        ISSN:<span class="NLM_cas:issn">0004-3591</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">To investigate the role of matrix metalloproteinase 13 (MMP-13; collagenase 3) in osteoarthritis (OA).  OA was surgically induced in the knees of MMP-13-knockout mice and wild-type mice, and mice were compared.  Histol. scoring of femoral and tibial cartilage aggrecan loss (0-3 scale), erosion (0-7 scale), and chondrocyte hypertrophy (0-1 scale), as well as osteophyte size (0-3 scale) and maturity (0-3 scale) was performed.  Serial sections were stained for type X collagen and the MMP-generated aggrecan neoepitope DIPEN.  Following surgery, aggrecan loss and cartilage erosion were more severe in the tibia than femur (P < 0.01) and tibial cartilage erosion increased with time (P < 0.05) in wild-type mice.  Cartilaginous osteophytes were present at 4 wk and underwent ossification, with size and maturity increasing by 8 wk (P < 0.01).  There was no difference between genotypes in aggrecan loss or cartilage erosion at 4 wk.  There was less tibial cartilage erosion in knock- out mice than in wild-type mice at 8 wk (P < 0.02).  Cartilaginous osteophytes were larger in knockout mice at 4 wk (P < 0.01), but by 8 wk osteophyte maturity and size were no different from those in wild-type mice.  Articular chondrocyte hypertrophy with pos. type X collagen and DIPEN staining occurred in both wild-type and knockout mouse joints.  Our findings indicate that structural cartilage damage in a mouse model of OA is dependent on MMP-13 activity.  Chondrocyte hypertrophy is not regulated by MMP-13 activity in this model and does not in itself lead to cartilage erosion.  MMP-13 deficiency can inhibit cartilage erosion in the presence of aggrecan depletion, supporting the potential for therapeutic intervention in established OA with MMP-13 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplFkB0jtAForVg90H21EOLACvtfcHk0liheMC8z3LWbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFKhtb%252FI&md5=995b082b9fb21a8b0a242b4703461a48</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1002%2Fart.25002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.25002%26sid%3Dliteratum%253Aachs%26aulast%3DLittle%26aufirst%3DC.%2BB.%26aulast%3DBarai%26aufirst%3DA.%26aulast%3DBurkhardt%26aufirst%3DD.%26aulast%3DSmith%26aufirst%3DS.%2BM.%26aulast%3DFosang%26aufirst%3DA.%2BJ.%26aulast%3DWerb%26aufirst%3DZ.%26aulast%3DShah%26aufirst%3DM.%26aulast%3DThompson%26aufirst%3DE.%2BW.%26atitle%3DMatrix%2520metalloproteinase%252013-deficient%2520mice%2520are%2520resistant%2520to%2520osteoarthritic%2520cartilage%2520erosion%2520but%2520not%2520chondrocyte%2520hypertrophy%2520or%2520osteophyte%2520development%26jtitle%3DArthritis%2520Rheum.%26date%3D2009%26volume%3D60%26spage%3D3723%26epage%3D3733%26doi%3D10.1002%2Fart.25002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Johnson, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pavlovsky, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ortwine, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prior, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Man, C.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bornemeier, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banotai, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mueller, W. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McConnell, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baragi, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lesch, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roark, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Datta, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guzman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, H.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dyer, R. D.</span><span> </span><span class="NLM_article-title">Discovery and characterization of a novel inhibitor of matrix metalloprotease-13 that reduces cartilage damage in vivo without joint fibroplasia side effects</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">282</span><span class="NLM_x">, </span> <span class="NLM_fpage">27781</span><span class="NLM_x">–</span> <span class="NLM_lpage">27791</span><span class="refDoi"> DOI: 10.1074/jbc.M703286200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01434&amp;key=10.1074%2Fjbc.M703286200" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=282&publication_year=2007&pages=27781-27791&author=A.+R.+Johnsonauthor=A.+G.+Pavlovskyauthor=D.+F.+Ortwineauthor=F.+Priorauthor=C.-F.+Manauthor=D.+A.+Bornemeierauthor=C.+A.+Banotaiauthor=W.+T.+Muellerauthor=P.+McConnellauthor=C.+Yanauthor=V.+Baragiauthor=C.+Leschauthor=W.+H.+Roarkauthor=M.+Wilsonauthor=K.+Dattaauthor=R.+Guzmanauthor=H.-K.+Hanauthor=R.+D.+Dyer&title=Discovery+and+characterization+of+a+novel+inhibitor+of+matrix+metalloprotease-13+that+reduces+cartilage+damage+in+vivo+without+joint+fibroplasia+side+effects&doi=10.1074%2Fjbc.M703286200"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M703286200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M703286200%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DA.%2BR.%26aulast%3DPavlovsky%26aufirst%3DA.%2BG.%26aulast%3DOrtwine%26aufirst%3DD.%2BF.%26aulast%3DPrior%26aufirst%3DF.%26aulast%3DMan%26aufirst%3DC.-F.%26aulast%3DBornemeier%26aufirst%3DD.%2BA.%26aulast%3DBanotai%26aufirst%3DC.%2BA.%26aulast%3DMueller%26aufirst%3DW.%2BT.%26aulast%3DMcConnell%26aufirst%3DP.%26aulast%3DYan%26aufirst%3DC.%26aulast%3DBaragi%26aufirst%3DV.%26aulast%3DLesch%26aufirst%3DC.%26aulast%3DRoark%26aufirst%3DW.%2BH.%26aulast%3DWilson%26aufirst%3DM.%26aulast%3DDatta%26aufirst%3DK.%26aulast%3DGuzman%26aufirst%3DR.%26aulast%3DHan%26aufirst%3DH.-K.%26aulast%3DDyer%26aufirst%3DR.%2BD.%26atitle%3DDiscovery%2520and%2520characterization%2520of%2520a%2520novel%2520inhibitor%2520of%2520matrix%2520metalloprotease-13%2520that%2520reduces%2520cartilage%2520damage%2520in%2520vivo%2520without%2520joint%2520fibroplasia%2520side%2520effects%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2007%26volume%3D282%26spage%3D27781%26epage%3D27791%26doi%3D10.1074%2Fjbc.M703286200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Baragi, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Becher, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bendele, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biesinger, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bluhm, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deng, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dodd, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Essers, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feuerstein, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallagher, B. M.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gege, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hochgürtel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hofmann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaworski, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiely, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Korniski, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kroth, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nix, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nolte, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piecha, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powers, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richter, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schneider, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steeneck, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sucholeiki, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taveras, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Timmermann, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Veldhuizen, J. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weik, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, B.</span><span> </span><span class="NLM_article-title">A new class of potent matrix metalloproteinase 13 inhibitors for potential treatment of osteoarthritis evidence of histologic and clinical efficacy without musculoskeletal toxicity in rat models</span> <span class="citation_source-journal">Arthritis Rheum.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">2008</span><span class="NLM_x">–</span> <span class="NLM_lpage">2018</span><span class="refDoi"> DOI: 10.1002/art.24629</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01434&amp;key=10.1002%2Fart.24629" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01434&amp;key=19565489" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01434&amp;key=1%3ACAS%3A528%3ADC%252BD1MXptlKku78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2009&pages=2008-2018&author=V.+M.+Baragiauthor=G.+Becherauthor=A.+M.+Bendeleauthor=R.+Biesingerauthor=H.+Bluhmauthor=J.+Boerauthor=H.+Dengauthor=R.+Doddauthor=M.+Essersauthor=T.+Feuersteinauthor=B.+M.+Gallagherauthor=C.+Gegeauthor=M.+Hochg%C3%BCrtelauthor=M.+Hofmannauthor=A.+Jaworskiauthor=L.+Jinauthor=A.+Kielyauthor=B.+Korniskiauthor=H.+Krothauthor=D.+Nixauthor=B.+Nolteauthor=D.+Piechaauthor=T.+S.+Powersauthor=F.+Richterauthor=M.+Schneiderauthor=C.+Steeneckauthor=I.+Sucholeikiauthor=A.+Taverasauthor=A.+Timmermannauthor=J.+V.+Veldhuizenauthor=J.+Weikauthor=X.+Wuauthor=B.+Xia&title=A+new+class+of+potent+matrix+metalloproteinase+13+inhibitors+for+potential+treatment+of+osteoarthritis+evidence+of+histologic+and+clinical+efficacy+without+musculoskeletal+toxicity+in+rat+models&doi=10.1002%2Fart.24629"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">A new class of potent matrix metalloproteinase 13 inhibitors for potential treatment of osteoarthritis. Evidence of histologic and clinical efficacy without musculoskeletal toxicity in rat models</span></div><div class="casAuthors">Baragi, Vijaykumar M.; Becher, Gabriel; Bendele, Alison M.; Biesinger, Ralf; Bluhm, Harald; Boer, Jurgen; Deng, Hongbo; Dodd, Rory; Essers, Michael; Feuerstein, Tim; Gallagher, Brian M., Jr.; Gege, Christian; Hochgurtel, Matthias; Hofmann, Michael; Jaworski, Andreas; Jin, Lixia; Kiely, Andrew; Korniski, Brian; Kroth, Heiko; Nix, Darrell; Nolte, Bert; Piecha, Dorothea; Powers, Timothy S.; Richter, Frank; Schneider, Matthias; Steeneck, Christoph; Sucholeiki, Irving; Taveras, Arthur; Timmermann, Andreas; van Veldhuizen, Joshua; Weik, Juergen; Wu, Xinyuan; Xia, Bing</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis & Rheumatism</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2008-2018</span>CODEN:
                <span class="NLM_cas:coden">ARHEAW</span>;
        ISSN:<span class="NLM_cas:issn">0004-3591</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Objective: Matrix metalloproteinases (MMPs) have long been considered excellent targets for osteoarthritis (OA) treatment.  However, clin. utility of broad-spectrum MMP inhibitors developed for this purpose has been restricted by dose-limiting musculoskeletal side effects obsd. in humans.  This study was undertaken to identify a new class of potent and selective MMP-13 inhibitors that would provide histol. and clin. efficacy without musculoskeletal toxicity.  Methods. Selectivity assays were developed using catalytic domains of human MMPs.  Freshly isolated bovine articular cartilage or human OA cartilage was used in in vitro cartilage degrdn. assays.  The rat model of monoiodoacetate (MIA)-induced OA was implemented for assessing the effects of MMP-13 inhibitors on cartilage degrdn. and joint pain.  The surgical medial meniscus tear model in rats was used to evaluate the chondroprotective ability of MMP-13 inhibitors in a chronic disease model of OA.  The rat model of musculoskeletal side effects (MSS) was used to assess whether selective MMP-13 inhibitors have the joint toxicity assocd. with broad-spectrum MMP inhibitors.  Results. A no. of non-hydroxamic acid-contg. compds. that showed a high degree of potency for MMP-13 and selectivity against other MMPs were designed and synthesized.  Steady-state kinetics expts. and Lineweaver-Burk plot anal. of rate vs. substrate concn. with one such compd., ALS 1-0635, indicated linear, noncompetitive inhibition, and Dixon plot anal. from competition studies with a zinc chelator (acetoxyhydroxamic acid) and ALS 1-0635 demonstrated nonexclusive binding.  ALS 1-0635 inhibited bovine articular cartilage degrdn. in a dose-dependent manner (48.7% and 87.1% at 500 nM and 5,000 nM, resp.) and was effective in inhibiting interleukin-1α- and oncostatin M-induced C1,C2 release in human OA cartilage cultures.  ALS 1-0635 modulated cartilage damage in the rat MIA model (mean ± SEM damage score 1.3 ± 0.3, vs. 2.2 ± 0.4 in vehicle-treated animals).  Most significantly, when treated twice daily with oral ALS 1-0635, rats with surgically induced medial meniscus tear exhibited histol. evidence of chondroprotection and reduced cartilage degeneration, without observable musculoskeletal toxicity.  Conclusion. The compds. investigated in this study represent a novel class of MMP-13 inhibitors.  They are mechanistically distinct from previously reported broad-spectrum MMP inhibitors and do not exhibit the problems previously assocd. with these inhibitors, including selectivity, poor pharmacokinetics, and MSS liability.  MMP-13 inhibitors exert chondro-protective effects and can potentially modulate joint pain, and are, therefore, uniquely suited as potential disease-modifying osteoarthritis drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWH6P91ktaKrVg90H21EOLACvtfcHk0lgDN-l6iov4QA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXptlKku78%253D&md5=87a8b16eaf252bf4fd3c28217a78f8d6</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1002%2Fart.24629&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.24629%26sid%3Dliteratum%253Aachs%26aulast%3DBaragi%26aufirst%3DV.%2BM.%26aulast%3DBecher%26aufirst%3DG.%26aulast%3DBendele%26aufirst%3DA.%2BM.%26aulast%3DBiesinger%26aufirst%3DR.%26aulast%3DBluhm%26aufirst%3DH.%26aulast%3DBoer%26aufirst%3DJ.%26aulast%3DDeng%26aufirst%3DH.%26aulast%3DDodd%26aufirst%3DR.%26aulast%3DEssers%26aufirst%3DM.%26aulast%3DFeuerstein%26aufirst%3DT.%26aulast%3DGallagher%26aufirst%3DB.%2BM.%26aulast%3DGege%26aufirst%3DC.%26aulast%3DHochg%25C3%25BCrtel%26aufirst%3DM.%26aulast%3DHofmann%26aufirst%3DM.%26aulast%3DJaworski%26aufirst%3DA.%26aulast%3DJin%26aufirst%3DL.%26aulast%3DKiely%26aufirst%3DA.%26aulast%3DKorniski%26aufirst%3DB.%26aulast%3DKroth%26aufirst%3DH.%26aulast%3DNix%26aufirst%3DD.%26aulast%3DNolte%26aufirst%3DB.%26aulast%3DPiecha%26aufirst%3DD.%26aulast%3DPowers%26aufirst%3DT.%2BS.%26aulast%3DRichter%26aufirst%3DF.%26aulast%3DSchneider%26aufirst%3DM.%26aulast%3DSteeneck%26aufirst%3DC.%26aulast%3DSucholeiki%26aufirst%3DI.%26aulast%3DTaveras%26aufirst%3DA.%26aulast%3DTimmermann%26aufirst%3DA.%26aulast%3DVeldhuizen%26aufirst%3DJ.%2BV.%26aulast%3DWeik%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DXia%26aufirst%3DB.%26atitle%3DA%2520new%2520class%2520of%2520potent%2520matrix%2520metalloproteinase%252013%2520inhibitors%2520for%2520potential%2520treatment%2520of%2520osteoarthritis%2520evidence%2520of%2520histologic%2520and%2520clinical%2520efficacy%2520without%2520musculoskeletal%2520toxicity%2520in%2520rat%2520models%26jtitle%3DArthritis%2520Rheum.%26date%3D2009%26volume%3D60%26spage%3D2008%26epage%3D2018%26doi%3D10.1002%2Fart.24629" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Wojtowicz-Praga, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Torri, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steen, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marshall, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ness, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dickson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sale, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rasmussen, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiodo, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hawkins, M. J.</span><span> </span><span class="NLM_article-title">Phase I trial of marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">2150</span><span class="NLM_x">–</span> <span class="NLM_lpage">2156</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01434&amp;key=9626215" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01434&amp;key=1%3ACAS%3A528%3ADyaK1cXktV2isbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1998&pages=2150-2156&author=S.+Wojtowicz-Pragaauthor=J.+Torriauthor=M.+Johnsonauthor=V.+Steenauthor=J.+Marshallauthor=E.+Nessauthor=R.+Dicksonauthor=M.+Saleauthor=H.+S.+Rasmussenauthor=T.+A.+Chiodoauthor=M.+J.+Hawkins&title=Phase+I+trial+of+marimastat%2C+a+novel+matrix+metalloproteinase+inhibitor%2C+administered+orally+to+patients+with+advanced+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I trial of marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer</span></div><div class="casAuthors">Wojtowicz-Praga, Slawomir; Torri, Jeff; Johnson, Michael; Steen, Virginia; Marshall, John; Ness, Elizabeth; Dickson, Robert; Sale, Mark; Rasmussen, Henrik S.; Chiodo, Tina Avanzato; Hawkins, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2150-2156</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">W. B. Saunders Co.</span>)
        </div><div class="casAbstract">This phase I study was performed to evaluate the safety and pharmacokinetics of escalating doses of Marimastat (British Biotech, Inc, Oxford, United Kingdom) in patients with advanced malignancies and to det. the phase II recommended dose to be used in subsequent studies.  A std. phase I design was used in this study, in which consecutive groups of three patients were treated with escalating doses of the study drug.  Marimastat was administered orally at 25, 50, or 100 mg twice daily to consecutive groups of patients with advanced lung cancer.  An addnl. three patients were added at the highest dose studied (100 mg orally twice daily) to assess whether the inflammatory polyarthritis obsd. at that dose level can be prevented by a concurrent administration of nonsteroidal antiinflammatory drugs (NSAIDS) and/or low-dose corticosteroids.  Blood was drawn for safety monitoring, pharmacokinetic anal., and plasma levels of metallo-proteinase (MMP)-2 and MMP-9 (detd. by zymog.).  A total of 12 patients were studied.  The most significant toxicity at the highest dose studied (100 mg orally twice daily) was a symptomatic inflammatory polyarthritis that persisted for up to 8 wk after discontinuation of the study drug and was dose-limiting.  The estd. plasma elimination half-life of Marimastat was 4 to 5 h.  The mean max. concn. (Cmax) at a reasonably well-tolerated dose (50 mg orally twice daily) was 196 ng/mL and was reached within 1 to 2 h (Tmax) after administration.  Areas under the curve (AUC) tended to correlate with the dose of Marimastat.  Zymog. anal. of peripheral-blood ratios of activated pro-enzymic forms of MMP-2 and -9 did not show any consistent patterns of change in MMP levels or in a degree of their activation during the course of treatment.  Marimastat was well absorbed from the gastrointestinal tract, with high levels of the study drug detected in plasma within hours after drug administration.  Plasma concns. of Marimastat achieved at dose levels 2 and 3 (50 mg and 100 mg orally twice daily) were substantially higher than those required for MMP inhibition in vitro.  The dose-limiting toxicity (DLT) was severe inflammatory polyarthritis, which seemed to be a cumulative toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_9iFywtSW1LVg90H21EOLACvtfcHk0lgDN-l6iov4QA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXktV2isbo%253D&md5=5d9d5362f38d4c6130fcd72e0a902d48</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWojtowicz-Praga%26aufirst%3DS.%26aulast%3DTorri%26aufirst%3DJ.%26aulast%3DJohnson%26aufirst%3DM.%26aulast%3DSteen%26aufirst%3DV.%26aulast%3DMarshall%26aufirst%3DJ.%26aulast%3DNess%26aufirst%3DE.%26aulast%3DDickson%26aufirst%3DR.%26aulast%3DSale%26aufirst%3DM.%26aulast%3DRasmussen%26aufirst%3DH.%2BS.%26aulast%3DChiodo%26aufirst%3DT.%2BA.%26aulast%3DHawkins%26aufirst%3DM.%2BJ.%26atitle%3DPhase%2520I%2520trial%2520of%2520marimastat%252C%2520a%2520novel%2520matrix%2520metalloproteinase%2520inhibitor%252C%2520administered%2520orally%2520to%2520patients%2520with%2520advanced%2520lung%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D1998%26volume%3D16%26spage%3D2150%26epage%3D2156" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Stickens, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Behonick, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ortega, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heyer, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartenstein, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fosang, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schorpp-Kistner, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angel, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Werb, Z.</span><span> </span><span class="NLM_article-title">Altered endochondral bone development in matrix metalloproteinase 13-deficient mice</span> <span class="citation_source-journal">Development</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">131</span><span class="NLM_x">, </span> <span class="NLM_fpage">5883</span><span class="NLM_x">–</span> <span class="NLM_lpage">5895</span><span class="refDoi"> DOI: 10.1242/dev.01461</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01434&amp;key=10.1242%2Fdev.01461" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01434&amp;key=15539485" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01434&amp;key=1%3ACAS%3A528%3ADC%252BD2MXnslersg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2004&pages=5883-5895&author=D.+Stickensauthor=D.+J.+Behonickauthor=N.+Ortegaauthor=B.+Heyerauthor=B.+Hartensteinauthor=Y.+Yuauthor=A.+J.+Fosangauthor=M.+Schorpp-Kistnerauthor=P.+Angelauthor=Z.+Werb&title=Altered+endochondral+bone+development+in+matrix+metalloproteinase+13-deficient+mice&doi=10.1242%2Fdev.01461"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Altered endochondral bone development in matrix metalloproteinase 13-deficient mice</span></div><div class="casAuthors">Stickens, Dominique; Behonick, Danielle J.; Ortega, Nathalie; Heyer, Babette; Hartenstein, Bettina; Yu, Ying; Fosang, Amanda J.; Schorpp-Kistner, Marina; Angel, Peter; Werb, Zena</div><div class="citationInfo"><span class="NLM_cas:title">Development (Cambridge, United Kingdom)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">131</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">5883-5895</span>CODEN:
                <span class="NLM_cas:coden">DEVPED</span>;
        ISSN:<span class="NLM_cas:issn">0950-1991</span>.
    
            (<span class="NLM_cas:orgname">Company of Biologists Ltd.</span>)
        </div><div class="casAbstract">The assembly and degrdn. of extracellular matrix (ECM) mols. are crucial processes during bone development.  In this study, we show that ECM remodeling is a crit. rate-limiting step in endochondral bone formation.  Matrix metalloproteinase (MMP) 13 (collagenase 3) is poised to play a crucial role in bone formation and remodeling because of its expression both in terminal hypertrophic chondrocytes in the growth plate and in osteoblasts.  Moreover, a mutation in the human MMP13 gene causes the Missouri variant of spondyloepimetaphyseal dysplasia.  Inactivation of Mmp13 in mice through homologous recombination led to abnormal skeletal growth plate development.  Chondrocytes differentiated normally but their exit from the growth plate was delayed.  The severity of the Mmp13-null growth plate phenotype increased until about 5 wk and completely resolved by 12 wk of age.  Mmp13-null mice had increased trabecular bone, which persisted for months.  Conditional inactivation of Mmp13 in chondrocytes and osteoblasts showed that increase in trabecular bone occur independently of the improper cartilage ECM degrdn. caused by Mmp13 deficiency in late hypertrophic chondrocytes.  Our studies identified the two major components of the cartilage ECM, collagen type II and aggrecan, as in vivo substrates for MMP13.  We found that degrdn. of cartilage collagen and aggrecan is a coordinated process in which MMP13 works synergistically with MMP9.  Mice lacking both MMP13 and MMP9 had severely impaired endochondral bone, characterized by diminished ECM remodeling, prolonged chondrocyte survival, delayed vascular recruitment and defective trabecular bone formation (resulting in drastically shortened bones).  These data support the hypothesis that proper ECM remodeling is the dominant rate-limiting process for programmed cell death, angiogenesis and osteoblast recruitment during normal skeletal morphogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJsfbwk37K8bVg90H21EOLACvtfcHk0lgDN-l6iov4QA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXnslersg%253D%253D&md5=704861e9cefe7fdde098bc493bfc3e0e</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1242%2Fdev.01461&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1242%252Fdev.01461%26sid%3Dliteratum%253Aachs%26aulast%3DStickens%26aufirst%3DD.%26aulast%3DBehonick%26aufirst%3DD.%2BJ.%26aulast%3DOrtega%26aufirst%3DN.%26aulast%3DHeyer%26aufirst%3DB.%26aulast%3DHartenstein%26aufirst%3DB.%26aulast%3DYu%26aufirst%3DY.%26aulast%3DFosang%26aufirst%3DA.%2BJ.%26aulast%3DSchorpp-Kistner%26aufirst%3DM.%26aulast%3DAngel%26aufirst%3DP.%26aulast%3DWerb%26aufirst%3DZ.%26atitle%3DAltered%2520endochondral%2520bone%2520development%2520in%2520matrix%2520metalloproteinase%252013-deficient%2520mice%26jtitle%3DDevelopment%26date%3D2004%26volume%3D131%26spage%3D5883%26epage%3D5895%26doi%3D10.1242%2Fdev.01461" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Kennedy, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inada, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krane, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christie, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harding, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">López-Otín, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sánchez, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pannett, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dearlove, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartley, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Byrne, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reed, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nesbit, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whyte, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thakker, R. V.</span><span> </span><span class="NLM_article-title">MMP13 mutation causes spondyloepimetaphyseal dysplasia, Missouri type (SEMDMO)</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">115</span><span class="NLM_x">, </span> <span class="NLM_fpage">2832</span><span class="NLM_x">–</span> <span class="NLM_lpage">2842</span><span class="refDoi"> DOI: 10.1172/JCI22900</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01434&amp;key=10.1172%2FJCI22900" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2005&pages=2832-2842&author=A.+M.+Kennedyauthor=M.+Inadaauthor=S.+M.+Kraneauthor=P.+T.+Christieauthor=B.+Hardingauthor=C.+L%C3%B3pez-Ot%C3%ADnauthor=L.+M.+S%C3%A1nchezauthor=A.+J.+Pannettauthor=A.+Dearloveauthor=C.+Hartleyauthor=M.+H.+Byrneauthor=A.+Reedauthor=M.+A.+Nesbitauthor=M.+P.+Whyteauthor=R.+V.+Thakker&title=MMP13+mutation+causes+spondyloepimetaphyseal+dysplasia%2C+Missouri+type+%28SEMDMO%29&doi=10.1172%2FJCI22900"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1172%2FJCI22900&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI22900%26sid%3Dliteratum%253Aachs%26aulast%3DKennedy%26aufirst%3DA.%2BM.%26aulast%3DInada%26aufirst%3DM.%26aulast%3DKrane%26aufirst%3DS.%2BM.%26aulast%3DChristie%26aufirst%3DP.%2BT.%26aulast%3DHarding%26aufirst%3DB.%26aulast%3DL%25C3%25B3pez-Ot%25C3%25ADn%26aufirst%3DC.%26aulast%3DS%25C3%25A1nchez%26aufirst%3DL.%2BM.%26aulast%3DPannett%26aufirst%3DA.%2BJ.%26aulast%3DDearlove%26aufirst%3DA.%26aulast%3DHartley%26aufirst%3DC.%26aulast%3DByrne%26aufirst%3DM.%2BH.%26aulast%3DReed%26aufirst%3DA.%26aulast%3DNesbit%26aufirst%3DM.%2BA.%26aulast%3DWhyte%26aufirst%3DM.%2BP.%26aulast%3DThakker%26aufirst%3DR.%2BV.%26atitle%3DMMP13%2520mutation%2520causes%2520spondyloepimetaphyseal%2520dysplasia%252C%2520Missouri%2520type%2520%2528SEMDMO%2529%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2005%26volume%3D115%26spage%3D2832%26epage%3D2842%26doi%3D10.1172%2FJCI22900" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Engel, C. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pirard, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schimanski, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirsch, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Habermann, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klingler, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlotte, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weithmann, K. U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wendt, K. U.</span><span> </span><span class="NLM_article-title">Structural basis for the highly selective inhibition of MMP-13</span> <span class="citation_source-journal">Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">181</span><span class="NLM_x">–</span> <span class="NLM_lpage">189</span><span class="refDoi"> DOI: 10.1016/j.chembiol.2004.11.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01434&amp;key=10.1016%2Fj.chembiol.2004.11.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01434&amp;key=15734645" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01434&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhslCmsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2005&pages=181-189&author=C.+K.+Engelauthor=B.+Pirardauthor=S.+Schimanskiauthor=R.+Kirschauthor=J.+Habermannauthor=O.+Klinglerauthor=V.+Schlotteauthor=K.+U.+Weithmannauthor=K.+U.+Wendt&title=Structural+basis+for+the+highly+selective+inhibition+of+MMP-13&doi=10.1016%2Fj.chembiol.2004.11.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Basis for the Highly Selective Inhibition of MMP-13</span></div><div class="casAuthors">Engel, Christian K.; Pirard, Bernard; Schimanski, Sandra; Kirsch, Reinhard; Habermann, Joerg; Klingler, Otmar; Schlotte, Volkhard; Weithmann, Klaus Ulrich; Wendt, K. Ulrich</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">181-189</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Summary: Inhibitors for matrix metalloproteinases (MMPs) are under investigation for the treatment of cancer, arthritis, and cardiovascular disease.  Here, the authors report a class of highly selective MMP-13 inhibitors (pyrimidine dicarboxamides) that exhibit no detectable activity against other MMPs.  The high-resoln. x-ray structures of three mols. of this series bound to MMP-13 reveal a novel binding mode characterized by the absence of interactions between the inhibitors and the catalytic zinc.  The inhibitors bind in the S1' pocket and extend into an addnl. S1' side pocket, which is unique to MMP-13.  The authors analyze the determinants for selectivity and describe the rational design of improved compds. with low nanomolar affinity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWxTXaerMLjLVg90H21EOLACvtfcHk0ljXnwuRoO8k7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhslCmsbY%253D&md5=92bf47d2ceb76db87ecae786fc89fc64</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2004.11.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2004.11.014%26sid%3Dliteratum%253Aachs%26aulast%3DEngel%26aufirst%3DC.%2BK.%26aulast%3DPirard%26aufirst%3DB.%26aulast%3DSchimanski%26aufirst%3DS.%26aulast%3DKirsch%26aufirst%3DR.%26aulast%3DHabermann%26aufirst%3DJ.%26aulast%3DKlingler%26aufirst%3DO.%26aulast%3DSchlotte%26aufirst%3DV.%26aulast%3DWeithmann%26aufirst%3DK.%2BU.%26aulast%3DWendt%26aufirst%3DK.%2BU.%26atitle%3DStructural%2520basis%2520for%2520the%2520highly%2520selective%2520inhibition%2520of%2520MMP-13%26jtitle%3DChem.%2520Biol.%26date%3D2005%26volume%3D12%26spage%3D181%26epage%3D189%26doi%3D10.1016%2Fj.chembiol.2004.11.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Li, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nahra, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bunker, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O'Brien, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yue, W.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ortwine, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Man, C.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baragi, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kilgore, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dyer, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, H.-K.</span><span> </span><span class="NLM_article-title">Quinazolinones and pyrido[3,4-d]pyrimidin-4-ones as orally active and specific matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">835</span><span class="NLM_x">–</span> <span class="NLM_lpage">841</span><span class="refDoi"> DOI: 10.1021/jm701274v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm701274v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=835-841&author=J.+J.+Liauthor=J.+Nahraauthor=A.+R.+Johnsonauthor=A.+Bunkerauthor=P.+O%27Brienauthor=W.-S.+Yueauthor=D.+F.+Ortwineauthor=C.-F.+Manauthor=V.+Baragiauthor=K.+Kilgoreauthor=R.+D.+Dyerauthor=H.-K.+Han&title=Quinazolinones+and+pyrido%5B3%2C4-d%5Dpyrimidin-4-ones+as+orally+active+and+specific+matrix+metalloproteinase-13+inhibitors+for+the+treatment+of+osteoarthritis&doi=10.1021%2Fjm701274v"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Fjm701274v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm701274v%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DJ.%2BJ.%26aulast%3DNahra%26aufirst%3DJ.%26aulast%3DJohnson%26aufirst%3DA.%2BR.%26aulast%3DBunker%26aufirst%3DA.%26aulast%3DO%2527Brien%26aufirst%3DP.%26aulast%3DYue%26aufirst%3DW.-S.%26aulast%3DOrtwine%26aufirst%3DD.%2BF.%26aulast%3DMan%26aufirst%3DC.-F.%26aulast%3DBaragi%26aufirst%3DV.%26aulast%3DKilgore%26aufirst%3DK.%26aulast%3DDyer%26aufirst%3DR.%2BD.%26aulast%3DHan%26aufirst%3DH.-K.%26atitle%3DQuinazolinones%2520and%2520pyrido%255B3%252C4-d%255Dpyrimidin-4-ones%2520as%2520orally%2520active%2520and%2520specific%2520matrix%2520metalloproteinase-13%2520inhibitors%2520for%2520the%2520treatment%2520of%2520osteoarthritis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D835%26epage%3D841%26doi%3D10.1021%2Fjm701274v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Schnute, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Brien, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nahra, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morris, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roark, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanau, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruminski, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scholten, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamper, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carroll, J. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patt, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shieh, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pavlovsky, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palmquist, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aston, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hitchcock, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rogers, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonald, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munie, G. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wittwer, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Man, C.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settle, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nemirovskiy, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vickery, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agawal, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dyer, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sunyer, T.</span><span> </span><span class="NLM_article-title">Discovery of (pyridin-4-yl)-2<i>H</i>-tetrazole as a novel scaffold to identify highly selective matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">576</span><span class="NLM_x">–</span> <span class="NLM_lpage">580</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2009.11.081</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01434&amp;key=10.1016%2Fj.bmcl.2009.11.081" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=576-580&author=M.+E.+Schnuteauthor=P.+M.+O%E2%80%99Brienauthor=J.+Nahraauthor=M.+Morrisauthor=W.+H.+Roarkauthor=C.+E.+Hanauauthor=P.+G.+Ruminskiauthor=J.+A.+Scholtenauthor=T.+R.+Fletcherauthor=B.+C.+Hamperauthor=J.+N.+Carrollauthor=W.+C.+Pattauthor=H.+S.+Shiehauthor=B.+Collinsauthor=A.+G.+Pavlovskyauthor=K.+E.+Palmquistauthor=K.+W.+Astonauthor=J.+Hitchcockauthor=M.+D.+Rogersauthor=J.+McDonaldauthor=A.+R.+Johnsonauthor=G.+E.+Munieauthor=A.+J.+Wittwerauthor=C.-F.+Manauthor=S.+L.+Settleauthor=O.+Nemirovskiyauthor=L.+E.+Vickeryauthor=A.+Agawalauthor=R.+D.+Dyerauthor=T.+Sunyer&title=Discovery+of+%28pyridin-4-yl%29-2H-tetrazole+as+a+novel+scaffold+to+identify+highly+selective+matrix+metalloproteinase-13+inhibitors+for+the+treatment+of+osteoarthritis&doi=10.1016%2Fj.bmcl.2009.11.081"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.11.081&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.11.081%26sid%3Dliteratum%253Aachs%26aulast%3DSchnute%26aufirst%3DM.%2BE.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DP.%2BM.%26aulast%3DNahra%26aufirst%3DJ.%26aulast%3DMorris%26aufirst%3DM.%26aulast%3DRoark%26aufirst%3DW.%2BH.%26aulast%3DHanau%26aufirst%3DC.%2BE.%26aulast%3DRuminski%26aufirst%3DP.%2BG.%26aulast%3DScholten%26aufirst%3DJ.%2BA.%26aulast%3DFletcher%26aufirst%3DT.%2BR.%26aulast%3DHamper%26aufirst%3DB.%2BC.%26aulast%3DCarroll%26aufirst%3DJ.%2BN.%26aulast%3DPatt%26aufirst%3DW.%2BC.%26aulast%3DShieh%26aufirst%3DH.%2BS.%26aulast%3DCollins%26aufirst%3DB.%26aulast%3DPavlovsky%26aufirst%3DA.%2BG.%26aulast%3DPalmquist%26aufirst%3DK.%2BE.%26aulast%3DAston%26aufirst%3DK.%2BW.%26aulast%3DHitchcock%26aufirst%3DJ.%26aulast%3DRogers%26aufirst%3DM.%2BD.%26aulast%3DMcDonald%26aufirst%3DJ.%26aulast%3DJohnson%26aufirst%3DA.%2BR.%26aulast%3DMunie%26aufirst%3DG.%2BE.%26aulast%3DWittwer%26aufirst%3DA.%2BJ.%26aulast%3DMan%26aufirst%3DC.-F.%26aulast%3DSettle%26aufirst%3DS.%2BL.%26aulast%3DNemirovskiy%26aufirst%3DO.%26aulast%3DVickery%26aufirst%3DL.%2BE.%26aulast%3DAgawal%26aufirst%3DA.%26aulast%3DDyer%26aufirst%3DR.%2BD.%26aulast%3DSunyer%26aufirst%3DT.%26atitle%3DDiscovery%2520of%2520%2528pyridin-4-yl%2529-2H-tetrazole%2520as%2520a%2520novel%2520scaffold%2520to%2520identify%2520highly%2520selective%2520matrix%2520metalloproteinase-13%2520inhibitors%2520for%2520the%2520treatment%2520of%2520osteoarthritis%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D576%26epage%3D580%26doi%3D10.1016%2Fj.bmcl.2009.11.081" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Nara, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sato, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naito, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mototani, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oki, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuno, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santou, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanzaki, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Terauchi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uchikawa, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kori, M.</span><span> </span><span class="NLM_article-title">Discovery of novel, highly potent, and selective quinazoline-2-carboxamide-based Matrix metalloproteinase (MMP)-13 inhibitors without a zinc binding group using a structure-based design approach</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">8886</span><span class="NLM_x">–</span> <span class="NLM_lpage">8902</span><span class="refDoi"> DOI: 10.1021/jm500981k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500981k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=8886-8902&author=H.+Naraauthor=K.+Satoauthor=T.+Naitoauthor=H.+Mototaniauthor=H.+Okiauthor=Y.+Yamamotoauthor=H.+Kunoauthor=T.+Santouauthor=N.+Kanzakiauthor=J.+Terauchiauthor=O.+Uchikawaauthor=M.+Kori&title=Discovery+of+novel%2C+highly+potent%2C+and+selective+quinazoline-2-carboxamide-based+Matrix+metalloproteinase+%28MMP%29-13+inhibitors+without+a+zinc+binding+group+using+a+structure-based+design+approach&doi=10.1021%2Fjm500981k"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Fjm500981k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500981k%26sid%3Dliteratum%253Aachs%26aulast%3DNara%26aufirst%3DH.%26aulast%3DSato%26aufirst%3DK.%26aulast%3DNaito%26aufirst%3DT.%26aulast%3DMototani%26aufirst%3DH.%26aulast%3DOki%26aufirst%3DH.%26aulast%3DYamamoto%26aufirst%3DY.%26aulast%3DKuno%26aufirst%3DH.%26aulast%3DSantou%26aufirst%3DT.%26aulast%3DKanzaki%26aufirst%3DN.%26aulast%3DTerauchi%26aufirst%3DJ.%26aulast%3DUchikawa%26aufirst%3DO.%26aulast%3DKori%26aufirst%3DM.%26atitle%3DDiscovery%2520of%2520novel%252C%2520highly%2520potent%252C%2520and%2520selective%2520quinazoline-2-carboxamide-based%2520Matrix%2520metalloproteinase%2520%2528MMP%2529-13%2520inhibitors%2520without%2520a%2520zinc%2520binding%2520group%2520using%2520a%2520structure-based%2520design%2520approach%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D8886%26epage%3D8902%26doi%3D10.1021%2Fjm500981k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Nara, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sato, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naito, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mototani, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oki, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuno, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santou, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanzaki, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Terauchi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uchikawa, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kori, M.</span><span> </span><span class="NLM_article-title">Thieno[2,3-d]pyrimidine-2-carboxamides bearing a carboxybenzene group at 5-position: Highly potent, selective, and orally available MMP-13 inhibitors interacting with the S1″ binding site</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">5487</span><span class="NLM_x">–</span> <span class="NLM_lpage">5505</span><span class="refDoi"> DOI: 10.1016/j.bmc.2014.07.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01434&amp;key=10.1016%2Fj.bmc.2014.07.025" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2014&pages=5487-5505&author=H.+Naraauthor=K.+Satoauthor=T.+Naitoauthor=H.+Mototaniauthor=H.+Okiauthor=Y.+Yamamotoauthor=H.+Kunoauthor=T.+Santouauthor=N.+Kanzakiauthor=J.+Terauchiauthor=O.+Uchikawaauthor=M.+Kori&title=Thieno%5B2%2C3-d%5Dpyrimidine-2-carboxamides+bearing+a+carboxybenzene+group+at+5-position%3A+Highly+potent%2C+selective%2C+and+orally+available+MMP-13+inhibitors+interacting+with+the+S1%E2%80%B3+binding+site&doi=10.1016%2Fj.bmc.2014.07.025"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2014.07.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2014.07.025%26sid%3Dliteratum%253Aachs%26aulast%3DNara%26aufirst%3DH.%26aulast%3DSato%26aufirst%3DK.%26aulast%3DNaito%26aufirst%3DT.%26aulast%3DMototani%26aufirst%3DH.%26aulast%3DOki%26aufirst%3DH.%26aulast%3DYamamoto%26aufirst%3DY.%26aulast%3DKuno%26aufirst%3DH.%26aulast%3DSantou%26aufirst%3DT.%26aulast%3DKanzaki%26aufirst%3DN.%26aulast%3DTerauchi%26aufirst%3DJ.%26aulast%3DUchikawa%26aufirst%3DO.%26aulast%3DKori%26aufirst%3DM.%26atitle%3DThieno%255B2%252C3-d%255Dpyrimidine-2-carboxamides%2520bearing%2520a%2520carboxybenzene%2520group%2520at%25205-position%253A%2520Highly%2520potent%252C%2520selective%252C%2520and%2520orally%2520available%2520MMP-13%2520inhibitors%2520interacting%2520with%2520the%2520S1%25E2%2580%25B3%2520binding%2520site%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2014%26volume%3D22%26spage%3D5487%26epage%3D5505%26doi%3D10.1016%2Fj.bmc.2014.07.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Gege, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bao, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bluhm, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallagher, B. M.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Korniski, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powers, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steeneck, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taveras, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baragi, V. M.</span><span> </span><span class="NLM_article-title">Discovery and evaluation of a non-Zn chelating, selective matrix metalloproteinase 13 (MMP-13) inhibitor for potential intra-articular treatment of osteoarthritis</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">709</span><span class="NLM_x">–</span> <span class="NLM_lpage">716</span><span class="refDoi"> DOI: 10.1021/jm201152u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201152u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=709-716&author=C.+Gegeauthor=B.+Baoauthor=H.+Bluhmauthor=J.+Boerauthor=B.+M.+Gallagherauthor=B.+Korniskiauthor=T.+S.+Powersauthor=C.+Steeneckauthor=A.+G.+Taverasauthor=V.+M.+Baragi&title=Discovery+and+evaluation+of+a+non-Zn+chelating%2C+selective+matrix+metalloproteinase+13+%28MMP-13%29+inhibitor+for+potential+intra-articular+treatment+of+osteoarthritis&doi=10.1021%2Fjm201152u"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fjm201152u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201152u%26sid%3Dliteratum%253Aachs%26aulast%3DGege%26aufirst%3DC.%26aulast%3DBao%26aufirst%3DB.%26aulast%3DBluhm%26aufirst%3DH.%26aulast%3DBoer%26aufirst%3DJ.%26aulast%3DGallagher%26aufirst%3DB.%2BM.%26aulast%3DKorniski%26aufirst%3DB.%26aulast%3DPowers%26aufirst%3DT.%2BS.%26aulast%3DSteeneck%26aufirst%3DC.%26aulast%3DTaveras%26aufirst%3DA.%2BG.%26aulast%3DBaragi%26aufirst%3DV.%2BM.%26atitle%3DDiscovery%2520and%2520evaluation%2520of%2520a%2520non-Zn%2520chelating%252C%2520selective%2520matrix%2520metalloproteinase%252013%2520%2528MMP-13%2529%2520inhibitor%2520for%2520potential%2520intra-articular%2520treatment%2520of%2520osteoarthritis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D709%26epage%3D716%26doi%3D10.1021%2Fjm201152u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Taylor, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abeywardane, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muegge, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padyana, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiong, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hill-Drzewi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farmer, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heim-Riether, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Proudfoot, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldberg, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zuvela-Jelaska, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaher, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farrow, N. A.</span><span> </span><span class="NLM_article-title">Fragment-based discovery of indole inhibitors of matrix metalloproteinase-13</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">8174</span><span class="NLM_x">–</span> <span class="NLM_lpage">8187</span><span class="refDoi"> DOI: 10.1021/jm201129m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201129m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=8174-8187&author=S.+J.+Taylorauthor=A.+Abeywardaneauthor=S.+Liangauthor=I.+Mueggeauthor=A.+K.+Padyanaauthor=Z.+Xiongauthor=M.+Hill-Drzewiauthor=B.+Farmerauthor=X.+Liauthor=B.+Collinsauthor=J.+X.+Liauthor=A.+Heim-Rietherauthor=J.+Proudfootauthor=Q.+Zhangauthor=D.+Goldbergauthor=L.+Zuvela-Jelaskaauthor=H.+Zaherauthor=J.+Liauthor=N.+A.+Farrow&title=Fragment-based+discovery+of+indole+inhibitors+of+matrix+metalloproteinase-13&doi=10.1021%2Fjm201129m"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fjm201129m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201129m%26sid%3Dliteratum%253Aachs%26aulast%3DTaylor%26aufirst%3DS.%2BJ.%26aulast%3DAbeywardane%26aufirst%3DA.%26aulast%3DLiang%26aufirst%3DS.%26aulast%3DMuegge%26aufirst%3DI.%26aulast%3DPadyana%26aufirst%3DA.%2BK.%26aulast%3DXiong%26aufirst%3DZ.%26aulast%3DHill-Drzewi%26aufirst%3DM.%26aulast%3DFarmer%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DCollins%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DJ.%2BX.%26aulast%3DHeim-Riether%26aufirst%3DA.%26aulast%3DProudfoot%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DGoldberg%26aufirst%3DD.%26aulast%3DZuvela-Jelaska%26aufirst%3DL.%26aulast%3DZaher%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DFarrow%26aufirst%3DN.%2BA.%26atitle%3DFragment-based%2520discovery%2520of%2520indole%2520inhibitors%2520of%2520matrix%2520metalloproteinase-13%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D8174%26epage%3D8187%26doi%3D10.1021%2Fjm201129m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Cai, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agrawal, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Putt, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hashim, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brodfuehrer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Surendran, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lash, L. H.</span><span> </span><span class="NLM_article-title">Assessment of the renal toxicity of novel anti-inflammatory compounds using cynomolgus monkey and human kidney cells</span> <span class="citation_source-journal">Toxicology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">258</span><span class="NLM_x">, </span> <span class="NLM_fpage">56</span><span class="NLM_x">–</span> <span class="NLM_lpage">63</span><span class="refDoi"> DOI: 10.1016/j.tox.2009.01.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01434&amp;key=10.1016%2Fj.tox.2009.01.006" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=258&publication_year=2009&pages=56-63&author=H.+Caiauthor=A.+K.+Agrawalauthor=D.+A.+Puttauthor=M.+Hashimauthor=A.+Reddyauthor=J.+Brodfuehrerauthor=N.+Surendranauthor=L.+H.+Lash&title=Assessment+of+the+renal+toxicity+of+novel+anti-inflammatory+compounds+using+cynomolgus+monkey+and+human+kidney+cells&doi=10.1016%2Fj.tox.2009.01.006"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.tox.2009.01.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tox.2009.01.006%26sid%3Dliteratum%253Aachs%26aulast%3DCai%26aufirst%3DH.%26aulast%3DAgrawal%26aufirst%3DA.%2BK.%26aulast%3DPutt%26aufirst%3DD.%2BA.%26aulast%3DHashim%26aufirst%3DM.%26aulast%3DReddy%26aufirst%3DA.%26aulast%3DBrodfuehrer%26aufirst%3DJ.%26aulast%3DSurendran%26aufirst%3DN.%26aulast%3DLash%26aufirst%3DL.%2BH.%26atitle%3DAssessment%2520of%2520the%2520renal%2520toxicity%2520of%2520novel%2520anti-inflammatory%2520compounds%2520using%2520cynomolgus%2520monkey%2520and%2520human%2520kidney%2520cells%26jtitle%3DToxicology%26date%3D2009%26volume%3D258%26spage%3D56%26epage%3D63%26doi%3D10.1016%2Fj.tox.2009.01.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Sallustio, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sabordo, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evans, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nation, R. L.</span><span> </span><span class="NLM_article-title">Hepatic disposition of electrophilic acyl glucuronide conjugates</span> <span class="citation_source-journal">Curr. Drug Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">163</span><span class="NLM_x">–</span> <span class="NLM_lpage">180</span><span class="refDoi"> DOI: 10.2174/1389200003339153</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01434&amp;key=10.2174%2F1389200003339153" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01434&amp;key=11465081" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01434&amp;key=1%3ACAS%3A528%3ADC%252BD3cXntlOrs7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2000&pages=163-180&author=B.+C.+Sallustioauthor=L.+Sabordoauthor=A.+M.+Evansauthor=R.+L.+Nation&title=Hepatic+disposition+of+electrophilic+acyl+glucuronide+conjugates&doi=10.2174%2F1389200003339153"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Hepatic disposition of electrophilic acyl glucuronide conjugates</span></div><div class="casAuthors">Sallustio, B. C.; Sabordo, L.; Evans, A. M.; Nation, R. L.</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Metabolism</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">163-180</span>CODEN:
                <span class="NLM_cas:coden">CDMUBU</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review with 148 refs.  Acyl glucuronides are a unique class of electrophilic metabolites, capable of non-enzymic reactions including acylation and/or glycation of endogenous macromols., hydrolysis to reform the parent aglycon, and intra-mol. rearrangement.  Three human UDP-glucuronosyltransferases (UGTs) catalyzing the hepatic glucuronidation of carboxylic acid drugs have been identified, UGT1A3, UGT1A9 and a UGT2B7 variant.  Within the liver, acyl glucuronides also undergo enzymic hydrolysis by β-glucuronidase and esterases which, like the UGTs, are located in the endoplasmic reticulum.  In addn., the liver also transports acyl glucuronides between the sinusoidal circulation and bile.  Due to their polarity, membrane transport of acyl glucuronides is carrier-mediated, resulting in the establishment of significant concn. gradients between sinusoidal circulation, hepatocyte and bile, in the order of 1:50:5000 in these compartments, resp.  As a result of exposure to high acyl glucuronide concns., the liver is a major target of protein adduct formation.  Dipeptidylpeptidase IV, UGTs and tubulin have been identified as intra-hepatic targets of adduct formation by acyl glucuronides.  Adduct formation results in altered protein activity and potentially contributes to hepatotoxicity.  Hepatic protein adducts are also immunogenic and may cause immune mediated cytotoxicity.  Both intra- and extra-hepatic exposure to acyl glucuronides depends not only on the efficiency of glucuronidation and hydrolysis by the liver, but also on the efficiency of the hepatic membrane transport systems.  Thus, changes in membrane transporter activities, as may occur due to satn. or drug-drug interactions, can significantly affect acyl glucuronide disposition, adduct formation and the disposition of parent aglycon, thereby affecting clin. efficacy and toxicity of acyl glucuronide forming drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-AkLxhuBjD7Vg90H21EOLACvtfcHk0lh98BAOEV4Giw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXntlOrs7o%253D&md5=dee87ae191547acf3e8b2e87fb87a013</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.2174%2F1389200003339153&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1389200003339153%26sid%3Dliteratum%253Aachs%26aulast%3DSallustio%26aufirst%3DB.%2BC.%26aulast%3DSabordo%26aufirst%3DL.%26aulast%3DEvans%26aufirst%3DA.%2BM.%26aulast%3DNation%26aufirst%3DR.%2BL.%26atitle%3DHepatic%2520disposition%2520of%2520electrophilic%2520acyl%2520glucuronide%2520conjugates%26jtitle%3DCurr.%2520Drug%2520Metab.%26date%3D2000%26volume%3D1%26spage%3D163%26epage%3D180%26doi%3D10.2174%2F1389200003339153" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Summerbell, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stephens, J. R.</span><span> </span><span class="NLM_article-title">The stereochemistry of several 2,5-disubstituted dioxanes</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1954</span><span class="NLM_x">, </span> <span class="NLM_volume">76</span><span class="NLM_x">, </span> <span class="NLM_fpage">6401</span><span class="NLM_x">–</span> <span class="NLM_lpage">6407</span><span class="refDoi"> DOI: 10.1021/ja01653a046</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja01653a046" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=1954&pages=6401-6407&author=R.+K.+Summerbellauthor=J.+R.+Stephens&title=The+stereochemistry+of+several+2%2C5-disubstituted+dioxanes&doi=10.1021%2Fja01653a046"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Fja01653a046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja01653a046%26sid%3Dliteratum%253Aachs%26aulast%3DSummerbell%26aufirst%3DR.%2BK.%26aulast%3DStephens%26aufirst%3DJ.%2BR.%26atitle%3DThe%2520stereochemistry%2520of%2520several%25202%252C5-disubstituted%2520dioxanes%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1954%26volume%3D76%26spage%3D6401%26epage%3D6407%26doi%3D10.1021%2Fja01653a046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Obach, R. S.</span><span> </span><span class="NLM_article-title">Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">1350</span><span class="NLM_x">–</span> <span class="NLM_lpage">1359</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01434&amp;key=10534321" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01434&amp;key=1%3ACAS%3A528%3ADyaK1MXntFSht7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=1999&pages=1350-1359&author=R.+S.+Obach&title=Prediction+of+human+clearance+of+twenty-nine+drugs+from+hepatic+microsomal+intrinsic+clearance+data%3A+An+examination+of+in+vitro+half-life+approach+and+nonspecific+binding+to+microsomes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes</span></div><div class="casAuthors">Obach, R. Scott</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1350-1359</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Twenty-nine drugs of disparate structures and physicochem. properties were used in an examn. of the capability of human liver microsomal lability data ("in vitro T1/2" approach) to be useful in the prediction of human clearance.  Addnl., the potential importance of nonspecific binding to microsomes in the in vitro incubation milieu for the accurate prediction of human clearance was investigated.  The compds. examd. demonstrated a wide range of microsomal metabolic labilities with scaled intrinsic clearance values ranging from less than 0.5 mL/min/kg to 189 mL/min/kg.  Microsomal binding was detd. at microsomal protein concns. used in the lability incubations.  For the 29 compds. studied, unbound fractions in microsomes ranged from 0.11 to 1.0.  Generally, basic compds. demonstrated the greatest extent of binding and neutral and acidic compds. the least extent of binding.  In the projection of human clearance values, basic and neutral compds. were well predicted when all binding considerations (blood and microsome) were disregarded, however, including both binding considerations also yielded reasonable predictions.  Including only blood binding yielded very poor projections of human clearance for these two types of compds.  However, for acidic compds., disregarding all binding considerations yielded poor predictions of human clearance.  It was generally most difficult to accurately predict clearance for this class of compds.; however the accuracy was best when all binding considerations were included.  Overall, inclusion of both blood and microsome binding values gave the best agreement between in vivo clearance values and clearance values projected from in vitro intrinsic clearance data.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWp2hUTOxyubVg90H21EOLACvtfcHk0lgfCkKEmIOMsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXntFSht7c%253D&md5=7804cd4dfb131caac45aff9b7a1df901</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DObach%26aufirst%3DR.%2BS.%26atitle%3DPrediction%2520of%2520human%2520clearance%2520of%2520twenty-nine%2520drugs%2520from%2520hepatic%2520microsomal%2520intrinsic%2520clearance%2520data%253A%2520An%2520examination%2520of%2520in%2520vitro%2520half-life%2520approach%2520and%2520nonspecific%2520binding%2520to%2520microsomes%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D1999%26volume%3D27%26spage%3D1350%26epage%3D1359" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Stepan, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karki, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonald, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dorff, P. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dutra, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiRico, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Won, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Subramanyam, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Efremov, I. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Donnell, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nolan, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Becker, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pustilnik, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sneed, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robshaw, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riddell, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Sullivan, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sibley, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capetta, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atchison, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hallgren, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Obach, R. S.</span><span> </span><span class="NLM_article-title">Metabolism-Directed Design of Oxetane-Containing Arylsulfonamide Derivatives as γ-Secretase Inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">7772</span><span class="NLM_x">–</span> <span class="NLM_lpage">7783</span><span class="refDoi"> DOI: 10.1021/jm200893p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200893p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01434&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlOgu7rK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=7772-7783&author=A.+F.+Stepanauthor=K.+Karkiauthor=W.+S.+McDonaldauthor=P.+H.+Dorffauthor=J.+K.+Dutraauthor=K.+J.+DiRicoauthor=A.+Wonauthor=C.+Subramanyamauthor=I.+V.+Efremovauthor=C.+J.+O%E2%80%99Donnellauthor=C.+E.+Nolanauthor=S.+L.+Beckerauthor=L.+R.+Pustilnikauthor=B.+Sneedauthor=H.+Sunauthor=Y.+Luauthor=A.+E.+Robshawauthor=D.+Riddellauthor=T.+J.+O%E2%80%99Sullivanauthor=E.+Sibleyauthor=S.+Capettaauthor=K.+Atchisonauthor=A.+J.+Hallgrenauthor=E.+Millerauthor=A.+Woodauthor=R.+S.+Obach&title=Metabolism-Directed+Design+of+Oxetane-Containing+Arylsulfonamide+Derivatives+as+%CE%B3-Secretase+Inhibitors&doi=10.1021%2Fjm200893p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolism-Directed Design of Oxetane-Containing Arylsulfonamide Derivatives as γ-Secretase Inhibitors</span></div><div class="casAuthors">Stepan, Antonia F.; Karki, Kapil; McDonald, W. Scott; Dorff, Peter H.; Dutra, Jason K.; DiRico, Kenneth J.; Won, Annie; Subramanyam, Chakrapani; Efremov, Ivan V.; O'Donnell, Christopher J.; Nolan, Charles E.; Becker, Stacey L.; Pustilnik, Leslie R.; Sneed, Blossom; Sun, Hao; Lu, Yasong; Robshaw, Ashley E.; Riddell, David; O'Sullivan, Theresa J.; Sibley, Evelyn; Capetta, Steven; Atchison, Kevin; Hallgren, Andrew J.; Miller, Emily; Wood, Anthony; Obach, R. Scott</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">7772-7783</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A metab.-based approach toward the optimization of a series of N-arylsulfonamide-based γ-secretase inhibitors is reported.  The lead cyclohexyl analog 6 suffered from extensive oxidn. on the cycloalkyl motif by cytochrome P 450 3A4, translating into poor human liver microsomal stability.  Knowledge of the metabolic pathways of 6 triggered a structure-activity relationship study aimed at lowering lipophilicity through the introduction of polarity.  This effort led to several tetrahydropyran and THF analogs, wherein the 3- and 4-substituted variants exhibited greater microsomal stability relative to their 2-substituted counterparts.  Further redn. in lipophilicity led to the potent γ-secretase inhibitor and 3-substituted oxetane 1 with a reduced propensity toward oxidative metab., relative to its 2-substituted isomer.  The slower rates of metab. with 3-substituted cyclic ethers most likely originate from redns. in lipophilicity and/or unfavorable CYP active site interactions with the heteroatom.  Preliminary animal pharmacol. studies with a representative oxetane indicate that the series is generally capable of lowering Aβ in vivo.  As such, the study also illustrates the improvement in drug likeness of mols. through the use of the oxetane motif.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1kWyZJuyD97Vg90H21EOLACvtfcHk0lgfCkKEmIOMsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlOgu7rK&md5=b3e9725954a155900563cc5d2f73263b</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fjm200893p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200893p%26sid%3Dliteratum%253Aachs%26aulast%3DStepan%26aufirst%3DA.%2BF.%26aulast%3DKarki%26aufirst%3DK.%26aulast%3DMcDonald%26aufirst%3DW.%2BS.%26aulast%3DDorff%26aufirst%3DP.%2BH.%26aulast%3DDutra%26aufirst%3DJ.%2BK.%26aulast%3DDiRico%26aufirst%3DK.%2BJ.%26aulast%3DWon%26aufirst%3DA.%26aulast%3DSubramanyam%26aufirst%3DC.%26aulast%3DEfremov%26aufirst%3DI.%2BV.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DC.%2BJ.%26aulast%3DNolan%26aufirst%3DC.%2BE.%26aulast%3DBecker%26aufirst%3DS.%2BL.%26aulast%3DPustilnik%26aufirst%3DL.%2BR.%26aulast%3DSneed%26aufirst%3DB.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DRobshaw%26aufirst%3DA.%2BE.%26aulast%3DRiddell%26aufirst%3DD.%26aulast%3DO%25E2%2580%2599Sullivan%26aufirst%3DT.%2BJ.%26aulast%3DSibley%26aufirst%3DE.%26aulast%3DCapetta%26aufirst%3DS.%26aulast%3DAtchison%26aufirst%3DK.%26aulast%3DHallgren%26aufirst%3DA.%2BJ.%26aulast%3DMiller%26aufirst%3DE.%26aulast%3DWood%26aufirst%3DA.%26aulast%3DObach%26aufirst%3DR.%2BS.%26atitle%3DMetabolism-Directed%2520Design%2520of%2520Oxetane-Containing%2520Arylsulfonamide%2520Derivatives%2520as%2520%25CE%25B3-Secretase%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D7772%26epage%3D7783%26doi%3D10.1021%2Fjm200893p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Ritchie, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macdonald, S. J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peace, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pickett, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luscombe, C. N.</span><span> </span><span class="NLM_article-title">The developability of heteroaromatic and heteroaliphatic rings – do some have a better pedigree as potential drug molecules than others?</span> <span class="citation_source-journal">MedChemComm</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">1062</span><span class="NLM_x">–</span> <span class="NLM_lpage">1069</span><span class="refDoi"> DOI: 10.1039/c2md20111a</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01434&amp;key=10.1039%2Fc2md20111a" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01434&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1GitLfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=1062-1069&author=T.+J.+Ritchieauthor=S.+J.+F.+Macdonaldauthor=S.+Peaceauthor=S.+D.+Pickettauthor=C.+N.+Luscombe&title=The+developability+of+heteroaromatic+and+heteroaliphatic+rings+%E2%80%93+do+some+have+a+better+pedigree+as+potential+drug+molecules+than+others%3F&doi=10.1039%2Fc2md20111a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">The developability of heteroaromatic and heteroaliphatic rings - do some have a better pedigree as potential drug molecules than others?</span></div><div class="casAuthors">Ritchie, Timothy J.; MacDonald, Simon J. F.; Peace, Simon; Pickett, Stephen D.; Luscombe, Christopher N.</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1062-1069</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Aq. soly., protein binding and CYP450 inhibition data for compds. contg. a variety of heteroarom. and heteroaliph. rings were analyzed and compared to det. which ring types fared best and worst in these developability screens.  The results suggest that certain heterorings are generally more developable than others: how this information may be used and some caveats to be borne in mind are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCkxdTaUGig7Vg90H21EOLACvtfcHk0lgfCkKEmIOMsg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1GitLfE&md5=6aad4bc48b351d9d20683ee9af1a3354</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1039%2Fc2md20111a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc2md20111a%26sid%3Dliteratum%253Aachs%26aulast%3DRitchie%26aufirst%3DT.%2BJ.%26aulast%3DMacdonald%26aufirst%3DS.%2BJ.%2BF.%26aulast%3DPeace%26aufirst%3DS.%26aulast%3DPickett%26aufirst%3DS.%2BD.%26aulast%3DLuscombe%26aufirst%3DC.%2BN.%26atitle%3DThe%2520developability%2520of%2520heteroaromatic%2520and%2520heteroaliphatic%2520rings%2520%25E2%2580%2593%2520do%2520some%2520have%2520a%2520better%2520pedigree%2520as%2520potential%2520drug%2520molecules%2520than%2520others%253F%26jtitle%3DMedChemComm%26date%3D2012%26volume%3D3%26spage%3D1062%26epage%3D1069%26doi%3D10.1039%2Fc2md20111a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">St. Jean, D. J.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fotsch, C.</span><span> </span><span class="NLM_article-title">Mitigating heterocycle metabolism in drug discovery</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">6002</span><span class="NLM_x">–</span> <span class="NLM_lpage">6020</span><span class="refDoi"> DOI: 10.1021/jm300343m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300343m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01434&amp;key=1%3ACAS%3A528%3ADC%252BC38XmtFWhsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=6002-6020&author=D.+J.+St.+Jeanauthor=C.+Fotsch&title=Mitigating+heterocycle+metabolism+in+drug+discovery&doi=10.1021%2Fjm300343m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Mitigating Heterocycle Metabolism in Drug Discovery</span></div><div class="casAuthors">St. Jean, David J.; Fotsch, Christopher</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">6002-6020</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Extensive data from metab. studies have allowed medicinal chemists to develop general principles for reducing compd. metab.  These methods include, but are not limited to, reducing lipophilicity, altering sterics and electronics, introducing a conformational constraint, and altering the stereochem. of their compds.  While no single method is able to solve every metabolic problem, these principles do give medicinal chemists guidance on how to improve the metabolic liabilities of their compds.  If the specific site of metab. is known, medicinal chemists block the site, typically with a fluorine, or replace the metabolically labile group with a bioisostere.  While several authors have reviewed these techniques for reducing metab., there is no review that summarizes different approaches to improving them metabolic stability of heterocycles.  In this review, we summarize examples where changes were made at or near the heterocycle to improve metabolic stability.  By summarizing these examples, we hope to provide a useful guide to medicinal chemists as they attempt to improve the metabolic profile of their own heterocyclic compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovQjdBBgXtPbVg90H21EOLACvtfcHk0liisxTjY2GXNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmtFWhsL0%253D&md5=48c262556b8a2cc7dc5539ff91a53a71</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fjm300343m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300343m%26sid%3Dliteratum%253Aachs%26aulast%3DSt.%2BJean%26aufirst%3DD.%2BJ.%26aulast%3DFotsch%26aufirst%3DC.%26atitle%3DMitigating%2520heterocycle%2520metabolism%2520in%2520drug%2520discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D6002%26epage%3D6020%26doi%3D10.1021%2Fjm300343m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Katz, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jewell, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guerin, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lim, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dinsmore, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deshmukh, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, B.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marshall, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Altman, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dahlberg, W. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Falcone, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gabarda, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hatch, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holmes, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kunii, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lumb, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lutterbach, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathvink, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nazef, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reilly, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rickert, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenstein, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soisson, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spencer, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szewczak, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeng, Q.</span><span> </span><span class="NLM_article-title">Discovery of a 5<i>H</i>-benzo[4,5]cyclohepta[1,2-b]pyridin-5-one (MK-2461) inhibitor of c-Met kinase for the treatment of cancer</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">4092</span><span class="NLM_x">–</span> <span class="NLM_lpage">4108</span><span class="refDoi"> DOI: 10.1021/jm200112k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200112k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01434&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmsFymtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=4092-4108&author=J.+D.+Katzauthor=J.+P.+Jewellauthor=D.+J.+Guerinauthor=J.+Limauthor=C.+J.+Dinsmoreauthor=S.+V.+Deshmukhauthor=B.-S.+Panauthor=C.+G.+Marshallauthor=W.+Luauthor=M.+D.+Altmanauthor=W.+K.+Dahlbergauthor=L.+Davisauthor=D.+Falconeauthor=A.+E.+Gabardaauthor=G.+Hangauthor=H.+Hatchauthor=R.+Holmesauthor=K.+Kuniiauthor=K.+J.+Lumbauthor=B.+Lutterbachauthor=R.+Mathvinkauthor=N.+Nazefauthor=S.+B.+Patelauthor=X.+Quauthor=J.+F.+Reillyauthor=K.+W.+Rickertauthor=C.+Rosensteinauthor=S.+M.+Soissonauthor=K.+B.+Spencerauthor=A.+A.+Szewczakauthor=D.+Walkerauthor=W.+Wangauthor=J.+Youngauthor=Q.+Zeng&title=Discovery+of+a+5H-benzo%5B4%2C5%5Dcyclohepta%5B1%2C2-b%5Dpyridin-5-one+%28MK-2461%29+inhibitor+of+c-Met+kinase+for+the+treatment+of+cancer&doi=10.1021%2Fjm200112k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a 5H-Benzo[4,5]cyclohepta[1,2-b]pyridin-5-one (MK-2461) Inhibitor of c-Met Kinase for the Treatment of Cancer</span></div><div class="casAuthors">Katz, Jason D.; Jewell, James P.; Guerin, David J.; Lim, Jongwon; Dinsmore, Christopher J.; Deshmukh, Sujal V.; Pan, Bo-Sheng; Marshall, C. Gary; Lu, Wei; Altman, Michael D.; Dahlberg, William K.; Davis, Lenora; Falcone, Danielle; Gabarda, Ana E.; Hang, Gaozhen; Hatch, Harold; Holmes, Rachael; Kunii, Kaiko; Lumb, Kevin J.; Lutterbach, Bart; Mathvink, Robert; Nazef, Naim; Patel, Sangita B.; Qu, Xianlu; Reilly, John F.; Rickert, Keith W.; Rosenstein, Craig; Soisson, Stephen M.; Spencer, Kerrie B.; Szewczak, Alexander A.; Walker, Deborah; Wang, Wenxian; Young, Jonathan; Zeng, Qinwen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4092-4108</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">C-Met is a transmembrane tyrosine kinase that mediates activation of several signaling pathways implicated in aggressive cancer phenotypes.  In recent years, research into this area has highlighted c-Met as an attractive cancer drug target, triggering a no. of approaches to disrupt aberrant c-Met signaling.  Screening efforts identified a unique class of 5H-benzo[4,5]cyclohepta[1,2-b]pyridin-5-one kinase inhibitors, exemplified by 1.  Subsequent SAR studies led to the development of MK-2461 (I), a potent inhibitor of c-Met that was efficacious in preclin. animal models of tumor suppression.  In addn., biochem. studies and x-ray anal. have revealed that this unique class of kinase inhibitors binds preferentially to the activated (phosphorylated) form of the kinase.  This report details the development of I and provides a description of its unique biochem. properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6ANuqa7a-NrVg90H21EOLACvtfcHk0liisxTjY2GXNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmsFymtbY%253D&md5=82cfe0a146d04d467531e1027f3a1266</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm200112k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200112k%26sid%3Dliteratum%253Aachs%26aulast%3DKatz%26aufirst%3DJ.%2BD.%26aulast%3DJewell%26aufirst%3DJ.%2BP.%26aulast%3DGuerin%26aufirst%3DD.%2BJ.%26aulast%3DLim%26aufirst%3DJ.%26aulast%3DDinsmore%26aufirst%3DC.%2BJ.%26aulast%3DDeshmukh%26aufirst%3DS.%2BV.%26aulast%3DPan%26aufirst%3DB.-S.%26aulast%3DMarshall%26aufirst%3DC.%2BG.%26aulast%3DLu%26aufirst%3DW.%26aulast%3DAltman%26aufirst%3DM.%2BD.%26aulast%3DDahlberg%26aufirst%3DW.%2BK.%26aulast%3DDavis%26aufirst%3DL.%26aulast%3DFalcone%26aufirst%3DD.%26aulast%3DGabarda%26aufirst%3DA.%2BE.%26aulast%3DHang%26aufirst%3DG.%26aulast%3DHatch%26aufirst%3DH.%26aulast%3DHolmes%26aufirst%3DR.%26aulast%3DKunii%26aufirst%3DK.%26aulast%3DLumb%26aufirst%3DK.%2BJ.%26aulast%3DLutterbach%26aufirst%3DB.%26aulast%3DMathvink%26aufirst%3DR.%26aulast%3DNazef%26aufirst%3DN.%26aulast%3DPatel%26aufirst%3DS.%2BB.%26aulast%3DQu%26aufirst%3DX.%26aulast%3DReilly%26aufirst%3DJ.%2BF.%26aulast%3DRickert%26aufirst%3DK.%2BW.%26aulast%3DRosenstein%26aufirst%3DC.%26aulast%3DSoisson%26aufirst%3DS.%2BM.%26aulast%3DSpencer%26aufirst%3DK.%2BB.%26aulast%3DSzewczak%26aufirst%3DA.%2BA.%26aulast%3DWalker%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DYoung%26aufirst%3DJ.%26aulast%3DZeng%26aufirst%3DQ.%26atitle%3DDiscovery%2520of%2520a%25205H-benzo%255B4%252C5%255Dcyclohepta%255B1%252C2-b%255Dpyridin-5-one%2520%2528MK-2461%2529%2520inhibitor%2520of%2520c-Met%2520kinase%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D4092%26epage%3D4108%26doi%3D10.1021%2Fjm200112k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Del Bello, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barocelli, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertoni, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonifazi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camalli, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giannella, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matucci, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nesi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pigini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quaglia, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piergentili, A.</span><span> </span><span class="NLM_article-title">1,4-Dioxane, a suitable scaffold for the development of novel M3 muscarinic receptor antagonists</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">1783</span><span class="NLM_x">–</span> <span class="NLM_lpage">1787</span><span class="refDoi"> DOI: 10.1021/jm2013216</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2013216" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01434&amp;key=1%3ACAS%3A528%3ADC%252BC38XntFKhsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=1783-1787&author=F.+Del+Belloauthor=E.+Barocelliauthor=S.+Bertoniauthor=A.+Bonifaziauthor=M.+Camalliauthor=G.+Campiauthor=M.+Giannellaauthor=R.+Matucciauthor=M.+Nesiauthor=M.+Piginiauthor=W.+Quagliaauthor=A.+Piergentili&title=1%2C4-Dioxane%2C+a+suitable+scaffold+for+the+development+of+novel+M3+muscarinic+receptor+antagonists&doi=10.1021%2Fjm2013216"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">1,4-Dioxane, a Suitable Scaffold for the Development of Novel M3 Muscarinic Receptor Antagonists</span></div><div class="casAuthors">Del Bello, Fabio; Barocelli, Elisabetta; Bertoni, Simona; Bonifazi, Alessandro; Camalli, Mercedes; Campi, Gaetano; Giannella, Mario; Matucci, Rosanna; Nesi, Marta; Pigini, Maria; Quaglia, Wilma; Piergentili, Alessandro</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1783-1787</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In this study the modulation of the pharmacol. profile from agonist to antagonist was successfully obtained by replacing the Me group in position 6 of the 1,4-dioxane scaffold of the potent M2/M3 muscarinic agonist 1 with bulkier groups.  In particular, the 6,6-di-Ph substitution provided the potent M3 preferring antagonist (±)-17 (I), which in in vivo study proved to be effective in reducing the vol.-induced contractions of rat urinary bladder and was devoid of cardiovascular effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopZzxYns6n0bVg90H21EOLACvtfcHk0liisxTjY2GXNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XntFKhsw%253D%253D&md5=35106d72f5138ae153800fb4efc80094</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fjm2013216&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2013216%26sid%3Dliteratum%253Aachs%26aulast%3DDel%2BBello%26aufirst%3DF.%26aulast%3DBarocelli%26aufirst%3DE.%26aulast%3DBertoni%26aufirst%3DS.%26aulast%3DBonifazi%26aufirst%3DA.%26aulast%3DCamalli%26aufirst%3DM.%26aulast%3DCampi%26aufirst%3DG.%26aulast%3DGiannella%26aufirst%3DM.%26aulast%3DMatucci%26aufirst%3DR.%26aulast%3DNesi%26aufirst%3DM.%26aulast%3DPigini%26aufirst%3DM.%26aulast%3DQuaglia%26aufirst%3DW.%26aulast%3DPiergentili%26aufirst%3DA.%26atitle%3D1%252C4-Dioxane%252C%2520a%2520suitable%2520scaffold%2520for%2520the%2520development%2520of%2520novel%2520M3%2520muscarinic%2520receptor%2520antagonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D1783%26epage%3D1787%26doi%3D10.1021%2Fjm2013216" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Mammoli, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonifazi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Del Bello, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diamanti, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giannella, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hudson, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mattioli, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perfumi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piergentili, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quaglia, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Titomanlio, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pigini, M.</span><span> </span><span class="NLM_article-title">Favourable involvement of α<sub>2A</sub>-adrenoreceptor antagonism in the I<sub>2</sub>-imidazoline binding sites-mediated morphine analgesia enhancement</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">2259</span><span class="NLM_x">–</span> <span class="NLM_lpage">2265</span><span class="refDoi"> DOI: 10.1016/j.bmc.2012.02.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01434&amp;key=10.1016%2Fj.bmc.2012.02.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01434&amp;key=22370341" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01434&amp;key=1%3ACAS%3A528%3ADC%252BC38XjtVyjt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2012&pages=2259-2265&author=V.+Mammoliauthor=A.+Bonifaziauthor=F.+Del+Belloauthor=E.+Diamantiauthor=M.+Giannellaauthor=A.+L.+Hudsonauthor=L.+Mattioliauthor=M.+Perfumiauthor=A.+Piergentiliauthor=W.+Quagliaauthor=F.+Titomanlioauthor=M.+Pigini&title=Favourable+involvement+of+%CE%B12A-adrenoreceptor+antagonism+in+the+I2-imidazoline+binding+sites-mediated+morphine+analgesia+enhancement&doi=10.1016%2Fj.bmc.2012.02.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Favourable involvement of α2A-adrenoreceptor antagonism in the I2-imidazoline binding sites-mediated morphine analgesia enhancement</span></div><div class="casAuthors">Mammoli, Valerio; Bonifazi, Alessandro; Del Bello, Fabio; Diamanti, Eleonora; Giannella, Mario; Hudson, Alan L.; Mattioli, Laura; Perfumi, Marina; Piergentili, Alessandro; Quaglia, Wilma; Titomanlio, Federica; Pigini, Maria</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2259-2265</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Aim of the present study was to obtain novel α2-adrenoreceptor (α2-AR) antagonists, possibly endowed with subtype-selectivity.  Therefore, inspired by the non subtype-selective α2-AR antagonist idazoxan, we designed 1,4-dioxane derivs. bearing an arom. area in position 5 or 6 and the imidazoline nucleus in position 2.  Among the novel mols. 1-6, compd. 2, with a trans stereochem. relationship between 5-Ph and 2-imidazoline groups, was able to antagonize the sole α2A-subtype.  Moreover, 2 showed an affinity at I2-imidazoline binding sites (I2-IBS) comparable to that at α2A-AR.  In in vivo studies 2 strongly increased morphine analgesia.  This interesting behavior appeared to be induced by the favorable involvement of α2A-AR antagonism in the I2-IBS-mediated morphine analgesia enhancement.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq26wuH-DYiprVg90H21EOLACvtfcHk0lgeQyjuxIWQTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjtVyjt7s%253D&md5=852ce990b6a7f269bbc4dfe406d5f57d</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2012.02.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2012.02.016%26sid%3Dliteratum%253Aachs%26aulast%3DMammoli%26aufirst%3DV.%26aulast%3DBonifazi%26aufirst%3DA.%26aulast%3DDel%2BBello%26aufirst%3DF.%26aulast%3DDiamanti%26aufirst%3DE.%26aulast%3DGiannella%26aufirst%3DM.%26aulast%3DHudson%26aufirst%3DA.%2BL.%26aulast%3DMattioli%26aufirst%3DL.%26aulast%3DPerfumi%26aufirst%3DM.%26aulast%3DPiergentili%26aufirst%3DA.%26aulast%3DQuaglia%26aufirst%3DW.%26aulast%3DTitomanlio%26aufirst%3DF.%26aulast%3DPigini%26aufirst%3DM.%26atitle%3DFavourable%2520involvement%2520of%2520%25CE%25B12A-adrenoreceptor%2520antagonism%2520in%2520the%2520I2-imidazoline%2520binding%2520sites-mediated%2520morphine%2520analgesia%2520enhancement%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2012%26volume%3D20%26spage%3D2259%26epage%3D2265%26doi%3D10.1016%2Fj.bmc.2012.02.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Settle, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vickery, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nemirovskiy, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vidmar, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bendele, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Messing, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruminski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schnute, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sunyer, T.</span><span> </span><span class="NLM_article-title">Cartilage degradation biomarkers predict efficacy of a novel, highly selective matrix metalloproteinase 13 inhibitor in a dog model of osteoarthritis confirmation by multivariate analysis that modulation of type II collagen and aggrecan degradation peptides parallels pathologic changes</span> <span class="citation_source-journal">Arthritis Rheum.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">3006</span><span class="NLM_x">–</span> <span class="NLM_lpage">3015</span><span class="refDoi"> DOI: 10.1002/art.27596</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01434&amp;key=10.1002%2Fart.27596" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01434&amp;key=20533541" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01434&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVSqtrvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2010&pages=3006-3015&author=S.+Settleauthor=L.+Vickeryauthor=O.+Nemirovskiyauthor=T.+Vidmarauthor=A.+Bendeleauthor=D.+Messingauthor=P.+Ruminskiauthor=M.+Schnuteauthor=T.+Sunyer&title=Cartilage+degradation+biomarkers+predict+efficacy+of+a+novel%2C+highly+selective+matrix+metalloproteinase+13+inhibitor+in+a+dog+model+of+osteoarthritis+confirmation+by+multivariate+analysis+that+modulation+of+type+II+collagen+and+aggrecan+degradation+peptides+parallels+pathologic+changes&doi=10.1002%2Fart.27596"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Cartilage degradation biomarkers predict efficacy of a novel, highly selective matrix metalloproteinase 13 inhibitor in a dog model of osteoarthritis</span></div><div class="casAuthors">Settle, Steven; Vickery, Lillian; Nemirovskiy, Olga; Vidmar, Tom; Bendele, Alison; Messing, Dean; Ruminski, Peter; Schnute, Mark; Sunyer, Teresa</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis & Rheumatism</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3006-3015</span>CODEN:
                <span class="NLM_cas:coden">ARHEAW</span>;
        ISSN:<span class="NLM_cas:issn">0004-3591</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Objective: To demonstrate that the novel highly selective matrix metalloproteinase 13 (MMP-13) inhibitor PF152 reduces joint lesions in adult dogs with osteoarthritis (OA) and decreases biomarkers of cartilage degrdn.  Methods: The potency and selectivity of PF152 were evaluated in vitro using 16 MMPs, TACE, and ADAMTS-4 and ADAMTS-5, as well as ex vivo in human cartilage explants.  In vivo effects were evaluated at 3 concns. in mature beagles with partial medial meniscectomy.  Gross and histol. changes in the femorotibial joints were evaluated using various measures of cartilage degeneration.  Biomarkers of cartilage turnover were examd. in serum, urine, or synovial fluid.  Results were analyzed individually and in combination using multivariate anal.  Results: The potent and selective MMP-13 inhibitor PF152 decreased human cartilage degrdn. ex vivo in a dose-dependent manner.  PF152 treatment of dogs with OA reduced cartilage lesions and decreased biomarkers of type II collagen (type II collagen neoepitope) and aggrecan (peptides ending in ARGN or AGEG) degrdn.  The dose required for significant inhibition varied with the measure used, but multivariate anal. of 6 gross and histol. measures indicated that all doses differed significantly from vehicle but not from each other.  Combined anal. of cartilage degrdn. markers showed similar results.  Conclusion: This highly selective MMP-13 inhibitor exhibits chondroprotective effects in mature animals.  Biomarkers of cartilage degrdn., when evaluated in combination, parallel the joint structural changes induced by the MMP-13 inhibitor.  These data support the potential therapeutic value of selective MMP-13 inhibitors and the use of a set of appropriate biomarkers to predict efficacy in OA clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFetQBLK-edLVg90H21EOLACvtfcHk0lgeQyjuxIWQTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVSqtrvL&md5=83b761d6731b0287d78bbee6263f4df5</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1002%2Fart.27596&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.27596%26sid%3Dliteratum%253Aachs%26aulast%3DSettle%26aufirst%3DS.%26aulast%3DVickery%26aufirst%3DL.%26aulast%3DNemirovskiy%26aufirst%3DO.%26aulast%3DVidmar%26aufirst%3DT.%26aulast%3DBendele%26aufirst%3DA.%26aulast%3DMessing%26aufirst%3DD.%26aulast%3DRuminski%26aufirst%3DP.%26aulast%3DSchnute%26aufirst%3DM.%26aulast%3DSunyer%26aufirst%3DT.%26atitle%3DCartilage%2520degradation%2520biomarkers%2520predict%2520efficacy%2520of%2520a%2520novel%252C%2520highly%2520selective%2520matrix%2520metalloproteinase%252013%2520inhibitor%2520in%2520a%2520dog%2520model%2520of%2520osteoarthritis%2520confirmation%2520by%2520multivariate%2520analysis%2520that%2520modulation%2520of%2520type%2520II%2520collagen%2520and%2520aggrecan%2520degradation%2520peptides%2520parallels%2520pathologic%2520changes%26jtitle%3DArthritis%2520Rheum.%26date%3D2010%26volume%3D62%26spage%3D3006%26epage%3D3015%26doi%3D10.1002%2Fart.27596" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Tortorella, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomasselli, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathis, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schnute, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woodard, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munie, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caspers, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wittwer, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malfait, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shieh, H. S.</span><span> </span><span class="NLM_article-title">Structural and inhibition analysis reveals the mechanism of selectivity of a series of aggrecanase inhibitors</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">284</span><span class="NLM_x">, </span> <span class="NLM_fpage">24185</span><span class="NLM_x">–</span> <span class="NLM_lpage">24191</span><span class="refDoi"> DOI: 10.1074/jbc.M109.029116</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01434&amp;key=10.1074%2Fjbc.M109.029116" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01434&amp;key=19586907" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01434&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVGgsr%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=284&publication_year=2009&pages=24185-24191&author=M.+D.+Tortorellaauthor=A.+G.+Tomasselliauthor=K.+J.+Mathisauthor=M.+E.+Schnuteauthor=S.+S.+Woodardauthor=G.+Munieauthor=J.+M.+Williamsauthor=N.+Caspersauthor=A.+J.+Wittwerauthor=A.+M.+Malfaitauthor=H.+S.+Shieh&title=Structural+and+inhibition+analysis+reveals+the+mechanism+of+selectivity+of+a+series+of+aggrecanase+inhibitors&doi=10.1074%2Fjbc.M109.029116"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Structural and Inhibition Analysis Reveals the Mechanism of Selectivity of a Series of Aggrecanase Inhibitors</span></div><div class="casAuthors">Tortorella, Micky D.; Tomasselli, Alfredo G.; Mathis, Karl J.; Schnute, Mark E.; Woodard, Scott S.; Munie, Grace; Williams, Jennifer M.; Caspers, Nicole; Wittwer, Arthur J.; Malfait, Anne-Marie; Shieh, Huey-Sheng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">284</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">24185-24191</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Several inhibitors of a series of cis-1(S)2(R)-amino-2-indanol-based compds. were reported to be selective for the aggrecanases, ADAMTS-4 and -5 over other metalloproteinases.  To understand the nature of this selectivity for aggrecanases, the inhibitors, along with the broad spectrum metalloproteinase inhibitor marimastat, were independently bound to the catalytic domain of ADAMTS-5, and the corresponding crystal structures were detd.  By comparing the structures, it was detd. that the specificity of the relative inhibitors for ADAMTS-5 was not driven by a specific interaction, such as zinc chelation, hydrogen bonding, or charge interactions, but rather by subtle and indirect factors, such as water bridging, ring rigidity, pocket size, and shape, as well as protein conformation flexibility.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoI39fzCSuJerVg90H21EOLACvtfcHk0lgeQyjuxIWQTw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVGgsr%252FP&md5=86e9879fb3359bc2ad78e2ce653ea0de</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M109.029116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M109.029116%26sid%3Dliteratum%253Aachs%26aulast%3DTortorella%26aufirst%3DM.%2BD.%26aulast%3DTomasselli%26aufirst%3DA.%2BG.%26aulast%3DMathis%26aufirst%3DK.%2BJ.%26aulast%3DSchnute%26aufirst%3DM.%2BE.%26aulast%3DWoodard%26aufirst%3DS.%2BS.%26aulast%3DMunie%26aufirst%3DG.%26aulast%3DWilliams%26aufirst%3DJ.%2BM.%26aulast%3DCaspers%26aufirst%3DN.%26aulast%3DWittwer%26aufirst%3DA.%2BJ.%26aulast%3DMalfait%26aufirst%3DA.%2BM.%26aulast%3DShieh%26aufirst%3DH.%2BS.%26atitle%3DStructural%2520and%2520inhibition%2520analysis%2520reveals%2520the%2520mechanism%2520of%2520selectivity%2520of%2520a%2520series%2520of%2520aggrecanase%2520inhibitors%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2009%26volume%3D284%26spage%3D24185%26epage%3D24191%26doi%3D10.1074%2Fjbc.M109.029116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 20 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hiroshi  Nara</span>, <span class="hlFld-ContribAuthor ">Akira  Kaieda</span>, <span class="hlFld-ContribAuthor ">Kenjiro  Sato</span>, <span class="hlFld-ContribAuthor ">Takako  Naito</span>, <span class="hlFld-ContribAuthor ">Hideyuki  Mototani</span>, <span class="hlFld-ContribAuthor ">Hideyuki  Oki</span>, <span class="hlFld-ContribAuthor ">Yoshio  Yamamoto</span>, <span class="hlFld-ContribAuthor ">Haruhiko  Kuno</span>, <span class="hlFld-ContribAuthor ">Takashi  Santou</span>, <span class="hlFld-ContribAuthor ">Naoyuki  Kanzaki</span>, <span class="hlFld-ContribAuthor ">Jun  Terauchi</span>, <span class="hlFld-ContribAuthor ">Osamu  Uchikawa</span>, and <span class="hlFld-ContribAuthor ">Masakuni  Kori</span>  . </span><span class="cited-content_cbyCitation_article-title">Discovery of Novel, Highly Potent, and Selective Matrix Metalloproteinase (MMP)-13 Inhibitors with a 1,2,4-Triazol-3-yl Moiety as a Zinc Binding Group Using a Structure-Based Design Approach. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2017,</strong> <em>60 </em>
                                    (2)
                                     , 608-626. <a href="https://doi.org/10.1021/acs.jmedchem.6b01007" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b01007</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b01007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b01007%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BNovel%25252C%252BHighly%252BPotent%25252C%252Band%252BSelective%252BMatrix%252BMetalloproteinase%252B%252528MMP%252529-13%252BInhibitors%252Bwith%252Ba%252B1%25252C2%25252C4-Triazol-3-yl%252BMoiety%252Bas%252Ba%252BZinc%252BBinding%252BGroup%252BUsing%252Ba%252BStructure-Based%252BDesign%252BApproach%26aulast%3DNara%26aufirst%3DHiroshi%26date%3D2017%26date%3D2017%26date%3D2016%26date%3D03092016%26date%3D09012017%26date%3D26012017%26date%3D14122016%26volume%3D60%26issue%3D2%26spage%3D608%26epage%3D626" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lin  Yue</span>, <span class="hlFld-ContribAuthor ">Yaojie  Shi</span>, <span class="hlFld-ContribAuthor ">Xingping  Su</span>, <span class="hlFld-ContribAuthor ">Liang  Ouyang</span>, <span class="hlFld-ContribAuthor ">Guan  Wang</span>, <span class="hlFld-ContribAuthor ">Tinghong  Ye</span>. </span><span class="cited-content_cbyCitation_article-title">Matrix metalloproteinases inhibitors in idiopathic pulmonary fibrosis: Medicinal chemistry perspectives. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>224 </em>, 113714. <a href="https://doi.org/10.1016/j.ejmech.2021.113714" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113714</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113714&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113714%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DMatrix%252Bmetalloproteinases%252Binhibitors%252Bin%252Bidiopathic%252Bpulmonary%252Bfibrosis%25253A%252BMedicinal%252Bchemistry%252Bperspectives%26aulast%3DYue%26aufirst%3DLin%26date%3D2021%26volume%3D224%26spage%3D113714" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anna M.  Knapinska</span>, <span class="hlFld-ContribAuthor ">Chandani  Singh</span>, <span class="hlFld-ContribAuthor ">Gary  Drotleff</span>, <span class="hlFld-ContribAuthor ">Daniela  Blanco</span>, <span class="hlFld-ContribAuthor ">Cedric  Chai</span>, <span class="hlFld-ContribAuthor ">Jason  Schwab</span>, <span class="hlFld-ContribAuthor ">Anu  Herd</span>, <span class="hlFld-ContribAuthor ">Gregg B.  Fields</span>. </span><span class="cited-content_cbyCitation_article-title">Matrix Metalloproteinase 13 Inhibitors for Modulation of Osteoclastogenesis: Enhancement of Solubility and Stability. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2021,</strong> <em>16 </em>
                                    (7)
                                     , 1133-1142. <a href="https://doi.org/10.1002/cmdc.202000911" title="DOI URL">https://doi.org/10.1002/cmdc.202000911</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.202000911&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.202000911%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DMatrix%252BMetalloproteinase%252B13%252BInhibitors%252Bfor%252BModulation%252Bof%252BOsteoclastogenesis%25253A%252BEnhancement%252Bof%252BSolubility%252Band%252BStability%26aulast%3DKnapinska%26aufirst%3DAnna%2BM.%26date%3D2021%26date%3D2021%26volume%3D16%26issue%3D7%26spage%3D1133%26epage%3D1142" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dan  Mao</span>, <span class="hlFld-ContribAuthor ">Mingsong  Wu</span>, <span class="hlFld-ContribAuthor ">Jiying  Wei</span>, <span class="hlFld-ContribAuthor ">Xiangwen  Zhou</span>, <span class="hlFld-ContribAuthor ">Lan  Yang</span>, <span class="hlFld-ContribAuthor ">Fang  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">MicroRNA‐101a‐3p could be involved in the pathogenesis of temporomandibular joint osteoarthritis by mediating UBE2D1 and FZD4. </span><span class="cited-content_cbyCitation_journal-name">Journal of Oral Pathology & Medicine</span><span> <strong>2021,</strong> <em>50 </em>
                                    (2)
                                     , 236-243. <a href="https://doi.org/10.1111/jop.13131" title="DOI URL">https://doi.org/10.1111/jop.13131</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/jop.13131&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fjop.13131%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Oral%2520Pathology%2520%2526%2520Medicine%26atitle%3DMicroRNA%2525E2%252580%252590101a%2525E2%252580%2525903p%252Bcould%252Bbe%252Binvolved%252Bin%252Bthe%252Bpathogenesis%252Bof%252Btemporomandibular%252Bjoint%252Bosteoarthritis%252Bby%252Bmediating%252BUBE2D1%252Band%252BFZD4%26aulast%3DMao%26aufirst%3DDan%26date%3D2021%26date%3D2020%26volume%3D50%26issue%3D2%26spage%3D236%26epage%3D243" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Qichan  Hu</span>, <span class="hlFld-ContribAuthor ">Melanie  Ecker</span>. </span><span class="cited-content_cbyCitation_article-title">Overview of MMP-13 as a Promising Target for the Treatment of Osteoarthritis. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2021,</strong> <em>22 </em>
                                    (4)
                                     , 1742. <a href="https://doi.org/10.3390/ijms22041742" title="DOI URL">https://doi.org/10.3390/ijms22041742</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms22041742&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms22041742%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DOverview%252Bof%252BMMP-13%252Bas%252Ba%252BPromising%252BTarget%252Bfor%252Bthe%252BTreatment%252Bof%252BOsteoarthritis%26aulast%3DHu%26aufirst%3DQichan%26date%3D2021%26date%3D2021%26volume%3D22%26issue%3D4%26spage%3D1742" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Theoharris  Frangos</span>, <span class="hlFld-ContribAuthor ">Wolfgang  Maret</span>. </span><span class="cited-content_cbyCitation_article-title">Zinc and Cadmium in the Aetiology and Pathogenesis of Osteoarthritis and Rheumatoid Arthritis. </span><span class="cited-content_cbyCitation_journal-name">Nutrients</span><span> <strong>2021,</strong> <em>13 </em>
                                    (1)
                                     , 53. <a href="https://doi.org/10.3390/nu13010053" title="DOI URL">https://doi.org/10.3390/nu13010053</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/nu13010053&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fnu13010053%26sid%3Dliteratum%253Aachs%26jtitle%3DNutrients%26atitle%3DZinc%252Band%252BCadmium%252Bin%252Bthe%252BAetiology%252Band%252BPathogenesis%252Bof%252BOsteoarthritis%252Band%252BRheumatoid%252BArthritis%26aulast%3DFrangos%26aufirst%3DTheoharris%26date%3D2021%26date%3D2020%26volume%3D13%26issue%3D1%26spage%3D53" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yichao  Wan</span>, <span class="hlFld-ContribAuthor ">Wei  Li</span>, <span class="hlFld-ContribAuthor ">Zhipeng  Liao</span>, <span class="hlFld-ContribAuthor ">Mi  Yan</span>, <span class="hlFld-ContribAuthor ">Xuwang  Chen</span>, <span class="hlFld-ContribAuthor ">Zilong  Tang</span>. </span><span class="cited-content_cbyCitation_article-title">Selective MMP-13 Inhibitors: Promising Agents for the Therapy of Osteoarthritis. </span><span class="cited-content_cbyCitation_journal-name">Current Medicinal Chemistry</span><span> <strong>2020,</strong> <em>27 </em>
                                    (22)
                                     , 3753-3769. <a href="https://doi.org/10.2174/0929867326666181217153118" title="DOI URL">https://doi.org/10.2174/0929867326666181217153118</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/0929867326666181217153118&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F0929867326666181217153118%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Medicinal%2520Chemistry%26atitle%3DSelective%252BMMP-13%252BInhibitors%25253A%252BPromising%252BAgents%252Bfor%252Bthe%252BTherapy%252Bof%252BOsteoarthritis%26aulast%3DWan%26aufirst%3DYichao%26date%3D2020%26volume%3D27%26issue%3D22%26spage%3D3753%26epage%3D3769" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Daniel  Szulczyk</span>, <span class="hlFld-ContribAuthor ">Anna  Bielenica</span>, <span class="hlFld-ContribAuthor ">Agnieszka  Głogowska</span>, <span class="hlFld-ContribAuthor ">Ewa  Augustynowicz-Kopeć</span>, <span class="hlFld-ContribAuthor ">Michał  Dobrowolski</span>, <span class="hlFld-ContribAuthor ">Piotr  Roszkowski</span>, <span class="hlFld-ContribAuthor ">Karolina  Stępień</span>, <span class="hlFld-ContribAuthor ">Alicja  Chrzanowska</span>, <span class="hlFld-ContribAuthor ">Marta  Struga</span>. </span><span class="cited-content_cbyCitation_article-title">Development of (4-methoxyphenyl)-1H-tetrazol-5-amine regioisomers as a new class of selective antitubercular agents. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>186 </em>, 111882. <a href="https://doi.org/10.1016/j.ejmech.2019.111882" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.111882</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.111882&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.111882%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDevelopment%252Bof%252B%2525284-methoxyphenyl%252529-1H-tetrazol-5-amine%252Bregioisomers%252Bas%252Ba%252Bnew%252Bclass%252Bof%252Bselective%252Bantitubercular%252Bagents%26aulast%3DSzulczyk%26aufirst%3DDaniel%26date%3D2020%26volume%3D186%26spage%3D111882" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Gregg B.  Fields</span>. </span><span class="cited-content_cbyCitation_article-title">The Rebirth of Matrix Metalloproteinase Inhibitors: Moving Beyond the Dogma. </span><span class="cited-content_cbyCitation_journal-name">Cells</span><span> <strong>2019,</strong> <em>8 </em>
                                    (9)
                                     , 984. <a href="https://doi.org/10.3390/cells8090984" title="DOI URL">https://doi.org/10.3390/cells8090984</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cells8090984&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcells8090984%26sid%3Dliteratum%253Aachs%26jtitle%3DCells%26atitle%3DThe%252BRebirth%252Bof%252BMatrix%252BMetalloproteinase%252BInhibitors%25253A%252BMoving%252BBeyond%252Bthe%252BDogma%26aulast%3DFields%26aufirst%3DGregg%2BB.%26date%3D2019%26date%3D2019%26volume%3D8%26issue%3D9%26spage%3D984" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Charles J.  Malemud</span>. </span><span class="cited-content_cbyCitation_article-title">Inhibition of MMPs and ADAM/ADAMTS. </span><span class="cited-content_cbyCitation_journal-name">Biochemical Pharmacology</span><span> <strong>2019,</strong> <em>165 </em>, 33-40. <a href="https://doi.org/10.1016/j.bcp.2019.02.033" title="DOI URL">https://doi.org/10.1016/j.bcp.2019.02.033</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bcp.2019.02.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bcp.2019.02.033%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochemical%2520Pharmacology%26atitle%3DInhibition%252Bof%252BMMPs%252Band%252BADAM%25252FADAMTS%26aulast%3DMalemud%26aufirst%3DCharles%2BJ.%26date%3D2019%26volume%3D165%26spage%3D33%26epage%3D40" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Thomas  Fischer</span>, <span class="hlFld-ContribAuthor ">Nicole  Senn</span>, <span class="hlFld-ContribAuthor ">Rainer  Riedl</span>. </span><span class="cited-content_cbyCitation_article-title">Design and Structural Evolution of Matrix Metalloproteinase Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Chemistry – A European Journal</span><span> <strong>2019,</strong> <em>25 </em>
                                    (34)
                                     , 7960-7980. <a href="https://doi.org/10.1002/chem.201805361" title="DOI URL">https://doi.org/10.1002/chem.201805361</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/chem.201805361&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fchem.201805361%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistry%2520%25E2%2580%2593%2520A%2520European%2520Journal%26atitle%3DDesign%252Band%252BStructural%252BEvolution%252Bof%252BMatrix%252BMetalloproteinase%252BInhibitors%26aulast%3DFischer%26aufirst%3DThomas%26date%3D2019%26date%3D2019%26volume%3D25%26issue%3D34%26spage%3D7960%26epage%3D7980" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Panpan  Zhang</span>, <span class="hlFld-ContribAuthor ">Yuhua  Chen</span>, <span class="hlFld-ContribAuthor ">Huafei  Zhao</span>, <span class="hlFld-ContribAuthor ">Hao  Du</span>. </span><span class="cited-content_cbyCitation_article-title">Protective effects of alogliptin against TNF-α-induced degradation of extracellular matrix in human chondrocytes. </span><span class="cited-content_cbyCitation_journal-name">International Immunopharmacology</span><span> <strong>2019,</strong> <em>68 </em>, 179-184. <a href="https://doi.org/10.1016/j.intimp.2018.11.007" title="DOI URL">https://doi.org/10.1016/j.intimp.2018.11.007</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.intimp.2018.11.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.intimp.2018.11.007%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Immunopharmacology%26atitle%3DProtective%252Beffects%252Bof%252Balogliptin%252Bagainst%252BTNF-%2525CE%2525B1-induced%252Bdegradation%252Bof%252Bextracellular%252Bmatrix%252Bin%252Bhuman%252Bchondrocytes%26aulast%3DZhang%26aufirst%3DPanpan%26date%3D2019%26volume%3D68%26spage%3D179%26epage%3D184" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chen-Yan  Cai</span>, <span class="hlFld-ContribAuthor ">Hai-Chao  Xu</span>. </span><span class="cited-content_cbyCitation_article-title">Dehydrogenative reagent-free annulation of alkenes with diols for the synthesis of saturated O-heterocycles. </span><span class="cited-content_cbyCitation_journal-name">Nature Communications</span><span> <strong>2018,</strong> <em>9 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41467-018-06020-8" title="DOI URL">https://doi.org/10.1038/s41467-018-06020-8</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41467-018-06020-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41467-018-06020-8%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Communications%26atitle%3DDehydrogenative%252Breagent-free%252Bannulation%252Bof%252Balkenes%252Bwith%252Bdiols%252Bfor%252Bthe%252Bsynthesis%252Bof%252Bsaturated%252BO-heterocycles%26aulast%3DCai%26aufirst%3DChen-Yan%26date%3D2018%26date%3D2018%26volume%3D9%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Rita  Fuerst</span>, <span class="hlFld-ContribAuthor ">Jun  Yong Choi</span>, <span class="hlFld-ContribAuthor ">Anna M.  Knapinska</span>, <span class="hlFld-ContribAuthor ">Lyndsay  Smith</span>, <span class="hlFld-ContribAuthor ">Michael D.  Cameron</span>, <span class="hlFld-ContribAuthor ">Claudia  Ruiz</span>, <span class="hlFld-ContribAuthor ">Gregg B.  Fields</span>, <span class="hlFld-ContribAuthor ">William R.  Roush</span>. </span><span class="cited-content_cbyCitation_article-title">Development of matrix metalloproteinase-13 inhibitors – A structure-activity/structure-property relationship study. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2018,</strong> <em>26 </em>
                                    (18)
                                     , 4984-4995. <a href="https://doi.org/10.1016/j.bmc.2018.08.020" title="DOI URL">https://doi.org/10.1016/j.bmc.2018.08.020</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2018.08.020&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2018.08.020%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDevelopment%252Bof%252Bmatrix%252Bmetalloproteinase-13%252Binhibitors%252B%2525E2%252580%252593%252BA%252Bstructure-activity%25252Fstructure-property%252Brelationship%252Bstudy%26aulast%3DFuerst%26aufirst%3DRita%26date%3D2018%26volume%3D26%26issue%3D18%26spage%3D4984%26epage%3D4995" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Aroa  Duro-Castano</span>, <span class="hlFld-ContribAuthor ">Ngee Han  Lim</span>, <span class="hlFld-ContribAuthor ">Isabelle  Tranchant</span>, <span class="hlFld-ContribAuthor ">Mehdi  Amoura</span>, <span class="hlFld-ContribAuthor ">Fabrice  Beau</span>, <span class="hlFld-ContribAuthor ">Heike  Wieland</span>, <span class="hlFld-ContribAuthor ">Otmar  Kingler</span>, <span class="hlFld-ContribAuthor ">Matthias  Herrmann</span>, <span class="hlFld-ContribAuthor ">Marc  Nazaré</span>, <span class="hlFld-ContribAuthor ">Oliver  Plettenburg</span>, <span class="hlFld-ContribAuthor ">Vincent  Dive</span>, <span class="hlFld-ContribAuthor ">María J.  Vicent</span>, <span class="hlFld-ContribAuthor ">Hideaki  Nagase</span>. </span><span class="cited-content_cbyCitation_article-title">In Vivo Imaging of MMP-13 Activity Using a Specific Polymer-FRET Peptide Conjugate Detects Early Osteoarthritis and Inhibitor Efficacy. </span><span class="cited-content_cbyCitation_journal-name">Advanced Functional Materials</span><span> <strong>2018,</strong> <em>28 </em>
                                    (37)
                                     , 1802738. <a href="https://doi.org/10.1002/adfm.201802738" title="DOI URL">https://doi.org/10.1002/adfm.201802738</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/adfm.201802738&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fadfm.201802738%26sid%3Dliteratum%253Aachs%26jtitle%3DAdvanced%2520Functional%2520Materials%26atitle%3DIn%252BVivo%252BImaging%252Bof%252BMMP-13%252BActivity%252BUsing%252Ba%252BSpecific%252BPolymer-FRET%252BPeptide%252BConjugate%252BDetects%252BEarly%252BOsteoarthritis%252Band%252BInhibitor%252BEfficacy%26aulast%3DDuro-Castano%26aufirst%3DAroa%26date%3D2018%26date%3D2018%26volume%3D28%26issue%3D37%26spage%3D1802738" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sabrina  Amar</span>, <span class="hlFld-ContribAuthor ">Dmitriy  Minond</span>, <span class="hlFld-ContribAuthor ">Gregg B.  Fields</span>. </span><span class="cited-content_cbyCitation_article-title">Clinical Implications of Compounds Designed to Inhibit ECM-Modifying Metalloproteinases. </span><span class="cited-content_cbyCitation_journal-name">PROTEOMICS</span><span> <strong>2017,</strong> <em>17 </em>
                                    (23-24)
                                     , 1600389. <a href="https://doi.org/10.1002/pmic.201600389" title="DOI URL">https://doi.org/10.1002/pmic.201600389</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/pmic.201600389&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fpmic.201600389%26sid%3Dliteratum%253Aachs%26jtitle%3DPROTEOMICS%26atitle%3DClinical%252BImplications%252Bof%252BCompounds%252BDesigned%252Bto%252BInhibit%252BECM-Modifying%252BMetalloproteinases%26aulast%3DAmar%26aufirst%3DSabrina%26date%3D2017%26date%3D2017%26volume%3D17%26issue%3D23-24%26spage%3D1600389" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anna  Bielenica</span>, <span class="hlFld-ContribAuthor ">Daniel  Szulczyk</span>, <span class="hlFld-ContribAuthor ">Wioletta  Olejarz</span>, <span class="hlFld-ContribAuthor ">Silvia  Madeddu</span>, <span class="hlFld-ContribAuthor ">Gabriele  Giliberti</span>, <span class="hlFld-ContribAuthor ">Ilona B.  Materek</span>, <span class="hlFld-ContribAuthor ">Anna E.  Koziol</span>, <span class="hlFld-ContribAuthor ">Marta  Struga</span>. </span><span class="cited-content_cbyCitation_article-title">1H-Tetrazol-5-amine and 1,3-thiazolidin-4-one derivatives containing 3-(trifluoromethyl)phenyl scaffold: Synthesis, cytotoxic and anti-HIV studies. </span><span class="cited-content_cbyCitation_journal-name">Biomedicine & Pharmacotherapy</span><span> <strong>2017,</strong> <em>94 </em>, 804-812. <a href="https://doi.org/10.1016/j.biopha.2017.07.152" title="DOI URL">https://doi.org/10.1016/j.biopha.2017.07.152</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.biopha.2017.07.152&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.biopha.2017.07.152%26sid%3Dliteratum%253Aachs%26jtitle%3DBiomedicine%2520%2526%2520Pharmacotherapy%26atitle%3D1H-Tetrazol-5-amine%252Band%252B1%25252C3-thiazolidin-4-one%252Bderivatives%252Bcontaining%252B3-%252528trifluoromethyl%252529phenyl%252Bscaffold%25253A%252BSynthesis%25252C%252Bcytotoxic%252Band%252Banti-HIV%252Bstudies%26aulast%3DBielenica%26aufirst%3DAnna%26date%3D2017%26volume%3D94%26spage%3D804%26epage%3D812" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xin-Wen  Xie</span>, <span class="hlFld-ContribAuthor ">Ren-Zhong  Wan</span>, <span class="hlFld-ContribAuthor ">Zhao-Peng  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">Recent Research Advances in Selective Matrix Metalloproteinase-13 Inhibitors as Anti-Osteoarthritis Agents. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2017,</strong> <em>12 </em>
                                    (15)
                                     , 1157-1168. <a href="https://doi.org/10.1002/cmdc.201700349" title="DOI URL">https://doi.org/10.1002/cmdc.201700349</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.201700349&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.201700349%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DRecent%252BResearch%252BAdvances%252Bin%252BSelective%252BMatrix%252BMetalloproteinase-13%252BInhibitors%252Bas%252BAnti-Osteoarthritis%252BAgents%26aulast%3DXie%26aufirst%3DXin-Wen%26date%3D2017%26date%3D2017%26volume%3D12%26issue%3D15%26spage%3D1157%26epage%3D1168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Stephanie J.  Gauci</span>, <span class="hlFld-ContribAuthor ">Heather  Stanton</span>, <span class="hlFld-ContribAuthor ">Christopher B.  Little</span>, <span class="hlFld-ContribAuthor ">Amanda J.  Fosang</span>. </span><span class="cited-content_cbyCitation_article-title">Proteoglycan and Collagen Degradation in Osteoarthritis. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 41-61. <a href="https://doi.org/10.1007/978-3-319-45803-8_3" title="DOI URL">https://doi.org/10.1007/978-3-319-45803-8_3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/978-3-319-45803-8_3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2F978-3-319-45803-8_3%26sid%3Dliteratum%253Aachs%26atitle%3DProteoglycan%252Band%252BCollagen%252BDegradation%252Bin%252BOsteoarthritis%26aulast%3DGauci%26aufirst%3DStephanie%2BJ.%26date%3D2017%26date%3D2017%26spage%3D41%26epage%3D61%26pub%3DSpringer%2520International%2520Publishing%26atitle%3DCartilage%26aulast%3DGr%25C3%25A4ssel%26aufirst%3DSusanne%26date%3D2017%26volume%3D274" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hiroshi  Nara</span>, <span class="hlFld-ContribAuthor ">Kenjiro  Sato</span>, <span class="hlFld-ContribAuthor ">Akira  Kaieda</span>, <span class="hlFld-ContribAuthor ">Hideyuki  Oki</span>, <span class="hlFld-ContribAuthor ">Haruhiko  Kuno</span>, <span class="hlFld-ContribAuthor ">Takashi  Santou</span>, <span class="hlFld-ContribAuthor ">Naoyuki  Kanzaki</span>, <span class="hlFld-ContribAuthor ">Jun  Terauchi</span>, <span class="hlFld-ContribAuthor ">Osamu  Uchikawa</span>, <span class="hlFld-ContribAuthor ">Masakuni  Kori</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis, and biological activity of novel, potent, and highly selective fused pyrimidine-2-carboxamide-4-one-based matrix metalloproteinase (MMP)-13 zinc-binding inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2016,</strong> <em>24 </em>
                                    (23)
                                     , 6149-6165. <a href="https://doi.org/10.1016/j.bmc.2016.09.009" title="DOI URL">https://doi.org/10.1016/j.bmc.2016.09.009</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2016.09.009&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2016.09.009%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%25252C%252Band%252Bbiological%252Bactivity%252Bof%252Bnovel%25252C%252Bpotent%25252C%252Band%252Bhighly%252Bselective%252Bfused%252Bpyrimidine-2-carboxamide-4-one-based%252Bmatrix%252Bmetalloproteinase%252B%252528MMP%252529-13%252Bzinc-binding%252Binhibitors%26aulast%3DNara%26aufirst%3DHiroshi%26date%3D2016%26volume%3D24%26issue%3D23%26spage%3D6149%26epage%3D6165" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01434/20160113/images/medium/jm-2015-01434x_0018.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01434/20160113/images/large/jm-2015-01434x_0018.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01434&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01434/20160113/images/medium/jm-2015-01434x_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01434/20160113/images/large/jm-2015-01434x_0002.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Representative non-zinc binding, highly selective MMP-13 inhibitors.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01434/20160113/images/large/jm-2015-01434x_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01434&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01434/20160113/images/medium/jm-2015-01434x_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01434/20160113/images/large/jm-2015-01434x_0003.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Key protein–ligand interactions between MMP-13 and compound <b>6</b>.<a onclick="showRef(event, 'ref13'); return false;" href="javascript:void(0);" class="ref ref13">(13)</a> Blue shading indicates ligand exposed regions; purple indicates polar residues; green indicates hydrophobic residues.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01434/20160113/images/large/jm-2015-01434x_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01434&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01434/20160113/images/medium/jm-2015-01434x_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01434/20160113/images/large/jm-2015-01434x_0006.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Pyridine Tetrazole <b>12</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01434/20160113/images/large/jm-2015-01434x_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01434&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) oxalyl chloride, DMF, CH<sub>2</sub>Cl<sub>2</sub>; <i>t</i>-butylamine; (b) POCl<sub>3</sub>, toluene, 110 °C; (c) Et<sub>3</sub>N·HCl, NaN<sub>3</sub>, toluene, 110 °C; (d) Et<sub>3</sub>N, dppf, Pd(OAc)<sub>2</sub>, MeOH, CO, 100 °C.</p></p></figure><figure data-id="sch2" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01434/20160113/images/medium/jm-2015-01434x_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01434/20160113/images/large/jm-2015-01434x_0007.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. General Synthesis of <b>14a</b>–<b>k</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01434/20160113/images/large/jm-2015-01434x_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01434&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) 3-methoxybenzylamine, 100 °C; (b) PS–PPh<sub>3</sub>, DBAD, ROH, THF; or in the case of <b>14e</b> and <b>14i</b>, ROSO<sub>2</sub>Y (Y = 4-toluenyl, 4-nitrophenyl), Et<sub>3</sub>N, DMA, 85 °C.</p></p></figure><figure data-id="sch3" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01434/20160113/images/medium/jm-2015-01434x_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01434/20160113/images/large/jm-2015-01434x_0008.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of <b>18</b> and <b>19</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01434/20160113/images/large/jm-2015-01434x_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01434&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) PS–PPh<sub>3</sub>, DBAD, methyl <i>trans</i>-4-(hydroxymethyl)cyclohexanecarboxylate, THF; (b) HCONH<sub>2</sub>, THF, 80 °C, NaOMe; (c) PS–PPh<sub>3</sub>, CCl<sub>4</sub>, DCE, 80 °C.</p></p></figure><figure data-id="sch4" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01434/20160113/images/medium/jm-2015-01434x_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01434/20160113/images/large/jm-2015-01434x_0009.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 4. Synthesis of <b>23</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01434/20160113/images/large/jm-2015-01434x_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01434&amp;id=sch4"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) PS–PPh<sub>3</sub>, DBAD, <b>13</b>, THF; (b) TFA, CH<sub>2</sub>Cl<sub>2</sub>; (c) Et<sub>3</sub>N, CH<sub>3</sub>SO<sub>2</sub>Cl or Ac<sub>2</sub>O, silica-bound DMAP, CH<sub>2</sub>Cl<sub>2</sub>.</p></p></figure><figure data-id="sch5" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Scheme 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01434/20160113/images/medium/jm-2015-01434x_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01434/20160113/images/large/jm-2015-01434x_0010.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 5. Synthesis of <b>27</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01434/20160113/images/large/jm-2015-01434x_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01434&amp;id=sch5"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) PS–PPh<sub>3</sub>, DBAD, <b>13</b>, THF; (b) TFA, CH<sub>2</sub>Cl<sub>2</sub>; (c) Et<sub>3</sub>N, CH<sub>3</sub>SO<sub>2</sub>Cl or Ac<sub>2</sub>O, silica-bound DMAP, CH<sub>2</sub>Cl<sub>2</sub>.</p></p></figure><figure data-id="sch6" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Scheme 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01434/20160113/images/medium/jm-2015-01434x_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01434/20160113/images/large/jm-2015-01434x_0011.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 6. Synthesis of <b>31</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01434/20160113/images/large/jm-2015-01434x_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01434&amp;id=sch6"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) PS–PPh<sub>3</sub>, DBAD, <b>13</b>, THF; (b) TFA, CH<sub>2</sub>Cl<sub>2</sub>; (c) Et<sub>3</sub>N, silica-bound DMAP, CH<sub>2</sub>Cl<sub>2</sub>; CH<sub>3</sub>SO<sub>2</sub>Cl or Ac<sub>2</sub>O.</p></p></figure><figure data-id="sch7" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Scheme 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01434/20160113/images/medium/jm-2015-01434x_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01434/20160113/images/large/jm-2015-01434x_0012.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 7. General Synthesis of <b>34a</b>–<b>k</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01434/20160113/images/large/jm-2015-01434x_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01434&amp;id=sch7"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) PS–PPh<sub>3</sub>, DBAD, <i>trans</i>-cyclohexane-1,4-dimethanol, THF; (b) LiOH, THF, water; (c) 1-hydroxybenzotriazole, DMF, <i>N</i>-methylmorpholine, EDCI, corresponding benzylamine.</p></p></figure><figure data-id="sch8" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Scheme 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01434/20160113/images/medium/jm-2015-01434x_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01434/20160113/images/large/jm-2015-01434x_0013.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 8. Synthesis of Cyanopyrimidine <b>39</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01434/20160113/images/large/jm-2015-01434x_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01434&amp;id=sch8"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) 13 M H<sub>2</sub>SO<sub>4</sub>, rt; (b) Pd(dppf)Cl<sub>2</sub>, iPr<sub>2</sub>EtN, MeOH, CO, 85 °C; (c) oxalyl chloride, DMA, CH<sub>2</sub>Cl<sub>2</sub>, reflux; (d) Et<sub>4</sub>N(CN), DABCO, CH<sub>2</sub>Cl<sub>2</sub>.</p></p></figure><figure data-id="sch9" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Scheme 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01434/20160113/images/medium/jm-2015-01434x_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01434/20160113/images/large/jm-2015-01434x_0014.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 9. Synthesis of <b>42</b>, <b>43</b>, and <b>45</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01434/20160113/images/large/jm-2015-01434x_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01434&amp;id=sch9"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label">Scheme a</span>Reagents and conditions: (a) corresponding benzylamine, iPr<sub>2</sub>EtN, MeOH, 35 °C; (b) NaN<sub>3</sub>, ZnBr<sub>2</sub>, water, reflux; (c) <b>16</b>, Et<sub>3</sub>N, DMA, 85 °C; (d) <b>43a</b>, pyridinium dichromate, DMF, rt.</p></p></figure><figure data-id="fig3" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01434/20160113/images/medium/jm-2015-01434x_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01434/20160113/images/large/jm-2015-01434x_0004.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Metalloproteinase selectivity (pIC<sub>50</sub>) of <b>43a</b> compared with broad-spectrum agent marimastat (highest concentration tested 10 μM, pIC<sub>50</sub> = 5).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01434/20160113/images/large/jm-2015-01434x_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01434&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01434/20160113/images/medium/jm-2015-01434x_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01434/20160113/images/large/jm-2015-01434x_0005.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Mean plasma concentration–time profiles of <b>43a</b> and carboxylic acid metabolite <b>45</b> after oral administration of <b>43a</b> (1.0 mg/kg) to female cynomolgus monkeys (<i>N</i> = 3).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-1/acs.jmedchem.5b01434/20160113/images/large/jm-2015-01434x_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01434&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i87">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_84202" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_84202" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 29 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Lawrence, R. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Felson, D. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Helmick, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arnold, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deyo, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gabriel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirsch, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hochberg, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunder, G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jordan, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Katz, J. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kremers, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolfe, F.</span><span> </span><span class="NLM_article-title">Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II</span> <span class="citation_source-journal">Arthritis Rheum.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">58</span><span class="NLM_x">, </span> <span class="NLM_fpage">26</span><span class="NLM_x">–</span> <span class="NLM_lpage">35</span><span class="refDoi"> DOI: 10.1002/art.23176</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01434&amp;key=10.1002%2Fart.23176" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01434&amp;key=18163497" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01434&amp;key=1%3ACAS%3A280%3ADC%252BD1c%252Flt1Ghsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=2008&pages=26-35&author=R.+C.+Lawrenceauthor=D.+T.+Felsonauthor=C.+G.+Helmickauthor=L.+M.+Arnoldauthor=H.+Choiauthor=R.+A.+Deyoauthor=S.+Gabrielauthor=R.+Hirschauthor=M.+C.+Hochbergauthor=G.+C.+Hunderauthor=J.+M.+Jordanauthor=J.+N.+Katzauthor=H.+M.+Kremersauthor=F.+Wolfe&title=Estimates+of+the+prevalence+of+arthritis+and+other+rheumatic+conditions+in+the+United+States.+Part+II&doi=10.1002%2Fart.23176"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II</span></div><div class="casAuthors">Lawrence Reva C; Felson David T; Helmick Charles G; Arnold Lesley M; Choi Hyon; Deyo Richard A; Gabriel Sherine; Hirsch Rosemarie; Hochberg Marc C; Hunder Gene G; Jordan Joanne M; Katz Jeffrey N; Kremers Hilal Maradit; Wolfe Frederick</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis and rheumatism</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">26-35</span>
        ISSN:<span class="NLM_cas:issn">0004-3591</span>.
    </div><div class="casAbstract">OBJECTIVE:  To provide a single source for the best available estimates of the US prevalence of and number of individuals affected by osteoarthritis, polymyalgia rheumatica and giant cell arteritis, gout, fibromyalgia, and carpal tunnel syndrome, as well as the symptoms of neck and back pain.  A companion article (part I) addresses additional conditions.  METHODS:  The National Arthritis Data Workgroup reviewed published analyses from available national surveys, such as the National Health and Nutrition Examination Survey and the National Health Interview Survey.  Because data based on national population samples are unavailable for most specific rheumatic conditions, we derived estimates from published studies of smaller, defined populations.  For specific conditions, the best available prevalence estimates were applied to the corresponding 2005 US population estimates from the Census Bureau, to estimate the number affected with each condition.  RESULTS:  We estimated that among US adults, nearly 27 million have clinical osteoarthritis (up from the estimate of 21 million for 1995), 711,000 have polymyalgia rheumatica, 228,000 have giant cell arteritis, up to 3.0 million have had self-reported gout in the past year (up from the estimate of 2.1 million for 1995), 5.0 million have fibromyalgia, 4-10 million have carpal tunnel syndrome, 59 million have had low back pain in the past 3 months, and 30.1 million have had neck pain in the past 3 months.  CONCLUSION:  Estimates for many specific rheumatic conditions rely on a few, small studies of uncertain generalizability to the US population.  This report provides the best available prevalence estimates for the US, but for most specific conditions more studies generalizable to the US or addressing understudied populations are needed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTRoGBggfl_DDdblLE_E9PWfW6udTcc2eYh3e0FQ2GUaLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD1c%252Flt1Ghsw%253D%253D&md5=8fb852bfb01285c89db9c7d87369e167</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1002%2Fart.23176&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.23176%26sid%3Dliteratum%253Aachs%26aulast%3DLawrence%26aufirst%3DR.%2BC.%26aulast%3DFelson%26aufirst%3DD.%2BT.%26aulast%3DHelmick%26aufirst%3DC.%2BG.%26aulast%3DArnold%26aufirst%3DL.%2BM.%26aulast%3DChoi%26aufirst%3DH.%26aulast%3DDeyo%26aufirst%3DR.%2BA.%26aulast%3DGabriel%26aufirst%3DS.%26aulast%3DHirsch%26aufirst%3DR.%26aulast%3DHochberg%26aufirst%3DM.%2BC.%26aulast%3DHunder%26aufirst%3DG.%2BC.%26aulast%3DJordan%26aufirst%3DJ.%2BM.%26aulast%3DKatz%26aufirst%3DJ.%2BN.%26aulast%3DKremers%26aufirst%3DH.%2BM.%26aulast%3DWolfe%26aufirst%3DF.%26atitle%3DEstimates%2520of%2520the%2520prevalence%2520of%2520arthritis%2520and%2520other%2520rheumatic%2520conditions%2520in%2520the%2520United%2520States.%2520Part%2520II%26jtitle%3DArthritis%2520Rheum.%26date%3D2008%26volume%3D58%26spage%3D26%26epage%3D35%26doi%3D10.1002%2Fart.23176" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Johnson, V. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunter, D. J.</span><span> </span><span class="NLM_article-title">The epidemiology of osteoarthritis</span> <span class="citation_source-journal">Best Pract. Res., Clin. Rheumatol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">5</span><span class="NLM_x">–</span> <span class="NLM_lpage">15</span><span class="refDoi"> DOI: 10.1016/j.berh.2014.01.004</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01434&amp;key=10.1016%2Fj.berh.2014.01.004" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01434&amp;key=24792942" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01434&amp;key=1%3ACAS%3A280%3ADC%252BC2cfgsVOqug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2014&pages=5-15&author=V.+L.+Johnsonauthor=D.+J.+Hunter&title=The+epidemiology+of+osteoarthritis&doi=10.1016%2Fj.berh.2014.01.004"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">The epidemiology of osteoarthritis</span></div><div class="casAuthors">Johnson Victoria L; Hunter David J</div><div class="citationInfo"><span class="NLM_cas:title">Best practice & research. Clinical rheumatology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">5-15</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Osteoarthritis (OA) is a leading cause of disability and its incidence is rising due to increasing obesity and an ageing population.  Risk factors can be divided into person-level factors, such as age, sex, obesity, genetics, race/ethnicity and diet, and joint-level factors including injury, malalignment and abnormal loading of the joints.  The interaction of these risk factors is complex and provides a challenge to the managing physician.  The purpose of this review is to illustrate how each of these factors interact together to instigate incident OA as well as to outline the need for ongoing epidemiologic studies for the future prevention of both incident and progressive OA.  It is only by understanding the impact of this disease and the modifiable risk factors that we will be able to truly target public health prevention interventions appropriately.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSoYx3AVD8nQDjk2McQZ6XmfW6udTcc2eYh3e0FQ2GUaLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cfgsVOqug%253D%253D&md5=d8b2c00e1eb2f40c89932f54b6904785</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.berh.2014.01.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.berh.2014.01.004%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DV.%2BL.%26aulast%3DHunter%26aufirst%3DD.%2BJ.%26atitle%3DThe%2520epidemiology%2520of%2520osteoarthritis%26jtitle%3DBest%2520Pract.%2520Res.%252C%2520Clin.%2520Rheumatol.%26date%3D2014%26volume%3D28%26spage%3D5%26epage%3D15%26doi%3D10.1016%2Fj.berh.2014.01.004" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">Felson, D. T.</span><span> </span><span class="NLM_article-title">Osteoarthritis of the Knee</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">354</span><span class="NLM_x">, </span> <span class="NLM_fpage">841</span><span class="NLM_x">–</span> <span class="NLM_lpage">848</span><span class="refDoi"> DOI: 10.1056/NEJMcp051726</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01434&amp;key=10.1056%2FNEJMcp051726" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01434&amp;key=16495396" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01434&amp;key=1%3ACAS%3A528%3ADC%252BD28Xhsl2gsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=354&publication_year=2006&pages=841-848&author=D.+T.+Felson&title=Osteoarthritis+of+the+Knee&doi=10.1056%2FNEJMcp051726"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Osteoarthritis of the knee</span></div><div class="casAuthors">Felson, David T.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">354</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">841-848</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">A 66-yr old woman who is overweight reports bilateral knee pain of gradual onset during the past several months that increasingly has limited her activities.  Last week, when walking down the stairs, she nearly fell when her knee gave way.  She does not recall having injured her knee, and has no morning stiffness and no pain in other joints.  She has tried taking up to eight extra-strength (500 mg each) acetaminophen tablets daily without successes and has never had ulcers or stomach bleeding.  How should the patient be evaluated and treated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTCATV64Md1bVg90H21EOLACvtfcHk0lgqZr8iO2zgwA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xhsl2gsL8%253D&md5=cf1550c58f79fcd220d8e540c31b47c1</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1056%2FNEJMcp051726&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMcp051726%26sid%3Dliteratum%253Aachs%26aulast%3DFelson%26aufirst%3DD.%2BT.%26atitle%3DOsteoarthritis%2520of%2520the%2520Knee%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2006%26volume%3D354%26spage%3D841%26epage%3D848%26doi%3D10.1056%2FNEJMcp051726" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Hellio le Graverand, M.-P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clemmer, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Redifer, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brunell, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hayes, C. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brandt, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abramson, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manning, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vignon, E.</span><span> </span><span class="NLM_article-title">A 2-year randomised, double-blind, placebo-controlled, multicentre study of oral selective iNOS inhibitor, cindunistat (SD-6010), in patients with symptomatic osteoarthritis of the knee</span> <span class="citation_source-journal">Ann. Rheum. Dis.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x">, </span> <span class="NLM_fpage">187</span><span class="NLM_x">–</span> <span class="NLM_lpage">195</span><span class="refDoi"> DOI: 10.1136/annrheumdis-2012-202239</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01434&amp;key=10.1136%2Fannrheumdis-2012-202239" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01434&amp;key=23144445" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01434&amp;key=1%3ACAS%3A280%3ADC%252BC3s7is1Wjsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2013&pages=187-195&author=M.-P.+Hellio+le+Graverandauthor=R.+S.+Clemmerauthor=P.+Rediferauthor=R.+M.+Brunellauthor=C.+W.+Hayesauthor=K.+D.+Brandtauthor=S.+B.+Abramsonauthor=P.+M.+Manningauthor=C.+G.+Millerauthor=E.+Vignon&title=A+2-year+randomised%2C+double-blind%2C+placebo-controlled%2C+multicentre+study+of+oral+selective+iNOS+inhibitor%2C+cindunistat+%28SD-6010%29%2C+in+patients+with+symptomatic+osteoarthritis+of+the+knee&doi=10.1136%2Fannrheumdis-2012-202239"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">A 2-year randomised, double-blind, placebo-controlled, multicentre study of oral selective iNOS inhibitor, cindunistat (SD-6010), in patients with symptomatic osteoarthritis of the knee</span></div><div class="casAuthors">Hellio le Graverand Marie-Pierre; Clemmer Ray S; Redifer Patricia; Brunell Robert M; Hayes Curtis W; Brandt Kenneth D; Abramson Steven B; Manning Pamela T; Miller Colin G; Vignon Eric</div><div class="citationInfo"><span class="NLM_cas:title">Annals of the rheumatic diseases</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">72</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">187-95</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">OBJECTIVE:  To determine if inhibition of inducible nitric oxide synthase (iNOS) with cindunistat hydrochloride maleate slows progression of osteoarthritis (OA)   METHODS:  This 2-year, multinational, double-blind, placebo-controlled trial enrolled patients with symptomatic knee OA (Kellgren and Lawrence Grade (KLG) 2 or 3).  Standard OA therapies were permitted throughout.  Patients were randomly assigned to cindunistat (50 or 200 mg/day) or placebo.  Randomisation was stratified by KLG.  Radiographs to assess joint space narrowing (JSN) were acquired using the modified Lyon-schuss protocol at baseline, week 48 and 96.  RESULTS:  Of 1457 patients (50 mg/day, n=485; 200 mg/day, n=486; placebo, n=486), 1048 (71.9%) completed the study.  Patients were predominantly women; 56% had KLG3.  The primary analysis did not demonstrate superiority of cindunistat versus placebo for rate of change in JSN.  In KLG2 patients, JSN after 48 weeks was lower with cindunistat 50 mg/day versus placebo (p=0.032).  Least-squares mean±SE JSN with cindunistat 50 mg/day ( -0.048±0.028 mm) and 200 mg/day (-0.062±0.028 mm) were 59.9% (95% CI 6.8% to 106.9%) and 48.7% (95% CI -8.4% to 93.9%) of placebo, improvement was not maintained at 96 weeks.  No improvement was observed for KLG3 patients at either time-point.  Cindunistat did not improve joint pain or function, but was generally well tolerated.  CONCLUSIONS:  Cindunistat (50 or 200 mg/day) did not slow the rate of JSN versus placebo.  After 48-weeks, KLG2 patients showed less JSN; however, the improvement was not sustained at 96-weeks. iNOS inhibition did not slow OA progression in KLG3 patients.  CLINICAL TRIAL LISTING:  NCT00565812.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcSMKkgHsOL37TAyhZbj3lKdfW6udTcc2ebrVgAAskiqzLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3s7is1Wjsg%253D%253D&md5=8336d2789698ffc1f9fd2861c3530419</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1136%2Fannrheumdis-2012-202239&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1136%252Fannrheumdis-2012-202239%26sid%3Dliteratum%253Aachs%26aulast%3DHellio%2Ble%2BGraverand%26aufirst%3DM.-P.%26aulast%3DClemmer%26aufirst%3DR.%2BS.%26aulast%3DRedifer%26aufirst%3DP.%26aulast%3DBrunell%26aufirst%3DR.%2BM.%26aulast%3DHayes%26aufirst%3DC.%2BW.%26aulast%3DBrandt%26aufirst%3DK.%2BD.%26aulast%3DAbramson%26aufirst%3DS.%2BB.%26aulast%3DManning%26aufirst%3DP.%2BM.%26aulast%3DMiller%26aufirst%3DC.%2BG.%26aulast%3DVignon%26aufirst%3DE.%26atitle%3DA%25202-year%2520randomised%252C%2520double-blind%252C%2520placebo-controlled%252C%2520multicentre%2520study%2520of%2520oral%2520selective%2520iNOS%2520inhibitor%252C%2520cindunistat%2520%2528SD-6010%2529%252C%2520in%2520patients%2520with%2520symptomatic%2520osteoarthritis%2520of%2520the%2520knee%26jtitle%3DAnn.%2520Rheum.%2520Dis.%26date%3D2013%26volume%3D72%26spage%3D187%26epage%3D195%26doi%3D10.1136%2Fannrheumdis-2012-202239" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Little, C. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barai, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Burkhardt, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fosang, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Werb, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, E. W.</span><span> </span><span class="NLM_article-title">Matrix metalloproteinase 13-deficient mice are resistant to osteoarthritic cartilage erosion but not chondrocyte hypertrophy or osteophyte development</span> <span class="citation_source-journal">Arthritis Rheum.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">3723</span><span class="NLM_x">–</span> <span class="NLM_lpage">3733</span><span class="refDoi"> DOI: 10.1002/art.25002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01434&amp;key=10.1002%2Fart.25002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01434&amp;key=19950295" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01434&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFKhtb%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2009&pages=3723-3733&author=C.+B.+Littleauthor=A.+Baraiauthor=D.+Burkhardtauthor=S.+M.+Smithauthor=A.+J.+Fosangauthor=Z.+Werbauthor=M.+Shahauthor=E.+W.+Thompson&title=Matrix+metalloproteinase+13-deficient+mice+are+resistant+to+osteoarthritic+cartilage+erosion+but+not+chondrocyte+hypertrophy+or+osteophyte+development&doi=10.1002%2Fart.25002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Matrix metalloproteinase 13-deficient mice are resistant to osteoarthritic cartilage erosion but not chondrocyte hypertrophy or osteophyte development</span></div><div class="casAuthors">Little, C. B.; Barai, A.; Burkhardt, D.; Smith, S. M.; Fosang, A. J.; Werb, Z.; Shah, M.; Thompson, E. W.</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis & Rheumatism</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">3723-3733</span>CODEN:
                <span class="NLM_cas:coden">ARHEAW</span>;
        ISSN:<span class="NLM_cas:issn">0004-3591</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">To investigate the role of matrix metalloproteinase 13 (MMP-13; collagenase 3) in osteoarthritis (OA).  OA was surgically induced in the knees of MMP-13-knockout mice and wild-type mice, and mice were compared.  Histol. scoring of femoral and tibial cartilage aggrecan loss (0-3 scale), erosion (0-7 scale), and chondrocyte hypertrophy (0-1 scale), as well as osteophyte size (0-3 scale) and maturity (0-3 scale) was performed.  Serial sections were stained for type X collagen and the MMP-generated aggrecan neoepitope DIPEN.  Following surgery, aggrecan loss and cartilage erosion were more severe in the tibia than femur (P < 0.01) and tibial cartilage erosion increased with time (P < 0.05) in wild-type mice.  Cartilaginous osteophytes were present at 4 wk and underwent ossification, with size and maturity increasing by 8 wk (P < 0.01).  There was no difference between genotypes in aggrecan loss or cartilage erosion at 4 wk.  There was less tibial cartilage erosion in knock- out mice than in wild-type mice at 8 wk (P < 0.02).  Cartilaginous osteophytes were larger in knockout mice at 4 wk (P < 0.01), but by 8 wk osteophyte maturity and size were no different from those in wild-type mice.  Articular chondrocyte hypertrophy with pos. type X collagen and DIPEN staining occurred in both wild-type and knockout mouse joints.  Our findings indicate that structural cartilage damage in a mouse model of OA is dependent on MMP-13 activity.  Chondrocyte hypertrophy is not regulated by MMP-13 activity in this model and does not in itself lead to cartilage erosion.  MMP-13 deficiency can inhibit cartilage erosion in the presence of aggrecan depletion, supporting the potential for therapeutic intervention in established OA with MMP-13 inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGplFkB0jtAForVg90H21EOLACvtfcHk0liGk0Oi9iTvKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFKhtb%252FI&md5=995b082b9fb21a8b0a242b4703461a48</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1002%2Fart.25002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.25002%26sid%3Dliteratum%253Aachs%26aulast%3DLittle%26aufirst%3DC.%2BB.%26aulast%3DBarai%26aufirst%3DA.%26aulast%3DBurkhardt%26aufirst%3DD.%26aulast%3DSmith%26aufirst%3DS.%2BM.%26aulast%3DFosang%26aufirst%3DA.%2BJ.%26aulast%3DWerb%26aufirst%3DZ.%26aulast%3DShah%26aufirst%3DM.%26aulast%3DThompson%26aufirst%3DE.%2BW.%26atitle%3DMatrix%2520metalloproteinase%252013-deficient%2520mice%2520are%2520resistant%2520to%2520osteoarthritic%2520cartilage%2520erosion%2520but%2520not%2520chondrocyte%2520hypertrophy%2520or%2520osteophyte%2520development%26jtitle%3DArthritis%2520Rheum.%26date%3D2009%26volume%3D60%26spage%3D3723%26epage%3D3733%26doi%3D10.1002%2Fart.25002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Johnson, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pavlovsky, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ortwine, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prior, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Man, C.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bornemeier, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Banotai, C. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mueller, W. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McConnell, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baragi, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lesch, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roark, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Datta, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guzman, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, H.-K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dyer, R. D.</span><span> </span><span class="NLM_article-title">Discovery and characterization of a novel inhibitor of matrix metalloprotease-13 that reduces cartilage damage in vivo without joint fibroplasia side effects</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">282</span><span class="NLM_x">, </span> <span class="NLM_fpage">27781</span><span class="NLM_x">–</span> <span class="NLM_lpage">27791</span><span class="refDoi"> DOI: 10.1074/jbc.M703286200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01434&amp;key=10.1074%2Fjbc.M703286200" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=282&publication_year=2007&pages=27781-27791&author=A.+R.+Johnsonauthor=A.+G.+Pavlovskyauthor=D.+F.+Ortwineauthor=F.+Priorauthor=C.-F.+Manauthor=D.+A.+Bornemeierauthor=C.+A.+Banotaiauthor=W.+T.+Muellerauthor=P.+McConnellauthor=C.+Yanauthor=V.+Baragiauthor=C.+Leschauthor=W.+H.+Roarkauthor=M.+Wilsonauthor=K.+Dattaauthor=R.+Guzmanauthor=H.-K.+Hanauthor=R.+D.+Dyer&title=Discovery+and+characterization+of+a+novel+inhibitor+of+matrix+metalloprotease-13+that+reduces+cartilage+damage+in+vivo+without+joint+fibroplasia+side+effects&doi=10.1074%2Fjbc.M703286200"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M703286200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M703286200%26sid%3Dliteratum%253Aachs%26aulast%3DJohnson%26aufirst%3DA.%2BR.%26aulast%3DPavlovsky%26aufirst%3DA.%2BG.%26aulast%3DOrtwine%26aufirst%3DD.%2BF.%26aulast%3DPrior%26aufirst%3DF.%26aulast%3DMan%26aufirst%3DC.-F.%26aulast%3DBornemeier%26aufirst%3DD.%2BA.%26aulast%3DBanotai%26aufirst%3DC.%2BA.%26aulast%3DMueller%26aufirst%3DW.%2BT.%26aulast%3DMcConnell%26aufirst%3DP.%26aulast%3DYan%26aufirst%3DC.%26aulast%3DBaragi%26aufirst%3DV.%26aulast%3DLesch%26aufirst%3DC.%26aulast%3DRoark%26aufirst%3DW.%2BH.%26aulast%3DWilson%26aufirst%3DM.%26aulast%3DDatta%26aufirst%3DK.%26aulast%3DGuzman%26aufirst%3DR.%26aulast%3DHan%26aufirst%3DH.-K.%26aulast%3DDyer%26aufirst%3DR.%2BD.%26atitle%3DDiscovery%2520and%2520characterization%2520of%2520a%2520novel%2520inhibitor%2520of%2520matrix%2520metalloprotease-13%2520that%2520reduces%2520cartilage%2520damage%2520in%2520vivo%2520without%2520joint%2520fibroplasia%2520side%2520effects%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2007%26volume%3D282%26spage%3D27781%26epage%3D27791%26doi%3D10.1074%2Fjbc.M703286200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Baragi, V. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Becher, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bendele, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Biesinger, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bluhm, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deng, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dodd, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Essers, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feuerstein, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallagher, B. M.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gege, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hochgürtel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hofmann, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jaworski, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiely, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Korniski, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kroth, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nix, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nolte, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piecha, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powers, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Richter, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schneider, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steeneck, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sucholeiki, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taveras, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Timmermann, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Veldhuizen, J. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weik, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, B.</span><span> </span><span class="NLM_article-title">A new class of potent matrix metalloproteinase 13 inhibitors for potential treatment of osteoarthritis evidence of histologic and clinical efficacy without musculoskeletal toxicity in rat models</span> <span class="citation_source-journal">Arthritis Rheum.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">60</span><span class="NLM_x">, </span> <span class="NLM_fpage">2008</span><span class="NLM_x">–</span> <span class="NLM_lpage">2018</span><span class="refDoi"> DOI: 10.1002/art.24629</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01434&amp;key=10.1002%2Fart.24629" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01434&amp;key=19565489" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01434&amp;key=1%3ACAS%3A528%3ADC%252BD1MXptlKku78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=60&publication_year=2009&pages=2008-2018&author=V.+M.+Baragiauthor=G.+Becherauthor=A.+M.+Bendeleauthor=R.+Biesingerauthor=H.+Bluhmauthor=J.+Boerauthor=H.+Dengauthor=R.+Doddauthor=M.+Essersauthor=T.+Feuersteinauthor=B.+M.+Gallagherauthor=C.+Gegeauthor=M.+Hochg%C3%BCrtelauthor=M.+Hofmannauthor=A.+Jaworskiauthor=L.+Jinauthor=A.+Kielyauthor=B.+Korniskiauthor=H.+Krothauthor=D.+Nixauthor=B.+Nolteauthor=D.+Piechaauthor=T.+S.+Powersauthor=F.+Richterauthor=M.+Schneiderauthor=C.+Steeneckauthor=I.+Sucholeikiauthor=A.+Taverasauthor=A.+Timmermannauthor=J.+V.+Veldhuizenauthor=J.+Weikauthor=X.+Wuauthor=B.+Xia&title=A+new+class+of+potent+matrix+metalloproteinase+13+inhibitors+for+potential+treatment+of+osteoarthritis+evidence+of+histologic+and+clinical+efficacy+without+musculoskeletal+toxicity+in+rat+models&doi=10.1002%2Fart.24629"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">A new class of potent matrix metalloproteinase 13 inhibitors for potential treatment of osteoarthritis. Evidence of histologic and clinical efficacy without musculoskeletal toxicity in rat models</span></div><div class="casAuthors">Baragi, Vijaykumar M.; Becher, Gabriel; Bendele, Alison M.; Biesinger, Ralf; Bluhm, Harald; Boer, Jurgen; Deng, Hongbo; Dodd, Rory; Essers, Michael; Feuerstein, Tim; Gallagher, Brian M., Jr.; Gege, Christian; Hochgurtel, Matthias; Hofmann, Michael; Jaworski, Andreas; Jin, Lixia; Kiely, Andrew; Korniski, Brian; Kroth, Heiko; Nix, Darrell; Nolte, Bert; Piecha, Dorothea; Powers, Timothy S.; Richter, Frank; Schneider, Matthias; Steeneck, Christoph; Sucholeiki, Irving; Taveras, Arthur; Timmermann, Andreas; van Veldhuizen, Joshua; Weik, Juergen; Wu, Xinyuan; Xia, Bing</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis & Rheumatism</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">60</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2008-2018</span>CODEN:
                <span class="NLM_cas:coden">ARHEAW</span>;
        ISSN:<span class="NLM_cas:issn">0004-3591</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Objective: Matrix metalloproteinases (MMPs) have long been considered excellent targets for osteoarthritis (OA) treatment.  However, clin. utility of broad-spectrum MMP inhibitors developed for this purpose has been restricted by dose-limiting musculoskeletal side effects obsd. in humans.  This study was undertaken to identify a new class of potent and selective MMP-13 inhibitors that would provide histol. and clin. efficacy without musculoskeletal toxicity.  Methods. Selectivity assays were developed using catalytic domains of human MMPs.  Freshly isolated bovine articular cartilage or human OA cartilage was used in in vitro cartilage degrdn. assays.  The rat model of monoiodoacetate (MIA)-induced OA was implemented for assessing the effects of MMP-13 inhibitors on cartilage degrdn. and joint pain.  The surgical medial meniscus tear model in rats was used to evaluate the chondroprotective ability of MMP-13 inhibitors in a chronic disease model of OA.  The rat model of musculoskeletal side effects (MSS) was used to assess whether selective MMP-13 inhibitors have the joint toxicity assocd. with broad-spectrum MMP inhibitors.  Results. A no. of non-hydroxamic acid-contg. compds. that showed a high degree of potency for MMP-13 and selectivity against other MMPs were designed and synthesized.  Steady-state kinetics expts. and Lineweaver-Burk plot anal. of rate vs. substrate concn. with one such compd., ALS 1-0635, indicated linear, noncompetitive inhibition, and Dixon plot anal. from competition studies with a zinc chelator (acetoxyhydroxamic acid) and ALS 1-0635 demonstrated nonexclusive binding.  ALS 1-0635 inhibited bovine articular cartilage degrdn. in a dose-dependent manner (48.7% and 87.1% at 500 nM and 5,000 nM, resp.) and was effective in inhibiting interleukin-1α- and oncostatin M-induced C1,C2 release in human OA cartilage cultures.  ALS 1-0635 modulated cartilage damage in the rat MIA model (mean ± SEM damage score 1.3 ± 0.3, vs. 2.2 ± 0.4 in vehicle-treated animals).  Most significantly, when treated twice daily with oral ALS 1-0635, rats with surgically induced medial meniscus tear exhibited histol. evidence of chondroprotection and reduced cartilage degeneration, without observable musculoskeletal toxicity.  Conclusion. The compds. investigated in this study represent a novel class of MMP-13 inhibitors.  They are mechanistically distinct from previously reported broad-spectrum MMP inhibitors and do not exhibit the problems previously assocd. with these inhibitors, including selectivity, poor pharmacokinetics, and MSS liability.  MMP-13 inhibitors exert chondro-protective effects and can potentially modulate joint pain, and are, therefore, uniquely suited as potential disease-modifying osteoarthritis drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWH6P91ktaKrVg90H21EOLACvtfcHk0liEqqUPCrJK1g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXptlKku78%253D&md5=87a8b16eaf252bf4fd3c28217a78f8d6</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1002%2Fart.24629&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.24629%26sid%3Dliteratum%253Aachs%26aulast%3DBaragi%26aufirst%3DV.%2BM.%26aulast%3DBecher%26aufirst%3DG.%26aulast%3DBendele%26aufirst%3DA.%2BM.%26aulast%3DBiesinger%26aufirst%3DR.%26aulast%3DBluhm%26aufirst%3DH.%26aulast%3DBoer%26aufirst%3DJ.%26aulast%3DDeng%26aufirst%3DH.%26aulast%3DDodd%26aufirst%3DR.%26aulast%3DEssers%26aufirst%3DM.%26aulast%3DFeuerstein%26aufirst%3DT.%26aulast%3DGallagher%26aufirst%3DB.%2BM.%26aulast%3DGege%26aufirst%3DC.%26aulast%3DHochg%25C3%25BCrtel%26aufirst%3DM.%26aulast%3DHofmann%26aufirst%3DM.%26aulast%3DJaworski%26aufirst%3DA.%26aulast%3DJin%26aufirst%3DL.%26aulast%3DKiely%26aufirst%3DA.%26aulast%3DKorniski%26aufirst%3DB.%26aulast%3DKroth%26aufirst%3DH.%26aulast%3DNix%26aufirst%3DD.%26aulast%3DNolte%26aufirst%3DB.%26aulast%3DPiecha%26aufirst%3DD.%26aulast%3DPowers%26aufirst%3DT.%2BS.%26aulast%3DRichter%26aufirst%3DF.%26aulast%3DSchneider%26aufirst%3DM.%26aulast%3DSteeneck%26aufirst%3DC.%26aulast%3DSucholeiki%26aufirst%3DI.%26aulast%3DTaveras%26aufirst%3DA.%26aulast%3DTimmermann%26aufirst%3DA.%26aulast%3DVeldhuizen%26aufirst%3DJ.%2BV.%26aulast%3DWeik%26aufirst%3DJ.%26aulast%3DWu%26aufirst%3DX.%26aulast%3DXia%26aufirst%3DB.%26atitle%3DA%2520new%2520class%2520of%2520potent%2520matrix%2520metalloproteinase%252013%2520inhibitors%2520for%2520potential%2520treatment%2520of%2520osteoarthritis%2520evidence%2520of%2520histologic%2520and%2520clinical%2520efficacy%2520without%2520musculoskeletal%2520toxicity%2520in%2520rat%2520models%26jtitle%3DArthritis%2520Rheum.%26date%3D2009%26volume%3D60%26spage%3D2008%26epage%3D2018%26doi%3D10.1002%2Fart.24629" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Wojtowicz-Praga, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Torri, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steen, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marshall, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ness, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dickson, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sale, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rasmussen, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chiodo, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hawkins, M. J.</span><span> </span><span class="NLM_article-title">Phase I trial of marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">2150</span><span class="NLM_x">–</span> <span class="NLM_lpage">2156</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01434&amp;key=9626215" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01434&amp;key=1%3ACAS%3A528%3ADyaK1cXktV2isbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=1998&pages=2150-2156&author=S.+Wojtowicz-Pragaauthor=J.+Torriauthor=M.+Johnsonauthor=V.+Steenauthor=J.+Marshallauthor=E.+Nessauthor=R.+Dicksonauthor=M.+Saleauthor=H.+S.+Rasmussenauthor=T.+A.+Chiodoauthor=M.+J.+Hawkins&title=Phase+I+trial+of+marimastat%2C+a+novel+matrix+metalloproteinase+inhibitor%2C+administered+orally+to+patients+with+advanced+lung+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Phase I trial of marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer</span></div><div class="casAuthors">Wojtowicz-Praga, Slawomir; Torri, Jeff; Johnson, Michael; Steen, Virginia; Marshall, John; Ness, Elizabeth; Dickson, Robert; Sale, Mark; Rasmussen, Henrik S.; Chiodo, Tina Avanzato; Hawkins, Michael J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">2150-2156</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">W. B. Saunders Co.</span>)
        </div><div class="casAbstract">This phase I study was performed to evaluate the safety and pharmacokinetics of escalating doses of Marimastat (British Biotech, Inc, Oxford, United Kingdom) in patients with advanced malignancies and to det. the phase II recommended dose to be used in subsequent studies.  A std. phase I design was used in this study, in which consecutive groups of three patients were treated with escalating doses of the study drug.  Marimastat was administered orally at 25, 50, or 100 mg twice daily to consecutive groups of patients with advanced lung cancer.  An addnl. three patients were added at the highest dose studied (100 mg orally twice daily) to assess whether the inflammatory polyarthritis obsd. at that dose level can be prevented by a concurrent administration of nonsteroidal antiinflammatory drugs (NSAIDS) and/or low-dose corticosteroids.  Blood was drawn for safety monitoring, pharmacokinetic anal., and plasma levels of metallo-proteinase (MMP)-2 and MMP-9 (detd. by zymog.).  A total of 12 patients were studied.  The most significant toxicity at the highest dose studied (100 mg orally twice daily) was a symptomatic inflammatory polyarthritis that persisted for up to 8 wk after discontinuation of the study drug and was dose-limiting.  The estd. plasma elimination half-life of Marimastat was 4 to 5 h.  The mean max. concn. (Cmax) at a reasonably well-tolerated dose (50 mg orally twice daily) was 196 ng/mL and was reached within 1 to 2 h (Tmax) after administration.  Areas under the curve (AUC) tended to correlate with the dose of Marimastat.  Zymog. anal. of peripheral-blood ratios of activated pro-enzymic forms of MMP-2 and -9 did not show any consistent patterns of change in MMP levels or in a degree of their activation during the course of treatment.  Marimastat was well absorbed from the gastrointestinal tract, with high levels of the study drug detected in plasma within hours after drug administration.  Plasma concns. of Marimastat achieved at dose levels 2 and 3 (50 mg and 100 mg orally twice daily) were substantially higher than those required for MMP inhibition in vitro.  The dose-limiting toxicity (DLT) was severe inflammatory polyarthritis, which seemed to be a cumulative toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr_9iFywtSW1LVg90H21EOLACvtfcHk0lg-Jx9Z_4AOZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXktV2isbo%253D&md5=5d9d5362f38d4c6130fcd72e0a902d48</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DWojtowicz-Praga%26aufirst%3DS.%26aulast%3DTorri%26aufirst%3DJ.%26aulast%3DJohnson%26aufirst%3DM.%26aulast%3DSteen%26aufirst%3DV.%26aulast%3DMarshall%26aufirst%3DJ.%26aulast%3DNess%26aufirst%3DE.%26aulast%3DDickson%26aufirst%3DR.%26aulast%3DSale%26aufirst%3DM.%26aulast%3DRasmussen%26aufirst%3DH.%2BS.%26aulast%3DChiodo%26aufirst%3DT.%2BA.%26aulast%3DHawkins%26aufirst%3DM.%2BJ.%26atitle%3DPhase%2520I%2520trial%2520of%2520marimastat%252C%2520a%2520novel%2520matrix%2520metalloproteinase%2520inhibitor%252C%2520administered%2520orally%2520to%2520patients%2520with%2520advanced%2520lung%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D1998%26volume%3D16%26spage%3D2150%26epage%3D2156" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Stickens, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Behonick, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ortega, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heyer, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartenstein, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fosang, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schorpp-Kistner, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Angel, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Werb, Z.</span><span> </span><span class="NLM_article-title">Altered endochondral bone development in matrix metalloproteinase 13-deficient mice</span> <span class="citation_source-journal">Development</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">131</span><span class="NLM_x">, </span> <span class="NLM_fpage">5883</span><span class="NLM_x">–</span> <span class="NLM_lpage">5895</span><span class="refDoi"> DOI: 10.1242/dev.01461</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01434&amp;key=10.1242%2Fdev.01461" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01434&amp;key=15539485" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01434&amp;key=1%3ACAS%3A528%3ADC%252BD2MXnslersg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2004&pages=5883-5895&author=D.+Stickensauthor=D.+J.+Behonickauthor=N.+Ortegaauthor=B.+Heyerauthor=B.+Hartensteinauthor=Y.+Yuauthor=A.+J.+Fosangauthor=M.+Schorpp-Kistnerauthor=P.+Angelauthor=Z.+Werb&title=Altered+endochondral+bone+development+in+matrix+metalloproteinase+13-deficient+mice&doi=10.1242%2Fdev.01461"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Altered endochondral bone development in matrix metalloproteinase 13-deficient mice</span></div><div class="casAuthors">Stickens, Dominique; Behonick, Danielle J.; Ortega, Nathalie; Heyer, Babette; Hartenstein, Bettina; Yu, Ying; Fosang, Amanda J.; Schorpp-Kistner, Marina; Angel, Peter; Werb, Zena</div><div class="citationInfo"><span class="NLM_cas:title">Development (Cambridge, United Kingdom)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">131</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">5883-5895</span>CODEN:
                <span class="NLM_cas:coden">DEVPED</span>;
        ISSN:<span class="NLM_cas:issn">0950-1991</span>.
    
            (<span class="NLM_cas:orgname">Company of Biologists Ltd.</span>)
        </div><div class="casAbstract">The assembly and degrdn. of extracellular matrix (ECM) mols. are crucial processes during bone development.  In this study, we show that ECM remodeling is a crit. rate-limiting step in endochondral bone formation.  Matrix metalloproteinase (MMP) 13 (collagenase 3) is poised to play a crucial role in bone formation and remodeling because of its expression both in terminal hypertrophic chondrocytes in the growth plate and in osteoblasts.  Moreover, a mutation in the human MMP13 gene causes the Missouri variant of spondyloepimetaphyseal dysplasia.  Inactivation of Mmp13 in mice through homologous recombination led to abnormal skeletal growth plate development.  Chondrocytes differentiated normally but their exit from the growth plate was delayed.  The severity of the Mmp13-null growth plate phenotype increased until about 5 wk and completely resolved by 12 wk of age.  Mmp13-null mice had increased trabecular bone, which persisted for months.  Conditional inactivation of Mmp13 in chondrocytes and osteoblasts showed that increase in trabecular bone occur independently of the improper cartilage ECM degrdn. caused by Mmp13 deficiency in late hypertrophic chondrocytes.  Our studies identified the two major components of the cartilage ECM, collagen type II and aggrecan, as in vivo substrates for MMP13.  We found that degrdn. of cartilage collagen and aggrecan is a coordinated process in which MMP13 works synergistically with MMP9.  Mice lacking both MMP13 and MMP9 had severely impaired endochondral bone, characterized by diminished ECM remodeling, prolonged chondrocyte survival, delayed vascular recruitment and defective trabecular bone formation (resulting in drastically shortened bones).  These data support the hypothesis that proper ECM remodeling is the dominant rate-limiting process for programmed cell death, angiogenesis and osteoblast recruitment during normal skeletal morphogenesis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrJsfbwk37K8bVg90H21EOLACvtfcHk0lg-Jx9Z_4AOZw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXnslersg%253D%253D&md5=704861e9cefe7fdde098bc493bfc3e0e</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1242%2Fdev.01461&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1242%252Fdev.01461%26sid%3Dliteratum%253Aachs%26aulast%3DStickens%26aufirst%3DD.%26aulast%3DBehonick%26aufirst%3DD.%2BJ.%26aulast%3DOrtega%26aufirst%3DN.%26aulast%3DHeyer%26aufirst%3DB.%26aulast%3DHartenstein%26aufirst%3DB.%26aulast%3DYu%26aufirst%3DY.%26aulast%3DFosang%26aufirst%3DA.%2BJ.%26aulast%3DSchorpp-Kistner%26aufirst%3DM.%26aulast%3DAngel%26aufirst%3DP.%26aulast%3DWerb%26aufirst%3DZ.%26atitle%3DAltered%2520endochondral%2520bone%2520development%2520in%2520matrix%2520metalloproteinase%252013-deficient%2520mice%26jtitle%3DDevelopment%26date%3D2004%26volume%3D131%26spage%3D5883%26epage%3D5895%26doi%3D10.1242%2Fdev.01461" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Kennedy, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Inada, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krane, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christie, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Harding, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">López-Otín, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sánchez, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pannett, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dearlove, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hartley, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Byrne, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reed, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nesbit, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Whyte, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thakker, R. V.</span><span> </span><span class="NLM_article-title">MMP13 mutation causes spondyloepimetaphyseal dysplasia, Missouri type (SEMDMO)</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">115</span><span class="NLM_x">, </span> <span class="NLM_fpage">2832</span><span class="NLM_x">–</span> <span class="NLM_lpage">2842</span><span class="refDoi"> DOI: 10.1172/JCI22900</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01434&amp;key=10.1172%2FJCI22900" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=115&publication_year=2005&pages=2832-2842&author=A.+M.+Kennedyauthor=M.+Inadaauthor=S.+M.+Kraneauthor=P.+T.+Christieauthor=B.+Hardingauthor=C.+L%C3%B3pez-Ot%C3%ADnauthor=L.+M.+S%C3%A1nchezauthor=A.+J.+Pannettauthor=A.+Dearloveauthor=C.+Hartleyauthor=M.+H.+Byrneauthor=A.+Reedauthor=M.+A.+Nesbitauthor=M.+P.+Whyteauthor=R.+V.+Thakker&title=MMP13+mutation+causes+spondyloepimetaphyseal+dysplasia%2C+Missouri+type+%28SEMDMO%29&doi=10.1172%2FJCI22900"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1172%2FJCI22900&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI22900%26sid%3Dliteratum%253Aachs%26aulast%3DKennedy%26aufirst%3DA.%2BM.%26aulast%3DInada%26aufirst%3DM.%26aulast%3DKrane%26aufirst%3DS.%2BM.%26aulast%3DChristie%26aufirst%3DP.%2BT.%26aulast%3DHarding%26aufirst%3DB.%26aulast%3DL%25C3%25B3pez-Ot%25C3%25ADn%26aufirst%3DC.%26aulast%3DS%25C3%25A1nchez%26aufirst%3DL.%2BM.%26aulast%3DPannett%26aufirst%3DA.%2BJ.%26aulast%3DDearlove%26aufirst%3DA.%26aulast%3DHartley%26aufirst%3DC.%26aulast%3DByrne%26aufirst%3DM.%2BH.%26aulast%3DReed%26aufirst%3DA.%26aulast%3DNesbit%26aufirst%3DM.%2BA.%26aulast%3DWhyte%26aufirst%3DM.%2BP.%26aulast%3DThakker%26aufirst%3DR.%2BV.%26atitle%3DMMP13%2520mutation%2520causes%2520spondyloepimetaphyseal%2520dysplasia%252C%2520Missouri%2520type%2520%2528SEMDMO%2529%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2005%26volume%3D115%26spage%3D2832%26epage%3D2842%26doi%3D10.1172%2FJCI22900" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Engel, C. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pirard, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schimanski, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirsch, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Habermann, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klingler, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlotte, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weithmann, K. U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wendt, K. U.</span><span> </span><span class="NLM_article-title">Structural basis for the highly selective inhibition of MMP-13</span> <span class="citation_source-journal">Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">181</span><span class="NLM_x">–</span> <span class="NLM_lpage">189</span><span class="refDoi"> DOI: 10.1016/j.chembiol.2004.11.014</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01434&amp;key=10.1016%2Fj.chembiol.2004.11.014" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01434&amp;key=15734645" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01434&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhslCmsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2005&pages=181-189&author=C.+K.+Engelauthor=B.+Pirardauthor=S.+Schimanskiauthor=R.+Kirschauthor=J.+Habermannauthor=O.+Klinglerauthor=V.+Schlotteauthor=K.+U.+Weithmannauthor=K.+U.+Wendt&title=Structural+basis+for+the+highly+selective+inhibition+of+MMP-13&doi=10.1016%2Fj.chembiol.2004.11.014"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Structural Basis for the Highly Selective Inhibition of MMP-13</span></div><div class="casAuthors">Engel, Christian K.; Pirard, Bernard; Schimanski, Sandra; Kirsch, Reinhard; Habermann, Joerg; Klingler, Otmar; Schlotte, Volkhard; Weithmann, Klaus Ulrich; Wendt, K. Ulrich</div><div class="citationInfo"><span class="NLM_cas:title">Chemistry & Biology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">181-189</span>CODEN:
                <span class="NLM_cas:coden">CBOLE2</span>;
        ISSN:<span class="NLM_cas:issn">1074-5521</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">Summary: Inhibitors for matrix metalloproteinases (MMPs) are under investigation for the treatment of cancer, arthritis, and cardiovascular disease.  Here, the authors report a class of highly selective MMP-13 inhibitors (pyrimidine dicarboxamides) that exhibit no detectable activity against other MMPs.  The high-resoln. x-ray structures of three mols. of this series bound to MMP-13 reveal a novel binding mode characterized by the absence of interactions between the inhibitors and the catalytic zinc.  The inhibitors bind in the S1' pocket and extend into an addnl. S1' side pocket, which is unique to MMP-13.  The authors analyze the determinants for selectivity and describe the rational design of improved compds. with low nanomolar affinity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWxTXaerMLjLVg90H21EOLACvtfcHk0lj9-7rdfqzAIg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhslCmsbY%253D&md5=92bf47d2ceb76db87ecae786fc89fc64</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2Fj.chembiol.2004.11.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.chembiol.2004.11.014%26sid%3Dliteratum%253Aachs%26aulast%3DEngel%26aufirst%3DC.%2BK.%26aulast%3DPirard%26aufirst%3DB.%26aulast%3DSchimanski%26aufirst%3DS.%26aulast%3DKirsch%26aufirst%3DR.%26aulast%3DHabermann%26aufirst%3DJ.%26aulast%3DKlingler%26aufirst%3DO.%26aulast%3DSchlotte%26aufirst%3DV.%26aulast%3DWeithmann%26aufirst%3DK.%2BU.%26aulast%3DWendt%26aufirst%3DK.%2BU.%26atitle%3DStructural%2520basis%2520for%2520the%2520highly%2520selective%2520inhibition%2520of%2520MMP-13%26jtitle%3DChem.%2520Biol.%26date%3D2005%26volume%3D12%26spage%3D181%26epage%3D189%26doi%3D10.1016%2Fj.chembiol.2004.11.014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Li, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nahra, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bunker, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O'Brien, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yue, W.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ortwine, D. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Man, C.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baragi, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kilgore, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dyer, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Han, H.-K.</span><span> </span><span class="NLM_article-title">Quinazolinones and pyrido[3,4-d]pyrimidin-4-ones as orally active and specific matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">835</span><span class="NLM_x">–</span> <span class="NLM_lpage">841</span><span class="refDoi"> DOI: 10.1021/jm701274v</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm701274v" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=835-841&author=J.+J.+Liauthor=J.+Nahraauthor=A.+R.+Johnsonauthor=A.+Bunkerauthor=P.+O%27Brienauthor=W.-S.+Yueauthor=D.+F.+Ortwineauthor=C.-F.+Manauthor=V.+Baragiauthor=K.+Kilgoreauthor=R.+D.+Dyerauthor=H.-K.+Han&title=Quinazolinones+and+pyrido%5B3%2C4-d%5Dpyrimidin-4-ones+as+orally+active+and+specific+matrix+metalloproteinase-13+inhibitors+for+the+treatment+of+osteoarthritis&doi=10.1021%2Fjm701274v"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1021%2Fjm701274v&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm701274v%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DJ.%2BJ.%26aulast%3DNahra%26aufirst%3DJ.%26aulast%3DJohnson%26aufirst%3DA.%2BR.%26aulast%3DBunker%26aufirst%3DA.%26aulast%3DO%2527Brien%26aufirst%3DP.%26aulast%3DYue%26aufirst%3DW.-S.%26aulast%3DOrtwine%26aufirst%3DD.%2BF.%26aulast%3DMan%26aufirst%3DC.-F.%26aulast%3DBaragi%26aufirst%3DV.%26aulast%3DKilgore%26aufirst%3DK.%26aulast%3DDyer%26aufirst%3DR.%2BD.%26aulast%3DHan%26aufirst%3DH.-K.%26atitle%3DQuinazolinones%2520and%2520pyrido%255B3%252C4-d%255Dpyrimidin-4-ones%2520as%2520orally%2520active%2520and%2520specific%2520matrix%2520metalloproteinase-13%2520inhibitors%2520for%2520the%2520treatment%2520of%2520osteoarthritis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D835%26epage%3D841%26doi%3D10.1021%2Fjm701274v" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Schnute, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Brien, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nahra, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morris, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roark, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hanau, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruminski, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scholten, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fletcher, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamper, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carroll, J. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patt, W. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shieh, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pavlovsky, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Palmquist, K. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aston, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hitchcock, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rogers, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonald, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, A. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munie, G. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wittwer, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Man, C.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settle, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nemirovskiy, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vickery, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agawal, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dyer, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sunyer, T.</span><span> </span><span class="NLM_article-title">Discovery of (pyridin-4-yl)-2<i>H</i>-tetrazole as a novel scaffold to identify highly selective matrix metalloproteinase-13 inhibitors for the treatment of osteoarthritis</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">576</span><span class="NLM_x">–</span> <span class="NLM_lpage">580</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2009.11.081</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01434&amp;key=10.1016%2Fj.bmcl.2009.11.081" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2010&pages=576-580&author=M.+E.+Schnuteauthor=P.+M.+O%E2%80%99Brienauthor=J.+Nahraauthor=M.+Morrisauthor=W.+H.+Roarkauthor=C.+E.+Hanauauthor=P.+G.+Ruminskiauthor=J.+A.+Scholtenauthor=T.+R.+Fletcherauthor=B.+C.+Hamperauthor=J.+N.+Carrollauthor=W.+C.+Pattauthor=H.+S.+Shiehauthor=B.+Collinsauthor=A.+G.+Pavlovskyauthor=K.+E.+Palmquistauthor=K.+W.+Astonauthor=J.+Hitchcockauthor=M.+D.+Rogersauthor=J.+McDonaldauthor=A.+R.+Johnsonauthor=G.+E.+Munieauthor=A.+J.+Wittwerauthor=C.-F.+Manauthor=S.+L.+Settleauthor=O.+Nemirovskiyauthor=L.+E.+Vickeryauthor=A.+Agawalauthor=R.+D.+Dyerauthor=T.+Sunyer&title=Discovery+of+%28pyridin-4-yl%29-2H-tetrazole+as+a+novel+scaffold+to+identify+highly+selective+matrix+metalloproteinase-13+inhibitors+for+the+treatment+of+osteoarthritis&doi=10.1016%2Fj.bmcl.2009.11.081"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2009.11.081&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2009.11.081%26sid%3Dliteratum%253Aachs%26aulast%3DSchnute%26aufirst%3DM.%2BE.%26aulast%3DO%25E2%2580%2599Brien%26aufirst%3DP.%2BM.%26aulast%3DNahra%26aufirst%3DJ.%26aulast%3DMorris%26aufirst%3DM.%26aulast%3DRoark%26aufirst%3DW.%2BH.%26aulast%3DHanau%26aufirst%3DC.%2BE.%26aulast%3DRuminski%26aufirst%3DP.%2BG.%26aulast%3DScholten%26aufirst%3DJ.%2BA.%26aulast%3DFletcher%26aufirst%3DT.%2BR.%26aulast%3DHamper%26aufirst%3DB.%2BC.%26aulast%3DCarroll%26aufirst%3DJ.%2BN.%26aulast%3DPatt%26aufirst%3DW.%2BC.%26aulast%3DShieh%26aufirst%3DH.%2BS.%26aulast%3DCollins%26aufirst%3DB.%26aulast%3DPavlovsky%26aufirst%3DA.%2BG.%26aulast%3DPalmquist%26aufirst%3DK.%2BE.%26aulast%3DAston%26aufirst%3DK.%2BW.%26aulast%3DHitchcock%26aufirst%3DJ.%26aulast%3DRogers%26aufirst%3DM.%2BD.%26aulast%3DMcDonald%26aufirst%3DJ.%26aulast%3DJohnson%26aufirst%3DA.%2BR.%26aulast%3DMunie%26aufirst%3DG.%2BE.%26aulast%3DWittwer%26aufirst%3DA.%2BJ.%26aulast%3DMan%26aufirst%3DC.-F.%26aulast%3DSettle%26aufirst%3DS.%2BL.%26aulast%3DNemirovskiy%26aufirst%3DO.%26aulast%3DVickery%26aufirst%3DL.%2BE.%26aulast%3DAgawal%26aufirst%3DA.%26aulast%3DDyer%26aufirst%3DR.%2BD.%26aulast%3DSunyer%26aufirst%3DT.%26atitle%3DDiscovery%2520of%2520%2528pyridin-4-yl%2529-2H-tetrazole%2520as%2520a%2520novel%2520scaffold%2520to%2520identify%2520highly%2520selective%2520matrix%2520metalloproteinase-13%2520inhibitors%2520for%2520the%2520treatment%2520of%2520osteoarthritis%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2010%26volume%3D20%26spage%3D576%26epage%3D580%26doi%3D10.1016%2Fj.bmcl.2009.11.081" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Nara, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sato, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naito, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mototani, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oki, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuno, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santou, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanzaki, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Terauchi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uchikawa, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kori, M.</span><span> </span><span class="NLM_article-title">Discovery of novel, highly potent, and selective quinazoline-2-carboxamide-based Matrix metalloproteinase (MMP)-13 inhibitors without a zinc binding group using a structure-based design approach</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">8886</span><span class="NLM_x">–</span> <span class="NLM_lpage">8902</span><span class="refDoi"> DOI: 10.1021/jm500981k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500981k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=8886-8902&author=H.+Naraauthor=K.+Satoauthor=T.+Naitoauthor=H.+Mototaniauthor=H.+Okiauthor=Y.+Yamamotoauthor=H.+Kunoauthor=T.+Santouauthor=N.+Kanzakiauthor=J.+Terauchiauthor=O.+Uchikawaauthor=M.+Kori&title=Discovery+of+novel%2C+highly+potent%2C+and+selective+quinazoline-2-carboxamide-based+Matrix+metalloproteinase+%28MMP%29-13+inhibitors+without+a+zinc+binding+group+using+a+structure-based+design+approach&doi=10.1021%2Fjm500981k"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1021%2Fjm500981k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500981k%26sid%3Dliteratum%253Aachs%26aulast%3DNara%26aufirst%3DH.%26aulast%3DSato%26aufirst%3DK.%26aulast%3DNaito%26aufirst%3DT.%26aulast%3DMototani%26aufirst%3DH.%26aulast%3DOki%26aufirst%3DH.%26aulast%3DYamamoto%26aufirst%3DY.%26aulast%3DKuno%26aufirst%3DH.%26aulast%3DSantou%26aufirst%3DT.%26aulast%3DKanzaki%26aufirst%3DN.%26aulast%3DTerauchi%26aufirst%3DJ.%26aulast%3DUchikawa%26aufirst%3DO.%26aulast%3DKori%26aufirst%3DM.%26atitle%3DDiscovery%2520of%2520novel%252C%2520highly%2520potent%252C%2520and%2520selective%2520quinazoline-2-carboxamide-based%2520Matrix%2520metalloproteinase%2520%2528MMP%2529-13%2520inhibitors%2520without%2520a%2520zinc%2520binding%2520group%2520using%2520a%2520structure-based%2520design%2520approach%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D8886%26epage%3D8902%26doi%3D10.1021%2Fjm500981k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Nara, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sato, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Naito, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mototani, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oki, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamamoto, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuno, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Santou, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanzaki, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Terauchi, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uchikawa, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kori, M.</span><span> </span><span class="NLM_article-title">Thieno[2,3-d]pyrimidine-2-carboxamides bearing a carboxybenzene group at 5-position: Highly potent, selective, and orally available MMP-13 inhibitors interacting with the S1″ binding site</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">22</span><span class="NLM_x">, </span> <span class="NLM_fpage">5487</span><span class="NLM_x">–</span> <span class="NLM_lpage">5505</span><span class="refDoi"> DOI: 10.1016/j.bmc.2014.07.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01434&amp;key=10.1016%2Fj.bmc.2014.07.025" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2014&pages=5487-5505&author=H.+Naraauthor=K.+Satoauthor=T.+Naitoauthor=H.+Mototaniauthor=H.+Okiauthor=Y.+Yamamotoauthor=H.+Kunoauthor=T.+Santouauthor=N.+Kanzakiauthor=J.+Terauchiauthor=O.+Uchikawaauthor=M.+Kori&title=Thieno%5B2%2C3-d%5Dpyrimidine-2-carboxamides+bearing+a+carboxybenzene+group+at+5-position%3A+Highly+potent%2C+selective%2C+and+orally+available+MMP-13+inhibitors+interacting+with+the+S1%E2%80%B3+binding+site&doi=10.1016%2Fj.bmc.2014.07.025"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2014.07.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2014.07.025%26sid%3Dliteratum%253Aachs%26aulast%3DNara%26aufirst%3DH.%26aulast%3DSato%26aufirst%3DK.%26aulast%3DNaito%26aufirst%3DT.%26aulast%3DMototani%26aufirst%3DH.%26aulast%3DOki%26aufirst%3DH.%26aulast%3DYamamoto%26aufirst%3DY.%26aulast%3DKuno%26aufirst%3DH.%26aulast%3DSantou%26aufirst%3DT.%26aulast%3DKanzaki%26aufirst%3DN.%26aulast%3DTerauchi%26aufirst%3DJ.%26aulast%3DUchikawa%26aufirst%3DO.%26aulast%3DKori%26aufirst%3DM.%26atitle%3DThieno%255B2%252C3-d%255Dpyrimidine-2-carboxamides%2520bearing%2520a%2520carboxybenzene%2520group%2520at%25205-position%253A%2520Highly%2520potent%252C%2520selective%252C%2520and%2520orally%2520available%2520MMP-13%2520inhibitors%2520interacting%2520with%2520the%2520S1%25E2%2580%25B3%2520binding%2520site%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2014%26volume%3D22%26spage%3D5487%26epage%3D5505%26doi%3D10.1016%2Fj.bmc.2014.07.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Gege, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bao, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bluhm, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallagher, B. M.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Korniski, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powers, T. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Steeneck, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taveras, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baragi, V. M.</span><span> </span><span class="NLM_article-title">Discovery and evaluation of a non-Zn chelating, selective matrix metalloproteinase 13 (MMP-13) inhibitor for potential intra-articular treatment of osteoarthritis</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">709</span><span class="NLM_x">–</span> <span class="NLM_lpage">716</span><span class="refDoi"> DOI: 10.1021/jm201152u</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201152u" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=709-716&author=C.+Gegeauthor=B.+Baoauthor=H.+Bluhmauthor=J.+Boerauthor=B.+M.+Gallagherauthor=B.+Korniskiauthor=T.+S.+Powersauthor=C.+Steeneckauthor=A.+G.+Taverasauthor=V.+M.+Baragi&title=Discovery+and+evaluation+of+a+non-Zn+chelating%2C+selective+matrix+metalloproteinase+13+%28MMP-13%29+inhibitor+for+potential+intra-articular+treatment+of+osteoarthritis&doi=10.1021%2Fjm201152u"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1021%2Fjm201152u&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201152u%26sid%3Dliteratum%253Aachs%26aulast%3DGege%26aufirst%3DC.%26aulast%3DBao%26aufirst%3DB.%26aulast%3DBluhm%26aufirst%3DH.%26aulast%3DBoer%26aufirst%3DJ.%26aulast%3DGallagher%26aufirst%3DB.%2BM.%26aulast%3DKorniski%26aufirst%3DB.%26aulast%3DPowers%26aufirst%3DT.%2BS.%26aulast%3DSteeneck%26aufirst%3DC.%26aulast%3DTaveras%26aufirst%3DA.%2BG.%26aulast%3DBaragi%26aufirst%3DV.%2BM.%26atitle%3DDiscovery%2520and%2520evaluation%2520of%2520a%2520non-Zn%2520chelating%252C%2520selective%2520matrix%2520metalloproteinase%252013%2520%2528MMP-13%2529%2520inhibitor%2520for%2520potential%2520intra-articular%2520treatment%2520of%2520osteoarthritis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D709%26epage%3D716%26doi%3D10.1021%2Fjm201152u" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Taylor, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abeywardane, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muegge, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padyana, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xiong, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hill-Drzewi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farmer, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collins, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heim-Riether, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Proudfoot, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goldberg, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zuvela-Jelaska, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaher, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Farrow, N. A.</span><span> </span><span class="NLM_article-title">Fragment-based discovery of indole inhibitors of matrix metalloproteinase-13</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">8174</span><span class="NLM_x">–</span> <span class="NLM_lpage">8187</span><span class="refDoi"> DOI: 10.1021/jm201129m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm201129m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=8174-8187&author=S.+J.+Taylorauthor=A.+Abeywardaneauthor=S.+Liangauthor=I.+Mueggeauthor=A.+K.+Padyanaauthor=Z.+Xiongauthor=M.+Hill-Drzewiauthor=B.+Farmerauthor=X.+Liauthor=B.+Collinsauthor=J.+X.+Liauthor=A.+Heim-Rietherauthor=J.+Proudfootauthor=Q.+Zhangauthor=D.+Goldbergauthor=L.+Zuvela-Jelaskaauthor=H.+Zaherauthor=J.+Liauthor=N.+A.+Farrow&title=Fragment-based+discovery+of+indole+inhibitors+of+matrix+metalloproteinase-13&doi=10.1021%2Fjm201129m"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1021%2Fjm201129m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm201129m%26sid%3Dliteratum%253Aachs%26aulast%3DTaylor%26aufirst%3DS.%2BJ.%26aulast%3DAbeywardane%26aufirst%3DA.%26aulast%3DLiang%26aufirst%3DS.%26aulast%3DMuegge%26aufirst%3DI.%26aulast%3DPadyana%26aufirst%3DA.%2BK.%26aulast%3DXiong%26aufirst%3DZ.%26aulast%3DHill-Drzewi%26aufirst%3DM.%26aulast%3DFarmer%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DX.%26aulast%3DCollins%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DJ.%2BX.%26aulast%3DHeim-Riether%26aufirst%3DA.%26aulast%3DProudfoot%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DQ.%26aulast%3DGoldberg%26aufirst%3DD.%26aulast%3DZuvela-Jelaska%26aufirst%3DL.%26aulast%3DZaher%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DJ.%26aulast%3DFarrow%26aufirst%3DN.%2BA.%26atitle%3DFragment-based%2520discovery%2520of%2520indole%2520inhibitors%2520of%2520matrix%2520metalloproteinase-13%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D8174%26epage%3D8187%26doi%3D10.1021%2Fjm201129m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Cai, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Agrawal, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Putt, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hashim, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reddy, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brodfuehrer, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Surendran, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lash, L. H.</span><span> </span><span class="NLM_article-title">Assessment of the renal toxicity of novel anti-inflammatory compounds using cynomolgus monkey and human kidney cells</span> <span class="citation_source-journal">Toxicology</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">258</span><span class="NLM_x">, </span> <span class="NLM_fpage">56</span><span class="NLM_x">–</span> <span class="NLM_lpage">63</span><span class="refDoi"> DOI: 10.1016/j.tox.2009.01.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01434&amp;key=10.1016%2Fj.tox.2009.01.006" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=258&publication_year=2009&pages=56-63&author=H.+Caiauthor=A.+K.+Agrawalauthor=D.+A.+Puttauthor=M.+Hashimauthor=A.+Reddyauthor=J.+Brodfuehrerauthor=N.+Surendranauthor=L.+H.+Lash&title=Assessment+of+the+renal+toxicity+of+novel+anti-inflammatory+compounds+using+cynomolgus+monkey+and+human+kidney+cells&doi=10.1016%2Fj.tox.2009.01.006"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1016%2Fj.tox.2009.01.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tox.2009.01.006%26sid%3Dliteratum%253Aachs%26aulast%3DCai%26aufirst%3DH.%26aulast%3DAgrawal%26aufirst%3DA.%2BK.%26aulast%3DPutt%26aufirst%3DD.%2BA.%26aulast%3DHashim%26aufirst%3DM.%26aulast%3DReddy%26aufirst%3DA.%26aulast%3DBrodfuehrer%26aufirst%3DJ.%26aulast%3DSurendran%26aufirst%3DN.%26aulast%3DLash%26aufirst%3DL.%2BH.%26atitle%3DAssessment%2520of%2520the%2520renal%2520toxicity%2520of%2520novel%2520anti-inflammatory%2520compounds%2520using%2520cynomolgus%2520monkey%2520and%2520human%2520kidney%2520cells%26jtitle%3DToxicology%26date%3D2009%26volume%3D258%26spage%3D56%26epage%3D63%26doi%3D10.1016%2Fj.tox.2009.01.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Sallustio, B. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sabordo, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Evans, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nation, R. L.</span><span> </span><span class="NLM_article-title">Hepatic disposition of electrophilic acyl glucuronide conjugates</span> <span class="citation_source-journal">Curr. Drug Metab.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">1</span><span class="NLM_x">, </span> <span class="NLM_fpage">163</span><span class="NLM_x">–</span> <span class="NLM_lpage">180</span><span class="refDoi"> DOI: 10.2174/1389200003339153</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01434&amp;key=10.2174%2F1389200003339153" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01434&amp;key=11465081" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01434&amp;key=1%3ACAS%3A528%3ADC%252BD3cXntlOrs7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2000&pages=163-180&author=B.+C.+Sallustioauthor=L.+Sabordoauthor=A.+M.+Evansauthor=R.+L.+Nation&title=Hepatic+disposition+of+electrophilic+acyl+glucuronide+conjugates&doi=10.2174%2F1389200003339153"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">Hepatic disposition of electrophilic acyl glucuronide conjugates</span></div><div class="casAuthors">Sallustio, B. C.; Sabordo, L.; Evans, A. M.; Nation, R. L.</div><div class="citationInfo"><span class="NLM_cas:title">Current Drug Metabolism</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">163-180</span>CODEN:
                <span class="NLM_cas:coden">CDMUBU</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review with 148 refs.  Acyl glucuronides are a unique class of electrophilic metabolites, capable of non-enzymic reactions including acylation and/or glycation of endogenous macromols., hydrolysis to reform the parent aglycon, and intra-mol. rearrangement.  Three human UDP-glucuronosyltransferases (UGTs) catalyzing the hepatic glucuronidation of carboxylic acid drugs have been identified, UGT1A3, UGT1A9 and a UGT2B7 variant.  Within the liver, acyl glucuronides also undergo enzymic hydrolysis by β-glucuronidase and esterases which, like the UGTs, are located in the endoplasmic reticulum.  In addn., the liver also transports acyl glucuronides between the sinusoidal circulation and bile.  Due to their polarity, membrane transport of acyl glucuronides is carrier-mediated, resulting in the establishment of significant concn. gradients between sinusoidal circulation, hepatocyte and bile, in the order of 1:50:5000 in these compartments, resp.  As a result of exposure to high acyl glucuronide concns., the liver is a major target of protein adduct formation.  Dipeptidylpeptidase IV, UGTs and tubulin have been identified as intra-hepatic targets of adduct formation by acyl glucuronides.  Adduct formation results in altered protein activity and potentially contributes to hepatotoxicity.  Hepatic protein adducts are also immunogenic and may cause immune mediated cytotoxicity.  Both intra- and extra-hepatic exposure to acyl glucuronides depends not only on the efficiency of glucuronidation and hydrolysis by the liver, but also on the efficiency of the hepatic membrane transport systems.  Thus, changes in membrane transporter activities, as may occur due to satn. or drug-drug interactions, can significantly affect acyl glucuronide disposition, adduct formation and the disposition of parent aglycon, thereby affecting clin. efficacy and toxicity of acyl glucuronide forming drugs.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-AkLxhuBjD7Vg90H21EOLACvtfcHk0lgra3R9Lp07ZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXntlOrs7o%253D&md5=dee87ae191547acf3e8b2e87fb87a013</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.2174%2F1389200003339153&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1389200003339153%26sid%3Dliteratum%253Aachs%26aulast%3DSallustio%26aufirst%3DB.%2BC.%26aulast%3DSabordo%26aufirst%3DL.%26aulast%3DEvans%26aufirst%3DA.%2BM.%26aulast%3DNation%26aufirst%3DR.%2BL.%26atitle%3DHepatic%2520disposition%2520of%2520electrophilic%2520acyl%2520glucuronide%2520conjugates%26jtitle%3DCurr.%2520Drug%2520Metab.%26date%3D2000%26volume%3D1%26spage%3D163%26epage%3D180%26doi%3D10.2174%2F1389200003339153" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Summerbell, R. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stephens, J. R.</span><span> </span><span class="NLM_article-title">The stereochemistry of several 2,5-disubstituted dioxanes</span> <span class="citation_source-journal">J. Am. Chem. Soc.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1954</span><span class="NLM_x">, </span> <span class="NLM_volume">76</span><span class="NLM_x">, </span> <span class="NLM_fpage">6401</span><span class="NLM_x">–</span> <span class="NLM_lpage">6407</span><span class="refDoi"> DOI: 10.1021/ja01653a046</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ja01653a046" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=76&publication_year=1954&pages=6401-6407&author=R.+K.+Summerbellauthor=J.+R.+Stephens&title=The+stereochemistry+of+several+2%2C5-disubstituted+dioxanes&doi=10.1021%2Fja01653a046"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1021%2Fja01653a046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fja01653a046%26sid%3Dliteratum%253Aachs%26aulast%3DSummerbell%26aufirst%3DR.%2BK.%26aulast%3DStephens%26aufirst%3DJ.%2BR.%26atitle%3DThe%2520stereochemistry%2520of%2520several%25202%252C5-disubstituted%2520dioxanes%26jtitle%3DJ.%2520Am.%2520Chem.%2520Soc.%26date%3D1954%26volume%3D76%26spage%3D6401%26epage%3D6407%26doi%3D10.1021%2Fja01653a046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Obach, R. S.</span><span> </span><span class="NLM_article-title">Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: An examination of in vitro half-life approach and nonspecific binding to microsomes</span> <span class="citation_source-journal">Drug Metab. Dispos.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1999</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">1350</span><span class="NLM_x">–</span> <span class="NLM_lpage">1359</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01434&amp;key=10534321" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01434&amp;key=1%3ACAS%3A528%3ADyaK1MXntFSht7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=1999&pages=1350-1359&author=R.+S.+Obach&title=Prediction+of+human+clearance+of+twenty-nine+drugs+from+hepatic+microsomal+intrinsic+clearance+data%3A+An+examination+of+in+vitro+half-life+approach+and+nonspecific+binding+to+microsomes"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes</span></div><div class="casAuthors">Obach, R. Scott</div><div class="citationInfo"><span class="NLM_cas:title">Drug Metabolism and Disposition</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1350-1359</span>CODEN:
                <span class="NLM_cas:coden">DMDSAI</span>;
        ISSN:<span class="NLM_cas:issn">0090-9556</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">Twenty-nine drugs of disparate structures and physicochem. properties were used in an examn. of the capability of human liver microsomal lability data ("in vitro T1/2" approach) to be useful in the prediction of human clearance.  Addnl., the potential importance of nonspecific binding to microsomes in the in vitro incubation milieu for the accurate prediction of human clearance was investigated.  The compds. examd. demonstrated a wide range of microsomal metabolic labilities with scaled intrinsic clearance values ranging from less than 0.5 mL/min/kg to 189 mL/min/kg.  Microsomal binding was detd. at microsomal protein concns. used in the lability incubations.  For the 29 compds. studied, unbound fractions in microsomes ranged from 0.11 to 1.0.  Generally, basic compds. demonstrated the greatest extent of binding and neutral and acidic compds. the least extent of binding.  In the projection of human clearance values, basic and neutral compds. were well predicted when all binding considerations (blood and microsome) were disregarded, however, including both binding considerations also yielded reasonable predictions.  Including only blood binding yielded very poor projections of human clearance for these two types of compds.  However, for acidic compds., disregarding all binding considerations yielded poor predictions of human clearance.  It was generally most difficult to accurately predict clearance for this class of compds.; however the accuracy was best when all binding considerations were included.  Overall, inclusion of both blood and microsome binding values gave the best agreement between in vivo clearance values and clearance values projected from in vitro intrinsic clearance data.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpWp2hUTOxyubVg90H21EOLACvtfcHk0lgra3R9Lp07ZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXntFSht7c%253D&md5=7804cd4dfb131caac45aff9b7a1df901</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DObach%26aufirst%3DR.%2BS.%26atitle%3DPrediction%2520of%2520human%2520clearance%2520of%2520twenty-nine%2520drugs%2520from%2520hepatic%2520microsomal%2520intrinsic%2520clearance%2520data%253A%2520An%2520examination%2520of%2520in%2520vitro%2520half-life%2520approach%2520and%2520nonspecific%2520binding%2520to%2520microsomes%26jtitle%3DDrug%2520Metab.%2520Dispos.%26date%3D1999%26volume%3D27%26spage%3D1350%26epage%3D1359" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Stepan, A. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Karki, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonald, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dorff, P. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dutra, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DiRico, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Won, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Subramanyam, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Efremov, I. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Donnell, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nolan, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Becker, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pustilnik, L. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sneed, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sun, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Robshaw, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riddell, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Sullivan, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sibley, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capetta, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atchison, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hallgren, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wood, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Obach, R. S.</span><span> </span><span class="NLM_article-title">Metabolism-Directed Design of Oxetane-Containing Arylsulfonamide Derivatives as γ-Secretase Inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">7772</span><span class="NLM_x">–</span> <span class="NLM_lpage">7783</span><span class="refDoi"> DOI: 10.1021/jm200893p</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200893p" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01434&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlOgu7rK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=7772-7783&author=A.+F.+Stepanauthor=K.+Karkiauthor=W.+S.+McDonaldauthor=P.+H.+Dorffauthor=J.+K.+Dutraauthor=K.+J.+DiRicoauthor=A.+Wonauthor=C.+Subramanyamauthor=I.+V.+Efremovauthor=C.+J.+O%E2%80%99Donnellauthor=C.+E.+Nolanauthor=S.+L.+Beckerauthor=L.+R.+Pustilnikauthor=B.+Sneedauthor=H.+Sunauthor=Y.+Luauthor=A.+E.+Robshawauthor=D.+Riddellauthor=T.+J.+O%E2%80%99Sullivanauthor=E.+Sibleyauthor=S.+Capettaauthor=K.+Atchisonauthor=A.+J.+Hallgrenauthor=E.+Millerauthor=A.+Woodauthor=R.+S.+Obach&title=Metabolism-Directed+Design+of+Oxetane-Containing+Arylsulfonamide+Derivatives+as+%CE%B3-Secretase+Inhibitors&doi=10.1021%2Fjm200893p"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Metabolism-Directed Design of Oxetane-Containing Arylsulfonamide Derivatives as γ-Secretase Inhibitors</span></div><div class="casAuthors">Stepan, Antonia F.; Karki, Kapil; McDonald, W. Scott; Dorff, Peter H.; Dutra, Jason K.; DiRico, Kenneth J.; Won, Annie; Subramanyam, Chakrapani; Efremov, Ivan V.; O'Donnell, Christopher J.; Nolan, Charles E.; Becker, Stacey L.; Pustilnik, Leslie R.; Sneed, Blossom; Sun, Hao; Lu, Yasong; Robshaw, Ashley E.; Riddell, David; O'Sullivan, Theresa J.; Sibley, Evelyn; Capetta, Steven; Atchison, Kevin; Hallgren, Andrew J.; Miller, Emily; Wood, Anthony; Obach, R. Scott</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">22</span>),
    <span class="NLM_cas:pages">7772-7783</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A metab.-based approach toward the optimization of a series of N-arylsulfonamide-based γ-secretase inhibitors is reported.  The lead cyclohexyl analog 6 suffered from extensive oxidn. on the cycloalkyl motif by cytochrome P 450 3A4, translating into poor human liver microsomal stability.  Knowledge of the metabolic pathways of 6 triggered a structure-activity relationship study aimed at lowering lipophilicity through the introduction of polarity.  This effort led to several tetrahydropyran and THF analogs, wherein the 3- and 4-substituted variants exhibited greater microsomal stability relative to their 2-substituted counterparts.  Further redn. in lipophilicity led to the potent γ-secretase inhibitor and 3-substituted oxetane 1 with a reduced propensity toward oxidative metab., relative to its 2-substituted isomer.  The slower rates of metab. with 3-substituted cyclic ethers most likely originate from redns. in lipophilicity and/or unfavorable CYP active site interactions with the heteroatom.  Preliminary animal pharmacol. studies with a representative oxetane indicate that the series is generally capable of lowering Aβ in vivo.  As such, the study also illustrates the improvement in drug likeness of mols. through the use of the oxetane motif.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr1kWyZJuyD97Vg90H21EOLACvtfcHk0ljNWI2lQxIjyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlOgu7rK&md5=b3e9725954a155900563cc5d2f73263b</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1021%2Fjm200893p&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200893p%26sid%3Dliteratum%253Aachs%26aulast%3DStepan%26aufirst%3DA.%2BF.%26aulast%3DKarki%26aufirst%3DK.%26aulast%3DMcDonald%26aufirst%3DW.%2BS.%26aulast%3DDorff%26aufirst%3DP.%2BH.%26aulast%3DDutra%26aufirst%3DJ.%2BK.%26aulast%3DDiRico%26aufirst%3DK.%2BJ.%26aulast%3DWon%26aufirst%3DA.%26aulast%3DSubramanyam%26aufirst%3DC.%26aulast%3DEfremov%26aufirst%3DI.%2BV.%26aulast%3DO%25E2%2580%2599Donnell%26aufirst%3DC.%2BJ.%26aulast%3DNolan%26aufirst%3DC.%2BE.%26aulast%3DBecker%26aufirst%3DS.%2BL.%26aulast%3DPustilnik%26aufirst%3DL.%2BR.%26aulast%3DSneed%26aufirst%3DB.%26aulast%3DSun%26aufirst%3DH.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DRobshaw%26aufirst%3DA.%2BE.%26aulast%3DRiddell%26aufirst%3DD.%26aulast%3DO%25E2%2580%2599Sullivan%26aufirst%3DT.%2BJ.%26aulast%3DSibley%26aufirst%3DE.%26aulast%3DCapetta%26aufirst%3DS.%26aulast%3DAtchison%26aufirst%3DK.%26aulast%3DHallgren%26aufirst%3DA.%2BJ.%26aulast%3DMiller%26aufirst%3DE.%26aulast%3DWood%26aufirst%3DA.%26aulast%3DObach%26aufirst%3DR.%2BS.%26atitle%3DMetabolism-Directed%2520Design%2520of%2520Oxetane-Containing%2520Arylsulfonamide%2520Derivatives%2520as%2520%25CE%25B3-Secretase%2520Inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D7772%26epage%3D7783%26doi%3D10.1021%2Fjm200893p" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Ritchie, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macdonald, S. J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peace, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pickett, S. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luscombe, C. N.</span><span> </span><span class="NLM_article-title">The developability of heteroaromatic and heteroaliphatic rings – do some have a better pedigree as potential drug molecules than others?</span> <span class="citation_source-journal">MedChemComm</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">1062</span><span class="NLM_x">–</span> <span class="NLM_lpage">1069</span><span class="refDoi"> DOI: 10.1039/c2md20111a</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01434&amp;key=10.1039%2Fc2md20111a" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01434&amp;key=1%3ACAS%3A528%3ADC%252BC38Xht1GitLfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=1062-1069&author=T.+J.+Ritchieauthor=S.+J.+F.+Macdonaldauthor=S.+Peaceauthor=S.+D.+Pickettauthor=C.+N.+Luscombe&title=The+developability+of+heteroaromatic+and+heteroaliphatic+rings+%E2%80%93+do+some+have+a+better+pedigree+as+potential+drug+molecules+than+others%3F&doi=10.1039%2Fc2md20111a"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">The developability of heteroaromatic and heteroaliphatic rings - do some have a better pedigree as potential drug molecules than others?</span></div><div class="casAuthors">Ritchie, Timothy J.; MacDonald, Simon J. F.; Peace, Simon; Pickett, Stephen D.; Luscombe, Christopher N.</div><div class="citationInfo"><span class="NLM_cas:title">MedChemComm</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1062-1069</span>CODEN:
                <span class="NLM_cas:coden">MCCEAY</span>;
        ISSN:<span class="NLM_cas:issn">2040-2503</span>.
    
            (<span class="NLM_cas:orgname">Royal Society of Chemistry</span>)
        </div><div class="casAbstract">Aq. soly., protein binding and CYP450 inhibition data for compds. contg. a variety of heteroarom. and heteroaliph. rings were analyzed and compared to det. which ring types fared best and worst in these developability screens.  The results suggest that certain heterorings are generally more developable than others: how this information may be used and some caveats to be borne in mind are discussed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpCkxdTaUGig7Vg90H21EOLACvtfcHk0ljNWI2lQxIjyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xht1GitLfE&md5=6aad4bc48b351d9d20683ee9af1a3354</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1039%2Fc2md20111a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1039%252Fc2md20111a%26sid%3Dliteratum%253Aachs%26aulast%3DRitchie%26aufirst%3DT.%2BJ.%26aulast%3DMacdonald%26aufirst%3DS.%2BJ.%2BF.%26aulast%3DPeace%26aufirst%3DS.%26aulast%3DPickett%26aufirst%3DS.%2BD.%26aulast%3DLuscombe%26aufirst%3DC.%2BN.%26atitle%3DThe%2520developability%2520of%2520heteroaromatic%2520and%2520heteroaliphatic%2520rings%2520%25E2%2580%2593%2520do%2520some%2520have%2520a%2520better%2520pedigree%2520as%2520potential%2520drug%2520molecules%2520than%2520others%253F%26jtitle%3DMedChemComm%26date%3D2012%26volume%3D3%26spage%3D1062%26epage%3D1069%26doi%3D10.1039%2Fc2md20111a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">St. Jean, D. J.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fotsch, C.</span><span> </span><span class="NLM_article-title">Mitigating heterocycle metabolism in drug discovery</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">6002</span><span class="NLM_x">–</span> <span class="NLM_lpage">6020</span><span class="refDoi"> DOI: 10.1021/jm300343m</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300343m" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01434&amp;key=1%3ACAS%3A528%3ADC%252BC38XmtFWhsL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=6002-6020&author=D.+J.+St.+Jeanauthor=C.+Fotsch&title=Mitigating+heterocycle+metabolism+in+drug+discovery&doi=10.1021%2Fjm300343m"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Mitigating Heterocycle Metabolism in Drug Discovery</span></div><div class="casAuthors">St. Jean, David J.; Fotsch, Christopher</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">6002-6020</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  Extensive data from metab. studies have allowed medicinal chemists to develop general principles for reducing compd. metab.  These methods include, but are not limited to, reducing lipophilicity, altering sterics and electronics, introducing a conformational constraint, and altering the stereochem. of their compds.  While no single method is able to solve every metabolic problem, these principles do give medicinal chemists guidance on how to improve the metabolic liabilities of their compds.  If the specific site of metab. is known, medicinal chemists block the site, typically with a fluorine, or replace the metabolically labile group with a bioisostere.  While several authors have reviewed these techniques for reducing metab., there is no review that summarizes different approaches to improving them metabolic stability of heterocycles.  In this review, we summarize examples where changes were made at or near the heterocycle to improve metabolic stability.  By summarizing these examples, we hope to provide a useful guide to medicinal chemists as they attempt to improve the metabolic profile of their own heterocyclic compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGovQjdBBgXtPbVg90H21EOLACvtfcHk0ljNWI2lQxIjyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XmtFWhsL0%253D&md5=48c262556b8a2cc7dc5539ff91a53a71</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1021%2Fjm300343m&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300343m%26sid%3Dliteratum%253Aachs%26aulast%3DSt.%2BJean%26aufirst%3DD.%2BJ.%26aulast%3DFotsch%26aufirst%3DC.%26atitle%3DMitigating%2520heterocycle%2520metabolism%2520in%2520drug%2520discovery%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D6002%26epage%3D6020%26doi%3D10.1021%2Fjm300343m" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Katz, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jewell, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guerin, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lim, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dinsmore, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deshmukh, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, B.-S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marshall, C. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Altman, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dahlberg, W. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Falcone, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gabarda, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hang, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hatch, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Holmes, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kunii, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lumb, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lutterbach, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathvink, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nazef, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reilly, J. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rickert, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosenstein, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Soisson, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spencer, K. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szewczak, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Young, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeng, Q.</span><span> </span><span class="NLM_article-title">Discovery of a 5<i>H</i>-benzo[4,5]cyclohepta[1,2-b]pyridin-5-one (MK-2461) inhibitor of c-Met kinase for the treatment of cancer</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">4092</span><span class="NLM_x">–</span> <span class="NLM_lpage">4108</span><span class="refDoi"> DOI: 10.1021/jm200112k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm200112k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01434&amp;key=1%3ACAS%3A528%3ADC%252BC3MXmsFymtbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=4092-4108&author=J.+D.+Katzauthor=J.+P.+Jewellauthor=D.+J.+Guerinauthor=J.+Limauthor=C.+J.+Dinsmoreauthor=S.+V.+Deshmukhauthor=B.-S.+Panauthor=C.+G.+Marshallauthor=W.+Luauthor=M.+D.+Altmanauthor=W.+K.+Dahlbergauthor=L.+Davisauthor=D.+Falconeauthor=A.+E.+Gabardaauthor=G.+Hangauthor=H.+Hatchauthor=R.+Holmesauthor=K.+Kuniiauthor=K.+J.+Lumbauthor=B.+Lutterbachauthor=R.+Mathvinkauthor=N.+Nazefauthor=S.+B.+Patelauthor=X.+Quauthor=J.+F.+Reillyauthor=K.+W.+Rickertauthor=C.+Rosensteinauthor=S.+M.+Soissonauthor=K.+B.+Spencerauthor=A.+A.+Szewczakauthor=D.+Walkerauthor=W.+Wangauthor=J.+Youngauthor=Q.+Zeng&title=Discovery+of+a+5H-benzo%5B4%2C5%5Dcyclohepta%5B1%2C2-b%5Dpyridin-5-one+%28MK-2461%29+inhibitor+of+c-Met+kinase+for+the+treatment+of+cancer&doi=10.1021%2Fjm200112k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of a 5H-Benzo[4,5]cyclohepta[1,2-b]pyridin-5-one (MK-2461) Inhibitor of c-Met Kinase for the Treatment of Cancer</span></div><div class="casAuthors">Katz, Jason D.; Jewell, James P.; Guerin, David J.; Lim, Jongwon; Dinsmore, Christopher J.; Deshmukh, Sujal V.; Pan, Bo-Sheng; Marshall, C. Gary; Lu, Wei; Altman, Michael D.; Dahlberg, William K.; Davis, Lenora; Falcone, Danielle; Gabarda, Ana E.; Hang, Gaozhen; Hatch, Harold; Holmes, Rachael; Kunii, Kaiko; Lumb, Kevin J.; Lutterbach, Bart; Mathvink, Robert; Nazef, Naim; Patel, Sangita B.; Qu, Xianlu; Reilly, John F.; Rickert, Keith W.; Rosenstein, Craig; Soisson, Stephen M.; Spencer, Kerrie B.; Szewczak, Alexander A.; Walker, Deborah; Wang, Wenxian; Young, Jonathan; Zeng, Qinwen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">4092-4108</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">C-Met is a transmembrane tyrosine kinase that mediates activation of several signaling pathways implicated in aggressive cancer phenotypes.  In recent years, research into this area has highlighted c-Met as an attractive cancer drug target, triggering a no. of approaches to disrupt aberrant c-Met signaling.  Screening efforts identified a unique class of 5H-benzo[4,5]cyclohepta[1,2-b]pyridin-5-one kinase inhibitors, exemplified by 1.  Subsequent SAR studies led to the development of MK-2461 (I), a potent inhibitor of c-Met that was efficacious in preclin. animal models of tumor suppression.  In addn., biochem. studies and x-ray anal. have revealed that this unique class of kinase inhibitors binds preferentially to the activated (phosphorylated) form of the kinase.  This report details the development of I and provides a description of its unique biochem. properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo6ANuqa7a-NrVg90H21EOLACvtfcHk0lh2Ievct4Ff4g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXmsFymtbY%253D&md5=82cfe0a146d04d467531e1027f3a1266</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1021%2Fjm200112k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm200112k%26sid%3Dliteratum%253Aachs%26aulast%3DKatz%26aufirst%3DJ.%2BD.%26aulast%3DJewell%26aufirst%3DJ.%2BP.%26aulast%3DGuerin%26aufirst%3DD.%2BJ.%26aulast%3DLim%26aufirst%3DJ.%26aulast%3DDinsmore%26aufirst%3DC.%2BJ.%26aulast%3DDeshmukh%26aufirst%3DS.%2BV.%26aulast%3DPan%26aufirst%3DB.-S.%26aulast%3DMarshall%26aufirst%3DC.%2BG.%26aulast%3DLu%26aufirst%3DW.%26aulast%3DAltman%26aufirst%3DM.%2BD.%26aulast%3DDahlberg%26aufirst%3DW.%2BK.%26aulast%3DDavis%26aufirst%3DL.%26aulast%3DFalcone%26aufirst%3DD.%26aulast%3DGabarda%26aufirst%3DA.%2BE.%26aulast%3DHang%26aufirst%3DG.%26aulast%3DHatch%26aufirst%3DH.%26aulast%3DHolmes%26aufirst%3DR.%26aulast%3DKunii%26aufirst%3DK.%26aulast%3DLumb%26aufirst%3DK.%2BJ.%26aulast%3DLutterbach%26aufirst%3DB.%26aulast%3DMathvink%26aufirst%3DR.%26aulast%3DNazef%26aufirst%3DN.%26aulast%3DPatel%26aufirst%3DS.%2BB.%26aulast%3DQu%26aufirst%3DX.%26aulast%3DReilly%26aufirst%3DJ.%2BF.%26aulast%3DRickert%26aufirst%3DK.%2BW.%26aulast%3DRosenstein%26aufirst%3DC.%26aulast%3DSoisson%26aufirst%3DS.%2BM.%26aulast%3DSpencer%26aufirst%3DK.%2BB.%26aulast%3DSzewczak%26aufirst%3DA.%2BA.%26aulast%3DWalker%26aufirst%3DD.%26aulast%3DWang%26aufirst%3DW.%26aulast%3DYoung%26aufirst%3DJ.%26aulast%3DZeng%26aufirst%3DQ.%26atitle%3DDiscovery%2520of%2520a%25205H-benzo%255B4%252C5%255Dcyclohepta%255B1%252C2-b%255Dpyridin-5-one%2520%2528MK-2461%2529%2520inhibitor%2520of%2520c-Met%2520kinase%2520for%2520the%2520treatment%2520of%2520cancer%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D4092%26epage%3D4108%26doi%3D10.1021%2Fjm200112k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Del Bello, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barocelli, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bertoni, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonifazi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camalli, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campi, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giannella, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matucci, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nesi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pigini, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quaglia, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piergentili, A.</span><span> </span><span class="NLM_article-title">1,4-Dioxane, a suitable scaffold for the development of novel M3 muscarinic receptor antagonists</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">55</span><span class="NLM_x">, </span> <span class="NLM_fpage">1783</span><span class="NLM_x">–</span> <span class="NLM_lpage">1787</span><span class="refDoi"> DOI: 10.1021/jm2013216</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2013216" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01434&amp;key=1%3ACAS%3A528%3ADC%252BC38XntFKhsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=1783-1787&author=F.+Del+Belloauthor=E.+Barocelliauthor=S.+Bertoniauthor=A.+Bonifaziauthor=M.+Camalliauthor=G.+Campiauthor=M.+Giannellaauthor=R.+Matucciauthor=M.+Nesiauthor=M.+Piginiauthor=W.+Quagliaauthor=A.+Piergentili&title=1%2C4-Dioxane%2C+a+suitable+scaffold+for+the+development+of+novel+M3+muscarinic+receptor+antagonists&doi=10.1021%2Fjm2013216"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">1,4-Dioxane, a Suitable Scaffold for the Development of Novel M3 Muscarinic Receptor Antagonists</span></div><div class="casAuthors">Del Bello, Fabio; Barocelli, Elisabetta; Bertoni, Simona; Bonifazi, Alessandro; Camalli, Mercedes; Campi, Gaetano; Giannella, Mario; Matucci, Rosanna; Nesi, Marta; Pigini, Maria; Quaglia, Wilma; Piergentili, Alessandro</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1783-1787</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In this study the modulation of the pharmacol. profile from agonist to antagonist was successfully obtained by replacing the Me group in position 6 of the 1,4-dioxane scaffold of the potent M2/M3 muscarinic agonist 1 with bulkier groups.  In particular, the 6,6-di-Ph substitution provided the potent M3 preferring antagonist (±)-17 (I), which in in vivo study proved to be effective in reducing the vol.-induced contractions of rat urinary bladder and was devoid of cardiovascular effects.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopZzxYns6n0bVg90H21EOLACvtfcHk0lhJ0RwVAdBImQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XntFKhsw%253D%253D&md5=35106d72f5138ae153800fb4efc80094</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1021%2Fjm2013216&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2013216%26sid%3Dliteratum%253Aachs%26aulast%3DDel%2BBello%26aufirst%3DF.%26aulast%3DBarocelli%26aufirst%3DE.%26aulast%3DBertoni%26aufirst%3DS.%26aulast%3DBonifazi%26aufirst%3DA.%26aulast%3DCamalli%26aufirst%3DM.%26aulast%3DCampi%26aufirst%3DG.%26aulast%3DGiannella%26aufirst%3DM.%26aulast%3DMatucci%26aufirst%3DR.%26aulast%3DNesi%26aufirst%3DM.%26aulast%3DPigini%26aufirst%3DM.%26aulast%3DQuaglia%26aufirst%3DW.%26aulast%3DPiergentili%26aufirst%3DA.%26atitle%3D1%252C4-Dioxane%252C%2520a%2520suitable%2520scaffold%2520for%2520the%2520development%2520of%2520novel%2520M3%2520muscarinic%2520receptor%2520antagonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D1783%26epage%3D1787%26doi%3D10.1021%2Fjm2013216" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Mammoli, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonifazi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Del Bello, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diamanti, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giannella, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hudson, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mattioli, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Perfumi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piergentili, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Quaglia, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Titomanlio, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pigini, M.</span><span> </span><span class="NLM_article-title">Favourable involvement of α<sub>2A</sub>-adrenoreceptor antagonism in the I<sub>2</sub>-imidazoline binding sites-mediated morphine analgesia enhancement</span> <span class="citation_source-journal">Bioorg. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">20</span><span class="NLM_x">, </span> <span class="NLM_fpage">2259</span><span class="NLM_x">–</span> <span class="NLM_lpage">2265</span><span class="refDoi"> DOI: 10.1016/j.bmc.2012.02.016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01434&amp;key=10.1016%2Fj.bmc.2012.02.016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01434&amp;key=22370341" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01434&amp;key=1%3ACAS%3A528%3ADC%252BC38XjtVyjt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=20&publication_year=2012&pages=2259-2265&author=V.+Mammoliauthor=A.+Bonifaziauthor=F.+Del+Belloauthor=E.+Diamantiauthor=M.+Giannellaauthor=A.+L.+Hudsonauthor=L.+Mattioliauthor=M.+Perfumiauthor=A.+Piergentiliauthor=W.+Quagliaauthor=F.+Titomanlioauthor=M.+Pigini&title=Favourable+involvement+of+%CE%B12A-adrenoreceptor+antagonism+in+the+I2-imidazoline+binding+sites-mediated+morphine+analgesia+enhancement&doi=10.1016%2Fj.bmc.2012.02.016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Favourable involvement of α2A-adrenoreceptor antagonism in the I2-imidazoline binding sites-mediated morphine analgesia enhancement</span></div><div class="casAuthors">Mammoli, Valerio; Bonifazi, Alessandro; Del Bello, Fabio; Diamanti, Eleonora; Giannella, Mario; Hudson, Alan L.; Mattioli, Laura; Perfumi, Marina; Piergentili, Alessandro; Quaglia, Wilma; Titomanlio, Federica; Pigini, Maria</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">20</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">2259-2265</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Aim of the present study was to obtain novel α2-adrenoreceptor (α2-AR) antagonists, possibly endowed with subtype-selectivity.  Therefore, inspired by the non subtype-selective α2-AR antagonist idazoxan, we designed 1,4-dioxane derivs. bearing an arom. area in position 5 or 6 and the imidazoline nucleus in position 2.  Among the novel mols. 1-6, compd. 2, with a trans stereochem. relationship between 5-Ph and 2-imidazoline groups, was able to antagonize the sole α2A-subtype.  Moreover, 2 showed an affinity at I2-imidazoline binding sites (I2-IBS) comparable to that at α2A-AR.  In in vivo studies 2 strongly increased morphine analgesia.  This interesting behavior appeared to be induced by the favorable involvement of α2A-AR antagonism in the I2-IBS-mediated morphine analgesia enhancement.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq26wuH-DYiprVg90H21EOLACvtfcHk0ljr5awGZ3p-cQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XjtVyjt7s%253D&md5=852ce990b6a7f269bbc4dfe406d5f57d</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2012.02.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2012.02.016%26sid%3Dliteratum%253Aachs%26aulast%3DMammoli%26aufirst%3DV.%26aulast%3DBonifazi%26aufirst%3DA.%26aulast%3DDel%2BBello%26aufirst%3DF.%26aulast%3DDiamanti%26aufirst%3DE.%26aulast%3DGiannella%26aufirst%3DM.%26aulast%3DHudson%26aufirst%3DA.%2BL.%26aulast%3DMattioli%26aufirst%3DL.%26aulast%3DPerfumi%26aufirst%3DM.%26aulast%3DPiergentili%26aufirst%3DA.%26aulast%3DQuaglia%26aufirst%3DW.%26aulast%3DTitomanlio%26aufirst%3DF.%26aulast%3DPigini%26aufirst%3DM.%26atitle%3DFavourable%2520involvement%2520of%2520%25CE%25B12A-adrenoreceptor%2520antagonism%2520in%2520the%2520I2-imidazoline%2520binding%2520sites-mediated%2520morphine%2520analgesia%2520enhancement%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2012%26volume%3D20%26spage%3D2259%26epage%3D2265%26doi%3D10.1016%2Fj.bmc.2012.02.016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Settle, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vickery, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nemirovskiy, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vidmar, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bendele, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Messing, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ruminski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schnute, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sunyer, T.</span><span> </span><span class="NLM_article-title">Cartilage degradation biomarkers predict efficacy of a novel, highly selective matrix metalloproteinase 13 inhibitor in a dog model of osteoarthritis confirmation by multivariate analysis that modulation of type II collagen and aggrecan degradation peptides parallels pathologic changes</span> <span class="citation_source-journal">Arthritis Rheum.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">62</span><span class="NLM_x">, </span> <span class="NLM_fpage">3006</span><span class="NLM_x">–</span> <span class="NLM_lpage">3015</span><span class="refDoi"> DOI: 10.1002/art.27596</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01434&amp;key=10.1002%2Fart.27596" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01434&amp;key=20533541" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01434&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhsVSqtrvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2010&pages=3006-3015&author=S.+Settleauthor=L.+Vickeryauthor=O.+Nemirovskiyauthor=T.+Vidmarauthor=A.+Bendeleauthor=D.+Messingauthor=P.+Ruminskiauthor=M.+Schnuteauthor=T.+Sunyer&title=Cartilage+degradation+biomarkers+predict+efficacy+of+a+novel%2C+highly+selective+matrix+metalloproteinase+13+inhibitor+in+a+dog+model+of+osteoarthritis+confirmation+by+multivariate+analysis+that+modulation+of+type+II+collagen+and+aggrecan+degradation+peptides+parallels+pathologic+changes&doi=10.1002%2Fart.27596"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Cartilage degradation biomarkers predict efficacy of a novel, highly selective matrix metalloproteinase 13 inhibitor in a dog model of osteoarthritis</span></div><div class="casAuthors">Settle, Steven; Vickery, Lillian; Nemirovskiy, Olga; Vidmar, Tom; Bendele, Alison; Messing, Dean; Ruminski, Peter; Schnute, Mark; Sunyer, Teresa</div><div class="citationInfo"><span class="NLM_cas:title">Arthritis & Rheumatism</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">3006-3015</span>CODEN:
                <span class="NLM_cas:coden">ARHEAW</span>;
        ISSN:<span class="NLM_cas:issn">0004-3591</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons, Inc.</span>)
        </div><div class="casAbstract">Objective: To demonstrate that the novel highly selective matrix metalloproteinase 13 (MMP-13) inhibitor PF152 reduces joint lesions in adult dogs with osteoarthritis (OA) and decreases biomarkers of cartilage degrdn.  Methods: The potency and selectivity of PF152 were evaluated in vitro using 16 MMPs, TACE, and ADAMTS-4 and ADAMTS-5, as well as ex vivo in human cartilage explants.  In vivo effects were evaluated at 3 concns. in mature beagles with partial medial meniscectomy.  Gross and histol. changes in the femorotibial joints were evaluated using various measures of cartilage degeneration.  Biomarkers of cartilage turnover were examd. in serum, urine, or synovial fluid.  Results were analyzed individually and in combination using multivariate anal.  Results: The potent and selective MMP-13 inhibitor PF152 decreased human cartilage degrdn. ex vivo in a dose-dependent manner.  PF152 treatment of dogs with OA reduced cartilage lesions and decreased biomarkers of type II collagen (type II collagen neoepitope) and aggrecan (peptides ending in ARGN or AGEG) degrdn.  The dose required for significant inhibition varied with the measure used, but multivariate anal. of 6 gross and histol. measures indicated that all doses differed significantly from vehicle but not from each other.  Combined anal. of cartilage degrdn. markers showed similar results.  Conclusion: This highly selective MMP-13 inhibitor exhibits chondroprotective effects in mature animals.  Biomarkers of cartilage degrdn., when evaluated in combination, parallel the joint structural changes induced by the MMP-13 inhibitor.  These data support the potential therapeutic value of selective MMP-13 inhibitors and the use of a set of appropriate biomarkers to predict efficacy in OA clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrFetQBLK-edLVg90H21EOLACvtfcHk0ljr5awGZ3p-cQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhsVSqtrvL&md5=83b761d6731b0287d78bbee6263f4df5</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1002%2Fart.27596&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fart.27596%26sid%3Dliteratum%253Aachs%26aulast%3DSettle%26aufirst%3DS.%26aulast%3DVickery%26aufirst%3DL.%26aulast%3DNemirovskiy%26aufirst%3DO.%26aulast%3DVidmar%26aufirst%3DT.%26aulast%3DBendele%26aufirst%3DA.%26aulast%3DMessing%26aufirst%3DD.%26aulast%3DRuminski%26aufirst%3DP.%26aulast%3DSchnute%26aufirst%3DM.%26aulast%3DSunyer%26aufirst%3DT.%26atitle%3DCartilage%2520degradation%2520biomarkers%2520predict%2520efficacy%2520of%2520a%2520novel%252C%2520highly%2520selective%2520matrix%2520metalloproteinase%252013%2520inhibitor%2520in%2520a%2520dog%2520model%2520of%2520osteoarthritis%2520confirmation%2520by%2520multivariate%2520analysis%2520that%2520modulation%2520of%2520type%2520II%2520collagen%2520and%2520aggrecan%2520degradation%2520peptides%2520parallels%2520pathologic%2520changes%26jtitle%3DArthritis%2520Rheum.%26date%3D2010%26volume%3D62%26spage%3D3006%26epage%3D3015%26doi%3D10.1002%2Fart.27596" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Tortorella, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tomasselli, A. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathis, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schnute, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woodard, S. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Munie, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caspers, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wittwer, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Malfait, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shieh, H. S.</span><span> </span><span class="NLM_article-title">Structural and inhibition analysis reveals the mechanism of selectivity of a series of aggrecanase inhibitors</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">284</span><span class="NLM_x">, </span> <span class="NLM_fpage">24185</span><span class="NLM_x">–</span> <span class="NLM_lpage">24191</span><span class="refDoi"> DOI: 10.1074/jbc.M109.029116</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01434&amp;key=10.1074%2Fjbc.M109.029116" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01434&amp;key=19586907" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01434&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhtVGgsr%252FP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=284&publication_year=2009&pages=24185-24191&author=M.+D.+Tortorellaauthor=A.+G.+Tomasselliauthor=K.+J.+Mathisauthor=M.+E.+Schnuteauthor=S.+S.+Woodardauthor=G.+Munieauthor=J.+M.+Williamsauthor=N.+Caspersauthor=A.+J.+Wittwerauthor=A.+M.+Malfaitauthor=H.+S.+Shieh&title=Structural+and+inhibition+analysis+reveals+the+mechanism+of+selectivity+of+a+series+of+aggrecanase+inhibitors&doi=10.1074%2Fjbc.M109.029116"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Structural and Inhibition Analysis Reveals the Mechanism of Selectivity of a Series of Aggrecanase Inhibitors</span></div><div class="casAuthors">Tortorella, Micky D.; Tomasselli, Alfredo G.; Mathis, Karl J.; Schnute, Mark E.; Woodard, Scott S.; Munie, Grace; Williams, Jennifer M.; Caspers, Nicole; Wittwer, Arthur J.; Malfait, Anne-Marie; Shieh, Huey-Sheng</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Biological Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">284</span>
        (<span class="NLM_cas:issue">36</span>),
    <span class="NLM_cas:pages">24185-24191</span>CODEN:
                <span class="NLM_cas:coden">JBCHA3</span>;
        ISSN:<span class="NLM_cas:issn">0021-9258</span>.
    
            (<span class="NLM_cas:orgname">American Society for Biochemistry and Molecular Biology</span>)
        </div><div class="casAbstract">Several inhibitors of a series of cis-1(S)2(R)-amino-2-indanol-based compds. were reported to be selective for the aggrecanases, ADAMTS-4 and -5 over other metalloproteinases.  To understand the nature of this selectivity for aggrecanases, the inhibitors, along with the broad spectrum metalloproteinase inhibitor marimastat, were independently bound to the catalytic domain of ADAMTS-5, and the corresponding crystal structures were detd.  By comparing the structures, it was detd. that the specificity of the relative inhibitors for ADAMTS-5 was not driven by a specific interaction, such as zinc chelation, hydrogen bonding, or charge interactions, but rather by subtle and indirect factors, such as water bridging, ring rigidity, pocket size, and shape, as well as protein conformation flexibility.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoI39fzCSuJerVg90H21EOLACvtfcHk0lhvuyHxWdQ1Xg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhtVGgsr%252FP&md5=86e9879fb3359bc2ad78e2ce653ea0de</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M109.029116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M109.029116%26sid%3Dliteratum%253Aachs%26aulast%3DTortorella%26aufirst%3DM.%2BD.%26aulast%3DTomasselli%26aufirst%3DA.%2BG.%26aulast%3DMathis%26aufirst%3DK.%2BJ.%26aulast%3DSchnute%26aufirst%3DM.%2BE.%26aulast%3DWoodard%26aufirst%3DS.%2BS.%26aulast%3DMunie%26aufirst%3DG.%26aulast%3DWilliams%26aufirst%3DJ.%2BM.%26aulast%3DCaspers%26aufirst%3DN.%26aulast%3DWittwer%26aufirst%3DA.%2BJ.%26aulast%3DMalfait%26aufirst%3DA.%2BM.%26aulast%3DShieh%26aufirst%3DH.%2BS.%26atitle%3DStructural%2520and%2520inhibition%2520analysis%2520reveals%2520the%2520mechanism%2520of%2520selectivity%2520of%2520a%2520series%2520of%2520aggrecanase%2520inhibitors%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2009%26volume%3D284%26spage%3D24185%26epage%3D24191%26doi%3D10.1074%2Fjbc.M109.029116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes-1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i83"><a href="/doi/suppl/10.1021/acs.jmedchem.5b01434">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_07633"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.5b01434">10.1021/acs.jmedchem.5b01434</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">Synthesis and X-ray data collection for the crystal structure of compound <b>44</b> and pharmacokinetic parameters of compounds <b>14i</b>, <b>42</b>, and <b>43b</b> in rat and compound <b>43a</b> in rat, dog, and cynomolgus monkey.(<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.5b01434/suppl_file/jm5b01434_si_001.pdf">PDF</a>)</p></li><li><p class="inline">SMILES representations of compounds with MMP13/FL <i>K</i><sub>i</sub> (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.5b01434/suppl_file/jm5b01434_si_002.xlsx">XLSX</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.5b01434/suppl_file/jm5b01434_si_001.pdf">jm5b01434_si_001.pdf (179.65 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.5b01434/suppl_file/jm5b01434_si_002.xlsx">jm5b01434_si_002.xlsx (12.93 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.5b01434&amp;pbContext=%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.5b01434%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2016.59.issue-1%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.5b01434" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                998KB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"6799c628cf833d3c","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
